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A Novel, Versatile DBCD Steroid Construction 
Strategy, Illustrated by the Total Syntheses of Estrone 
and Desogestrel 
 
By Vincent Foucher 
 
Proposed are the total syntheses of the steroids desogestrel and estrone, utilizing a 1,4-
addition/alkylation process to install the correct stereochemistry at C8, C13 and C14 in a 
single-pot  operation.  The  racemic  total  synthesis  of  desogestrel  includes  a  successful 
domino anionic cyclisation leading to the formation of the steroid C and B rings in a single 
operation  with  complete  stereocontrol  at  C9.  The  -keto  phosphonates  obtained  were 
subsequently subjected to A-ring annelation via a multistep one-pot process. 
The enantioselective synthesis as well as the racemic total synthesis of estrone include a 
sequential  C and B-ring  formation  through ring  closing metathesis  and intramolecular 
Heck reaction. iii 
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Chapter 1, Introduction 
1.1  Steroids 
 
1.1.1  Introduction to steroids 
 
Steroids are a class of compounds whose structure is based on the tetracyclic ring system 
as illustrated in Figure 1.1. By convention, it is agreed that the rings are labeled with a 
letter and that this begins with the lower left hand ring, working towards the upper right 
hand ring. It is also convention to begin the carbon numbering in the A-ring.
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Figure 1.1 
 
By convention, the upper and lower faces of the steroid are defined as the -face and the 
-face, as shown in Figure 1.2. 
 
Figure 1.2 
 
Another commonly used nomenclature within steroids is the nor-prefix which indicates the 
lack  of  a particular  group.
1 As illustrated  in Figure 1.3, 19-norcholesterol  (1.2)  is the 
analogue of cholesterol (1.3), with a missing methyl group at C10 (the C19 methyl group). 
 2 
 
 
Figure 1.3 
 
Hundreds of distinct steroids have been identified in plants and animals, where they play 
an essential role in many physiological  functions.
1-8 For  instance,  they are  particularly 
involved within the reproduction process and the regulation of growth. 
1.1.2  Steroid hormones
9 
 
Within the human body, two classes of steroid hormones can be distinguished: the sex 
hormones which include androgens, progestogens and oestrogens; and the adrenal cortex 
hormones  which  include  glucocorticoids  and  mineralocorticoids.  There  are  many 
examples of individual steroids within each class, natural or synthetic steroids. Figure 1.4 
presents some of the naturally occurring steroids. 
 
Figure 1.4 
 
Androgens are mainly produced in the testes, though they are produced in small amounts 
in  the  adrenal  cortex  and  ovaries,  and  are  associated  with  the  development  and 
maintenance of male characteristics, fertility, muscle growth and mood effects. The most 3 
 
well-known androgen is testosterone (1.4). Progestogens, like progesterone (1.5) which is 
the  only  naturally  occurring  human  one,  are  associated  with  the  regulation  of  the 
menstrual cycle, the maintenance of pregnancy and the inhibition of ovulation. They are 
secreted by the ovaries and the placenta. Oestrogens are associated with the development 
and maintenance of female characteristics, fertility, muscle growth and mood effects. They 
are also involved in the control of the menstrual cycle and are mainly produced by the 
ovaries and the placenta. Estrone (1.6) is one of the three natural oestrogens that account 
for most of the estrogenic activity in humans. Mineralocorticoids and glucocorticoids are 
produced by the cortex of the adrenal gland. Mineralocorticoids, like aldosterone (1.7), 
maintain the balance of sodium and potassium in the body and are therefore associated 
with blood volume and pressure. Glucocorticoids are involved in carbohydrate, protein 
and fat metabolism. They also have anti-inflammatory properties and cortisol (1.8), also 
called hydrocortisone, is the most important human glucocorticoid. 
1.1.3  Biosynthesis of steroid hormones 
 
Any  steroid  hormone  produced  within  nature  has  cholesterol  (1.3)  as  the  common 
precursor, which biosynthesis is shown in Scheme 1.1.
10  
 
Scheme 1.1 
 
From squalene (1.9), which has 30 carbon atoms (24 in the chain and 6 in the form of 
methyl-group branches), the first step is an enzymatic epoxidation that forms squalene 
oxide  (1.10)  as  a  single  enantiomer,  which  then  undergoes  a  complex  cationic 
polycyclization leading to the tetracyclic cation intermediate (1.11). Cation (1.11) then 4 
 
undergoes  a  series of  1,2-shifts  to form  lanosterol  (1.12). Finally,  lanosterol  (1.12)  is 
converted to cholesterol (1.3) by CO2-elimination of the methyl groups at C4 and C14, 
transposition of the C8-9 to the C5-6 double bond and reduction of the side chain double 
bond.
10 
A key consequence of the use of squalene oxide (1.10) as steroid precursor is the resulting 
methyl group at the C13 position. Steroids with other groups than a methyl at C13 are 
synthetic steroids.  
1.1.4  Hemi-synthesis of steroid hormones 
 
Since steroids are such an important class of compounds, it is hardly surprising to discover 
that work  concerning  the  synthesis  of  these compounds  has  been  underway for  many 
years. Beside the natural compounds, many synthetic steroids have been prepared in order 
to  increase  potency,  limit  side  effects  or  improve  other  molecular  characteristics 
(examples in Figure 1.5). 
 
Figure 1.5 
 
The industrial production of steroids, natural or synthetic, requires high yields and cheap 
and readily  available starting  materials.  Although totally  synthetic  methods have  been 
employed, these syntheses are not convenient as they often lead to isomeric mixtures of 
products. The steroid backbone itself often contains six asymmetric carbon centres, which 
means that up to 64 (2
6) stereoisomers are theoretically possible.
5 To avoid this problem, 
steroids  are  frequently  obtained  by  hemi-synthesis  from  an  abundant  natural  steroid. 
Natural steroid starting materials, a few examples are shown in Figure 1.6, are mainly 
extracted from plants: diosgenin (1.18) (Dioscorea), hecogenin (1.19) (Agave Sisalana), 
smilagenin (1.20) (Smilax), sitosterol (1.21) or stigmasterol (1.22) (soya seeds). 5 
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Figure 1.6 
 
Diosgenin (1.18) and sitosterol (1.21) are the main sources of natural steroids for hemi-
synthesis. For example, the commercial synthesis of desogestrel (1.14) is a hemi-synthesis 
starting  from  diosgenin (1.18) which is transformed  to dehydroepiandrosterone acetate 
(DHA) (1.27) in six steps via the Marker process (Scheme 1.2). 
 
Scheme 1.2 
 
The first step of the Marker process is to cleave the F-ring in diosgenin by heating the 
compound at 200 °C with acetic anhydride. Chromic acid oxidation at the C20-22 double 
bond in (1.23) converts this compound into the keto ester diacetate (1.24) and immediate 
treatment of the keto ester diacetate with base eliminates the C16 side chain, forming the 
enone (1.25). Treatment of (1.25) with hydroxylamine forms the C17-oxime (1.26). POCl3 
is used to drive the Beckmann rearrangement of (1.26), and DHA (1.27) is formed after 
acid  hydrolysis.  Overall,  DHA  can  be  prepared  from  diosgenin  in  74%  yield  on  an 
industrial scale.
1 The industrial desogestrel synthesis consists of 24 steps from diosgenin 
(1.18) but is not discussed in this thesis. 6 
 
1.2  The  role  of  steroid  hormones  during  menstruation  and 
pregnancy
11,12 
 
1.2.1  The menstrual cycle 
 
The term menstrual cycle defines the periodic series of changes in the female reproductive 
system associated with the preparation of the uterus, key to which is the production and 
the release of an egg from the ovaries. The release of an egg is called ovulation and occurs 
every 28-35 days from non-pregnant women. The lining of the uterus, the endometrium, 
builds up in a synchronized fashion. If implantation of a foetus doesn’t take place, the 
expanded endometrium is broken down and excreted which is known as the menstruation. 
 
All aspects of the menstrual cycle are controlled  and synchronized by five hormones: 
gonadotrophin releasing hormone (GnRH), luteinizing hormone (LH), follicle-stimulating 
hormone  (FSH),  oestrogen  and  progesterone  (Figure  1.6).  GnRH  is  produced  by  the 
hypothalamus. FSH and LH are both gonadotrophin hormones and are secreted by the 
anterior pituitary gland (in the brain). Oestrogen and progesterone (1.5) are both steroid 
hormones and are mainly produced by the ovaries. As already mentioned in part 1.1.2, 
progesterone (1.5) is the only naturally occurring human steroid hormone that belongs to 
progestogens. Oestrogens, however, are represented by three naturally occurring steroids: 
estrone (1.6), estradiol (1.28) and estriol (1.29) (Scheme 1.3). 
 
Scheme 1.3 
 
These  are  all  produced  in  the  body  from  androgens  (like  testosterone  (1.4))  through 
enzyme action. Estradiol (1.28) is the primary oestrogen: it is 12 times more potent than 
estrone (1.6) and 80 times more potent than estriol (1.29). Estradiol is converted to estrone 
in the blood. Estriol is produced in the liver by oxidation of the other two. 7 
 
Figure 1.7 shows the change of blood levels for each hormone during the menstrual cycle. 
 
Figure 1.7 
 
No  units  are  displayed  on  the  Y-axis  as  what  is  really  important  is  the  relative 
concentration of each hormone. 
By convention, the “cycle day one” refers to the first day of menstrual bleeding. From day 
one, the hypothalamus releases GnRH, which causes the secretion of relatively low levels 
of LH and FSH from the pituitary gland (section 1, Figure 1.7). Under the influence of the 
FSH, a number of follicles in the ovary start to grow. The cells of these growing follicles 
release  oestrogen  (primarily  estradiol)  which  partly  stimulates  the  rebuilding  of  the 
endometrium.  As  the  oestrogen  levels  become  higher,  the  oestrogen  stimulates  the 
hypothalamus to increase the output of GnRH, and as a result increases gonadotrophin 
(LH and FSH) release. This in turn leads to a further increase in oestrogen production. The 
overall effect of this is to cause a surge in oestrogen, LH and FSH production, which in 
turn stimulates the release of an egg, and ovulation occurs (section 2, Figure 1.7). 
After  the ovulation,  the  residual  follicle transforms  into  the  corpum luteum under the 
effect of the LH. The corpus luteum will produce progesterone in addition to oestrogens 
for the next two weeks. The progesterone works in conjunction with the oestrogen to stop 
the secretion of LH and FSH so no other follicle can develop during the cycle. In the 
absence of pregnancy, the corpus luteum demises and oestrogen and progesterone levels 
fall.  Progesterone  withdrawal  leads  to  menstrual  shedding,  while  the  falling  oestrogen 
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levels allow FSH levels to rise resulting in the beginning of a new cycle (section 3, Figure 
1.7). 
1.2.2  Pregnancy 
 
If fertilization of an egg has occurred, the corpus luteum does not degenerate but persists. 
This is the result of another hormone: the human chorionic gonadotrophin (hCG), secreted 
by the placenta. The corpus luteum is now able to continue to produce progesterone and 
low levels of oestrogen until the 3
rd- 4
th month of gestation, when the placenta replaces it.  
 
 
 
 
 
 
 
Figure 1.8 
 
The placenta then secretes increasing amounts of oestrogen and progesterone until the end 
of pregnancy. The main oestrogen produced by the placenta is estriol. The high levels of 
oestrogen  and progesterone  during pregnancy  maintain  the  development  of  the  uterus, 
prevent menstruation and inhibit the production of FSH so that no further follicles can 
develop. They are also required by the mother’s body to prepare for birth. For instance, 
they allow changes to the uterine musculature and also allow the development and the 
maintenance of the mammary glands for lactation. Variations in hormone levels during 
pregnancy are shown in Figure 1.8.  
1.3  The contraceptive pill 
 
1.3.1  Introduction to contraception 
 
Months 9 
 
Contraceptives  and  other  forms  of  fertility  control  have  quite  possibly  always  been 
employed in mankind history and the methods used have evolved alongside society.
13 The 
role of contraception is to reduce fertility in a reversible manner. There are many forms of 
contraception,  which  include  diaphragms,  caps,  male  or  female  condoms,  the  rhythm 
method, intrauterine contraceptive devices (IUCDs) and steroidal contraceptives.  
1.3.2  Steroidal contraceptives 
 
Steroidal oral contraceptives are one of the most innovative pharmacological products of 
the 20
th century and no other pharmacological agents have been more widely studied.
14 
They were introduced in the 1950s but they only became reliable and acceptably effective 
in the 1960s. 
Two  types  or  oral  contraceptives  can  be  distinguished:  preparations  that  contain  a 
combination  of  an  oestrogen  and  a  progestogen,  and preparations  that  only  contain  a 
progestogen. The roles of these hormones in relation to contraception are explained in the 
next section.  
1.3.3  Mode of action of oral contraceptives 
 
During  the  female  cycle,  progesterone  is  produced  after  ovulation  for  the  purpose  of 
preventing  additional  eggs  from  developing  by  inhibiting  the  production  of  the 
gonadotrophin hormones FSH and LH.  During pregnancy, the persistent production of 
progesterone  also  prevents  further  follicles  from  developing.  The  idea  behind  oral 
contraceptives was to supply a continuous source of a progestogen so as to inhibit the 
production of FSH and LH, and as a result ovulation could not occur. This is what the 
contraceptive pill does as it serves as an artificial source of a progestogen. The biggest 
weakness with this type of contraceptive is that the effects only last for 22-26 hours and 
therefore  must  be  taken  daily.  Non-oral  progestogen  contraceptives  do  not  have  this 
problem. Injection is effective for 8 weeks and sub-dermal implants are effective for up to 
five years. 
In the combined oral contraceptives, the oestrogen is present in very small amounts and 
assists the progesterone in preventing the production of FSH and LH. The oestrogen is 
thought  to  promote  the  development  of  progesterone  receptors,  thus  making  the 
progestogens in the contraceptive pill more effective. 10 
 
1.3.4  Side effects of the contraceptive pill 
 
Oral  contraceptives  have  a  number  of  associated  side-effects.
15,16  They  may  influence 
coagulation, increasing the risk of blood clots causing deep venous thrombosis, pulmonary 
embolism,  stroke  and  myocardial  infarction.  This  is  especially  true  for  women  who 
already have some pre-existing vascular disease, for women who have a familial tendency 
to form blood clots, women with obesity or hypercholesterolaemia or smokers. The pill 
has also been linked to an increased risk of breast cancer, although this was mostly related 
to the high doses of oestrogen contained in the first pill type.
17 Minor side effects include 
weight gain, nausea, headaches, depression, libido changes or skin problems. 
Not all of the side effects of taking oral contraceptives are negative however. Indeed, oral 
contraceptives users have a reduced risk of developing ovarian and endometrial cancers, 
and these effects can persist for up to ten years after discontinuation of oral contraceptive 
use.
14 Oral contraceptives also help women with menstrual disorders and have sometimes 
been found to reduce the incidences of acne amongst users.  
1.3.5  The evolution of oral contraceptives
17-21 
 
The first steroid to be used as an oral contraceptive was norethisterone (1.30), synthesised 
in 1951 (Figure 1.9). Norethisterone and all of the synthetic progestogens are derived from 
19-nortestosterone  (1.13).  Norethisterone  is  extremely  similar  in  structure  to  19-
nortestosterone; the only difference is that norethisterone has an additional 17-ethinyl 
group. It is this combination of the 17-ethinyl and the 17-hydroxyl groups that appear 
to mimic the 17-acetyl group found in progesterone (1.5).
18 
 
Figure 1.9 11 
 
 
The first generation of oral contraceptives had a number of serious side effects associated 
with them. In order to eliminate these problems, a few structural changes were made, from 
which the second generation of oral contraceptive were born (levonorgestrel, norgestrel). 
These  new  steroids had  different  selectivity profiles,  which meant that  they  remained 
active progestogens but no longer caused the side effects previously observed. The second 
generation steroids were also found to be more potent than the first generation compounds, 
which meant that smaller doses could be used to maintain contraceptive efficiency. The 
key structural difference between the first and second generation compounds was that the 
later compounds had an additional methyl group on C18 (a C13 ethyl group) (Figure 1.9, 
levonorgestrel  versus  norethisterone).  This  group  was  believed  responsible  for  the 
increased potency of the second generation compounds.
19 The different selectivity profile 
was not at all for the better, however, as the second generation oral contraceptives were 
found to cause androgenic effects (e.g. facial hair) which were clearly not desirable in a 
pill for women. A solution was found to this problem by altering the dose of progestogen, 
leading to bi or tri-phasic oral contraceptives. Meanwhile, further research was underway 
into  the development of new progestogens. These became the third generation of oral 
contraceptives,  of  which  desogestrel (1.14) was  the  first on  the  market;  introduced in 
Europe in 1981. Several years later, two more third generation oral contraceptives were 
introduced:  gestodene  (1.32)  and  norgestimate  (1.33)  (Figure  1.9).  Compared  with 
norethisterone  and  levonorgestrel,  the  third generation oral contraceptives  again  had a 
higher binding affinity to progesterone receptors (in vitro studies) and fewer androgenic 
effects according to in vivo studies.
20 In terms of structure, gestodene is very similar to 
levonorgestrel, the only difference is an additional double bond between C15 and C16 in 
gestodene.  Norgestimate  and  desogestrel  both  have  two  stuctural  changes  from 
levonorgestrel. Norgestimate has both the C17-acetate and the C3 oxime groups whereas 
desogestrel  has  no  oxygenated  C3  functional  group,  but  it  does  have  an  exocyclic 
methylene  group  at  C11.  The  C11  methylene  group  is  responsible  for  the  increased 
progestogenic  but  reduced  androgenic  activity  of  desogestrel.
20  The pharmacologically 
active form of desogestrel is its metabolite, 3-keto-desogestrel
17 (1.34) (Figure 1.9), which 
can  be injected,  implanted,  or  it can  be  formed  in  the  liver  from  orally administered 
desogestrel (1.14). 
 12 
 
1.4  Previous syntheses of desogestrel 
 
1.4.1  Synthetic challenges 
Three main challenges can be identified for the synthesis of desogestrel (1.14) as shown in 
Figure 1.10:        
  Construction of the A-ring with the double bond at the C4-C5 position 
  Introduction of the exocyclic C11-methylene group 
  Introduction of the angular C13-ethyl group, without contamination with 
the cis-fused C-D ring system 
 
Figure 1.10 
 
Each of these challenges is discussed below, as well as a discussion of selected examples 
of existing total syntheses of desogestrel. Hemi-synthesis approaches will not be discussed 
however. 
1.4.2  Introduction of the C13-ethyl group 
 
One of the most common method that enables the introduction of the C13-ethyl group 
involves the use of 2-ethyl-1,3-cyclopentanedione (1.35) as the D-ring precursor. Many 
groups including Smith,
22 Corey,
23 Saucy
24,25 or Tietze
26 have employed this precursor in 
related total syntheses of desogestrel. 
An example of the synthesis devised by Smith and co-workers
22 is shown in Scheme 1.4 
where the triketone (1.37) is obtained by a Michael addition of the enolate of (1.35) onto 
the enone (1.36). 13 
 
 
Scheme 1.4 
 
Acid mediated cyclisation led to the racemic tetracyclised steroid (1.38) which upon regio- 
and  stereoselective  hydrogenation  afforded  the  desired  trans-hydrindane  ring  system 
(1.39).  Due  to  the  ease  of  the  synthesis  of  steroid  (1.39),  this  starting  material  has 
frequently been used for C13-ethyl steroids.
27,28 
 
The Parrish-Hajos diketone
29,30 (1.43) has also been frequently employed for C13-ethyl 
steroids,
31-33 and can be synthesized enantioselectively by organocatalysis from (1.35) as 
shown in Scheme 1.5. 
 
Scheme 1.5 
 
A Michael addition conducted in aqueous media between diketone (1.35) and the enone 
(1.40) led to the triketone (1.41) in 82% yield. The next asymmetric aldol reaction, using a 
catalytic amount of (S)-(-)-proline, led to the optically pure trans-hydrindane (1.42) in 
71% after recrystallization. The Parrish-Hajos diketone (1.43) was obtained by subsequent 
acid catalysed dehydration in quantitative yield.
31 
An example from Corey and Huang
23 is given below (Scheme 1.6) which illustrates the 
use of the Parrish-Hajos ketone (1.43) towards desogestrel synthesis.   14 
 
 
Scheme 1.6 
 
From the Parrish-Hajos ketone (1.43), the ketone was selectively reduced in the presence 
of the enone using sodium borohydride and the intermediate alcohol was protected as a 
silyl ether (1.44). Using a catalytic amount of 
tBuCu (0.3 equiv) in the presence of an 
excess  of  DIBAL-HMPA  complex  (2  equiv),  the  ,-double  bond  in  (1.44)  was 
stereoselectively reduced. The trans-hydrindane compound (1.45) was obtained in 91% 
yield. The regioselectivity was problematic for the next -methoxycarbonylation leading 
to (1.46) using dimethyl carbonate, sodium hydride and sodium methoxide in a 1 : 1 
mixture  of  THF/hexane.  The  optimized  conditions  still  led  to  a  6.3  :  1  mixture  of 
regioisomers. The tricyclic -keto ester (1.48) was then obtained by sequential double 
deprotonation with NaH followed by 
nBuLi and regio- and stereoselective alkylation with 
(1.47).  The cationic cyclization was achieved with 10% TFA in DCM that formed the 
tetracyclic steroid skeleton with the correct geometry at C8, C13 and C14. However, the 
use  of  TFA  partially  deprotected  the  C17-silyl  ether,  forming  the  C17-trifluoroacetate 
which was cleaved by methanolic base (also hydrolysing the C11-ester). The C17-silyl 
ether was reintroduced with TBS-Cl leading to (1.50) in 73% overall 4 steps. Details for 
the C11-methylene introduction are given below (part 1.4.3.4) and the final steps of the 
synthesis of desogestrel are discussed in part 1.4.4. 
In a recent publication, Tietze and co-workers
26 also introduced the C13-ethyl group from 
a modification of the Parrish-Hajos ketone, where the steroid backbone was constructed 
via a double Heck reaction as illustrated in Scheme 1.7. 15 
 
 
Scheme 1.7 
 
Reduction of the carbonyl group in (1.51) was achieved with DIBAL-H in DCM with 
attack of the hydride taking place exclusively from the less hindered -face to give alcohol 
(1.52). Treatment of (1.52) with N-formylimidazole afforded allyl formate (1.53), which 
was further transformed into the trans-hydrindane compound (1.54) by stereoselective Pd-
catalysed rearrangement. 
 For the first Heck reaction, coupling of (1.54) and (1.55), the 
oxidative addition of the palladium catalyst exclusively took place at the more reactive 
vinyl  iodide  moiety  in  (1.55).  Although  the  reaction  was  very  stereoselective,  with 
exclusive insertion into the double bond in (1.54) from the -face (the C13-ethyl group 
shielding the -face), regioselectivity was not so great as a 7 : 1 mixture of regioisomers 
was  obtained.  The  intramolecular  Heck  reaction,  using  Herrmann  catalyst  (1.57), 
proceeded in  a  highly  stereoselective  fashion,  leading  exclusively  to  the  unnatural cis 
junction of the B- and C-rings (1.58). The less sterically hindered benzylic 6,7-double 
bond  in (1.58) was then selectivily reduced with PtO2.H2O, and the remaining 11,12-
double  bond  was  isomerized  to  the  9,11-position  (1.59).  Many  total  syntheses  of 
desogestrel rely on this particular 9,11-double bond for the introduction of the exocyclic 
C11-methylene group, as discussed below (part 1.4.3). Tietze and co-workers have also 
employed this double Heck methodology in a related total synthesis of estrone (1.6).
34 
Beside  those  examples  that  rely  on  2-ethyl-1,3-cyclopentanedione  (1.35)  for  the 
introduction of the C13-ethyl group, Corey and co-workers
35,36 have demonstrated it could 
be  introduced  via  an  enantioselective  Diels-Alder  reaction  between  Dane’s  diene
37,38 16 
 
(1.60)  and  the  dienophile  (1.61)  in  presence  of  an  oxazoborilidine  catalyst
36  (1.62) 
(Scheme 1.8, Figure 1.11). 
 
Scheme 1.8 
 
The  ABC  steroid  precursor  (1.63)  was  obtained  in  94%  and  in  97%  ee,  which  was 
improved  to  100%  ee  after  a  single  recrystallization.  Such  good  enantioselectivity  is 
explained by the diene (1.60) attacking the  catalyst-dienophile complex (1.65) (Figure 
1.11) from the sterically less shielded front face, directing the [4+2] cycloaddition to form 
(1.63). 
 
Figure 1.11 
 
From  (1.63),  the  D-ring precursor  (1.64)  was  obtained in  83%  by addition  of methyl 
magnesium bromide to the aldehyde followed by LAH reduction of the ester and Swern 
oxidation  of  the  resulting  two  alcohols.  Aldol  reaction  followed  by  acid  mediated 
dehydration constructed the D-ring (1.38), from which point literature methods were used 
to synthesise desogestrel.
23,39 Corey and co-workers have also employed this methodology 
in a related total synthesis of estrone (1.6).
35 17 
 
1.4.3  Introduction of the C11-methylene group 
 
In the previous syntheses of desogestrel, the most frequently employed method for the 
introduction of the exocyclic methylene group has been via a C11-ketone introduced from 
a C11-hydroxyl group. Although several methods have been reported for the insertion of 
the C11-hydroxyl group,
40 only the methods used towards desogestrel synthesis shall be 
discussed in the following sections. 
1.4.3.1  Introduction of the C11-hydroxyl group 
1.4.3.1.1  Hydroboration/alkaline hydrogen peroxide 
 
The most frequently employed method for the introduction of the C11-hydroxyl group has 
been  the  hydroboration  of  a  C9-11  double  bond  followed  by  treatment  with  alkaline 
hydrogen  peroxide.  Many  groups  including  Tietze
26  (Scheme  1.9),  Corey,
35  Gao,
27 
Schwarz
39 or Stéphan
41 have employed this methodology in related desogestrel syntheses. 
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Scheme 1.9 
 
This hydroboration/alkaline hydrogen peroxide is particularly efficient (90% yield), but 
there are several limitations. The main limitation is the requirement of the C9-11 double 
bond and this could take several steps to install if not already present. 
The other disadvantage is that the reaction seems not to be reliable. To illustrate this, 
Scheme 1.10 shows the results obtained by Gao and co-workers.
27 
 
Scheme 1.10 
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Gao only reported a yield of 56% of desired 11-OH product (1.68) along with 16% 9-H 
product (1.69) and 4% of 11-OH product (1.70). The two side-products are not always 
obtained  or  mentioned  in  the  literature  examples  when  this  hydroboration/alkaline 
hydrogen peroxide is employed. 
1.4.3.1.2  Microbial oxidation 
 
The  other  common  method  for  the  introduction  of  the  C11--OH  group  has  been  a 
microbial  oxidation
42  from  the  corresponding  C11-hydrocarbon.  For  instance,  the 
microbial  oxidation  is  used  in  the  industrial  desogestrel  synthesis,  and  Gao  and  co-
workers
43 have also employed this procedure (Scheme 1.11). 
 
Scheme 1.11 
 
Although this method is advantageous as it is a direct insertion of the hydroxyl group, 
which means no requirement of any functional group interconversion and so less steps, the 
yields  are  rarely  excellent.  This  is  in  part  due  to  the  fact  that  by-products  are  often 
observed due to over-oxidation or non-selective oxidation. 
1.4.3.1.3  Other methods 
 
Other methods of insertion of the C11-hydroxyl group include oxygen-peroxidation
44,45 
and epoxidation.
46 However, only the oxygen-peroxidation method has been successfully 
employed for the synthesis of desogestrel. This is illustrated in Scheme 1.12 which shows 
how Liu and co-workers have employed this methodology for the insertion of the 11-OH 
group. 
 19 
 
 
Scheme 1.12 
 
Compared  to the previously mentioned methods, this reaction  is the only method that 
inserts the C11-hydroxyl group  at the -position.  Upon exposure to oxygen, the diene 
(1.73) was peroxidized to the C11--hydroperoxide (1.74) which was reduced to the C11-
-alcohol (1.75) by reduction with sodium iodide. 
1.4.3.2  Oxidation of the C11-hydroxyl group to the C11-ketone 
 
Many  reagents  have  been  successfully  used  for  this  transformation  such  as  Jones’s 
reagent,
43 PCC,
27 Dess-Martin periodinane
26 or activated DMSO methods.
39  
1.4.3.3  Conversion of the C11-ketone to the C11-methylene group 
 
Conversion of the C11-ketone to the C11-methylene can be achieved by one of the three 
followings methods: Peterson olefination,  Wittig reaction or  nucleophilic addition of a 
methyl group followed by dehydration of the resulting tertiary alcohol. 
1.4.3.3.1  Peterson olefination 
 
Although the Peterson olefination has been used in the original synthesis of desogestrel,
47 
it has not really been used since, apart from the recent desogestrel synthesis of Tietze
26 
(Scheme 1.13). 
 
Scheme 1.13 
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Addition  of  LiCH2TMS  to  (1.76)  in  THF  afforded  the  -hydroxy  intermediate  (1.77) 
which upon acid-catalyzed Peterson olefination led to the C11-exo-methylene compound 
(1.78) in excellent yield. 
1.4.3.3.2  Wittig reaction 
 
The  introduction  of  the  C11-methylene  has  also  been  accomplished  on  separate 
occasions
39,48 by Wittig olefination with methylene triphenylphosphorane. An example is 
given in Scheme 1.14 from the group of Schwarz.
39 
 
Scheme 1.14 
 
Interestingly, the lack of functionality at C3 resulted in the reaction being very slow and 
with moderate yields. This was circumvented by running the reaction under sonication. 
Tietze has also reported this non-reactivity issue in his total synthesis of desogestrel.
26 
1.4.3.3.3  Nucleophilic addition of a methyl group/dehydration 
 
The  last method  relies on  the  addition  of  methyl  magnesium  iodide or  methyllithium 
followed by dehydration in formic acid. Gao and co-workers have used this method as 
illustrated in Scheme 1.15.
48 
 
Scheme 1.15 
 
Treatment of the C11-ketone (1.81) with methyllithium in Et2O and benzene proceeded in 
good yield. The conditions required for the dehydration at the newly formed hydroxyl 21 
 
group also removed the two acetal groups, and steroid (1.71) was obtained in 65% yield 
over both steps.  
1.4.3.4  Other method 
 
The only synthesis of desogestrel where the C11-methylene group is not inserted from the 
C11-ketone is the synthesis from Corey and Huang,
23 as shown in Scheme 1.16, via an 
allylic diazine-sigmatropic rearrangement.
49,50  
 
Scheme 1.16 
 
The  C11-acid  (1.50)  was  reduced  to  the  primary  alcohol  (1.83)  with  LAH.  The  C11-
methylene  group  was  then  introduced  via  a  Mitsunobu  reaction  leading  to  the 
sulphonamide  intermediate  (1.84),  which  upon  a  [3,3]-sigmatropic  rearrangement
49,50 
stereoselectively introduced the C9- proton as well as the exocyclic methylene group 
(1.85). 
1.4.4  Modification/Construction of the A-ring 
 
From a total synthesis point of view, only two methods exist for the formation of the A-
ring  for  C19-norsteroids:  Construction  of  the  A-ring  via  a  Robinson  annulation  or 
reduction of an aromatic A-ring.  Towards the total synthesis of desogestrel,  only the 
modification  of an aromatic A-ring  has  been  used.  This methodology  is  illustrated  in 
Scheme 1.17,  for  the  final steps  of  the  total synthesis  of  desogestrel  from  Corey  and 
Huang.
23 22 
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A Birch reduction was employed for the de-aromatization of the A-ring in (1.85) using 
lithium in ammonia. Subsequent treatment of intermediate (1.86) with acid formed the 
,-unsaturated ketone (1.87) and also removed the TBS protecting group. From (1.87), 
the C3-ketone was converted to a thioacetal which was reduced using lithium in ammonia 
in 85% over two steps. The final steps proceeded in high yields, where the C17-hydroxyl 
group in (1.88) was oxidized to the ketone (1.89) which allowed the introduction of the 
C17--ethinyl group in the final desogestrel product (1.14). 
The Robinson annulation is also a very common reaction in steroid chemistry and has 
been employed on separate occasions for the construction of the A, B and D rings.
51 As an 
example,  the  Robinson-type  chemistry  has  successfully  been  employed  for  the 
construction  of  the  A-ring  in  both  natural  steroids  and  C19-norsteroids.  Scheme  1.18 
shows how Parrish and Hajos have used this reaction to construct the A-ring in a total 
synthesis of 19-nortestosterone (1.13).
32 
 
Scheme 1.18 
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Interestingly, 19-nortestosterone (1.13) was obtained from diketone (1.90) in 27% overall 
yield  in  13  steps  (or  an  average  yield  per  chemical  reaction  of  93%)  without  any 
purification.  The  intermediate  diketone  (1.93)  underwent  an  intramolecular  aldol 
reaction/dehydration (which also deprotected the C17-OtBu group) that completed the A-
ring. 
1.5  Previous syntheses of estrone 
1.5.1  Introduction 
 
Although (+)-estrone was the  first  steroid  hormone ever  isolated and one of the most 
synthesized, its synthesis still represents an appealing challenge in steroid methodology. 
The  stereochemical  complexity  of  the  steroid backbone  requires  highly  stereoselective 
steps to create new asymmetric centres with the desired geometry and in high yields. 
 
Figure 1.12 
 
The enantiopure form of estrone, as shown in Figure 1.12, which is also the naturally 
occurring  enantiomer,  was  first  achieved  in  1948  by  Anner  and  Miescher.
52  Many 
syntheses of estrone have been described in the literature since, even very recently. Many 
ingenious methodologies have been developed, and as such only some of the most recent 
selected examples shall be discussed in the following sections.  
1.5.2  Selected examples using Dane’s diene 
 
Among the most commonly used precursors for the synthesis of estrone is Dane’s diene 
(1.60).
37,38 This is illustrated in Scheme 1.19 for the synthesis of estrone by Ogasawara and 
co-workers
53 via a stereoselective Diels-Alder reaction between Dane’s diene (1.60) and 
chiral dioxycyclopentenone (1.94).  24 
 
 
Scheme 1.19 
 
The Diels-Alder reaction was conducted in presence of diethyl aluminum chloride which 
furnished the single steroid (1.95) diastereoselectively. Although the dioxolane moiety in 
enone  (1.94)  served  as  an  excellent  stereocontroling  element,  the  reaction  proceeded 
following the orbital-controlled endo rule as indicated by the cis-C9-C11 stereochemistry 
observed in (1.95). Treatment of (1.95) with aluminum amalgam in aqueous ethanol gave 
the C15- ketol which was converted to the Torgov diene
54 (1.96) with HCl/CH3COOH in 
70% over 2 steps. The conversion of the Torgov diene to estrone (1.6) was carried out in 
three steps following literature procedures.
55,56 
Corey and co-workers
35,36,57 have also conducted significant research in this area where 
the Dane’s diene (1.60) is subjected to a Diels-Alder reaction using chiral oxazoborilidine 
catalysts (Scheme 1.20). 
 
Scheme 1.20 
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From the Dane’s diene (1.60), they have developed two different synthetic pathways that 
both lead to the Torgov diene (1.96). The first one, involving a stereoselective Diels-Alder 
reaction with the ester aldehyde (1.98) has already been touched upon for a similar total 
synthesis of desogestrel (part 1.4.2).
35,36  In this case, the Torgov diene could be obtained 
in 58% overall  yield in six steps. More recently in 2008,
57 they reported a regio- and 
stereoselective  Diels-Alder  reaction  between Dane’s  diene  and  cyclopentenone  (1.100) 
using catalyst (1.101) which afforded cis-C13-C14 steroid (1.102) in 82% and 99% ee after 
a single recrystallization.  
A final example involving Dane’s diene is given below in Scheme 1.21, for the formal 
synthesis of estrone devised by Knochel and co-workers,
58 where the Torgov diene (1.96) 
is obtained via an asymmetric allylic substitution. 
 
Scheme 1.21 
 
Dane’s  diene  (1.60)  was  converted  to  the  zinc  organometallic  derivative  (1.104)  by 
hydroboration followed by a boron/zinc exchange sequence in excellent yield. The yield of 
the reaction was determined by GC analysis of hydrolyzed reaction aliquots. The chiral 
cycloalkenyl iodide (1.106) was then obtained by a copper(I)-mediated anti-SN2’-allylic 
substitution of the dialkylzinc (1.104) with the allylic pentafluorobenzoate (1.105) in 66% 
yield. The cyclopentenyl iodide (1.106) was then converted to the corresponding ketone 
(1.107)  by  a  one-pot  sequence  by  treatment  with  t-BuLi  followed  by  the  addition  of 
B(OMe)3, and oxidation with sodium perborate. From the ketone (1.107), acid-mediated 
ring closure followed by TBAF deprotection and subsequent oxidation of the C17-alcohol 
with CrO3 led to the Torgov diene (1.96) in 61% overall yield in 3 steps. 26 
 
1.5.3  Other selected methods 
 
In 1963, Torgov and Anachenko disclosed a remarkably short synthesis of racemic Torgov 
diene (1.96) (from which the total synthesis of estrone has already been explained) which 
was based on the high yielding coupling of the readily available components (1.108) and 
(1.109) (Scheme 1.22).
54,59 
 
Scheme 1.22 
 
Very  recently,  Corey  and  co-workers
60  have  developed  a  new  method  for  the 
enantioselective and diastereoselective reduction of the achiral Torgov diketone (1.110). 
The  key  chirogenic  step  (Scheme  1.22),  the  reduction  of  (1.110)  to  (1.112)  was 
successfully  achieved  by  a  slow  addition  of  catecholborane  (1.8  equiv)  to  a  -50  °C 
solution of diketone (1.110) in presence of catalytic amounts of oxazoborilidine (1.111) 
and N,N-diethylaniline. The enantiopure C17--alcohol (1.112) was obtained in 86% with 
a 99%  ee  after  recrystallization. The C-ring  cyclization was achieved by  treatment of 
(1.112) with methalonic HCl, and subsequent oxidation with IBX gave the enantiopure 
Torgov diene (1.96) in 97% overall yield in 2 steps. Enantiopure O-methyl-estrone (1.113) 
was then obtained in high yield by two successive hydrogenation steps.  
Another  very  interesting  synthetic  approach  is  the  one  devised  by  Pattenden  and  co-
workers,
61,62 where the steroid B- C- and D-rings are constructed via a cascade radical-
macrocyclisation and successive trans-annnulation reactions from a substituted aryl vinyl 
cyclopropane precursor (1.114) as shown in Scheme 1.23. 27 
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Scheme 1.23 
 
The iodide (1.114) was refluxed with Bu3SnH and AIBN in toluene, leading, through a 
regio-  and  stereoselective  sequence  of  radical  cyclizations,  to  a  mixture  of  estradiol 
derivatives as a mixture of C17-OMe epimers (1.119) in 15% yield. The cascade of radical 
reactions from (1.114) to (1.119) involves 4 successive C-C bond formation reactions. 
First, a 12-endo trig macrocyclization of (1.115) to (1.116). Then, a cyclopropenyl to but-
2-enyl carbon equilibration of (1.116) to (1.117). The two final reactions involve a 6-exo 
trig  transannulation  leading  to  (1.118)  and  finally  a 5-exo  trig  transannulation  and  H-
quench  which  led  to  (1.119).  Chromium  trioxide  oxidation  afforded  O-methyl-estrone 
(1.113) which was deprotected to estrone (1.6) with BBr3. 
Finally, Tietze and co-workers
34 have reported the total synthesis of estradiol derivative 
(1.125), easily converted to estrone (1.6) via known reactions, by two successive Heck 
reactions  between  the  doubly  functionalized  arene  (1.120)  and  the  chiral  hydrindene 
(1.121) allowing the construction of the steroid skeleton (Scheme 1.24). 
 
Scheme 1.24 
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Although the same methodology has already been described for a related total synthesis of 
desogestrel (Scheme 1.7, page 15), the final steps of our total synthesis of estrone mainly 
rely on this publication. The first Heck reaction, between (1.120) and (1.121), proceeded 
in a very stereoselective fashion, with the only (1.122) reported. As already explained, it is 
believed that the angular C13-methyl group shielded the -face of (1.121). For the high 
regioselectivity in the C-C bond formation, it is believed that stereoelectronic effects force 
the attack of the palladium at C9 from the less hindered -face in (1.121) to allow a chair-
like  transition  state  with  subsequent  syn-addition  of  the  vinyl  group  in  (1.120)  at  C8 
(Figure 1.13). 
H
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Figure 1.13 
 
The next intramolecular Heck reaction using the Herrmann catalyst (1.57) proceeded in 
nearly quantitative yield, leading to (1.123) as a single diastereoisomer with the cis-ring 
junction between rings B and C. Selective  hydrogenation of the more accessible 6,7-
double bond with Wilkinson catalyst under homogeneous conditions led to intermediate 
(1.124) in 94% yield. The estradiol derivative (1.125) was then obtained in 76% yield by 
isomerisation of the remaining 11,12-double bond followed by hydrogenation using Pd/C 
with a large excess of 1,4-cyclohexadiene. However, the equilenin derivative (1.126) was 
also obtained in 24% yield. 
1.6  Aim of the project 
 
The aim of this project was to develop a new general steroid construction in which three 
stereocenters C8, C13 and C14 would be established prior to the actual formation of the 
steroid  backbone.  So  as  to  demonstrate  the  versatility  of  the  methodology,  two  very 
different steroid targets (estrone (1.6) and desogestrel (1.14)) have been envisioned, as 
shown in Scheme 1.25 below. 29 
 
 
Scheme 1.25 
  
The retrosynthetic analysis for both steroids via this approach involved a B- and C-ring 
disconnection in (1.6) and (1.14) leading to a key intermediate (1.127), which possesses 
appropriate  R,  R
1  and  R
2  groups.  This  intermediate  was  envisioned  to  be  directly 
accessible by a one-pot process involving an allylic phosphonate/phosphonamide (1.130) 
to  a  2-alkyl-2-cyclopentenone  Michael  acceptor  (1.100,  1.131),  followed  by 
diastereoselective  alkylation  of  the  resulting  enolate  with  alkyl-bromide  (1.129). 
Conjuguate  addition  reactions  of  allylic  phosphonates  are  known  to  be  very 
diastereoselective
63 with the allylic double bond configuration being translated into the 
relative configuration of the sp
3-centres of the formed C-C bond. The desired relative C8-
C14 configuration requires a Z-configuration of the phosphonate double bond. By using a 
chiral  phosphonamide  auxiliary,  an  enantioselective  synthesis  would  be  possible. 
Introduction of the R, R
1 and R
2 groups as required for each steroid target would be easily 
achieved by appropriate choice of starting materials (1.129)-(1.131) and (1.100).  
Each  of  the  key  steps  towards  both  steroid targets  is  described  in  more  detail  in  the 
subsequent chapters: 
chapter  2  discusses  the  synthesis  of  the  various  1,4-addition  precursors  (1.130)  used 
towards desogestrel/estrone total syntheses. 30 
 
chapter  3  details  the  results  of  the  Hanessian  1,4-addition  reactions,  leading  to 
intermediates (1.127), for both desogestrel and estrone projects. 
chapter 4 emphasizes the tandem C-B ring cyclisation from (1.127) to (1.128) towards the 
total synthesis of desogestrel and its C13-methyl analogue. 
chapter 5 discusses the A-ring annelation from (1.128) as well as the completion of the 
total synthesis of desogestrel and its C13-methyl analogue. 
chapter 6 emphasizes the completion of the enantioselective and racemic total syntheses 
of estrone from (1.127). 
chapter 7 details future plans for the project. 
chapter 8 gives an overall summary. 
chapter 9 describes the experimental details. 
Although both total syntheses of desogestrel and estrone have been achieved during this 
PhD, the estrone synthesis had already been achieved in our group by B. Guizzardi,
64 and 
was only repeated for optimization and data reasons. The desogestrel synthesis was first 
investigated by R. Clarkson,
21 though was not yet completed. 31 
 
Results and Discussion 
Chapter 2, Synthesis of the allylic phosphonates/ 
phosphonamide for the conjuguate addition reactions 
2.1  Introduction 
 
The synthesis of the phosphonate/phosphonamide substrates for the pivotal 1,4-addition 
reaction  is  relatively  similar  for  both  estrone  and  desogestrel  synthesis  (Figure  2.1). 
Hence, they are described together in this chapter. The desogestrel synthesis has only been 
achieved in racemic form, via a Z-allylic phosphonate. The synthesis of two phosphonates 
(2.1)  and  (2.2),  with  a  different  protecting  group  for  the  required  ester  moiety  was 
attempted.  
 
Figure 2.1 
 
For  the  estrone  synthesis,  both  the  achiral  phosphonate  (2.3)  and  the  homo  chiral 
phosphonamide (2.4) have been synthesised. 
2.2  Desogestrel synthesis 
 
The initial plan involved a trioxabicyclo-octane protecting group,
65,66 leading to (2.1) as 
the target. This synthesis was not successful and a revised plan involved the use of a 
dioxolane  group,  a well  known aldehyde protecting group. The synthesis of (2.2) had 
already been achieved by R. Clarkson,
21 and was further optimised on large scale. 32 
 
2.2.1  The attempted synthesis of orthoester (2.1) 
2.2.1.1    Retrosynthetic analysis 
The proposed retrosynthetic analysis towards the synthesis of the Z-allylic phosphonate 
(2.1) is shown in Scheme 2.1. 
 
Scheme 2.1 
 
The  desired  Z-allylic  phosphonate  (2.1)  would  be  obtained  via  a  Z-selective  Wittig 
reaction  from  the  aldehyde  (2.5),  which  would  be  synthesised  from  either  the  chloro 
orthoester (2.6) or the bromo orthoester (2.7). Two routes were explored towards these 
orthoesters, the first one involving the imidate salt (2.8), the second one involving the 
reaction between the oxetane (2.9) with the corresponding acid chlorides (2.10, 2.11). 
2.2.1.2    Route 1: Synthesis of orthoester (2.6) 
Ethyl-4-chloro-1-butanimidate hydrochloride (2.8) was synthesised using a Pinner reaction 
(Scheme 2.2).
67-71 This reaction involved the treatment of 4-chlorobutyronitrile (2.12) with 
gaseous HCl,  prepared in situ,  in  a mixture of anhydrous DCM and anhydrous EtOH 
affording the desired imidate salt (2.6) in excellent yields (98%). Although this reaction 
was very efficient, it was necessary to keep the reaction mixture sealed, once the addition 
of HCl was complete, in the fridge for four days. The obtained salt could be stored for 
weeks when well protected from moisture. The gaseous HCl, generated by the addition of 
conc. H2SO4 onto conc. HCl, was bubbled through the reaction mixture by mean of a 
nitrogen gas steam. 
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Golding and co-workers
66 reported the synthesis of orthoester (2.6) derived from cheap 
and commercially available 1,1,1-tris(hydroxymethyl)ethane triol (2.13) and the tri-ethoxy 
orthoester  derived  from  (2.8).  In  order  to  save  time,  it  was  decided  to  apply  their 
methodology by direct esterification of the imidate (2.8). 
The  imidate salt (2.8) was refluxed overnight in toluene with triol (2.13)  yielding the 
desired compound (2.6) in up to 37% yield. As the triol was not completely soluble in 
toluene,  even  while  refluxing,  EtOH  (1.1  equiv)  was  added  at  the  beginning  of  the 
reaction;  leading  to  an  improved  yield  of  56%.  The  purification  by  column 
chromatography  led  to  the  desired  compound  but  an  impurity  was  always  remaining, 
necessitating an additional purification by distillation.  
2.2.1.3    Route 2: Synthesis of orthoesters (2.6) and (2.7) 
Although the desired product was obtained in acceptable  yield,  the long reaction time 
prompted us to investigate an alternative in which an acid chloride was reacted with an 
oxetane (2.9), followed by acid-catalysed rearrangement (Scheme 2.3).
 72-74 
 
Scheme 2.3 
 
Treatment of commercially  available 3-methyl-3(hydroxymethyl)oxetane (2.9) with  the 
corresponding acid chloride in presence of pyridine in DCM quantitatively yielded upon 
simple  work-up  the  intermediates  (2.14,  2.15)  after  1  h  of  reaction.  The  desired 
trioxabicyclo-octane  orthoesters  (2.6,  2.7)  were  then  obtained  by  boron  trifluoride-
mediated rearrangement in good yields after column chromatography. 
2.2.1.4    Oxidation to the aldehyde (2.5) 
Oxidation of organic halides to the corresponding carbonyl compounds is a well known 
transformation in organic synthesis. Several methods have been developed to carry out this 34 
 
conversion  such  as  the  Sommelet  reaction
75  and  the  Kornblum  reaction 
(DMSO/NaHCO3).
76  More  recently,  Das  and co-workers
77 reported  the  use  of NaIO4-
DMF to oxidise various primary and secondary halides to the corresponding aldehydes or 
ketones under mild conditions (150 °C/40-60 min) in high yields (70-90%). 
The NaIO4 oxidation
77 was first explored (Scheme 2.4).  
 
Scheme 2.4 
 
Despite several attempts, only traces of aldehyde could be observed by 
1H NMR, present 
in  a  very  complex  mixture  of  compounds.  The  desired  aldehyde  (2.5)  could  not  be 
isolated.  It  was  believed  that  the  orthoester  group  was  not  stable  under  the  reaction 
conditions. 
The Kornblum method (NaHCO3/DMSO)
76 was also explored with both orthoesters (2.6, 
2.7).  However,  again  only  traces  of  aldehyde  could  be  observed  (
1H  NMR)  and  the 
protecting group was not stable under those conditions. This was quite surprising as the 
use of NaHCO3 during the oxidation should have prevented the orthoester from being 
hydrolysed. 
Finally, the oxidation was achieved using an amine-N-oxide as described by Ganem and 
co-workers (Scheme 2.5).
78 
 
Scheme 2.5 
 
They  discovered  that  anhydrous  trimethylamine-N-oxide  (TMANO)  (2.16)  transforms 
nitrosamides  to  aldehydes  under  mild  conditions.  As  DMSO  enhances  bimolecular 
nucleophilic displacements, the use of TMANO in DMSO could slowly oxidise aliphatic 
halides. Crystalline anhydrous TMANO, easily prepared with the method of Soderquist,
79 
was only moderately soluble in DMSO, however the mixture reacted smoothly at room 35 
 
temperature with the halide (2.7) to afford the desired aldehyde (2.5) in medium yields 
(47%). Enough material was at least obtained to explore the subsequent key Z-selective 
Wittig reaction. 
2.2.1.5    Z-selective Wittig reaction
80,81 
The Z-selective Wittig reaction with aldehyde (2.5), that would lead to phosphonate (2.1), 
was first investigated following the procedure of Shen and co-workers (Scheme 2.6).
80 
 
Scheme 2.6 
 
They reported that the CuBr-catalysed reaction of vinyl triphenyl phosphonium bromide 
(2.18) with dialkyl potassium phosphite (2.17) resulted in phosphorane (2.19), which can 
be reacted with aldehydes giving substituted allylphosphonates, in various yields, with the 
Z-isomer being formed exclusively in most cases. Because initial attempts with aldehyde 
(2.5) were unsuccessful, the reaction was also attempted with benzaldehyde (2.20).  
Carrying-out the reaction under the described conditions, with either the aldehyde (2.5) or 
benzaldehyde (2.20), no reaction occurred, leading only to the recovery of the starting 
material. Interestingly, when the reaction was carried out with NaH as a base instead of 
KO
tBu, the reactivity was completely different. In the case of benzaldehyde (2.20), the 
desired Z-allylic phosphonate
82 (2.21) was obtained in 7% yield, but the E-isomer (2.22) 
was also isolated in 26 % yield; or a (Z/E) ratio of (21/79) (Scheme 2.7). 
 
Scheme 2.7 
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Unfortunately, under the same conditions (using NaH), the aldehyde (2.5) was almost fully 
consumed but no allylic phosphonate (2.1) was neither observed nor isolated. Given the 
lack of success, another route was explored. 
Minami  and  co-workers
81  reported  that  when  cyclobutenyltriphenylphosphonium  salt 
(2.23)  (Scheme  2.8)  was  treated  with  a  catalytic  amount  of 
nBuLi  in  presence  of 
diethylphosphite (2.17), a phosphinyl-triphenylphosphonium salt (2.24) was generated in 
situ. This salt could then be deprotonated to generate the ylide (2.25), which could react 
with aldehydes to undergo a Wittig reaction.  
 
Scheme 2.8 
 
This methodology was explored with benzaldehyde (2.20), with a few changes however 
(Scheme  2.9).  Instead  of  using 
nBuLi,  NaH  or  NaHMDS  were  used,  to  avoid  the 
competing elimination reaction transforming vinyl triphenyl phosphonium bromide (2.18) 
to triphenyl phosphine and acetylene.
83 
 
Scheme 2.9 
 
Table 2.1 shows the results obtained with the different bases used. The use of NaH or 
NaHMDS gave almost the same results in terms of yield. 
Base 1 (0.1 equiv)  Base 2 (1 equiv)  Yield of 
(2.22) 
NaH  NaH  27% 
NaH  NaHMDS  31% 
NaHMDS  NaHMDS  25% 
 
Table 2.1 
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Unfortunately,  once  again,  the  E-allylic  phosphonate  (2.22)  was  the  isomer  that  was 
isolated. The Z-isomer was not observed. This methology was as efficient as the Shen 
method, but only gave the undesired isomer, so it was never attempted with aldehyde 
(2.5).  
Given the lack of success with the Z-selective Wittig reaction, an alternative route was 
investigated based on a partial reduction of a propargylic triple bond. 
2.2.1.6  Synthesis of the propargylic alcohol (2.34) 
The  final  attempts  towards  the  synthesis  of  Z-allylic  phosphonate  (2.1)  involved  the 
synthesis of propargylic alcohol (2.34) via alkylation of propargyl alcohol (2.31) with the 
known
84 bromide (2.30) (Scheme 2.10). 
 
Scheme 2.10 
 
The synthesis of (2.30) was achieved by treatment of commercially available 3-methyl-
3(hydroxymethyl)oxetane (2.9) with 3-bromo propionic chloride (2.28) in the presence of 
pyridine in THF, which yielded after simple work-up the intermediate (2.29) in 92% after 
3 h of reaction. The compound suffered HBr elimination to produce the corresponding 
alkene  upon column  chromatography  so  it  was  taken  to the  next  step without  further 
purification.  Eventually,  it could be purified by  vacuum distillation, in which case the 
desired  ester  (2.29)  was  only  isolated  in  51%  yield.  Boron  trifluoride-mediated 
rearrangement led to the desired trioxabicyclo-octane orthoester (2.30) in medium yields 
(49%), after direct recrystallization of the crude mixture. When the pure ester (2.29) was 
used for this rearrangement, the desired orthoester (2.30) was obtained in 60% yield. 38 
 
By using lithium amide
85,86 to doubly deprotonate propargyl alcohol (2.31) and subsequent 
alkylation  with  the  bromide (2.30),  the  propargylic  alcohol  (2.34)  was  expected. This 
reaction led again to disappointing results. The desired propargylic alcohol (2.34) was 
obtained in very low yield, 8%, as the main compound isolated was the alkene (2.32) in 
61%  yield.  Presumably,  the  orthoester  group  results  in  the  adjacent  protons  to  be 
sufficiently acidic, resulting in a competing E2 reaction. The unexpected propargylic ether 
(2.33) was also isolated in 5% yield.  
2.2.1.7    Conclusion 
Further  studies  towards  the  synthesis  of  Z-allylic  phosphonate  orthoester  (2.1)  were 
discontinued  because  of  lack  of  any  positive  results.  The  orthoester  protecting  group 
would have been beneficial compared to a dioxolane group in terms of number of steps 
needed to obtain the required ester group for the B-ring closure. It was decided to proceed 
with the synthesis using the latter protecting group. 
2.2.2  The synthesis of the dioxolane containing Z-allylic phosphonate (2.2) 
2.2.2.1    Retrosynthetic analysis 
The proposed retrosynthetic analysis towards the synthesis of the Z-allylic phosphonate 
(2.2) is shown in Scheme 2.11. 
 
Scheme 2.11 
 
Following  this  plan,  phosphonate  (2.2)  would  be  obtained  from  allylic  alcohol  (2.35) 
which would be obtained via a key stereoselective reduction of propargylic alcohol (2.36). 
This synthesis had already been achieved by R. Clarkson,
21 though optimisations were 
required  to achieve a reproducible and reliable synthesis of (2.2). 39 
 
2.2.2.2    Synthesis of propargylic alcohol (2.36) 
Propargyl alcohol (2.36) had previously been synthesised by Deslongchamps and Roy
87 
via the following two-steps procedure (Scheme 2.12). 
 
Scheme 2.12 
 
Alkyne  (2.38)  was  deprotonated  with 
nBuli  at  -30 
oC  followed  by  alkylation  with 
commercially  available  bromide  (2.37),  affording  THP  protected  propargylic  alcohol 
(2.39) which was deprotected to alcohol (2.36) with PPTS in MeOH in 73% overall yield. 
So as to avoid the use of large amounts of HMPA (3 equiv) on large scale, another route 
was explored where the desired propargylic alcohol (2.36) was obtained in a single-step 
process with excellent results (Scheme 2.13). 
 
Scheme 2.13 
 
By using lithium amide
85,86 to doubly deprotonate propargyl alcohol (2.31) and subsequent 
alkylation with the bromide (2.37), the propargylic alcohol (2.36) could be reproducibly 
synthesised in 91% yield on a 15 g scale. It was also found that alcohol (2.36) could be 
easily purified by distillation which proved to be time- and cost-efficient compared to 
column chromatography, without decrease in yields. The 91% yield obtained represented a 
real improvement in the methodology towards the desired propargyl alcohol (2.36) as an 
efficient one-step synthesis was achieved, without the need for HMPA. On the other hand, 
this scale required the use of 1 L of liquid ammonia, which represented the upper limit of 
our technical abilities. 40 
 
2.2.2.3     Z-selective reduction of the alkyne (2.36) 
Typical  hydrogenation  conditions  using  either  Lindlar  catalyst  (Pd/CaCO3)
88  or 
Rosenmund catalyst (Pd/BaSO4) were not explored as those conditions were previously 
found by R. Clarkson
21 to be difficult to reproduce, upon scaling-up (Scheme 2.14). 
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Scheme 2.14 
 
Whatever the solvent used with Lindlar catalyst, the only products obtained were the fully 
reduced alcohol (2.40) along with the resulting aldehyde (2.41). However, Clarkson had 
demonstrated  that  the  use  of  Rosenmund  catalyst  in  DMSO  was  very  efficient  and 
selective, but upon scaling-up (>10 g), the yields dropped to 55-76% and crucially the (Z : 
E) ratio varied from (97 : 3) to (87 : 13).  
Actually, one reduction was attempted using KOH in conjunction with quinoline to poison 
the catalyst for the partial hydrogenation of the alkyne to give the Z-alkene.
89 This was 
subsequently  investigated  for  the  partial  hydrogenation  of  the  alkyne  (2.36)  using 
Rosenmund catalyst with very poor results (Scheme 2.15). 
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After  column  chromatography,  the  desired  alcohol  (2.35)  was  obtained  however 
contaminated with the fully reduced alcohol (2.40). They could not be obtained pure, and 
the yield of desired alcohol (2.35) did not exceed 42% (
1H NMR). 
Alternative reduction conditions  were found  which  involved the use  of  activated  zinc 
instead of hydrogenation conditions (Scheme 2.16, Table 2.2).
90-97  41 
 
 
Scheme 2.16 
 
Table 2.2 
Entry  Conditions  Solvent  Yield of (2.35)  (Z:E) ratio 
1  Zn, CuBr, LiBr, C2H4Br2,   EtOH  72%  93:7 
2  Zn, Cu(OAc)2, AgNO3  MeOH/H2O  56%  95:5 
3  Zn dust, C2H4Br2,   EtOH  no reaction  - 
4  Zn powder, C2H4Br2,   EtOH  no reaction  - 
5  Zn, C2H4Br2,   EtOH  86-94%  >95:5 
6  activated Zn powder, C2H4Br2,   EtOH  10%  >95:5 
7  activated Zn dust, C2H4Br2,   EtOH  97-98%  >95:5 
8  activated Zn dust,   EtOH  no reaction  - 
 
Activation  of  the  zinc  with  copper(I)  bromide  and  lithium  bromide
93,97  was  first 
investigated  (entry  1)  and  gave  acceptable  results.  The  desired  Z-allylic  alcohol  was 
isolated  in  72%  yield  with  approximately  7%  of  the  E-double  bond  isomer.  The 
Zn(Cu/Ag) system in aqueous MeOH was also investigated (entry 2).
91 Despite 7 days of 
reaction and gradual increase in heating, the reaction never went to completion affording 
56% of the Z-alkene (2.35) with a good selectivity. Because the reaction did not go to 
completion and the use of 25 equiv of Zn would have made scaling-up very difficult, no 
further optimisation was attempted with this procedure.  
Activation of zinc with 1,2-dibromoethane
90 was then explored. This procedure had been 
previously used in our group but with irreproducible results (entry 5). Whatever the type 
of zinc used (powder or dust), as described in the literature, the reaction only led to the 
complete recovery of the starting alkyne (2.36); even after overnight reflux (entries 3-4). 
Although the activation of the zinc with 1,2-dibromoethane was achieved as the ethane 
evolution was perfectly observed, the lack of reactivity observed was quite possibly due to 
the zinc. It was then decided to pre-activate the zinc so as to remove the zinc-oxide coating 
by using a HCl 0.1 M solution (entries 6,7). 42 
 
Interestingly, the type of zinc used led to very different results. When zinc powder was 
employed, after 6 hours of reflux, 90% of the starting alkyne (2.36) was still remaining 
(entry 6). When zinc dust was employed, after 4 hours of reaction, total conversion was 
observed by TLC; and after simple work-up the desired allylic alcohol (2.35) was obtained 
in 98% yield with an excellent (Z : E) ratio of (96 : 4) (entry 7). 
Upon  scaling-up,  the  Z-alkene  product  (2.35)  was  always  obtained  in  97-98%  yields, 
consistently with <5% of the E-double bond isomer. The success of this reduction is in 
part due to the presence of the propargyl alcohol moiety as this can coordinate to the 
metal, assisting the adsorption of the C≡C bond onto the metal surface.
90 The solvent is 
thought to be the hydrogen source for this reduction and it is believed to be introduced via 
an intramolecular proton transfer with an organometallic intermediate.
92 
This  new  practical  procedure  for  the  Z-selective  reduction  of  alkyne  also  shows  the 
importance of the use of pre-activated zinc dust in conjunction with 1,2-dibromoethane. 
Indeed, when the reaction was conducted without the use of 1,2-dibromoethane (entry 8), 
the reduction did not occur leading only to the recovery of the starting alkyne (2.36). 
2.2.2.4    Determination of the E/Z ratio 
Once  the  Z-alkene  (2.35)  was  obtained,  an  analytical  tool  had  to  be  found  so  as  to 
precisely  determine  the  E/Z  ratio  of  the  mixture  of  isomers.  For  this  purpose,  the 
corresponding E-isomer (2.42) was prepared via a LAH reduction of alkyne (2.36) in THF 
(Scheme 2.17).
21  
 
Scheme 2.17 
 
Wang  and  co-workers
98  had  previously  reported  this  compound  but  no  experimental 
conditions or analytical data were published. Using 6 equiv of LAH in refluxing THF, the 
propargyl alcohol (2.36) was reduced exclusively to the desired E-allylic alcohol (2.42) in 
75% yield after column chromatography. This enabled a direct comparison of the two 
1H 
NMR spectra of the E- and Z-allylic alcohols. The 
1H NMR for each isomer is displayed in 
Figure 2.2. 43 
 
 
 
                    
Figure 2.2 
 
Unfortunately, the alkene protons completely overlapped. However, excellent resolution 
appeared in the medium-field region ( 4.0-4.2 ppm) corresponding to the protons HA in 
-position to the alcohol group. The (E:Z) ratio was determined based on the integration 
of those signals. 
2.2.2.5    Synthesis of the Z-allylic phosphonate (2.2) 
The phosphonate (2.2) was synthesised from the alcohol (2.35) via the allylic chloride 
(2.43) (Scheme 2.18). 
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The  use  of  hexachloroacetone  (HCA) with  PPh3
99-101  in DCM  was  explored  and gave 
excellent results. The reaction was complete after 30 min of reaction but the purification 
was found much easier on a large scale than on a small scale. Indeed, on large scale, after 
removal  of  the  resulting  triphenylphosphine  oxide  by  taking  the  crude  in  hot  hexane 
followed  by  filtration,  the  resulting  crude  oil  was  distilled  under  reduced  pressure 
affording the pure desired chloride (2.43) in excellent yield despite the distillation step. 
Treatment of the Z-allylic chloride (2.43) with triethyl phosphite
102,103 at 110 to 130 °C 
gave good yields of the Z-allylic phosphonate (2.2), which was also isolated by vacuum 
distillation. This reaction required longer reaction times than many literature examples, 
presumably because of the double bond geometry. The first step in the mechanism of the 
Michaelis-Arbuzov reaction is  a SN2 displacement of the chloride by  the  nucleophilic 
phosphite.
102 It was thought that the Z-geometry of the double bond hindered the carbon of 
the CH2Cl from SN2 attack resulting, overall, in a longer time of reaction. 
2.2.2.6    Synthesis of the E-allylic phosponate (2.45) 
This E-phosphonate (2.45) was not required for the total synthesis of desogestrel but it 
would allow access to isomers of the key 1,4-addition reaction products in order to fully 
investigate  this  reaction.  The  phosphonate  (2.45)  was  synthesised  from  the  precursor 
(2.42) via the allylic chloride (2.45) (Scheme 2.19). 
 
Scheme 2.19 
 
The procedures used were the same as for the synthesis of the Z-phosphonate (2.2). The 
main noticeable difference was the reaction time from the allylic chloride (2.44) to the 
synthesis of the E-phosphonate (2.45) to go to completion. The reaction was complete in 
only 26 h, compared to 48 h for the Z-phosphonate (2.2), in similar yields, confirming the 
slower SN2 process in case of the Z-alkene. 45 
 
2.2.2.7    Conclusion 
The Z-allylic phosphonate (2.2) was synthesised on large scale in four steps and in 83% 
overall yield. This synthesis could be completed in 5 days, finishing with 23 g of the Z-
allylic  phosphonate  starting  from  bromide  (2.37).  Importantly,  all  intermediates  were 
isolated by vacuum distillation. The avoidance of chromatography (no silica, less solvents) 
represents an environmentally friendlier synthesis of the Z-allylic phosphonate (2.2) with 
still excellent yields. 
2.3  Estrone synthesis 
 
For  the  estrone  total  synthesis,  two  different  substrates  were  synthesised:  an  achiral 
phosponate (2.3) that would enable a racemic total synthesis, and a chiral phosphonamide 
(2.4)  that  would  enable  an  enantioselective  total  synthesis.  Both  compounds  were 
previously synthesized by B. Guizzardi.
64 
2.3.1  Retrosynthetic analysis 
 
The proposed retrosynthetic analysis towards the synthesis of the Z-allylic phosphonate 
(2.3) and phosphonamide (2.4) is shown in Scheme 2.20. 
 
Scheme 2.20 
 
This  plan  incorporated  a  degree  of  convergence  as  both  phosphonate  (2.3)  and 
phosphonamide  (2.4)  would  be  obtained  from  the  common  precursor  (2.46)  through 
Arbuzov reactions. Allylic chloride (2.46) could be obtained  in  a  few steps  from  the 
known dibromide (2.48).
104 The Z-selective alkyne reduction of (2.47) was planned as the 
key step. Optimization of most of the steps had already been achieved by B. Guizzardi.
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2.3.2  Synthesis of the allylic chloride common precursor (2.46) 
2.3.2.1    Synthesis of the Z-allylic alcohol (2.52) 
The synthesis of the Z-allylic alcohol (2.52) started from the known dibromide (2.48), 
which  was  prepared  from  3-methylanisole  following  a  literature  procedure  (Scheme 
2.21).
104 
 
Scheme 2.21 
 
The desired dibromide (2.48) was synthesized several times on large scale (15-20 g) but 
literature results could not be reproduced, yielding after recrystallisation the dibromide 
(2.48) in 61%, along with 16% of the tribromide (2.50). In this process, the electrophilic 
aromatic substitution step is the slow process, leading to a double radical halogenation 
reaction. Optimisation of the yield was not successful. 
Chain  extension  was  achieved  by  treatment  of  (2.48)  with  a  large  excess  of  allenyl 
magnesium bromide
105,106 in Et2O/THF, to give the desired alkyne (2.51) in excellent yield 
after distillation. 
So as to introduce the propargyl alcohol, alkyne (2.51) was deprotonated with LDA (1.2 
equiv),
106 followed by addition of gaseous formaldehyde in large excess,
107 yielding the 
desired alcohol (2.47) in a reproducible 83% yield. The formaldehyde was generated in a 
separate  flask  by  heating  paraformaldehyde  to  400-500  °C  with  a  heat  gun  and  then 
bubbled into the solution by mean of a nitrogen stream. 
The  subsequent  Z-selective  reduction  of  the  triple  bond,  using  activated 
Zn/dibromoethane/EtOH
90  worked very  well.  The method  had already been developed 47 
 
during the desogestrel project, but the reaction time in this case was critical to avoid the 
formation  of  debrominated  adduct  (2.53)  which cannot  be  separated  from  the  desired 
alcohol (2.52) (Figure 2.3). 
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Figure 2.3 
 
The  reaction  mixture  was  complete  after  3  h,  affording  the  desired  alcohol  (2.52)  in 
excellent yield. Despite irradiation experiments, the (Z/E) ratio could not be determined by 
1H NMR as no clear signals corresponding to the E-isomer could be observed. Therefore, 
the (Z/E) ratio was estimated on the basis of the 
13C NMR spectrum (Figure 2.4).  
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Figure 2.4 
2.3.2.2    Conversion of the alcohol (2.52) to the chloride (2.46) 
The next step, the conversion of the allylic alcohol (2.52) into the chloride (2.46) was 
achieved using hexachloroacetone and PPh3 in nearly quantitative yield (Scheme 2.22).
99-
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Scheme 2.22 
 
Although this reaction had been successfully used several times during the desogestrel 
project,  an unexpected rearrangement  was  observed once,  leading to  the  formation of 
(2.54), when purification by distillation was first attempted (Table 2.3). 
Entry  Scale  Method of purification  Overall yield 
(%) 
Ratio of products
a (%) 
(2.46)  (2.54) 
1  41 mmol  Distillation  94%  75-70  25-30 
2  53 mmol  Column chromatography  99%  100  0 
a = ratio determined by 
1H NMR 
Table 2.3 
 
Interestingly, allylic chlorides like (2.46) are not known to rearrange to allylic chlorides 
like (2.54), and this could only be explained by the temperature required for the distillation 
(b.p. = 126 °C / 0.2 mmHg); resulting in an inseparable 12 g mixture of (2.46) and (2.54).  
2.3.3  Synthesis of the Z-allylic phosphonate (2.3) 
2.3.3.1    Synthesis of the Z-allylic phosphonate (2.3): Arbuzov reaction 
The Z-allylic phosphonate (2.3) was synthesised through Arbuzov reaction of the chloride 
(2.46) with triethyl phosphite (Scheme 2.23).
102,103 
 
Scheme 2.23 
 
Conducting the reaction as described in the literature
102 didn’t afford the desired Z-allylic 
phosphonate  (2.3).
64  Interestingly,  conducting  the  reaction  with  1  equiv  NaI  had  a 49 
 
dramatic  effect  on  the  time  required  for  completion  of  the  reaction  as  well  as  the 
temperature required (60 °C instead of 130 °C). After 2 h of reaction, excess P(OEt)3 was 
removed by distillation and phosphonate (2.3) was isolated in excellent yield by column 
chromatography. 
Without the use of NaI, procedure used for the desogestrel project, the reaction required 
48 h to reach completion at 130 °C (part 2.2.2.5, synthesis of (2.2)). 
2.3.3.2   Synthesis of the Z-allylic phosphonate (2.3): Corey-Winter olefination
108 
From a synthetic  point of view, it was interesting to know whether the desired Z-allylic 
phosphonate (2.3) could be obtained from the 12 g mixture of allylic chlorides (2.46) and 
(2.54) obtained by distillation (Scheme 2.24). 
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Scheme 2.24 
 
To do so, the mixture of allylic chlorides (2.46) and (2.54) was subjected to Arbuzov 
reaction,  leading  to  a  mixture  of  (E/Z)  allylic  phosphonates  (2.3)  and  (2.55)  which 
unfortunately  couldn’t  be  separated.  Separation  by  derivatisation  was  attempted. 
OsO4/NMO cis-dihydroxylation,
109 leading to inseparable racemic diols (2.56) and (2.57) 
(only one enantiomer of each is shown), followed by cyclic isothiocarbonate formation
110 
using thiocarbonyldiimidazole led to adducts (2.58) and (2.59) which could be separated 
by column chromatography. None of the steps were optimized as the sequence was only 
attempted once on small scale. 
The  final  syn-elimination
111  using  a  trialkylphosphite  was  only  achieved  with 
isothiocarbonate (2.59), with good results (Scheme 2.25).  50 
 
 
Scheme 2.25 
 
Under  the  same  conditions,  isothiocarbonate  (2.58)  would  lead  exclusively  to  the  E-
phosphonate (2.55), but this was not attempted. 
2.3.4  Synthesis of the Z-allylic phosphonamide (2.4) 
2.3.4.1    Synthesis of the chiral phospholidine precursor (2.65) 
The synthesis of the key chiral phospholidine precursor (2.65) started with the preparation 
of trans-1,2-diaminocyclohexane (2.62) in enantiopure form, following Hanessian and co-
workers procedure,
112,113 by treatment of commercially available racemic mixture of cis 
and trans-1,2-diaminocyclohexane (2.60) with L-(+)-tartaric acid (2.61) (Scheme 2.26). 
 
Scheme 2.26 
 
The precipated monotartrate salt (2.62) was easily obtained in high diastereoisomeric form 
by filtration followed by a series of MeOH washes to  the filtered  salt that effectively 
removed traces of the unwanted isomer.
114 The precise e.e. of the product was not actually 
determined since a good []D correspondence with literature data
112 was found for the 
intermediates (2.63) and (2.64) (Scheme 2.27).  
 
Scheme 2.27 
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(R,R)-1,2-diaminocyclohexane  tartaric  salt  (2.62)  was  then  treated  with  simultaneous 
addition of ethyl chloroformate and NaOH 4 M in toluene at 5 °C to afford enantiopure 
dicarbamate  (2.63)  in  good  yield.  Reduction  of  the  dicarbamate  (2.63)  to  the  N,N’-
dimethyl-diaminocyclohexane (2.64) was achieved via a LAH reduction in refluxing THF 
in  excellent  yield.  Finally,  chiral  phospholidine  (2.65)  was  obtained  by  treatment  of 
diamine  (2.64)  with  HMPT  in  refluxing  toluene  overnight.  Excess  HMPT  was 
successfully  removed  by  Kugelröhr  distillation  to  afford  phospholidine  (2.65)  in  77% 
yield.  The  very  low  stability  of  phospholidine  (2.65)  that  would  have  required  its 
immediate use was circumvented as it was found it could be stored as a 0.2 M solution in 
toluene under nitrogen.
115  
2.3.4.2    Arbuzov reaction with homochiral phospholane (2.66) 
From phospholidine (2.65), the key intermediate required for the final Arbuzov reaction 
with  the  previously  obtained  allylic  chloride  (2.46)  was  phospholane  (2.66)  (Scheme 
2.28). 
 
Scheme 2.28 
 
As described in  the  literature,
113,115 phospholane  (2.66) showed  very  low  stability and 
therefore had to be used in a one-pot sequence. 
In practice, phospholidine (2.65) (1 equiv) was refluxed with EtOH (1.15 equiv) in toluene 
until exclusion of dimethylamine was complete. The phospholane (2.66) solution was then 
added to allylic chloride (2.46) (0.75 equiv) in presence of NaI (0.75 equiv). The Arbuzov 
reaction was complete after 2 h of reaction and up-to 3 g of Z-allylic phosphonamide (2.4) 
was obtained in good yield.  
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2.4  Summary 
 
Although the synthesis of the orthoester phosphonate (2.1) has not been achieved, a very 
efficient procedure was developed for the synthesis of the dioxolane containing achiral 
phosphonate  1,4-addition  precursor.  The  Z-allylic  phosphonate  (2.2)  could be  reliably 
synthesised in four steps and 83% overall yield from commercially available reagents. All 
intermediates were isolated by vacuum distillation and the synthesis could be completed in 
five days, finishing with 23 g of the Z-allylic phosphonate. 
Towards estrone total synthesis, two different 1,4-addition precursors were prepared (a 
chiral  phosphonamide  and  an  achiral  phosphonate)  from  a  common  precursor.  From 
commercial reagents, Z-allylic phosphonate (2.3) was obtained in 42% overall yield in six 
steps that could be completed in five days finishing with 18 g of phosphonate. The Z-
allylic phosphonamide (2.4) was also obtained, on 3 g scale in 10 overall steps. 53 
 
Chapter 3, The Hanessian 1,4-addition reactions 
3.1  Introduction 
 
The 1,4-addition reaction or Michael addition is an invaluable C-C bond forming reaction 
and is planned as the first key step in the proposed syntheses of desogestrel and estrone. 
The expected products from this 1,4-addition/alkylation step, as shown in Figure 3.1, are 
relatively similar  for  both the estrone and desogestrel  synthesis, although each  steroid 
target requires specific functionalization for the later cyclisation reactions. Hence, they are 
described together in this chapter. 
 
Figure 3.1 
 
The 1,4-addition utilizes a heteroatom stabilized allyl anion and quite different results can 
be obtained depending on the choice of this stabilizing group. In the following sections, 
the regioselectivity and the stereoselectivity of the 1,4-addition reaction are discussed, 
followed by an overview of the expected 1,4-addition reactions for both projects. 
 
3.1.1  Regioselectivity of the 1,4-addition reaction 
 
Regioselectivity can be a problem during the addition of heteroatom stabilized allyl anion 
to enones, as four products are possible: 1,2--addition, 1,2--addition, 1,4--addition and 
1,4--addition. The four possible products are summarised in Scheme 3.1. 
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Haynes and others have shown that the heteroatom directly affects the regioselectivity of 
the reaction. Sulfides and selenides are known to undergo 1,2-addition with a mixture of  
and attack. If these additions are conducted in the presence of HMPA however, the 1,4-
addition products are exclusively produced, with ~95 : 5,  :  selectivity (Scheme 3.2).
116-
118 
 
Scheme 3.2 
 
Phosphine  oxides  and  sulfoxides  have  been  reported  to  undergo  exclusive  1,4--
addition,
118-120 even at temperatures as low as -100 °C.
121 The addition of HMPA to these 
reactions did not affect the selectivity and it was even found to have a deleterious effect on 
the yields.
118,120 Additionally, conducting these reactions at temperatures as high as 0 °C 
had no detectable loss on diastereoselection.
118 
With phosphonamide systems, Hanessian and co-workers have also found that the addition 
of HMPA improves the ratio of 1,4- to 1,2-addition.
122,123 
During the investigation of the conjugate addition of allyl-1,3,2-oxazaphosphoriname-2-
oxides  (3.11),  Denmark  and  co-workers
124  found  that  the  1,4--addition  product  was 
produced with a minor amount of the 1,2--addition product but neither of the 1,4-- and 
1,2--addition products were detected (Scheme 3.3). 
 
Scheme 3.3 55 
 
Denmark’s observations are consistent with the hard-soft, acid-base principle,
125 which 
states that hard nucleophiles would rather attack hard electrophiles and vice-versa. A hard 
nucleophile has no stabilizing effect (e.g. allyl
-) and a soft nucleophile is stabilized (e.g. 
heteroatom-allyl group). The hard position of an enone is the carbonyl as no stabilization 
is offered whereas 1,4-addition forms the enolate, which is stabilized. 
3.1.2  Stereoselectivity during the 1,4-addition reaction 
 
Hanessian and co-workers proposed that this 1,4-addition proceeds via a trans-decalinoid 
Li-chelated  transition  state,
122,123,126,127and  that  this  accounts  for  the  high  levels  of 
stereocontrol observed during the reaction.  Scheme 3.4 shows an example of the 1,4-
addition reaction from Hanessian’s group and shows two transition states where the enone 
component has either approached from the “right cleft” or the “left cleft”. Hanessian and 
co-workers proposed that the approach from the “right cleft” (3.15) is less favorable due to 
the steric interaction between the N-Me group of the phosphonamide and the -CH2 of the 
enone and that the reaction therefore proceeded via the “left cleft” (3.16), resulting in a si-
face attack. 
 
Scheme 3.4 
 
The  trans-decalinoid  transition  state  is  directly  responsible  for  the  stereocontrolled 
introduction  of  the relative  stereochemistry of C8  and C14,  whilst  the  chiral  auxiliary 
defines the absolute stereochemistry of two centres. Transition state (3.16) leads to the (S)-56 
 
configuration at C8 and C14, whilst transition state (3.15) leads to the (R)-configuration at 
C8 and C14. Both of these examples make use of a (R,R)-phosphonamide (3.14). Quite 
clearly, using an achiral phosphonate instead of a chiral phosphonamide like (3.14) would 
result in both “left cleft” and “right cleft” approaches to happen simultaneously and would 
lead to a racemic mixture of enolates like (3.17, 3.18). However, since a trans-decalinoid 
transition state would still be involved, the relative stereochemistry at C8 and C14 would 
still be stereocontrolled.   
Importantly, the geometry of the double bond in the 1,4-addition precursor is translated 
into the particular C8 configuration in (3.18), due to the closed trans-decalinoid transition 
state. Haynes and co-workers
118-121,128 have conducted  significant research in this area, 
demonstrating the different stereochemical outcomes for E or Z crotyl phosphine oxides as 
shown in Scheme 3.5 (only one enantiomer of each enolate is shown).   
 
Scheme 3.5 
 
The chirality at the position which becomes C13 in the steroid products is controlled after 
the 1,4-addition reaction via a diastereoselective alkylation of the intermediate enolate.
129 
Scheme 3.6 shows an example from Hanessian’s group. 
 
Scheme 3.6 
 
In the enolate (3.25), the adjacent C14 moiety directs the attack of the electrophile to the 
least  hindered  back  face.  Many  groups  including  Hanessian,
122,123,130  Haynes,
131-133 
Jones,
134,135 and Fuji
136 have employed this methodology in related 1,4-addition reactions. 
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3.1.3  Overview of the expected 1,4-addition/alkylation reactions 
 
For both steroid targets, desogestrel (1.14) and estrone (1.6), the diastereoselective 1,4-
addition/alkylation  process,  as  shown  in  Scheme  3.7,  would  introduce  in  a  single-
operation  three  contiguous  stereogenic  centers  (C8,  C13  and  C14)  of  the  final  steroid 
products.   
 
Scheme 3.7 
 
Both projects rely on the  same methodology, but the expected 1,4--addition products 
(3.30,  3.2)  require  specific  functional  groups:  depending  on  the  starting  Z-allylic-
phosphorus  based products (1.130),  the choice  of the Michael acceptor (1.100, 1.131) 
would introduce the required C13-alkyl group (methyl for estrone, ethyl for desogestrel). 
The diastereoselective alkylation of enolates (3.27) with electrophiles (3.28, 3.29) would 
also introduce the required C13 substituent for the later cyclisation reactions.  
As described in chapter 2, three different 1,4-addition precursors (1.130) were prepared. 
Towards estrone (1.6), the achiral phosphonate (2.3) and the chiral phosphonamide (2.4) 
will  both lead,  upon  1,4-addition  with  methyl-enone (1.100)  and alkylation  with allyl 
bromide (3.28), to key intermediates (3.30). The results obtained are discussed below in 
part 3.3. Towards desogestrel (1.14), only the achiral phosphonate (2.2) was synthesised. 
Although key intermediate (3.2) would be obtained via a 1,4-addition with ethyl-enone 
(1.131)/alkylation with iodide (3.29), the reaction was also explored with commercially 
available  methyl-enone  (1.100).  The  results  obtained  with both Michael acceptors are 
shown together in the section below.  58 
 
3.2  Desogestrel synthesis 
 
R. Clarkson
21 had already achieved significant progress on this Hanessian 1,4-addition 
reaction. However, given the complexity of the reaction and despite taking advantage of 
his previous research, much optimization was required to achieve acceptable yields. 
3.2.1  Synthesis of the Michael acceptor (1.131) and electrophile (3.27) 
 
3.2.1.1  Synthesis of 2-ethylcyclopent-2-en-1-one (1.131) 
 
For the desogestrel synthesis, the 2-ethylcyclopentenone (1.131) Michael acceptor was 
required and it was not commercially available, although several preparative procedures 
have  been  reported.
56,137  Eventually,  (1.131)  was  synthesised  using  a  variation  of  the 
Organon N. V. Procedure as previously achieved by R. Clarkson (Scheme 3.8).
21 
 
Scheme 3.8 
 
Condensation of the diketone (1.35) with sec-butanol in refluxing toluene in the presence 
of  an  acid  catalyst  afforded  the  enol  ether  (3.31)  in  excellent  yield  after  distillation. 
Reduction of the keto group followed by acid hydrolysis of the enol ether and subsequent 
elimination  of  the  hydroxyl  group  gave  the  enone  (1.131)  in  30-43%  yield  after 
distillation. Although R. Clarkson successfully achieved the reaction on both 5 g and 20 g 
scale of diketone (1.35) in 52% overall yield, those results could not be reproduced. The 
condensation step leading to enol ether (3.31) was actually optimized by replacing CSA 
for ClSO3H as the acid catalyst. In which case, the reaction was complete after only 7 days 
instead  of  23  days,  in  similar  yields.  Unfortunately,  the  DIBAL-H  reduction/HCl 
hydrolysis reaction led to very different results depending on the scale of the reaction. 
Ethyl-cyclopentenone  (1.131)  could  only  be  obtained  in  30-43%  yield  by  vacuum 
distillation. Moreover, it showed very low stability which did also complicate the 1,4-
addition optimization process. 59 
 
3.2.1.2  Synthesis of the electrophile (3.29) 
 
From  previous  studies  by  R.  Clarkson,
21  the  iodide  (3.29)  was  also  required  for  the 
alkylation  step,  since  the  corresponding  bromide  was  not  reactive  enough.  It  was 
successfully prepared from the bromide (3.32) via a Finkelstein exchange
138 as shown in 
Scheme 3.9. 
 
Scheme 3.9 
 
An  alternative  purification  of  iodide  (3.29)  was  developed  in  which  column 
chromatography was avoided as it was successfully purified by vacuum distillation. This 
was easier to handle on large scale: 1) the iodide (3.29) was relatively volatile (b.p. = 68-
72 °C/5 mmHg) and losses were being suffered as this compound partially co-evaporated 
on the rotary evaporator. 2) the thus obtained iodide was solvent-free, pure and could be 
stored for weeks over molecular sieves when well protected from light. 
3.2.2  Attempted 1,4-additions 
 
The 1,4-addition/alkylation reaction  was conducted several times with both methyl-enone 
(1.100) and ethyl-enone (1.131) (Scheme 3.10, Table 3.1). Although ethyl-enone (1.131) 
was required for the completion of desogestrel total synthesis, initial experiments led to 
very poor results. The reaction was then optimized with methyl-enone (1.100), as scaling-
up  the  process was quickly  required and  it  was  commercially  available.  Interestingly, 
under the same conditions, very different results were obtained depending on the Michael 
acceptor.  Characteristic  results obtained  during  the optimization  process  are  shown  in 
Scheme 3.10 and Table 3.1 below.   
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Scheme 3.10 
 
As a typical procedure, the phosphonate (2.2) was deprotonated with 
nBuLi at -78 °C for 
15 min. in THF or Et2O. Then a solution of the enone (1.100) or (1.131) in the reaction 
solvent was added at -78 °C and the reaction mixture was stirred for 1 h at 0 °C. The 
iodide (3.29) was then added neat and the reaction mixture warmed to room temperature. 
 
Entry  R 
Scale 
(mmol) 
of (2.2) 
equiv of 
(1.100)/ 
(1.131) 
equiv of 
(3.29)  Solvent 
Yield of products (%) 
1,4-  1,4-  1,4- 
dialkylated 
1,4- 
non-
alkylated 
(2.2) 
1
a  Et  2.23  1.2  1.2  THF  8  e  0  e  55 
2  Et  1.80  1.2  1.2  THF  10  4  0  e  61 
3
b,c  Et  1.80  1.3  1.3  THF  11  7  0  e  59 
4
c  Et  1.80  1.3  1.3  Et2O  13  8  0  e  63 
5  Me  1.80  1.3  5  Et2O  20  6  e  e  35 
6  Me  1.80  1.2  1.2  Et2O  24  5  e  14  26 
7  Me  1.80  0.83  1.5  Et2O  38  11  4  5  21 
8  Me  12.48  0.83  1.5  Et2O  42  13  7  8  24 
9  Me  30.24  0.83  1.5  Et2O + 
HMPA
d  54  6  4-5  3  17 
10  Me  13.78  0.83  1.5  THF  31  8  6  5  39 
11  Et  12.52  0.83  1.5  Et2O + 
HMPA
d  21  23  traces  4  36 
12  Et  17.76  0.83  1.5  THF  43  8  5  7  24 
a = temperature raised to rt after enone addition; 
b = 1.3 equiv 
nBuLi; 
c = enone added at 0 °C; 
d = added after 
the electrophile addition; e = not isolated 
Table 3.1 
 
It was not possible to display 100% mass balance of the products because decomposition 
leading  to  base-line  material  was  observed  (TLC).  Additionally,  products  were 
occasionally isolated by HPLC analysis that could not be assigned a structure. The 
1H 
NMR of these compounds was typically  extremely messy-possibly the indication of a 
number of compounds despite eluting from the HPLC as a single peak. 61 
 
When  the enone  (1.131)  was  employed  (entries  1-4), only three  compounds  could  be 
isolated  and  determined:  the  desired  -1,4-addition  product  (3.2)  as  a  single 
diastereoisomer,  the  -1,4-addition  product (3.34)  as  a single  diastereoisomer  and  the 
starting phosphonate (2.2) with unchanged double bond geometry. 
Varying the temperature of the reaction mixture before the enone addition did not seem to 
influence the course of the reaction (entries 1, 2 and 4 versus 3). The temperature of the 
reaction mixture after the enone addition seemed important however. Better yields in 1,4-
addition products as well as starting material recovery were obtained when the reaction 
was kept at 0 °C instead of room temperature (entries 2-4 versus 1). The use of an excess 
of the reactants enone (1.131), iodide (3.29) and 
nBuLi did not seem to give better results 
(entry 3 versus 1 and 2). 
However, the solvent used during the 1,4-addition reaction seemed quite important (entry 
4 versus 3). The use of Et2O instead of THF didn’t afford a significative improvement in 
the yield of desired -1,4-addition product, but really eased the purification, with less by-
products observed than when THF was employed. When Et2O was used, a precipitate was 
observed which was presumed to be intermediate enolate (3.39) (Figure 3.2).   
 
Figure 3.2 
 
This observation, also noticed when the enone (1.100) was employed could have led us to 
modify the procedure of the alkylation. 
In a bid to identify the factor leading to the high recovery of starting material when the 
ethyl-cyclopentenone  (1.131)  was  used,  the  deprotonated  phosphonate  was  directly 
alkylated with iodide (3.29) (Scheme 3.11). 
 
Scheme 3.11 62 
 
This reaction afforded 81% of the -addition product (3.40) and 9% of the -addition 
product (3.41). None of the starting material (2.2) was recovered and no other products 
were detected other than base-line material. It became clear that from the 90% conversion 
of starting material into products that one equivalent of base and of the electrophile was 
sufficient for this reaction. Interestingly, the alkene geometry in (3.40) was found to be Z 
by 
1H NMR, which led us to assign the same alkene configuration for the -1,4-addition 
products (3.33) and (3.34). Also, since this was the first result where all of the starting 
material allylic phosphonate had been consumed, it led us to suspect that the 1,4-addition 
process itself was responsible for the high recovery of the allylic phosphonate material 
during the 1,4-addition reaction.  
Alternatively, another possible explanation for the high recovery of the starting allylic 
phosphonate material during the 1,4-addition process (Table 3.1, entries 1-4) is shown in 
Scheme 3.12. 
 
Scheme 3.12 
 
Instead of undergoing a 1,4-addition, this route proposes that the enone (3.19) could be 
deprotonated by the phosphonium anion (3.42). In this event, the allylic phosphonate (2.2) 
would  be  reformed  and  the  enolate  of  the  enone  would be formed (3.43). This  anion 
should be rather unreactive and would most likely be quenched, returning to the enone 
(3.19), but the possibility of alkylation with (3.29) also exists, leading to the enone (3.44). 
Despite  the  significant  amounts  of  apolar  products  that  were  separated  from  the  1,4-
addition products after each reaction, the alkylated enone (3.44) was never isolated nor 
identified. Since the use of an excess of enone (1.131) led to high yields of recovered 
starting phosphonate (2.2) (Table 3.1, entries 1-4), one obvious option would be to use an 
excess  of  phosphonate  (2.2) instead.  This  might  favor  1,4-addition  over  the  supposed 
deprotonation of the enone.   63 
 
Returning  to  the  1,4-addition  investigations,  the  reaction  was  also  explored  with  the 
methyl-enone (1.100)  to see if the ethyl  group in the enone (1.131) could be a factor 
responsible for the poor yields obtained (Table 3.1, entries 5-10). 
Under  the  same  conditions  (entry  6  versus  2), the desired -1,4-addition  product was 
isolated in 24% yield with interestingly 14% of the non-alkylated product (3.37). This 
showed that the 1,4-addition process proceeded better with the methyl-enone (1.100) than 
with the ethyl-enone (1.131). 
The use of an excess of the starting phosphonate (2.2) was then explored (entries 7-10). 
The results obtained were in this case quite promising, leading on a 12.48 mmol scale of 
(2.2) to 42% yield of isolated -1,4-addition product (3.1) (entry 8). However, a technical 
issue arose while scaling-up the reaction. Alkylation of the presumed precipitated enolate 
(3.39) led to the formation of a very sticky oil which hampered stirring of the reaction 
mixture. Adding more of the electrophile didn’t solve the problem, but this was overcome 
by adding HMPA. This effectively solubilised the enolate and up to 54% of 1,4--product 
(3.1) could be obtained on a 30  mmol scale (entry 9). Unfortunately, under  the same 
conditions,  the  reaction  with  ethyl-enone  (1.131)  led  to  a  (1:1)  (1,4-:1,4- 
regioselectivity,  in 44% overall  yield  (entry 11). However, conducting the reaction in 
THF (entry 12) afforded 1,4--product (3.2) in 43% yield along with 8% of 1,4--product 
(3.34) on a 17 mmol scale. 
Overall, the greatest yield obtained for the 1,4--addition compound (3.2) using the ethyl-
enone (1.131) was 43% compared with 54% achieved for the same 1,4-addition reaction 
using  the methyl-enone (1.100). It  was  thought that  the  larger  ethyl  group caused  an 
increased steric interaction in the transition state and this was responsible for the poorer 
yield, as well as favouring the 1,4--addition (Figure 3.3). 
 
Figure 3.3 
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However, it still remains unclear why such differences of regioselectivity were observed 
depending on the solvent used and the use of HMPA.  
 
During this 1,4-addition investigation, two side-products were often commonly observed: 
the bis-alkylated 1,4--addition products (3.35, 3.36) and the non-alkylated 1,4--addition 
compounds (3.37, 3.38). Although they were not always isolated, it is believed that they 
both  originate  from  the  intermediate  enolate  (3.39)  following  the  suggested  process 
(Scheme 3.13).  
 
Scheme 3.13 
 
Assuming the alkylation of enolate (3.39) is a relatively slow process, (3.39) could exist at 
the same time as the 1,4--addition product (3.45). In this event it would be possible for 
the enolate (3.39) to abstract a hydrogen from (3.45), leading to both enolate (3.47) and 
non-alkylated  adduct  (3.46).  Alkylation  of  enolate  (3.47)  would  then  lead  to  the  bis-
alkylated adduct (3.48). This is still quite speculative, but since both side-products were 
also observed during the 1,4-addition/alkylation reactions towards estrone (part 3.3), this 
pathway remains quite reasonable. 
Finally, quite possibly the most interesting but also troublesome was the formation of the 
1,4--addition products (3.33, 3.34). Troublesome, as separation from the desired 1,4--
addition products (3.1, 3.2) could only be achieved  by HPLC,  which also  meant  very 
lengthy  separation  on  large  scale.  Interesting,  as  this  regioselectivity  is  almost 
unprecedented  with  phosphorus-based  Michael  addition  reactions.  Although  the  1,4- 
regioselectivity  is  precedented  with  allyl-phosphonates  and  acyclic  ,-unsaturated 65 
 
ketones,
63,139 only 1,4--and 1,2- regioselectivities have been reported with cyclic 
--unsaturated ketones.
119,122-123 It was also demonstrated that depending on the Michael 
acceptor, the solvent used was critical for the /-regioselectivity.   
As a conclusion, the 1,4--addition products (3.1, 3.2) and the 1,4--addition products 
(3.33, 3.34) were obtained as single diastereoisomers but they were all oils. This meant 
that  X-ray  analysis  could  not  be  used  to  ascertain  the  configuration  of  the  newly 
established C8, C13 and C14 stereogenic centres at this point. The 1,4--adducts relative 
stereochemistry was however unambiguously proven on separate occasions later on during 
the course of the project (Chapter 4).   
3.3  Estrone synthesis 
 
The estrone project was first investigated by B. Guizzardi
64 who also achieved significant 
research  on this  Hanessian  1,4-addition  reaction.  Nevertheless,  the reaction  had to  be 
repeated with both phosphonate (2.3) and phosphonamide (2.4) in order to obtain clean 
characterisation data. Identification of possible side-products during the reaction was also 
required. 
3.3.1  Racemic synthesis 
 
With the Z-allylic phosphonate (2.3) in hand, the 1,4-addition/ alkylation process could be 
investigated (Scheme 3.14). Optimisation of the process was done by B. Guizzardi,
64 who 
reported an excellent 75%  yield of 1,4--addition product (3.3), though no mention of 
side-products was made (Table 3.2, entry 1). 
 
Scheme 3.14 
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Phosphonate (2.3) was treated with 
nBuLi at -78 °C for 15 min. Cyclopentenone (1.100) 
was then added at 0 °C, followed 1 h later by alkylation with (3.28). The results obtained 
are shown in Table 3.2. 
 
Entry  Scale of 
(2.3) 
equiv of 
nBuLi  
equiv of 
(1.100) 
equiv of 
(3.28) 
‘’Purification’’ 
of (3.28) 
Yield of products (%) 
(3.3)  (3.50)  (3.51) 
1
a  1.23 mmol  1.3  1.3  5  n.a.  75 
c  c 
2  2.56 mmol  1.3  1.3  10  none  64
b  13
b  4-5
b 
3  2.58 mmol  1.1  1.3  10  over mol.sieves  63  15  4 
4  2.53 mmol  1.1  1.3  10  freshly distilled  69  11  5 
a= previous results by B. Guizzardi, 
b = contaminated with 10-15% debrominated product, 
c = yields not 
given. 
Table 3.2 
 
The  desired  1,4--adduct  (3.2)  was  indeed  isolated  in  good  yield  (69%)  as  a  single 
diastereoisomer, with traces of diallylated adduct (3.51) and 11% yield of non-allylated 
adduct (3.50) when allyl bromide (3.28) used was freshly distilled (entry 3). The amount 
of 
nBuLi employed for the deprotonation of (2.3) was found quite important as the use of 
1.3 equiv 
nBuLi led to the formation of 10-15% of debrominated adducts (3.52), (3.53) 
and (3.54) (Figure 3.4) which could not be separated from the brominated ones (entry 2) 
(ratio determined by 
1H NMR). 
 
Figure 3.4 
 
Delightfully,  recrystallization  of  (3.3)  in  DCM/Hexane  allowed  access  to  X-ray 
crystallographic analysis, as shown in Figure 3.5. 67 
 
 
Figure 3.5: X-Ray structure of (3.3) 
 
The  expected  relative  stereochemistry  at  the  newly  established  C8,  C13  and  C14 
stereogenic  centres  was  thus  unambiguously  proven,  confirming  that  the  1,4-
addition/alkylation  process  occurred  as  shown  above  (Scheme  3.7).  This  result  was 
interesting,  as  the  relative  stereochemistry  of  none  of  the  previously  mentioned  1,4-
addition products (desogestrel project) had been unambiguously proven so far. 
Interestingly, despite the fact that the reaction had a very similar TLC profile compared 
with desogestrel project (part 3.2),  no trace of 1,4--addition product (3.55) was ever 
observed (Figure 3.6). 
O
H
(3.55)
P
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O Br
O
 
Figure 3.6 
 
Also interesting, the bis-allylated product (3.51) and the non-allylated product (3.50) were 
once again obtained. This observation might be another hint that they could both originate 
from the intermediate 1,4-addition enolate, as depicted above in Scheme 3.13.  68 
 
3.3.2  Enantioselective synthesis 
 
The enantioselective 1,4-addition/alkylation reaction was only attempted at the very end of 
this  PhD,  and  therefore  remains  not  fully  optimized  (Scheme  3.15,  Table  3.3).  The 
reaction  with  phosphonamide  (2.4)  required  very  different  conditions  than  when  the 
phosphonate (2.3) was employed. Although B.Guizzardi reported a good 59% yield of 
desired 1,4--addition product (3.4) on a 100 mg scale of starting phosphonamide (2.4) 
(entry 1), lower yields were obtained on bigger scale.     
 
Scheme 3.15 
Table 3.3 
Entry  Scale of 
(2.4) 
C 
(mol/L) 
equiv 
of 
nBuLi 
equiv 
of 
(1.100) 
equiv 
of 
(3.28) 
time of 
alkylation 
(h) 
additive
b 
Yield of products (%) 
(3.4)  (3.56)  (3.57) 
1
a  0.22 mmol  0.10  1.3  1.3  5  1  none  59 
c  c 
2  0.42 mmol  0.14  1.1  1.3  10  1  none  20 
c  27 
3  0.90 mmol  0.23  1.1  1.3  10  16  none  26 
c  23 
4  0.89 mmol  0.30  1.1  1.3  10  1  HMPA  52  7  9 
a= previous results by B. Guizzardi; 
b = added after the electrophile addition; 
c = yields not given. 
 
Quite clearly, the weak spot of the reaction was the alkylation step (entries 2-4). Despite 
the use of 10 equiv of allyl bromide (3.28) (entry 2), a 27% yield of non-allylated product 
(3.57) was obtained after 1 h of alkylation at room temperature. Even by increasing the 
concentration of the reaction as well as allowing 16 h for the alkylation step to take place 
(entry 3), 23% of undesired non-allylated adduct was isolated. This was circumvented, in a 
final attempt, by adding HMPA after the electrophile addition (entry 4). The desired 1,4--
product (3.4) was then obtained in 52% yield, along with only 9% of non-allylated adduct 
(3.57) and 7% of bis-allylated (3.56). Even if those results were not as good as the results 
obtained with phosphonate (2.3), enough material  was obtained so as to  complete the 
enantiospecific total synthesis of estrone.   69 
 
3.4  Summary 
 
The  1,4-addition  reaction  has  been  investigated  on  a  number  of  phosponate  and 
phosphonamide  substrates.  Towards  desogestrel  total  synthesis,  with  a  Z-allylic 
phosphonate, the 1,4-addition/alkylation process was successfully achieved on large scale 
with two different Michael acceptors. Considering the complexity of the 1,4--addition 
products obtained (as single diastereoisomers), the medium 54% yield obtained with a 
methyl-enone and the 43%  yield  with the required  ethyl-enone  were considered  good 
results. 
Towards  estrone  synthesis,  the  same  1,4-addition/alkylation  process  was  successfully 
achieved  in a  racemic  and  more  importantly  in an  enantioselective  fashion.  Using  an 
achiral phosphonate, an excellent 85% overall yield of 1,4-addition products was obtained. 
Although the 75% yield of desired 1,4--product obtained by B. Guizzardi could not be 
reproduced, the 69% yield obtained was an excellent result. Moreover, an X-Ray of the 
1,4--product was obtained. Not only did this proved the relative stereochemistry of the 
specific  product,  this  also  validated  the  entire  methodology  for  both  projects.  The 
enantioselective  version  of  the  reaction  however,  with  the  Z-allylic  phosphonamide 
proceeded in slightly lower yields. 
Finally, the determination of the diastereoselectivity for the desired 1,4--Michael addition 
manifold was beyond the limits of NMR. Careful examination of the 
1H and 
31P NMR 
spectra showed a single set of resonances and single peak, respectively. The 
13C NMR, 
though  complicated  due  to  extensive  phosphorus  couplings,  indicated  single 
diastereoisomers as well.     
Those results are, to  date,  also believed to be the first examples that the 1,4-addition 
process is stereoselective on more complex allylic phosphonates and phosphonamides than 
the crotyl examples used by Haynes and co-workers or Hanessian and co-workers. 70 
 
Chapter 4, Desogestrel: the tandem C-B ring cyclisation 
4.1  Introduction 
 
With  the  key  C8,  C13  and  C14  stereogenic  centres  introduced  by  the  phosphonate 
conjuguate addition, the next key operation concerned the C and B ring closure. This was 
planned via a tandem process, made possible by the particular functionality introduced in 
the 1,4-addition/alkylation step (Scheme 4.1). 
 
Scheme 4.1 
 
The next key step of the synthesis was a domino anionic cyclisation from (4.1), prepared 
in four steps from the 1,4-addition product (3.2), that would diastereoselectively construct 
the steroid C and B-rings, in a single operation. From -keto-phosphonate (4.2), the A-ring 
would be achieved through a Horner-Wadsworth-Emmons reaction with aldehyde
140 (4.3), 
subsequent  hydrogenation  of  the  enone  (4.4)  followed  by  acid  mediated 
aldol/dehydration,
31  that  would  lead  to  the  known  diketone  (1.71).
31,48  Completion  of 
desogestrel synthesis from (1.71) would be achieved via known reactions.  
4.2  Steroid C and B ring formation 
 
4.2.1  Introduction to the domino reaction 
 
Domino  reactions  are  defined  by:  “The  process  involving  two  or  more  bond-forming 
transformations (usually C-C bonds) which take place under the same reaction conditions 
without adding additional reagents and catalysts, and in which the subsequent reactions 71 
 
result as a consequence of the functionality formed in the previous step.”
141 The benefits 
of using domino reactions are both economic and ecological (reduced amounts of solvents, 
reagents, adsorbents and consequently waste). 
4.2.2    Overview of the expected domino C-B reaction 
 
So  as  to  enable  the  construction  of  the  A-ring,  the  enolate  (4.7)  was  the  crucial 
intermediate required, as this would lead exclusively to C10-alkylated products. Clearly 
this enolate could not be synthesised cleanly from the ketone (4.5) since a mixture of the 
enolates (4.6) and (4.7) would be expected as shown in Scheme 4.2.
142 
 
Scheme 4.2 
 
A synthetic equivalent of enolate (4.7) was therefore required to circumvent this problem. 
It  was  envisioned that  the -keto phosphonate  (4.2) which  would be obtained  by  the 
cyclisation process, as shown in Scheme 4.3, would be an ideal precursor to selectively 
afford the desired C5-C10 enolate-type anion (4.8) which upon HWE chemistry would 
allow access to suitable C10-alkylated precursors for A-ring closure. 
 
Scheme 4.3 
 
The envisioned domino route to the expected -keto phosphonate (4.2), starting from a 
specifically functionalized precursor (4.1) is shown in Scheme 4.4 below.  
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Scheme 4.4 
 
Bromine-lithium exchange of the vinyl bromide (4.1) with 
tBuLi was expected to induce 
the intramolecular addition onto the ,-unsaturated phosphonate (4.10), forming the C-
ring. The anion (4.11) would then attack the carbonyl of the ester, forming the B-ring 
(4.12). Finally, oxyanion (4.12) would reform the carbonyl by eliminating methoxide, a 
synthetic pathway which was precedented.
143-146 It was also envisioned that the methoxide 
species  could  eventually deprotonate  -keto phosphonate  (4.2)  to  in  situ  generate  key 
enolate  (4.8)  (Scheme  4.5)  that  would  allow  a  one-pot  C-B-ring  formation  and  C10-
alkylation sequence. 
 
Scheme 4.5 
 
An alternative synthetic pathway could also be expected from oxyanion (4.12) as shown in 
Scheme 4.6. 
 
Scheme 4.6 
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Instead  of  eliminating  methoxide,  oxyanion  (4.12)  could  undergo  an  IntraMolecular 
Horner-Wittig (IMHW) reaction that would lead to enol ether (4.14). IMHW reactions on 
esters leading to enol ethers were precedented,
147-149 but from the outset it was not clear 
which pathway would be adopted by the planned domino C-B reaction.  
4.2.3  Lessons learned from previous studies by R. Clarkson
21 
 
As already mentioned several times, this project was first investigated by R. Clarkson
21 
who  did  extensive  research  towards  achieving  this  domino  C-B  reaction.  For  clarity 
reasons,  only  the  key  lessons  learned  from  his  previous  work  are  summarized  in  the 
following sections.  
4.2.3.1  Lesson 1: C17-ketone protection requirement prior to cyclisation/ Choice 
of the base for the halogen/metal exchange. 
 
The  first  key  lesson  learned  was  that  if  the  cylisation  was  conducted on  a  non  C17-
protected ketone (3.2), the desired trans-hydrindane compound (4.15) was formed together 
with the undesired bicyclo-[3.2.0]-heptane (4.16) (Scheme 4.7).  
 
Scheme 4.7 
 
Initial investigations also looked at the choice of base and the effect of additives known to 
be beneficial  in halogen/metal  exchange-intramolecular  cyclisations.
150-158 Interestingly, 
nBuLi or lithium-2-thienylcyanocuprate were not strong enough to initiate any reaction 
and the starting material was recovered in  high  yields.  In contrast, 
tBuLi  was able to 
promote this reaction and depending on the additives, various ratios of (4.15) and (4.16) 
were obtained.  
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4.2.3.2  Lesson 2: Protection of the C17-ketone 
 
Having established that 
tBuli was the base of choice for the halogen/metal exchange, the 
second key lesson learned was that the protection of the C17-ketone in (3.2) was not an 
easy task. Protection of the ketone as either a hydrazone
159 or as a cyanohydrin
160 were 
both irrelevant as they would be suitable electrophiles for cyclization to take place. 
Many  other  protecting  groups  were  explored:  the  O,O-acetal  formation,
161  the 
hemithioacetal  formation,
162  or  protection  as  an  enamine.
163  In  each  cases,  either  no 
reaction took place, side-reactions were observed or very low yields were obtained.  
However, success came when protection of the ketone (3.2) as a silyl enol ether (4.17) was 
attempted (Scheme 4.8).
164 
 
Scheme 4.8 
Taking advantage of those results, the C-ring formation was first explored. 
4.2.4  Preamble to a successful domino C-B reaction: C-ring formation 
 
As it was suspected that the C-ring cyclisation would be a more difficult process than the 
B-ring formation, it was decided to investigate the first step of the domino cyclisation. The 
1,4-addition/alkylation  product  (3.1)  was  chosen  as  it  was  directly  available  in 
considerable quantities. 
4.2.4.1  C17-ketone protection 
 
Given the high lability of TMS enol ethers,
163 the C17-ketone protection was achieved as a 
TBDMS enol ether using TBDMS-OTf (Scheme 4.9).
21,164  
 
Scheme 4.9 75 
 
 
Using 3.0 equiv of TBDMS-OTf at -50 °C afforded the desired silyl enol ether (4.18) in 
very  good  yield.  After  3  hours  the  reaction  was  worked-up  and  purified  by  column 
chromatography using pre-neutralized silica gel; affording the enol ether (4.18) in 86% 
yield. Having obtained the C17-protected compound (4.18), the C-ring cyclisation could be 
investigated. 
4.2.4.2  C-ring formation 
 
Following previous studies,
21 the best conditions for this C-ring formation were found to 
be the use of 
tBuLi as a base. The temperature was also found to be extremely important 
so as to achieve control on the highly reactive 
tBuLi; meaning the lower the temperature 
the better the results were (Scheme 4.10). 
 
Scheme 4.10 
 
In practice, the reaction was conducted  at -116 °C, by  forming  an EtOH/N2  slurry.
165 
Occasionally the reaction mixture became frozen at this temperature, in which case it had 
to be removed from the cold bath and stirred until homogeneous. The reaction could then 
be replaced into the cold bath and the 
tBuLi addition continued. This procedure could be 
used without incurring any problems or even loss in the yield of product obtained. 
This result was obviously of great importance: the anion (4.20) (Figure 4.1) must have 
been formed which should then enable a successful domino process, as B-ring cyclisation 
could occur if an appropriate electrophile was also present in the molecule (for instance, a 
methyl ester like (4.21)).  . 
 
Figure 4.1 76 
 
 
The above compound was obtained as a single diastereoisomer as determined by NMR. 
Although the stereochemistry of (4.19) couldn’t be proven at this point, it was expected 
that the hydrogen on C9 adopts the -position. This configuration was expected because it 
would be obtained through the lowest energy reactive conformation. Scheme 4.11 shows a 
three  dimensional  projection  of  this  cyclization  including  the  expected  reactive 
conformation. The 
1H NMR spectrum shows a 
3JH8-H9 of 10.0 Hz, which indicates that H8 
and H9 adopt an anti conformation as shown in (4.23). 
 
Scheme 4.11 
 
4.2.4.3  Establishing the C-ring formation stereochemistry 
 
In parallel to the main project (part 4.2.5), further studies on the C-ring cyclised adduct 
(4.19) were conducted in an attempt to prove the stereochemistry involved, by preparing 
the acid derivative (4.26) which was hoped to be crystalline (Scheme 4.12).  
 
Scheme 4.12 
 
The C-ring product (4.19) was treated with TBAF
166 in THF to afford the deprotected 
ketone  (4.24)  in  excellent  yield.  The  acetal  (4.24)  was  then  hydrolysed  using  cerium 
ammonium  nitrate  (CAN)  as  reported  by  Markó  and  co-workers.
167,168  Finally,  the 
intermediate aldehyde (4.25) (not shown)  was  smoothly oxidized to the corresponding 
acid using sodium chlorite
169,170 with excellent yields. As expected, the desired acid (4.26) 
could be recrystallised from DCM/hexane to afford fine white crystals in excellent yield. 77 
 
X-ray  crystallographic  analysis  (Figure  4.2)  allowed  determination  of  the  relative 
stereochemistry, which confirmed that the cyclisation occurred as shown above (Scheme 
4.11). 
 
Figure 4.2: X-Ray structure of (4.26)  
 
The expected C9-stereochemistry was thus clearly demonstrated. 
4.2.5  Synthesis of the methyl ester domino C-B precursors (4.1) and (4.33) 
 
To achieve the tandem cyclisation, the acetal group was converted to a methyl ester. From 
the 1,4-addition products (3.1) and (3.2), a number of functional group transformations 
were required to prepare the domino precursors (4.1) and (4.33). 
4.2.5.1  Acetal to methyl ester transformations 
 
As shown in Scheme 4.13, the methyl esters (4.31) and (4.32) were formed by cleavage of 
the acetal group and subsequent ester formation of the intermediate aldehyde or acid. 
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Scheme 4.13  
It was found
21 that the best conditions for the acetal hydrolysis involved using cerium 
ammonium nitrate (CAN) as reported by Markó and co-workers.
167,168 The acetals (3.1) 
and (3.2)  were  stirred  in a  buffer  suspension (pH 8)  of CAN  in  an  acetonitrile/water 
solvent system at 60 °C until the reaction had gone to completion to afford the desired 
aldehydes (4.27) and (4.28) in very good yields. The only drawback was that the reaction 
would appear to have gone to completion as judged by TLC, but still have up to 10% of 
the acetal remaining, in which case the reaction was repeated on the crude mixture without 
loss in yield. 
The next step, the direct oxidation of the aldehyde to the methyl ester (4.31), was not 
optimised and was only attempted with the aldehyde (4.27). Usually, this esterification is 
accomplished via a two-step procedure where the aldehyde is oxidized to the acid which is 
then esterified. 
Unfortunately, the use of Oxone
®
 (KHSO5) in MeOH only afforded the desired methyl 
ester (4.31) in 41% yield.
171 This was quite disappointing as the starting material was fully 
consumed (TLC analysis). Actually, the main spot observed was an intermediate which 
decomposed during the work-up to partially recover the starting aldehyde (4.27) in 23% 
yield. The process was not optimised as the two-step preparation via the carboxylic acid 
was preferred.  
Indeed, the aldehydes (4.27) and (4.28) were smoothly oxidized to the corresponding acids 
using  sodium  chlorite
169,170  with  excellent  yields.  Despite  similar  results  for  both 
compounds,  only the C13-methyl acid  (4.29)  could be  recrystallized from Et2O  which 
allowed access to crystallographic analysis as shown in Figure 4.3.  
 
Figure 4.3: X-Ray structure of (4.29) 79 
 
On the time-scale of this PhD, this was the very first X-Ray obtained which proved the 
relative stereochemistry at C8, C13 and C14 involved during the 1,4-addition/alkylation 
process (Chapter 3), as well as the trans-configuration of the unsaturated phosphonate. 
The final esterification reaction leading to (4.31) and (4.32) using MeI  in presence of 
K2CO3 in DMF gave good results.
172,173 After 2 h of reaction, the desired esters could be 
isolated by column chromatography. Obviously, the use of diazomethane would have been 
advantageous for this type of reaction, but this was not possible for safety reasons. 
4.2.5.2  C17-ketone protection 
 
Chemoselective protection of a ketone as a silyl enol ether in the presence of an ester was 
precedented
163,164,174,175 by using 1-2 equiv of TBDMSOTf at room temperature. Following 
these procedures, the methology used to prepare the silyl enol ether (4.18) (part 4.2.4.1) 
was employed (Scheme 4.14).  
 
Scheme 4.14 
 
Using 3 equiv of Et3N/TBDMSOTf at -50 °C, the desired silyl enol ethers (4.33) and (4.1) 
were obtained in excellent yields. After 2 h, the reaction was worked-up and purified by 
column chromatography using pre-neutralized silica gel; affording the enol ether (4.33) in 
91% yield. However, the yield was dependent on the concentration of the reaction. When a 
concentration  of  0.05  M  was  used,  only  13%  of  the  ketone  (4.31)  had  reacted.  By 
increasing the concentration to 0.25 M, the reaction was complete after 2-3 h at -50 °C. 
The silyl enol ether protection was found more difficult with the crucial ketone (4.32). 
Under the same conditions, the reaction required 9 h to reach completion to afford (4.1) in 
75% yield. By increasing the concentration to 0.5 M, the reaction was complete after 2 h 
affording (4.1) in 82% yield. The temperature was also found critical. Above -30/-20 °C, 
only baseline material was observed by TLC.  80 
 
Although the silyl  enol ether  protection was very  efficient,  the protection of the C17-
ketone was also attempted as an O,O-acetal, which would  have been more stable and 
easier to handle for the reactions to follow (Scheme 4.15). 
 
Scheme 4.15 
 
The use of trimethyl orthoformate
161 as an internal drying agent only afforded, after 24 h 
of reaction, the desired acetal (4.34) in 44% yield, with only 18 % of recovered starting 
material (4.31). The O,O-acetal protection was not further optimised as those results were 
in accord with previous studies by R. Clarkson.
21   
To conclude, the desired methyl ester domino precursors (4.1) and (4.34) were synthesised 
in 4 steps from the 1,4-addition products (3.1) and (3.2), which were amenable to scale-up. 
4.2.6  Attempted domino C-B reactions 
 
4.2.6.1  Main domino C-B reactions 
 
The domino C-B cyclisation was conducted under the same conditions used previously for 
the C-ring formation (Scheme 4.16). 
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Scheme 4.16 
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The silyl enol ethers (4.1) and (4.33) were treated with 
tBuLi at -116 °C in THF for 15 min 
and then allowed to warm to room temperature. The desired -keto phosphonates (4.2, 
4.35) and (4.2, 4.35) were isolated along with the monocyclised esters (4.38, 4.39) and 
the products resulting  from the nucleophilic attack on the  ester by 
tBuLi (4.36, 4.37). 
Table  4.1  presents  characteristic  results  obtained  for  the  methyl  and  ethyl  series. 
Optimisation of the reaction was achieved with the C13-methyl series showing that a few 
parameters drove the effectiveness of the process. 
Entry  R =  [C] 
(mol/L) 
Equiv of 
tBuLi / 
Method of 
addition 
Yield of Products (%) 
(4.2) / 
(4.35) 
(4.2) / 
(4.35) 
(4.36) / 
(4.37) 
(4.38) / 
(4.39) 
(4.33) / 
(4.1) 
1
a  Me  0.14  2.2 / dropwise  42  0  18  6  12 
2
a  Me  0.08  2.2 / dropwise  36  0  21  c  16 
3
b  Me  0.2  2.4 / dropwise  27  10  22  9  10 
4
b  Me  0.2  2.4 / very fast  46  5  14  11  6 
5
b  Me  0.12  2.4 / very fast  21  15  28  13  8 
6
b  Et  0.2  2.4 / very fast  39  11  15  10  7 
a = scale of 0.4 mmol, 
b = scale > 2 mmol, 
c = not isolated. 
Table 4.1 
 
While  conducting  initial  experiments  on  small  scale  (entries  1-2),  the  C10--epimer 
(4.35) was never observed. It also appeared that the use of 2.2 equiv of 
tBuLi was not 
enough to fully initiate the reaction as the starting material was recovered in 12% yield 
(entry 1). The biggest issue at this point was the formation of the undesired monocyclised 
ketone  (4.36)  as  separation  of  compounds  (4.35)  and  (4.36),  due  to  the  need  of 
neutralized  silica,  was  particularly  complex.  Despite  several  attempts,  separation  by 
preparative HPLC or using alumina was unsuccessful. Conducting the reaction under more 
diluted conditions, in order to disfavor the intermolecular side-reaction of 
tBuLi towards 
the  ester  actually  had  the  opposite  effect  (entry  1  versus  2),  and decreased  yields  of 
(4.35) were observed. Other experiments looked at the use of activated molecular sieves, 
without change in the outcome of the reaction. Conducting the reaction in Et2O instead of 
THF was a complete failure as none of the previously mentioned products were observed. 
While scaling-up the reaction, the concentration was increased as well as the amount of 
tBuLi (entry 3), in an attempt to avoid any recovery of starting material (4.33). Clearly, 
adding 2.4 equiv of 
tBuLi dropwise had the same effect as decreasing the concentration. 82 
 
This led to an increased yield of undesired monocyclised ketone (4.36). The breakthrough 
came when instead of adding 
tBuLi dropwise, it was added very quickly (entry 4). The 
desired -keto phosphonates (4.35) and (4.35) were isolated in 51% combined yield. 
The procedure was successfully repeated with the precious C13-ethyl precursor (4.1) in 
which case the main isomer (4.2) was obtained in 39% and minor isomer (4.2) in 11% 
yield (entry 6). 
Although it is still unclear why such different ratios of the C10--epimers and C10--
epimers were obtained, one of the reasons was the purification using pre-neutralized silica 
gel. Indeed, on large scale which also meant a lengthy separation, epimerisation of (4.35) 
and  (4.2)  was  clearly  observed  during  the  column  chromatography  which  led  to 
increased yields of (4.35) and (4.2). 
The stereochemistry at the newly established C10-epimeric centre was first determined by 
1H NMR as shown in Figure 4.4 below for the C13-ethyl products (4.2, 4.2). 
Chemical Shift (ppm)
0.0 1.0 2.0 3.0 4.0 5.0
Chemical Shift (ppm)
0.0 1.0 2.0 3.0 4.0 5.0   
Figure 4.4  
 
Significant differences are displayed in the medium-field region ( =  3.3 to 3.6 ppm) 
corresponding to the protons on C10. As expected, main isomer (4.2) displayed a higher 
Jax-ax coupling constant, between H on C10 and H on C9, of 8.7 Hz whereas minor isomer 
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(4.2)  displayed  a  Jeq-ax  coupling  constant  of  4.0  Hz.  The  stereochemistry  was  later 
unambiguously proven by X-Ray of the deprotected derivatives (part 4.2.6.3).  
As a conclusion, the domino C-B reaction was successfully achieved for both C13-methyl 
and C13-ethyl series, in good yields (50-51%) for a challenging reaction. By increasing the 
concentration and very fast addition of 
tBuLi, the formation of the undesired monocyclised 
ketones  (4.36,  4.37)  could  be  limited,  but  the  monocyclised  esters  (4.38,  4.39)  were 
unfortunately always present. Avoiding the formation of the monocyclised side-products 
was clearly desired and other substrates were envisioned that could also undergo a domino 
C-B  cyclisation  (part  4.2.7  and  4.2.8).  Finally,  the  -keto  phosphonates  were  quite 
unstable and could not be stored for a long time despite storage in the freezer even flushed 
with N2.   
4.2.6.2  Alternative domino C-B reaction 
 
Initial investigations on the domino C-B reaction also looked at a direct deprotection of 
the C17-silyl enol ether by quenching the reaction with HCl 2M (Scheme 4.17) 
 
Scheme 4.17 
 
In this case, despite  no  increase  in  the  yield of  desired tricyclic product  (4.40),  the 
separation with the undesired monocyclised ketone (4.42) could easily be achieved. This 
was obviously of great importance for identification purposes. However, this sequence 
was only attempted once, as the C17-protection was required for the construction of the A-
ring. 
4.2.6.3  Derivatisation of the domino C-B products 
 
Because adducts obtained from the domino C-B reaction were quite unstable, deprotection 
of the C17-ketone was achieved for  characterisation  purposes, also  allowing access to 
crystallographic determination of the relative  stereochemistry.  Scheme  4.18 shows the 84 
 
deprotection of the main isomers (4.35) and (4.2) obtained during the domino  C-B 
reaction. 
 
Scheme 4.18 
 
Upon  TBAF  deprotection (2  equiv),
166  a  mixture of the two deprotected  phosphonate 
epimers was  obtained.  Although  completion  was  observed  after  2  min  of  reaction,  in 
which  case  only  the  C10--epimers  (4.40,  4.43)  were  observed,  the  reaction  was 
deliberately conducted for over 1 h, allowing for epimerisation at the C10-centre to also 
afford the (4.40, 4.43) epimers. 
Depending on the C13-series, recrystallisation in DCM/hexane gave crystals for (4.40) 
and (4.43) (Figures 4.5, 4.6). 
 
 
 
Derivatisation was also achieved on the monocyclised esters (4.38, 4.39) (Scheme 4.19). 
 
Scheme 4.19 
 
Figure 4.5: X-Ray structure of (4.40)  Figure 4.6: X-Ray structure of (4.43) 85 
 
Deprotection with TBAF proceeded  smoothly,  affording (4.41) and (4.44) in excellent 
yields. Saponification
176 with NaOH in MeOH afforded carboxylic acids (4.26) and (4.45). 
Recrystallisation of (4.45) in DCM/hexane gave access to the X-Ray shown in Figure 4.7. 
An  X-Ray  of  (4.26)  had  previously  been  obtained  (Figure  4.2),  and  the  NMR  data 
following this path were consistent with the previously obtained NMRs. 
 
Figure 4.7: X-Ray structure of (4.45) 
 
Obviously, monocyclised ketones (4.36, 4.37) were also deprotected (Scheme 4.20). 
 
Scheme 4.20 
 
Despite many attempts, none of the diketones (4.42, 4.46) could be recrystallised. The C9-
stereochemistry  involved during the domino C-B reaction  having already been proven 
several times, an unambiguous proof of the stereochemistry of those diketones wasn’t 
really required. 
4.2.7  Domino C-B reactions with Weinreb amides 
 
In order to avoid/limit the formation of the monocyclised esters during the domino C-B 
reaction, the Weinreb amides (4.47) and (4.48) were also envisioned (Scheme 4.21). 86 
 
 
Scheme 4.21 
 
For  instance,  employing  a  Weinreb  amide  (4.48)  would  lead,  upon  domino  C-B 
cyclisation, to a tetrahedral intermediate (4.49) by chelating the counter-cation Li, which 
upon  work-up  would  lead  to  the  desired  -keto  phosphonate  (4.2)  (Scheme  4.21). 
Formation  of  the  tetrahedral  intermediate  (4.49)  was  hoped  would  favor  the  B-ring 
cyclisation. 
4.2.7.1  Synthesis of the domino C-B precursors (4.47) and (4.48) 
 
The desired Weinreb amides were easily prepared from the carboxylic acids (4.29, 4.30) 
(Scheme 4.22). 
 
 
Scheme 4.22 
 
Initial experiments to  prepare (4.50)  following literature examples
177 using 1 equiv of 
DCC in combination with 1 equiv of Et3N and 1 equiv of amine was a very slow process, 
needing the addition of an extra 0.5 equiv of all the reagents to reach completion. The 
desired  Weinreb amide  (4.50)  was  then  isolated  in 56%  yield  along  with 21% of the 
undesired urea (4.52) (Figure 4.8).   
 
Figure 4.8 87 
 
 
The procedure was then modified, using DIC instead of DCC; and directly adding to the 
acids (4.29) and (4.30) 1.5 equiv of all the reagents. This procedure afforded the desired 
Weinreb amides (4.50) and (4.51) in 83% and 86 % yield respectively, after 2 h of reaction 
and with only traces of undesired rearranged ureas like (4.53) (TLC).  
Protection of a  ketone  in the presence of an amide as a  silyl enol ether  is quite well 
documented
178-184 and is reported to be usually quite high yielding (Scheme 4.23). 
 
Scheme 4.23 
 
However, using our standard procedure
164 with 3 equiv Et3N/TBDMSOTf at -50 °C, the 
expected profile by TLC monitoring was not observed, since silylation at the C17-ketone 
induces a great decrease in polarity. Warming to room temperature was not efficient either 
and adding more TBDMSOTf/Et3N only led to decomposition. 
The  combination  of  collidine/TBDMSOTf  was  then  explored.
183  Using  10  equiv  of 
collidine with 6 equiv of TBDMSOTf, the desired TLC profile was observed. However, 
after  24  h  of  reaction,  only  a  small  part  of  the  starting  material  had  reacted  and  a 
competitive decomposition reaction could be observed. Adding more TBDMSOTf led to 
decomposition and removal of the collidine from the desired product was problematic. 
Collidine was replaced by pyridine, and after many attempts, the best conditions found 
were the use of 10 equiv of pyridine with successive additions of 3 equiv TBDMSOTf in 
very diluted conditions, so  as to  avoid  complete  decomposition.  In the best cases, the 
desired silyl enol ethers (4.47) and (4.48) were isolated in 16% and 22% respectively 
along with 25-30% of starting material.  
Pre-mixing LDA with TBDMSOTf at -78 °C prior to the addition of the Weinreb amide 
(4.51), known as the in situ quench technique,
185,186 only led to the recovery of the starting 
material.  
The strategy needed to be modified, in which case the C17-ketone had to be protected prior 
to the introduction of the Weinreb amide (Scheme 4.24).
187 88 
 
 
Scheme 4.24 
 
In practice, the amine (6 equiv) in THF was treated with 
nBuLi (9 equiv) from -78 °C to 
room temperature until complete dissolution of the salt. A solution of the ester (4.1) in 
THF was then added at -78 °C. The reaction was complete after 1 h leading to the desired 
Weinreb amide (4.48) in excellent yield.  
4.2.7.2  C17-ketone protection with LDA/TBDMSOTf: B-ring cyclisation 
 
While examining protection of the Weinreb amide (4.51) with LDA/TBDMSOTf, some 
very interesting side reactions were observed, which are described in this section (Scheme 
4.25).
188,189  
 
Scheme 4.25 
 
Treatment of the Weinreb amide (4.51) with LDA at -78 °C for 2 h followed by quenching 
with TBDMSOTf (2.5 equiv) led to the unexpected B-ring cyclised adduct (4.56) in good 
yield as a (4/1) mixture of diastereoisomers. The use of 2.5 equiv of LDA was necessary 
for the reaction to go to completion, or only starting material was recovered with (4.56) in 
lower  yields. Interestingly,  no traces of C17-silyl enol ether were observed despite the 
large excess of LDA.  89 
 
Also interesting, the intermediate oxyanion (4.55), readily trapped at -78 °C, could also 
undergo elimination at room temperature leading to the -keto phosphonate (4.57). 
Indeed, when Weinreb amide (4.51) was treated with 2.5 equiv of LDA at -78 °C for 15 
min,  then  warmed  to  room  temperature,  quenching  with  TBDMSOTf  didn’t  trap  the 
oxyanion as the unsaturated -keto phosphonate (4.57) was already formed in good yield 
(Scheme 4.25). Those results were very interesting, since alternative C-ring cyclisation 
pathways could now be envisaged from either (4.56) or (4.57).  
  
Although the presence of oxyanion (4.55) had been demonstrated, its origin still remains 
unclear.  As  an  alternative  to  the  direct  deprotonation  of  the  unsaturated-phosphonate 
(4.51) as shown in Scheme 4.25, the possibility of a Michael Initiated – Condensation – 
Elimination (MICE) sequence also exists (Scheme 4.26).
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Scheme 4.26 
 
Following this pathway, LDA would add onto the ,-unsaturated phosphonate (4.51), 
initiating the B-ring cyclisation  leading to  intermediate (4.58).  A second equivalent of 
LDA would then re-establish the alkene via elimination of the amine, leading to oxyanion 
(4.55).  
Conversion of (4.56) to the corresponding -keto unsaturated phosphonate (4.57) was also 
attempted, with some unexpected results (Scheme 4.27). 
 
Scheme 4.27 
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Very surprisingly, treatment of (4.56) with TBAF led to the desired -keto phosphonate 
(4.57) in 57% but also gave rise to a B-ring opening side reaction. Indeed, the Weinreb 
amide  (4.51)  was  also  obtained  in  26%.  To  the  best  of  our  knowledge,  this  is 
unprecedented in the literature, and suggests that the reaction of (4.54) to (4.55) can be 
reversed.  The  strong  red  colour  observed  upon  addition  of  TBAF  also  suggests  the 
presence of phosphonium anion (4.54).  
4.2.7.3  Attempted domino C-B reactions  
 
The domino C-B cyclisation was conducted under the same conditions successfully used 
previously for the methyl esters (part 4.2.6) (Scheme 4.28). 
 
Scheme 4.28 
 
The Weinreb amide (4.48) was treated with 
tBuLi (2.4 equiv) at -116 °C in THF for 15 
min and then allowed to warm to room temperature. Unfortunately, the reaction was a 
complete failure and no trace of the desired -keto phosphonate (4.2) was observed. Three 
products could clearly be observed by TLC but separation was unsuccessful and none 
were identified. Assuming the conditions were too harsh, the reaction was repeated with 
gradual temperature increase from -116 °C to room temperature and careful monitoring of 
the reaction. Above -78 °C, a very complex mixture was observed, and (4.2) was not 
isolated. 
 
As a single product was observed at -78 °C, the reaction was repeated one last time with 
TBDMSOTf quenching (2.5 equiv) so as to trap any oxyanion intermediate as previously 
achieved when the B-ring cyclisation was observed (Scheme 4.29). 91 
 
 
Scheme 4.29 
 
Unfortunately,  under  those  conditions,  tricyclic  phosphonate  (4.59)  was  not  isolated. 
Instead, the monocyclised C17-ketone (4.60) was obtained in 62% yield. Quite clearly, B-
ring cyclisation didn’t occur at -78 °C, and using an excess of TBDMSOTf under those 
conditions possibly introduced enough TfOH leading to deprotection of the C17-silyl enol 
ether.  
Clearly, the Weinreb amide was not electrophilic enough to undergo a B-ring cyclisation, 
which is in apparent contrast with the cyclisation of (4.51) to give (4.57) in excellent yield. 
.  
4.2.8  Domino C-B reactions with other substrates 
 
Two other substrates were envisioned in order to obtain better results during the domino 
C-B reaction: a MEM-ester that could also chelate the counter cation Li, and a phenyl 
ester. 
4.2.8.1  The attempted synthesis of a MEM-ester domino C-B precursor 
 
The  attempted  synthesis  of  a  MEM-ester  domino  C-B  precursor  (4.62)  is  shown  in 
Scheme 4.30. 
 
Scheme 4.30 
 
The carboxylic acid (4.30) was treated with DIPEA (1.1 equiv) in presence of MEM-Cl 
(1.2 equiv) in DCM at 0 °C for 2 h.
190 The desired MEM-ester (4.61) was isolated in good 92 
 
yield. Protection of the C17-ketone was attempted following the procedure used several 
times during the project.
164 Unfortunately, only decomposition was observed, even at -50 
°C, so no further experiments were attempted.  
4.2.8.2  Domino C-B reaction with a phenyl ester (4.64) 
 
The synthesis of a phenyl-ester domino C-B precursor (4.64) is shown in Scheme 4.31. 
 
Scheme 4.31 
 
The phenyl ester (4.63) was easily prepared from the carboxylic acid (4.30) following a 
literature  procedure  in  good  yield.
191  Protection  of  the  C17-ketone  using  3  equiv  of 
Et3N/TBDMS-OTf at -50 °C afforded the desired silyl enol ether (4.64) in good yield after 
2 h of reaction. None of the steps were optimized and were conducted on small scale. 
Enough material was obtained to attempt the domino C-B cyclisation reaction (Scheme 
4.32). 
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Scheme 4.32 
 
Surprisingly, the results were once again disappointing. The behaviour of the reaction was 
completely different than when a methyl ester  was employed. Only the desired -keto 
phosphonate (4.2) and the monocyclised ketone (4.37) were isolated respectively in 20 
and 12% yields. Lots of baseline material was observed however. This was obviously a 
very disappointing conclusion to the attempted optimizations of the domino C-B reaction.    
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4.2.9    Conclusion 
 
The domino C-B cyclisation reaction was successfully achieved for the C13-methyl and 
the C13-ethyl series on a methyl ester precursor. The stereochemistry involved during the 
process  was  unambiguously  proven  on  separate  occasions.  Attempts  to  optimize  this 
complex reaction with other substrates were however all equally unsuccessful.   94 
 
Chapter  5,  Desogestrel:  A-ring  annelation  and  synthesis 
conclusion. 
5.1  Introduction 
 
As mentioned in the retrosynthetic analysis, the last key step of the synthesis from -keto 
phosphonate  (4.2)  was  planned  to  be  an  A-ring  annelation  via  a  Horner-Wadsworth-
Emmons  (HWE)  reaction  with  aldehyde  (4.3),
140  hydrogenation  of  the  enone  (4.4) 
followed by acid mediated aldol/dehydration,
31 that would lead to the known diketone
31,48 
(1.71) (Path A, Scheme 5.1).  
 
Scheme 5.1 
 
However, as the HWE reaction with aldehyde (4.3) could not be achieved, the plan was 
modified.  HWE reaction with formaldehyde would lead to the enone (5.1) that would 
undergo a complex Michael addition/cyclization/dehydration/decarboxylation process that 
would also construct the A-ring (Path B).
31,192 
5.2  The Horner-Wadsworth-Emmons reactions 
 
5.2.1  Initial experiments with aldehyde (4.3) 
 
HWE  reactions  with  -keto  phosphonates  are  well documented.  They  usually  involve 
K2CO3 in THF,
193 dioxane
194 or EtOH.
195 Other examples involve NaH in THF.
196,197 The 
HWE  reaction  was  first  investigated  with  the  two  -keto  phosphonates  (4.35)  and 
(4.40) obtained previously with similar results when the aldehyde
140 (4.3) was employed 
(Scheme 5.2). 95 
 
 
Scheme 5.2 
 
In both cases, the use of aqueous K2CO3 in THF
193 never afforded the desired products. 
The starting material was  in each case recovered or partially recovered in the case of 
(4.35) as the silyl enol ether partially decomposed. Using NaH
196,197 on the deprotected 
-keto phosphonate (4.40) gave a very complex mixture of compounds where the desired 
HWE adduct (5.2) was not observed but what seemed to be the result of an aldol reaction. 
Unfortunately,  the  aldol  adduct  could  not  be  separated  from  the  starting  phosphonate 
(4.40).  NaH  conditions  were  not  attempted  with  the  protected  -keto  phosphonate 
(4.35) as a promising procedure using DBU/LiCl/MeCN
198 was preferred. Once again, 
no HWE product (5.3) was observed but the result of a competitve aldol reaction (5.4) in 
36% yield (Figure 5.1). 
 
Figure 5.1 
 
Those preliminary results were very disappointing as the phosphonate moiety didn’t react 
with any conditions used, probably due to steric hindrance. A more reactive aldehyde had 
to  be  employed  and  paraformaldehyde/formaldehyde  seemed  the  best  choice.  This  is 
discussed in the section below. 
5.2.2  HWE reactions with formaldehyde 
 96 
 
The HWE reaction was investigated on the -keto phosphonate (4.35) with very different 
results  when  paraformaldehyde  or  formaldehyde  was  used,  as  well  as  the  base  used 
(Scheme 5.3). 
 
Scheme 5.3 
 
Table 4.2 presents a part of the results obtained during the investigation process. In each 
case, the reaction was carried out at room temperature on a 0.2 mmol scale. 
Entry  Conditions 
Yield of products (%) 
(5.5)  (5.6)  (4.35)  (4.35) 
1  (CH2O)n (1.1 equiv), K2CO3  (1 equiv), THF, 8h  /  /  62  20 
2  (CH2O)n (3 equiv), K2CO3  (3 equiv), THF, 20h  traces  6  40  33 
3  (CH2O)n (1.1 equiv), K2CO3 8M (15 equiv), THF, 8h  8  /  43  25 
4  (CH2O)n (4 equiv), K2CO3 8M (15 equiv), THF, 8h  14  /  36  18 
5  (CH2O)n (4 equiv), K2CO3 8M (15 equiv), THF, 20h  12  15  21  25 
6  CH2O (15 equiv), K2CO3 8M (15 equiv), THF, 5h  41  5  9  29 
7  CH2O (15 equiv), KOH 1M (1 equiv), THF, 1h  /  63  /  / 
8  CH2O (g) (4 equiv), NaH (1 equiv), THF  /  /  /  / 
Table 5.1 
 
This  HWE  reaction  proved  to  be  more  complicated  than  expected  as  the  starting 
phosphonate (4.35) didn’t show reactivity under the usual conditions. Hence, the use of 
(CH2O)n with K2CO3 was unsuccessful (entries 1, 2).
193 Only isomerisation of (4.35) to 
(4.35)  was  observed  in  these  cases  and  longer  reaction  times  led  to  the  partial 
deprotection of the silyl enol ether. Under these conditions, conducting the reaction in 
dioxane or DMF didn’t change the course of the reaction. The HWE was then attempted 97 
 
using a K2CO3 8M solution in large excess
193 with slightly better results. Using an excess 
of (CH2O)n was a little more efficient (entries 3, 4, 5) but again, lots of starting material 
was recovered and the reaction was too slow, meaning that longer reaction times mainly 
led to the formation of diol (5.6) resulting from a competitive aldol reaction. The fact that 
a mixture of isomers (4.354.35) was always obtained suggested that deprotonation of 
the -keto phosphonate occurred but then only slowly reacted with the aldehyde. 
To increase the reactivity, formaldehyde as a water solution (37% w/w) was used with 
better results (entry 6).
193 Using a large excess (15 equiv) of formaldehyde afforded the 
desired enone (5.4) in medium yields along with still 29% of the isomer (4.35). These 
results actually suggested that the isomer (4.35) was far less reactive and so a procedure 
had  to  be  found  to  achieve  that  reaction  as  fast  as  possible  in  order  to  avoid  the 
isomerisation as well as the competitive aldol reaction. 
To do so, KOH was used as a base (entry 7). After 1 h, all the starting material was 
consumed but  no  trace  of  desired  enone  (5.5) was  observed.  Instead,  only  diol  (5.6) 
resulting from a HWE reaction followed by an aldol reaction was obtained in 63% yield.  
A final experiment was attempted by deprotonating -keto phosphonate (4.35) with NaH 
(1 equiv) followed by the addition of gaseous formaldehyde (entry 8). The reaction led to 
a very complex mixture of products. 
So far, the enone (5.5) could only be synthesised in up to 41% which at least allowed 
investigating the next A-ring annelation. However, this enone couldn’t be caracterized as 
it  almost  immediately  dimerised,  via  a  hetero  Diels-Alder  reaction,  to  dimer  (5.7). 
Although this fact was precedented on this type of enone,
31 attempts to purify it with a 
very quick column chromatography or storage were not possible neither. This meant that 
the crude mixture, obtained after a quick work-up, had to be used straightaway for the A-
ring annelation (see part 5.3). 
 
It seemed also very clear that minor C10- isomer (4.35), obtained in various yields from 
the domino C-B reaction, would not react under those conditions. In which case it was 
easily converted to the C10- isomer (4.35) (Scheme 5.4). 98 
 
 
Scheme 5.4 
 
The C10- isomers (4.2, 4.35) were treated with 2 equiv of NaH in THF for 1 h which 
almost exclusively led to the C10- isomers after quenching (4.2, 4.35). 
5.2.3  Attempted dephosphonylation reactions 
 
Because at that time, the 41% obtained for the HWE reaction had not been achieved, other 
methodologies were explored. First, Liu and co-workers
199 described that the phosphonate 
functionality, being  to a ketone carbonyl, could be reductively removed using lithium 
naphthalenide and the ensuing enolate readily trapped by an alkylating agent (Scheme 
5.5). 
 
Scheme 5.5 
 
The reaction was attempted twice using allyl bromide as a model alkylating agent but 
under those conditions, only decomposition of the starting material was observed and the 
desired adduct (5.8) was not observed in any case. 
Investigations  also  looked  at  the  dephosphonylation  of  -fully  substituted  -keto 
phosphonates  using  LAH  as  described  by  Oh  and  co-workers.
200,201  In  that  case,  the 
phosphonate is used as a temporary activating group for -alkylation of a ketone (Scheme 
5.6). 
 99 
 
 
Scheme 5.6 
 
Once again, only disappointing results were obtained as the desired alkylated products 
(5.9) couldn’t be observed or isolated. However, the starting phosphonate (4.35) was in 
each case recovered in 30-35 % along with the isomer (4.35) in 60-65% meaning that the 
enolate  intermediate  was  formed but  the  alkylation  didn’t  take  place,  presumably  for 
hindrance reasons. 
5.3  A-ring formation: 7 reactions in a one-pot process 
 
The A-ring formation, planned as the last key step of the total synthesis would be achieved 
via  a  Robinson-type  annelation  which  has  been  used  on  separate  occasions  for  the 
construction of the A, B and D rings.
51 However, in our plan, that A-ring annelation would 
only be achieved after a Michael condensation between the methylene ketones (5.1, 5.5) 
and ethyl-acetoacetate (Scheme 5.7). 
 
Scheme 5.7 
 
The series of reactions consisting of a Michael condensation between a methylene ketone 
like (5.1, 5.5) and annulating agent, in situ alkaline cyclization-dehydration (5.11 → 5.12) 100 
 
to  form  in  our  case  the  A-ring  and  finally  decarboxylation  was  precedented  in  the 
literature.
31,192 
In practice, the crude methylene ketones (5.5, 5.1) obtained from the HWE reaction from 
(4.2, 4.35) and formaldehyde were treated with 2 equiv of ethyl acetoacetate to give 
intermediate (5.11). At this point, the reaction mixture was quenched with water in order 
to isolate intermediate (5.11). However, upon addition of water, disappearance of (5.11) 
from the reaction mixture was observed (TLC). Unfortunately, extraction of the product 
proved not possible at this stage. Acidification followed by TBAF treatment did lead to 
the desired steroid products (5.13) and (1.71) in respectively 22% and 19%, along with the 
deprotected  -keto  phosponates  (4.43)  and  (4.40)  in  31%  and  26  %  yields.  The 
procedure was then improved closely following the literature,
  31,192 while up-scaling, as 
shown in Scheme 5.7, by treating intermediate (5.11) with NaOH 5M for 30 min followed 
by  the  addition  of  HCl  2M.  Decarboxylation  of  (5.12)  was  successfully  achieved  by 
heating the crude mixture at 70 °C under high vacuum for 1 h. The desired diketones 
(5.13) and (1.71) were then obtained in respectively 27% and 32% yields, on a 100 mg 
scale of desired products. In those experiments, -keto phosponates (4.43) and (4.40) 
were not isolated. 
 X-ray crystallographic analyses (Figures 5.2 and 5.3) unambiguously proved the relative 
stereochemistry at the newly established C10 centres. 
 
 
 
Even if the overall  yields of (1.71) and (5.13) from (4.2) and (4.35) are quite low, 
taking in account that the HWE reaction is so far very limiting (~40% yield) and that in a 
single  operation  7  consecutive  reactions  occurred,  this  result  was  obviously  of  great 
Figure 5.2: X-Ray structure of (1.71)  Figure 5.3: X-Ray structure of (5.13) 101 
 
importance as (1.71) and (5.13) are known compounds
26,27,48 and the last key intermediates 
in our synthesis, the latest functionalisation reactions more or less already described. This 
also  meant that the formal syntheses of desogestrel and its C13-methyl analogue were 
completed. 
5.4  Total synthesis of desogestrel 
 
Although (1.71) is a known compound, it has only been successfully been employed in the 
industrial process of desogestrel.
21 However, initial experiments on very small scale were 
unsuccessful which compelled us to explore another route towards desogestrel (Scheme 
5.8).  
 
Scheme 5.8 
 
The first step involved a C5-thioacetal protection, followed by a Raney-Ni deprotection 
and finally introduction of the C17-ethinyl group.  
5.4.1  Dithioacetal protection 
 
The  selective  protection  of  the  C5-,-unsaturated  ketone  was  easily  achieved  as  a 
thioacetal (Scheme 5.9).
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Scheme 5.9 
 
Steroids  (5.13)  and  (1.71)  were  treated  with  ethane-1,2-dithiol  (1.9  equiv)  and  boron 
trifluoride-etherate  (0.8  equiv)  in  MeOH  for  16  h  at  room  temperature.  The  desired 102 
 
thioketals  (5.14)  and  (5.15)  were  obtained  in  excellent  yields.  X-ray  crystallographic 
analyses were also obtained for both steroids (Figures 5.4, 5.5). 
 
 
5.4.2  Desulfurization reactions 
 
Although desulfurization at the C5 position has been reported on separate occasions by 
Corey
23 or Tietze
26 using Li/NH3, this was not applicable with steroids (5.14, 5.15) due to 
the C17-ketone. Instead, desulfurization was achieved with Raney nickel (Scheme 5.10).
202 
 
Scheme 5.10 
 
The reaction proceeded well but in both cases, a migration of the double bond from the 
4,5 (5.16, 5.18) to the 3,4 (5.17, 5.19) was observed and separation by chromatography 
or recrystallization was not successful. Thus, the synthesis had to be continued with a 
mixture of isomers. 
5.4.3  Introduction of the C17-ethinyl group 
 
For the final introduction of the C17-ethinyl group, the angular ethyl group at C13, which 
is responsible for a 50-fold enhancement of biological potency relative to the C13-methyl 
analogue,
23 posed a great synthetic obstacle. 
Figure 5.4: X-Ray structure of (5.14)  Figure 5.5: X-Ray structure of (5.15) 103 
 
For instance, the ethinyl group was easily introduced for the C13-methyl analogue using a 
commercial solution of sodium acetylide (Scheme 5.11). 
 
Scheme 5.11 
 
The mixture of 4,5 (5.16) and 3,4  (5.17) isomers was treated with sodium acetylide (20 
equiv) in THF. The reaction was repeated twice. First, by adding the acetylide at -40 °C 
and then slowly warming to room temperature in which case steroids (5.20) and (5.21) 
were obtained in 76%, as a (80/20) inseparable mixture, after 16 h of reaction.  When 
acetylide was added at room temperature, the reaction was complete after 4 h and a yield 
of 74% was obtained.  
Interestingly,  under  the  same  conditions,  conducting  the  reaction  with  the  C13-ethyl 
steroids (5.18) and (5.19) only led to decomposition for both attempts. However, the total 
synthesis of desogestrel (1.14) was finally completed following the procedure used by 
Organon for the commercial synthesis of desogestrel (Scheme 5.12).
203  
 
Scheme 5.12 
 
Potassium acetylide was generated in situ by bubbling acetylene through a THF solution 
of KOtBu (5 equiv) at -25 °C for 1 h. A solution of steroids (5.18, 5.19) (1 equiv) in THF 
was then added and acetylene was passed through the mixture for 1 h at -25 °C. The 
reaction proceeded in very high yields and desogestrel (1.14) was obtained along with the 
3,4-isomer (5.22). Separation of the two isomers was not achieved however.  
 
 104 
 
5.5  Conclusion 
 
The total syntheses of desogestrel and its C13-methyl analogue have been successfully 
achieved. By employing a domino anionic cyclization, the stereoselective construction of 
the steroids C and B-rings was achieved, in a single operation. Construction of the A-ring 
was efficient, although the HWE reaction with -keto phosphonates proceeded in quite 
low yields. Final conversion led to desogestrel, which unfortunately could not be obtained 
pure. 105 
 
Chapter 6, Steroid C and B ring formation: Completion of 
Estrone total synthesis 
6.1  Introduction 
 
From the previously obtained phosphonate (3.3) and phosphonamide (3.4), only a few 
steps  were  required  to  complete  a  racemic  and  enantioselective  synthesis  of  estrone 
(Scheme 6.1). 
 
Scheme 6.1 
 
The last key step, from both (3.3) and (3.4), was a ring closing metathesis (RCM) that 
would allow the formation of a trans-hydrindene ring system intermediate (6.1). The RCM 
would also introduce the required C9-C11 double bond for the B-ring closure, through an 
intramolecular Heck reaction as described by Tietze.
34 Estrone would then be obtained in 
two steps via known reactions.
34,204 
6.2  The C-ring closing metathesis 
 
Although  the  RCM  leading  to  the  strained  trans-hydrindene  ring  system  was 
precedented,
205,206 those examples involved two terminal double bonds. RCM reactions 
involving ,-unsaturated phosphonates or phosphonamides are not well documented and 
have mainly been explored to enable the formation of P-heterocycles.
207-211 Achieving the 
RCM on phosphonate (3.3) and phosphonamide (3.4) required much optimization using 
different conditions,
64 and are therefore discussed separately. 
 
 
  106 
 
6.2.1  Racemic synthesis: RCM with phosphonate (3.3) 
 
With the phosphonate-based substrate (3.3),  the RCM
207,208,210-216 was achieved, taking 
advantage of the optimisations made by B. Guizzardi
64 whose best conditions were the use 
of 35 mol% 2
nd generation Grubbs catalyst in DCM as a 0.01 M solution (Scheme 6.2). 
 
Scheme 6.2  
 
Some results obtained during the optimisation process are shown in Table 6.1. 
Entry  catalyst 
catalyst  C  
Solvent 
T  Time  Yield of products (%) 
loading  (mol/L)  (°C)   (h)  (rac-6.1)  (rac-6.2) 
1
a  Grubbs II  5 mol%  0.05  DCM  40  48  24 
c 
2
a  Grubbs II  25 mol%  0.05  DCM  40  48  42 
c 
3  Grubbs II  35 mol%  0.01  DCM  40  24  56  6-7 
4  Grubbs II  35 mol%  0.01  toluene  80  48  54  2-3 
5
b  Grubbs II  35 mol%  0.01  toluene  80  48  50  3 
6  Hov-Gru II  35 mol%  0.01  toluene  80  48  61  traces 
a= previous results by B. Guizarddi, 
b = 2 x 17.5 mol %, 
c = yields not given, Grubbs II = Grubbs catalyst 
2
nd generation, Hov-Gru II = Hoveyda-Grubbs catalyst 2
nd generation.
 
Table 6.1 
 
When the reaction was carried out in DCM with 5 mol% Grubbs II catalyst and refluxing 
the solution for 48 h (entry 1),
215 the desired product was only isolated in 24%. Increasing 
the catalyst loading to 25 mol% (entry 2) led to a marked increase in yield.
213   
Since RCM reactions are also described as leading to different results depending on the 
concentration,
214 the reaction was repeated on a more diluted solution (entry 3). Using 35 
mol % Grubbs II catalyst, the bromide (rac-6.1) was obtained in acceptable yield along 
with the debrominated  adduct (rac-6.2). Separation of the two products could only be 
achieved by HPLC. The next parameter explored was the solvent effect.
212 
The reaction in refluxing DCM seemed faster than in toluene at 80 °C, giving under the 
same conditions (entry 3 versus 4) better yields of cyclised adducts after 24 h of reaction. 107 
 
However, the TLC profile was better with toluene and formation of debrominated adduct 
(rac-6.2) was almost avoided, so toluene was kept as the solvent for further experiments. 
Finally, replacing Grubbs catalyst for Hoveyda-Grubbs II catalyst (entry 6),
216 which was 
described as giving sometimes better results with toluene at 80 °C,
212 afforded (rac-6.1) in 
61% yield along with only traces of debrominated-adduct (rac-6.2). 
As a conclusion, the RCM C-ring closure with phophonate (3.3) was only achieved in 
moderate yields (up to 61%), requiring a pretty large 35 mol % catalyst loading, in accord 
with literature examples where strained ring systems are synthesised via a RCM.
213 
6.2.2  Enantioselective synthesis 
 
For the enantioselective synthesis of estrone, from phosphonamide (3.4), the RCM was 
only achieved at the very end of this PhD, in order to obtain clean characterization data. 
6.2.2.1  Phosphonamide RCM reactions 
 
Although RCM reactions on  phosphonamides were  precedented,
209 the attempts  by  B. 
Guizzardi
64 all resulted in very low yields with phosphonamide (3.4) (Scheme 6.3). 
 
Scheme 6.3 
 
Applying the then best conditions for the achiral phosphonate (3.3) (35 mol % Grubbs II 
catalyst  in refluxing  DCM as  a 0.01 M solution), the desired bromide (6.1) was only 
obtained in 6% yield. The phosphonamide (3.4) therefore needed to be derivatised prior to 
undergoing the RCM reaction. Very interestingly, after extensive research, she found that 
phosphonamide (3.4) could be easily hydrolysed to the corresponding phosphonic acid 
(6.3) that did undergo C-ring cyclisation with relatively good results (Scheme 6.4). 
 108 
 
6.2.2.2  RCM reactions with phosphonic acid (6.3) 
 
The hydrolysis of phosphonamide (3.4) was easily achieved by treatment with 2 N HCl in 
refluxing THF overnight (Scheme 6.4).
112,217 
 
Scheme 6.4 
 
Phosphonic acid (6.3) was obtained in 97% yield after simple acid work-up and was used 
without further purification. 
The ring closing metathesis on phosphonic acid (6.3) was performed applying the same 
conditions successfully employed with the racemic phosphonate (3.3) (Table 6.2). 
Entry  catalyst 
catalyst  C  
Solvent 
T  Time  Yield of products (%) 
loading  (mol/L)  (°C)   (h)  (6.1)  (6.2) 
1  Hov-Gru II  35 mol %  0.01  toluene  80  24  41  traces 
2  Grubbs II  35 mol %  0.01  DCM  40  24  44  4 
3
a  Grubbs II  35 mol %  0.01  DCM  40  24  58  n. d. 
a= previous results by B. Guizarddi, Grubbs II = Grubbs catalyst 2
nd generation, 
 Hov-Gru II = Hoveyda-Grubbs catalyst 2
nd generation, n.d. = not determined.
 
Table 6.2 
 
Conducting the RCM with Hoveyda-Grubbs II catalyst in toluene at 80 °C (entry 1),
212 
which  were  the  best  conditions  found  with  the  phosphonate  (3.3),  the  reaction  was 
complete after 24 h but only afforded bromide (6.1) in 41% yield. Grubbs II catalyst in 
refluxing DCM gave slightly better results (entry 2).
213 The enantiopure bromide (6.1) was 
then obtained in 44% yield along with 4% of debrominated adduct (6.2). Those results 
were quite disappointing, as previous results
64 could not be reproduced (entry 3), but at 
least enough material was obtained so as to complete the enantioselective synthesis of O-
methyl-estrone (1.113). However, to the best of our knowledge, this is the first example of 
a RCM where a phosphonic acid is present. 109 
 
6.3  B-ring closure and synthesis conclusion 
 
6.3.1  Heck reaction 
 
The  B-ring  closure  was  achieved  through  an  intramolecular  Heck  reaction  using  the 
Herrmann catalyst (1.57) as described in the estrone synthesis of Tietze (Scheme 6.5).
34  
 
Scheme 6.5 
 
A solution of bromide (6.1) and 
nBu4OAc in DMF/MeCN/H2O (1/1/0.2) was stirred at 
110-120 °C for 3 h in presence of 2 mol % catalyst to give steroid (6.4) in reproducible 
quantitative yields. The reaction didn’t present any problem as long as the solution was 
carefully degassed. This condition also applied to every solvent used in the work-up, since 
steroid (6.4) proved to be air sensitive and therefore had to be used straightaway; even 
overnight storage in the freezer led to partial decomposition. 
The Herrmann catalyst (1.57) was easily prepared following Herrmann and co-workers 
procedure as shown in Scheme 6.6.
218 
 
Scheme 6.6 
 
6.3.2  Reduction of the 11,12-double bond: synthesis of O-methyl-estrone 
 
For the final conversion of the Heck-ring closure product (6.4) to O-methyl-estrone, the 
11,12- double bond needed to be reduced but, more importantly, the C9 stereochemistry 
had to be inverted. To reduce the double bond, the estrone synthesis of Tietze was once 
again  followed,
34  where  the  transformation  was  achieved  through  a  hydrogenation 110 
 
catalysed by Pd/C using 1,4-cyclohexadiene as source of hydrogen. In Tietze’s estrone 
synthesis  using  intermediate  (1.124),  the  conversion  was  achieved  by  transfer 
hydrogenation upon isomerisation of the double bond to the 9-11 position,  which  led 
exclusively to the desired C9 stereochemistry (Scheme 6.7).  
 
Scheme 6.7 
 
This  isomerisation/hydrogenation  reaction  was  first  attempted  following  Tietze’s 
procedure  with  however  one  modification:  cyclohexene  was  used  instead  of  1,4-
cyclohexadiene as (6.4) couldn’t be stored and 1,4-cyclohexadiene was unavailable at this 
time, leading to the results shown in Scheme 6.8 and Table 6.3.  
 
Scheme 6.8  
 
Entry  Scale  C (mol/L)  Source of H2  Purity of (6.4)  Overall yield  Ratio 
(1.113)/ (6.5) 
1  0.10 mmol  0.025  cyclohexene  overnight stored  63%  70/30 
2  0.15 mmol  0.05  cyclohexene  freshly prepared  82%  70/30 
3  0.11 mmol  0.025  1,4-cyclohexadiene  freshly prepared  98%  70/30 
 
Table 6.3 
 
The reaction was attempted under different conditions, with the same ratio outcome as 
determined by 
1H NMR whatever the source of H2 used: formation of approximately 70% 
of the desired C8-9 trans-configuration (1.113) along with 30% of undesired C8-9 cis-
configuration (6.5). A yield of 98% was achieved by using a freshly prepared adduct (6.4) 111 
 
(entry 3); whereas an overnight-stored sample of (6.4) only led to 63% of a mixture of 
(1.113)/(6.5) with still a ratio of 70/30 (entry 1). 
Despite  several  HPLC  attempts,  steroids  (1.113)  and  (6.5)  could  not  be  separated. 
However, partial recrystallization in DCM/Hexane provided access to a pure sample of 
(1.113) of which analytical data corresponded well with literature data.
55,205,219 
Chemical Shift (ppm)
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Figure 6.1 
 
Although those results were in accord with a literature report,
220 it still remains unclear 
whether the lack of stereoselectivity observed was due to the presence of the C17-ketone in 
the substrate, due to a competitive C=C migration/hydrogenation process or due to a non-
selective 9,11-double bond hydrogenation.  
6.3.3  Isomerisation  of  the  11,12-  to  9,11-double  bond  followed  by 
hydrogenation 
 
In an attempt to improve the selectivity during the hydrogenation step the 11,12-double 
bond in (6.4) was isomerized under basic conditions using 2.6 equiv of KO
tBu in DMSO 
to  obtain  the  9,11-double  bond  steroid  (6.6),
205,221-223  following  Tietze’s  desogestrel 
synthesis
26 which is to our knowledge the only example of a 11,12 to 9,11-double bond 
migration (Scheme 6.9). 
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Scheme 6.9 
 
Isomerization  didn’t  prove  very  efficient,  presumably  because  of  the  C17-ketone,  as 
decomposition  adducts  were  observed  by  TLC,  and  (6.6)  was  not  stable.  Under 
hydrogenation conditions, using 1,4-cyclohexadiene, a mixture of (1.113) and (6.5) was 
again obtained, though in a better (85-80/15-20) ratio, meaning that with our substrate, the 
9,11-double bond hydrogenation didn’t seem to be selective. The low yield observed was 
explained  by  the  use  of  a  partially  decomposed  adduct  (6.6).  Unfortunately,  time 
constraints prevented us from investigating this control experiment with freshly-made pure 
(6.6). 
Because many examples in the literature showed stereoselective reduction of the 9,11-
double bond  using Et3SiH,
35,55,205,224,225  we  focused on  isomerisation of the 11,12  to 
9,11-double bond. Unfortunately, apart from Tietze’s KO
tBu procedure, only examples of  
8,9 or 8,14 to 9,11-double bond migrations were found.
223 
 
Scheme 6.10 
 
Unfortunately, neither acidic conditions nor basic conditions were successful (Table 6.4). 
Entry  Conditions  Outcome 
1  NaOMe/MeOH rt  No reaction 
2  KO
tBu / THF rt  decomposition 
3  TFA/benzene rt then   decomposition 
4  HCl conc./MeOH rt and   No reaction 
 
Table 6.4 113 
 
 
No reaction was observed when NaOMe (2 equiv)/MeOH was used even after 2 days of 
reaction (entry 1). Using KO
tBu (2 equiv)/THF only led to decomposition after 10 min of 
reaction (entry 2). Under acidic conditions, with TFA (20 equiv)/benzene, no reaction was 
observed  at  room  temperature  and  overnight  reflux  only  led  to  partial  decomposition 
(entry 3). Finally, no reaction was observed with HCl conc./MeOH even after overnight 
reflux (entry 4).
223    
6.3.4  Deprotection to Estrone 
 
The final deprotection to estrone was only achieved from the racemic O-methyl-estrone 
(1.113) (Scheme 6.11). 
 
Scheme 6.11 
 
Several  reagents could have been explored to achieve  this  final deprotection, such as 
pyridine  hydrochloride
226 or  BBr3.
205 Instead,  the  AlCl3/NaI  couple  was choosen with 
excellent results.
204 Estrone (1.6) was obtained in 92% yield after 5 h of reaction at room 
temperature. 
6.4  Summary 
 
The enantioselective and the racemic total syntheses of O-methyl-estrone (1.113) were 
successfully accomplished. The C-ring closure by RCM on an achiral phosphonate was 
optimised up-to 61% using Hoveyda-Grubbs II catalyst. Although the C-ring closure could 
not be achieved on the chiral phosphonamide, the problem was overcome by transforming 
the  phosphonamide  to  a  phosphonic  acid on  which the RCM proceeded,  however, in 
medium yields. The Heck reaction, that constructed the steroid backbone, proceeded in 
quantitative  yield.  The  reduction  of  the  residual  double  bond  unfortunately  led  to  a 
mixture of 9-H (1.113) and 9-H (6.5) O-methyl-estrone, though in almost quantitative 
yield. Efforts to avoid the formation of the 9-H isomer (6.5) were unsuccessful. 114 
 
Chapter 7, Future directions of the research 
7.1  Short term 
 
Since the racemic and enantioselective total syntheses of estrone have been achieved, apart 
from improving some medium yielding reactions within the project, no further research 
towards  this  steroid  seems  interesting;  based  on  the  diastereoselective  1,4-
addition/alkylation  methodology  employed  during  this  PhD.  Desogestrel  however,  not 
only because it is synthetically more demanding, has only been synthesized in racemic 
form. Achieving an enantioselective synthesis of desogestrel would be one of the primary 
objectives.     
7.1.1  Enantioselective synthesis of desogestrel 
 
7.1.1.1  Via a domino C-B reaction 
 
Based on the same methology described in this thesis for the racemic total synthesis of 
desogestrel, the next aim would be to achieve an enantioselective synthesis by using one 
of  the  known  chiral  auxiliaries  for  the  1,4-addition  reaction,  as  already  achieved  for 
estrone synthesis. Some examples are given in Figure 7.1. 
 
Figure 7.1 
 
The synthesis of achiral phosphonate (7.2) has already been achieved by R. Clarkson. The 
synthesis of the homochiral version of this compound could be achieved using homochiral 
BINOL.
227-230Although Fuji and co-workers
136 had reported a number of successful results 
using  this  type  of  compound  in  related  diastereoselective  1,4-addition  reactions, 
preliminary results by R. Clarkson
21 indicates that much optimisation would be required 
with more complex substrates like (7.2).   115 
 
On the other hand, the synthesis of homochiral phosphonamide (7.1) (Scheme 7.1) should 
be quite straightforward, as the synthesis of an analogue has already been achieved for 
estrone synthesis (part 2.3.4.2, page 51).
112,113 
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Scheme 7.1 
 
The 1,4--addition product (7.2) should be accessible via a diastereoselective 1,4-addition 
between  phosphonamide  (7.1)  and  ethyl-enone  (1.131)/alkylation  with  iodide  (3.29). 
Taking in account the differences of reactivity observed during the 1,4-addition/alkylation 
step depending on the Michael acceptor and the phosphorus substrates (Chapter 3), this 
process  would  quite  possibly  require  much  optimisation:  1)  Lower  yields  have  been 
obtained with the ethyl-enone (1.131) than with the corresponding methyl-enone (1.100), 
2) Lower yields have been obtained with phosphonamides than with phosphonates, 3) The 
reaction seems to be substrate, solvent and scale dependent. 
Should the synthesis of 1,4--addition product (7.3) prove possible on large scale, the most 
convenient way of completing the synthesis might be through the phosphonate (4.32). 
Conversion of the acetal to the methyl-ester has been touched upon (part 4.2.5). From a 
practical  point  of  view,  it  seems  worthwile  to  convert  phosphonamide  (7.4)  to  the 
corresponding  phosphonate  (4.32),  via  the  corresponding  phosphonic  acid.
231  From 
enantiopure phosphonate (4.32), completion of the synthesis  has been demonstrated in 
Chapters 4-5.  
  
 116 
 
7.1.1.2  Via a sequential C and B-ring cyclisation 
 
Another  possible  enantioselective  synthesis  of  desogestrel  would  rely  on  the  exact 
methodology  used  for  the  enantioselective  total  synthesis  of  estrone  described  in  this 
thesis, as shown in Scheme 7.2. 
 
Scheme 7.2 
 
The  diastereoselective  1,4-addition  of  phosphonamide  (2.4)  with  ethyl-enone  (1.131)/ 
alkylation with allyl bromide (3.28) would lead to the 1,4--addition product (7.5). The 
trans-hydrindene product (7.6) would be obtained by hydrolysis of the phosphonamide to 
the corresponding phosphonic acid, followed by RCM reaction as described in part 6.2.2. 
Reduction of the C17-ketone  with  NaBH4,
232  and subsequent  protection  of  the  C17--
alcohol would give bromide (7.7). Intramolecular Heck reaction, followed by 11-12 to 9-
11  double  bond  migration  with  KOtBu
26  (for  which  the  C17-ketone  protection  seems 
important) would afford known steroids (1.67)
27 or (1.59).
26 Completion of desogestrel 
from any of the two steroids has already been touched upon in Chapter 1. 
7.2  Medium term 
 
Although what follows could not be really classified as a primary objective, given the 
considerable quantities of phosphonate (2.3) that were still available after the completion 
of the racemic total synthesis of estrone, it was thought to be a better use of research-time 
to investigate another tandem anionic cyclisation strategy towards desogestrel. 117 
 
7.2.1  Towards a new desogestrel synthesis via a domino B-C cyclisation. 
 
So as to  illustrate the versatility of our  methodology towards  steroid synthesis, a new 
strategy was considered that could eventually lead to desogestrel starting for the estrone 
phosphonate precursor (2.3) (Scheme 7.3). 
 
Scheme 7.3 
 
Desogestrel would be obtained from the tetracyclic phosphonate (7.8) which would be 
obtained  via  a  domino  B-C  cyclisation  reaction  from  bromide  (7.9).  Bromine-lithium 
exchange of (7.9) with BuLi was expected to induce the intramolecular addition onto the 
--unsaturated phosphonate,  forming the B-ring (Figure 7.2).  The intermediate anion 
would then undergo a mesylate displacement, forming the C-ring (7.8). It was expected 
that  the  protons  on  C9  would  adopt  the  -position.  This  configuration  was  expected 
because  it  would be  obtained through  the  lowest energy  reactive  conformation  (7.10) 
(Figure 7.2). 
 
Figure 7.2 
 
Finally,  precursor  (7.9)  would be obtained  via  a  conjuguate  1,4-addition  followed  by 
“alkylation” of the intermediate enolate starting from our estrone precursor (2.3). Initial 
experiments  were  conducted  using  methyl-cyclopentenone  (1.100)  as  it  had  been 118 
 
demonstrated that enolate (7.11) (Figure 7.2) could be obtained in very high yields under 
our standard conditions (part 3.3.1), allowing investigations of the proper alkylating agent 
to use. 
7.2.1.1  Investigations of direct functionalisation of enolate (7.11) 
 
The first choice was the use of formaldehyde as alkylating agent, which would have led to 
the alcohol (7.12) via an aldol reaction (Scheme 7.4). 
 
Scheme 7.4 
 
The reaction was only attempted once, without the desired outcome. The use of gaseous 
formaldehyde
107 led to a very complex mixture of products where  the desired alcohol 
(7.12) was not observed nor identified. 
The  use  of  methyl  chloroformate  (7.14)  and  methyl  cyanoformate  (7.13)  were  then 
considered, which would both have led to ester (7.15) (Scheme 7.5). 
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Scheme 7.5 
 
Interestingly, reactions with (7.13) or (7.14) led to completely different results as shown in 
Table 7.1. 
Entry  Scale of 
(2.3) 
equiv 
of 
nBuLi  
equiv of 
(1.100) 
alkylating  equiv of (7.13)   T of  Yield of products  
agent  or (7.14)  alkylation  (7.15)  (7.16) 
1  2.6 mmol  1.1  1.3  (7.14)  10  0 
°C  0%  79% 
2  2.6 mmol  1.1  1.3  (7.14)  5  -78 
°C  0%  42% 
3  2.6 mmol  1.1  1.3  (7.13)  2  -78 
°C  Not determined    0% 
Table 7.1 119 
 
 
When methyl chloroformate (7.14) was employed (entries 1-2), no trace of desired ester 
(7.15) was observed. Instead, the undesired enolate-trapped carbonate (7.16) was obtained 
in up-to 79% when the reaction was performed at 0  °C (entry 1). The use of methyl 
cyanoformate (7.13) led to a very complex mixture of products (entry 3). 
Those preliminary  results  suggested  that  many  reactions  would  have  been  required  in 
order to really investigate this reaction. Since the enolate (7.11) seemed relatively easily 
trapped, it was envisioned that the desired alcohol (7.12) might be accessible via a cross-
aldol reaction through a silyl enol ether. 
7.2.1.2  Investigations of a stepwise alkylation of enolate (7.11) 
7.2.1.2.1  Synthesis of the silyl enol ether (7.17) 
 
As  an  alternative  to  the direct  reaction  of  the  enolate  formed  during  the  1,4-addition 
reaction, attempts were made to trap the enolate (7.11) as a TBS enol ether (7.17) (Scheme 
7.6, Table 7.2).  
 
Scheme 7.6 
Table 7.2 
Entry  Pathway  conditions 
Yield of products (%) 
(7.17)  (7.18)  (3.50) 
1  A  TBSOTf/Et3N (3 equiv), DCM, -50 to -20 °C  0  62  
2  A  TBSCl/Et3N (3 equiv), DCM, rt  0  0  98 
3  A  TBSCl/Et3N/NaI (1.5 equiv), MeCN, rt  0  0  84 
4  B  TBSCl (3 equiv), 0 °C to rt  57  0  25 
5  B  TBSCl/Et3N (premixed), rt  0   0  89 
6  B  TBSOTf (2 equiv), 0 °C  84  0  0 
 = not isolated 
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Two different pathways towards (7.17) were explored. Following pathway A,  the 1,4-
addition enolate (7.11) was quenched to the corresponding non-allylated product (3.50) in 
82% yield on a 2.6 mmol scale. Protection of the C17-ketone as a silyl enol ether was 
expected to give the thermodynamic product (7.17).
233 The use of TBSOTf/Et3N
164 at low 
temperature (entry 1) exclusively led to the formation of the kinetic product (7.18) in 62% 
yield.  Other  attempts to favorise the thermodynamic product (7.17) (entries 2-3)
234 all 
resulted in complete recovery of the starting material (3.50).  
Following pathway B, the enolate was directly trapped (entries 4-6). The reaction with 
TBSCl was a very slow process, despite the use of 3 equiv of reagent, but at least the 
desired silyl enol ether was obtained in 57% yield (entry 4). Finally the use of 2 equiv 
TBDMSOTf (entry 6) afforded an excellent 84% yield of isolated (7.17).  
7.2.1.2.2  Cross-aldol reactions: synthesis of alcohol (7.12) 
 
Makaiyama  and  co-workers
235  have  conducted  significant  research  on  cross-aldol 
reactions  involving  silyl  enol  ethers  with  carbonyl  compounds  activated  with  various 
metal  salts.  Noteworthly,  they  described  the  preparation of  monomethylol  compounds 
from  silyl  enol  ethers  and  trioxane  as  formaldehyde  source  in  the  presence  of  TiCl4. 
Despite several attempts, the desired alcohol (7.12) (Scheme 7.7) was not obtained under 
those  conditions.  However,  (7.12)  was  synthesized  following  Snider  and  co-workers 
precedent as shown in Scheme 7.7.
236    
 
Scheme 7.7 
 
Treatment of silyl enol ether (7.17) with CH2O.Me3Al in DCM at 0 °C, followed by acid 
treatment of the ene-type intermediate exclusively led to alcohol (7.12) in medium yield. 
The procedure was not fully optimised, due to time-constraints and enough material was 
obtained towards domino B-C precursor (7.19). 121 
 
7.2.1.3  Attempted domino B-C reaction 
 
With  alcohol  (7.12)  in  hand,  the  domino  B-C  precursor  (7.19)  was  easily  prepared 
(Scheme 7.8). 
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Scheme 7.8 
 
Treatment of alcohol (7.12) with methanesulfonyl chloride in presence of Et3N in DCM at 
0 °C afforded the desired mesylate (7.19) in good yield.
237 The subsequent domino B-C 
reaction was  however only  attempted once,  for project-priority reasons.  Unfortunately, 
lithium-bromide exchange with 
nBuLi gave rise to a complex mixture of products. No 
further experiments were attempted within this strategy, as in the meantime the complete 
enantioselective synthesis of estrone had to be achieved.  
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7.3  Long term 
 
Since  this  new  steroid  synthesis  methodology,  based  on  a  DBCD  steroid  skeleton 
construction,  has  been  successfully  employed  for  two  structurally  diverse  steroids 
desogestrel and estrone, it could be used to make other steroids (both new and known). 
Simple modifications include changing the methyl/ethyl group  at C13 or changing the 
exocyclic methylene group  at C11,  which are not easy transformations within existing 
steroid total syntheses. Also interesting, this methodology could lend itself towards the 
synthesis  of  steroids  containing  a  heteroatom  at  the  C11  position.  To-date,  all  these 
steroids are made through  hemi-syntheses  via  C-ring  opening  reactions,
238,239 but  it  is 
known  that  steroids  with  a  heteroatom  at  C11 possess  interesting  biological activities. 
Following the proposed synthetic route (Scheme 7.9), steroids such as (7.22) should be 
accessible  since  for  example,  heteroatom  conjuguate  addition  to  ,-unsaturated 
sulfoxides is known.
240,241 
 
Scheme 7.9 123 
 
Chapter 8, Overall summary  
 
We  have  demonstrated  that  the  Hanessian  1,4-addition/alkylation  can  be used  for  the 
synthesis of structurally diverse steroids via a novel strategy based on prior formation of 
the correct C8, C13 and C14 stereochemistry, followed by ring formation processes. The 
synthesis of desogestrel and estrone have been achieved using this method. Highlights of 
this method include: 
  The  development/optimization  of  efficient  syntheses  of  achiral  phosphonates  and 
chiral phosphonamide 1,4-addition precursors. 
  Utilization of a 1,4-addition/alkylation sequence to synthesize highly functionalized 
complex products with three controllable chiral centres, and identification of a few 
side-products. 
  Optimization  of  the  domino  C-B  reaction  to  afford  cyclised  products  as  single 
diastereoisomers in up to 50% yield. 
  Construction of the A-ring via a seven reaction one-pot process. 
  Determination  of  the  relative  stereochemistry  on  separate  occasions  by  X-ray 
crystallographic analyses. 
Areas where there is scope for improvement within this project include: 
  The  poor  yield  associated  with  the  1,4-addition  reaction  with  the  ethyl-
cyclopentenone. 
  Avoiding  the  formation  of  the  side  products  during  the  domino  C-B  cyclisation 
process. 
  The poor yield associated with the HWE reaction on -keto phosphonates leading to 
exocyclic enones. 124 
 
Chapter 9, Experimental 
General  information.  'H  and 
13C  NMR  spectra  were  recorded  on  a  Bruker  AV300 
spectrometer or Bruker AC300 or Bruker DPX400 spectrometer. 'H spectra conducted in 
CDCl3  are  referenced  to  CHCl3  as  7.27  ppm. 
13C  spectra  conducted  in  CDCl3  are 
referenced to CHCl3 as 77.00 ppm. Where assignments of atoms have been made in the 
NMR  data,  this  is  determined  by  the  use 
13C
1H  correlation  (HMQC)  and/or 
1H
1H 
correlation (COSY) NMR experiments. The following abbreviations were used to explain 
the multiplicities: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad; Q, 
quaternary  carbon  centre. 
31P  spectra  were  recorded  on  a  Bruker  AV300  externally 
referenced to 85% H3PO4. IR spectra were recorded on a BIORAD Golden Gate FTS 135. 
Optical rotations were conducted on an Optical Activity Polaar 2001. Mass spectrometry 
was  performed  using  ES,  EI  or  CI  techniques.  Melting  points  were  carried  out  on  a 
Gallenkamp melting point apparatus and are uncorrected. X-Ray analyses were provided 
at  the  EPSRC  Crystallography  Service,  Southampton  University.  All  reactions  were 
carried out under a N2 atmosphere with dry, freshly distilled solvents under anhydrous 
conditions,  unless  otherwise  noted.  All  reactions  were  monitored  by  thin-layer 
chromatography carried out on 0.25 mm E. Merck silica gel plates (60F-254) using UV 
light  (254  nm)  as  visualizing  agent  and  KMnO4,  Vanillin  or  Anisaldehyde  dyes  as 
developing agents. E. Merck silica gel (60, particle size 0.040-0.063 mm) was used for 
flash chromatography. All reaction vessels were oven dried overnight or flame dried under 
vacuum (<1 mmHg) and cooled under N2 prior to use. Preparative HPLC was performed 
using a Kontron pump KU38 with a Kontron refractive index detector 475. 
Materials. THF and Et2O were distilled from sodium/benzophenone ketyl. Toluene was 
distilled from sodium. MeOH and EtOH were distilled with a small amount of magnesium 
and I2. DCM, MeCN, Et3N, DIPEA and HMPA were distilled from CaH2. 125 
 
9.1  Experimental data for Chapter 2 
 
Ethyl-4-chlorobutanimidate hydrochloride (2.8) 
 
 
Into an ice cooled solution of 4-chlorobutyronitrile (2.12) (4.64 mL, 52 mmol, 1.0 equiv) 
and dry ethanol (2.70 mL, 52 mmol, 1.0 equiv) in dry DCM (50 mL) was bubbled in situ 
prepared HCl (g) until ca. 18 equiv of HCl had been absorbed. The reaction vessel was 
sealed and left in the fridge for 4 days. The reaction mixture was concentrated to ca. 2/3 of 
the original volume under  vacuum and the precipitated imidate salt (2.8) was filtered, 
washed with several portions of Et2O (5 x 20 mL) and finally dried over CaSO4 in an 
evacuated dessicator to give the title hydrochloride as fine white crystals (8.32 g, 98%, 
m.p. = 99-101 °C).  
 
MW = 186.079 (C6H13ONCl2). 
1H NMR (300 MHz; CDCl3):  12.51 (1H, s, NH), 11.63 (1H, s, NH), 4.67 (2H, q, J = 6.9 
Hz, HE), 3.62 (2H, t, J = 6.2 Hz, HA), 2.94 (2H, t, J = 6.2 Hz, HC), 2.25 (2H, pentet, J = 
6.2 Hz, HB), 1.50 (3H, t, J = 6.9 Hz, HF) ppm. 
13C NMR (75 MHz; CDCl3):  178.3 (Q, CD), 71.1 (CH2, CE), 43.2 (CH2, CA), 30.8 (CH2, 
CC), 28.4 (CH2, CB), 13.6 (CH3, CF) ppm. 
The NMR data correspond to the reported data.
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3-Methyl-3-oxetanemethyl-4-chlorobutanoate (2.14) 
 
 
To an ice cooled solution of 3-hydroxymethyl-3-methyloxetane (2.9) (4.05 mL, 40 mmol, 
1.0 equiv) and pyridine (3.88 mL, 48 mmol, 1.2 equiv) in dry DCM (20 mL) was slowly 
added 4-chloro-butyryl-chloride (2.10) (4.49 mL, 40 mmol, 1.0 equiv). After the addition, 
the reaction was allowed to stand at 0 °C for 1 h. The reaction mixture was droped over 126 
 
crushed ice (10 g) and then extracted with DCM (3 x 20 mL). The organic phase was 
washed  with  brine  (10  mL),  dried  over  Na2SO4,  filtered  and  then  concentrated  under 
vacuum. This yielded (2.14) as a colourless oil (8.65 g, quantitative) which was found 
pure enough for the next step. 
 
MW = 206.667 (C9H15O3Cl). 
Rf = 0.53 (Petroleum ether/Acetone 60:40). 
1H NMR (300 MHz; CDCl3):  4.44 (2H, d, J = 6.2 Hz, HG/H), 4.31 (2H, d, J = 6.2 Hz, 
HG/H), 4.12 (2H, s, HE), 3.54 (2H, t, J = 6.4 Hz, HA), 2.49 (2H, t, J = 6.4 Hz, HC), 2.05 
(2H, pentet,  J = 6.4 Hz, HB), 1.27 (3H, s, HI) ppm. 
13C NMR (75 MHz; CDCl3):  172.4 (Q, CD), 79(2 x CH2, CG+CH), 68.5 (CH2, CE), 43.7 
(CH2, CA), 38.9 (Q, CF), 30.9 (CH2, CB), 27.4 (CH2, CC), 20.9 (CH3, CI) ppm.  
The NMR data correspond to the literature data.
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3-Methyl-3-oxetanemethyl-4-bromobutanoate (2.15) 
 
 
To an ice cooled solution of 3-hydroxymethyl-3-methyloxetane (2.9) (4.05 mL, 40 mmol, 
1.0 equiv) and pyridine (3.88 mL, 48 mmol, 1.2 equiv) in dry DCM (20 mL) was slowly 
added 4-bromo-butyryl-chloride (2.11) (5.11 mL, 44 mmol, 1.1 equiv). After the addition, 
the reaction was allowed to stand at 0 °C for 1 h. The reaction mixture was droped over 
crushed ice (10 g) and then extracted with DCM (3 x 20 mL). The organic phase was 
washed  with  brine  (10  mL),  dried  over  Na2SO4,  filtered  and  then  concentrated  under 
vacuum. This yielded (2.15) as a colourless oil (10.55 g, quantitative) which was found 
pure enough for the next step. 
 
MW = 251.118 (C9H15O3Br). 
Rf = 0.55 (Petroleum ether/Acetone 60:40). 
1H NMR (300 MHz; CDCl3):  4.46 (2H, d, J = 6.0 Hz, HG/H), 4.34 (2H, d, J = 6.0 Hz, 
HG/H), 4.14 (2H, s, HE), 3.34 (2H, t, J = 6.5 Hz, HA), 2.52 (2H, t, J = 7.0 Hz, HC), 2.15 
(2H, quintet, J = 6.8 Hz, HB), 1.30 (3H, s, HI) ppm. 127 
 
13C NMR (75 MHz; CDCl3):  172.4 (Q, CD), 79.3 (2 x CH2, CG+CH), 68.6 (CH2, CE), 
38.9 (Q, CF), 32.4 (CH2, CA), 32.2 (CH2, CC), 27.5 (CH2, CB), 21.0 (CH3, CI) ppm.  
The NMR data correspond to the literature data.
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1-(3-Chloro-propyl)-4-methyl-2,6,7-trioxa-bicyclo[2.2.2]octane (2.6) 
 
Route 1: 
 
 
 
Route 2:  
 
 
Route 1: 
To a mixture of the imidate salt (2.8) (5.00 g, 27 mmol, 1.0 equiv), toluene (100 mL) and 
1,1,1-tris(hydroxymethyl)ethane  (2.13)  (3.23  g,  27  mmol,  1.0  equiv)  was  added  dry 
ethanol (2.72 mL, 46 mmol, 1.7 equiv). The reaction mixture was refluxed for 16 h, then 
cooled,  filtered through celite and concentrated under  vacuum.  Purification by column 
chromatography on neutralized silica (Petroleum ether/EtOAc 4:1) followed by Kugelröhr 
distillation yielded (2.6) as a colourless oil (3.10 g, 56%). 
Route 2: 
BF3.Et2O (1.25 mL, 10 mmol, 0.25 equiv) was added to a cooled (-20 °C) solution of the 
ester (2.14) (8.65 g, 40 mmol, 1.0 equiv) in dry DCM (35 mL) under N2 atmosphere. The 
reaction was stirred for 24 h at the same temperature and a solution of Et3N (5.58 mL, 40 
mmol, 1.0 equiv) in Et2O (50 mL) was then added to quench the reaction. The reaction 
mixture was filtered and the solvent was removed under vacuum. The resulting crude was 
purified by column chromatography (DCM + 1% Et3N), yielding (2.6) as a colourless oil 
which crystallised in the fridge (5.37 g, 65%). 
 
MW = 206.666 (C9H15O3Cl). 
Rf = 0.48 (Petroleum ether/EtOAc 60:40). 
IR (neat): 2961 (w), 2932 (w), 2876 (m), 1472 (w), 1458 (w), 1446 (w), 1399 (m), 1262 
(m), 1055 (s), 1101 (s), 960 (m), 948 (m), 936 (m) cm
-1. 
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1H NMR (300 MHz; CDCl3):  3.87 (6H, s, HE), 3.55 (2H, t, J = 6.8 Hz, HA), 1.93-1.88 
(2H, m, HB), 1.81-1.78 (2H, m, HC), 0.78 (3H, s, HG) ppm. 
13C NMR (75 MHz; CDCl3):  108.7 (Q, CD), 72.5 (3 x CH2, CE), 44.8 (CH2, CA), 33.8 
(CH2, CB/C), 30.2 (Q, CF), 26.7 (CH2, CB/C), 14.4 (CH3, CG) ppm. 
The IR and NMR spectra correspond to the literature data.
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1-(3-Bromo-propyl)-4-methyl-2,6,7-trioxa-bicyclo[2.2.2]octane (2.7) 
 
 
BF3.Et2O (1.25 mL, 10 mmol, 0.25 equiv) was added to a cooled (-20 °C) solution of the 
ester (2.15) (10.13 g, 40 mmol, 1.0 equiv) in dry DCM (35 mL) under N2 atmosphere. The 
reaction  was  stirred  for  6  h  at  the  same  temperature,  then  allowed  to  warm  to  room 
temperature for 18 h and a solution of Et3N (5.58 mL, 40 mmol, 1.0 equiv) in Et2O (50 
mL) was then added to quench the reaction. The reaction mixture was filtered and the 
solvent  was  removed  under  vacuum.  The  resulting  crude  was  purified  by  column 
chromatography (DCM + 1% Et3N), yielding (2.7) as a colourless oil which crystallised in 
the fridge (7.19 g, 71%). 
 
MW = 251.118 (C9H15O3Br). 
Rf = 0.46 (Petroleum ether/EtOAc 60:40). 
IR (neat): 2961 (w), 2932 (w), 2876 (m), 1472 (w), 1458 (w), 1446 (w), 1399 (m), 1262 
(m), 1055 (s), 1101 (s), 960 (m), 948 (m), 936 (m) cm
-1. 
1H NMR (300 MHz; CDCl3):  3.87 (6H, s, HE), 3.55 (2H, t, J = 6.8 Hz, HA), 1.93-1.88 
(2H, m, HB), 1.81-1.78 (2H, m, HC), 0.78 (3H, s, HG) ppm. 
13C NMR (75 MHz, CDCl3):  108.7 (Q, CD), 72.5 (3 x CH2, CE), 44.8 (CH2, CA), 33.8 
(CH2, CB/C), 30.2 (Q, CF), 26.7 (CH2, CB/C), 14.4 (CH3, CG) ppm. 
The IR and NMR spectra correspond to the literature data.
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3-(4-methyl-2,6,7-trioxa-bicyclo[2.2.2]oct-1yl)-propionaldehyde (2.5) 
 
 
To a mixture of Trimethyl Amine N-Oxide (TMANO) (2.16) (657 mg, 8 mmol, 4.0 equiv) 
in dry DMSO (5 mL) was added neat bromide (2.7) (502 mg, 2 mmol, 1.0 equiv) at room 
temperature under  N2  atmosphere.  The  reaction  mixture  was  stirred  for 4  h  and  then 
poured into an ice cooled, half-saturated aqueous NaCl solution (10 mL) and extracted 
with Et2O (4 x 10 mL). The combined organic layers were washed with brine (2 x 10 mL), 
dried over Na2SO4 and concentrated in vacuo. The resulting crude was purified by column 
chromatography (Petroleum ether/EtOAc 80:20 + 1% Et3N) yielding (2.5) as a colourless 
oil crystallizing in the fridge (171 mg, 47 %). 
 
MW = 186.205 (C9H14O4). 
Rf = 0.30 (Hexane/EtOAc 60:40). 
IR (neat): 2959 (w), 2935 (w), 2878 (m), 1720 (s), 1473 (w), 1459 (w), 1440 (w), 1399 
(m), 1354 (w), 1272 (m), 1192 (m), 1053 (s), 986 (s), 972 (s), 951 (s), 885 (m), 826 (m) 
cm
-1. 
1H NMR (300 MHz; CDCl3):  9.70 (1H, t, J = 1.8 Hz, HA), 3.86 (6H, s, HE), 2.51 (2H, 
td, J1 = 7.3, 1.8 Hz, HB), 2.02 (2H, t, J = 7.3 Hz, HC), 0.78 (3H, s, HG) ppm. 
13C NMR (75 MHz, CDCl3):  202.0 (Q, CA), 108.4 (Q, CD), 72.5 (3 x CH2, CE), 38.0 
(CH2, CB), 30.3 (Q, CF), 29.5 (CH2, CC), 14.4 (CH3, CG) ppm. 
CIMS: m/z (%): 187 ((M+H)
+, 100), 158 (24), 138 (2), 85 (42), 72 (11), 55 (12). 
HRES
+MS: For C9H15O4 (M+H)
+: calcd 187.0970, found 187.0965. 
 
(Z)-(3-Phenyl-2-propenyl)phosphonic acid diethyl ether (2.21) and (E)-(3-Phenyl-2-
propenyl)phosphonic acid diethyl ether (2.22) 
 
 
Route 1:  
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Route 2: 
 
They are known compounds,
82 but were synthesized here via two new procedures: 
Route 1: 
Diethyl phosphite (2.17) (258 L, 2 mmol, 2.0 equiv), was added dropwise to a solution of 
NaH (60% dispersion in mineral oil) (56 mg, 1.4 mmol, 1.4 equiv) in dry DCM (3 mL) at 
0 °C under N2. The reaction mixture was then stirred for 1h at 0 °C and cooled to -40 °C. 
Then,  CuBr  (25 mg,  0.18  mmol,  0.18 equiv) and vinyltriphenylphosphonium  bromide 
(2.18) (479 mg, 1.35 mmol, 1.35 equiv) were added and the reaction mixture was stirred 
for 20 min. Benzaldehyde (2.20) (137 L, 1 mmol, 1.0 equiv) was added and the reaction 
mixture was allowed to warm to room temperature and stirred overnight. Then 5 mL of 10 
% NH4Cl solution was added followed by 5 mL of DCM. The organic layer was separated, 
washed with 5 mL of water and dried. Evaporation of the solvent gave a residue which 
was  purified  by  column  chromatography  (Petroleum  ether/EtOAc  70:30)  to  afford  a 
colourless oil, mixture of (2.21) and (2.22), which was further purified by preparative 
HPLC, yielding (E)-phosphonate (2.22) (64 mg, 26%) and (Z)-phosphonate (2.21) (17 mg, 
7%) as colourless oils.   
Route 2: 
To a solution containing vinyltriphenylphosphonium bromide (2.18) (500 mg, 1.35 mmol, 
1.0 equiv) and diethyl phosphite (2.17) (244 L, 1.89 mmol, 1.4 equiv) in dry THF/DMF 
(10/1, 3 mL) was added NaH (8 mg, 0.135 mmol, 0.1 equiv) or NaHMDS (68 L, 0.135 
mmol, 0.1 equiv) and the solution was stirred at room temperature for 10 h. Then NaH (59 
mg, 1.485 mmol, 1.1 equiv) or NaHMDS (743 L, 1.485 mmol, 1.1 equiv) was added and 
the solution was stirred for 30 min. Then benzaldehyde (2.20) (137 L, 1.35 mmol, 1.0 
equiv)  was  added  dropwise  and  the  reaction  mixture  was  stirred  for  24  h.  After 
evaporation of  the  solvent  in  vacuo,  the  residue  was  diluted  with DCM  (10  mL)  and 
extracted with water (10 mL), dried over Na2SO4, filtered and evaporated. The resulting 
crude was purified by column chromatography (Petroleum ether/EtOAc 70:30) to afford 
(2.22) as the only isomer (105 mg, 31 %). 
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Data for (2.21): 
MW = 244.267 (C13H19O3P). 
Rf = 0.39 (Petroleum ether/EtOAc 60:40). 
1H NMR (300 MHz; CDCl3):  7.40-7.20 (5H, m, phenyl), 6.56 (1H, dd, J =13.4, 4.8 Hz, 
HA), 6.20 (1H, m, HB), 4.28-4.02 (4H, m, HD), 2.82 (2H, ddd, J =22.0, 7.5, 1.3 Hz, HC), 
1.37 (6H, t, J = 5.7 Hz, HE) ppm. 
13C NMR (75 MHz; CDCl3):   132.7, 128.6, 128.5, 127.3, 126.2, 126.1 (5CH + 1Q, 
phenyl), 129.7 (CH, CA), 104.1 (CH, CB), 63.8 (CH2, CD), 28.6 (CH2, CC), 16.5 (CH3, CE) 
ppm.  
The NMR data correspond to the literature data.
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Data for (2.22): 
MW = 244.267 (C13H19O3P). 
Rf = 0.38 (Petroleum ether/EtOAc 60:40). 
1H NMR (300 MHz; CDCl3):  7.40-7.20 (5H, m, phenyl), 6.55 (1H, dd, J =16.0, 5.3 Hz, 
HA), 6.18 (1H, m, HB), 4.30-4.05 (4H, m, HD), 2.79 (2H, ddd, J =22.0, 7.5, 1.3 Hz, HC), 
1.34 (6H, t, J = 6.3 Hz, HE) ppm. 
13C NMR (75 MHz; CDCl3):   136.7, 128.6, 128.5, 128.1, 127.5, 126.1 (5CH + 1Q, 
phenyl), 134.5 (CH, CA), 118.7 (CH, CB), 62.2 (CH2, CD), 31.0 (CH2, CC), 16.5 (CH3, CE) 
ppm.  
The NMR data correspond to the literature data.
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5-(4-methyl-2,6,7-trioxa-bicyclo[2.2.2]octan-1-yl)pent-2-yn-1-ol (2.34) and 4-methyl-1-
(2-(prop-2-ynyloxy)ethyl)-2,6,7-trioxabicyclo[2.2.2]octane  (2.33)  and  4-methyl-1-
vinyl-2,6,7-trioxabicyclo[2.2.2]octane (2.32) 
 
 
Into a 500 mL, 3-neck flask equipped with a large cold finger was condensed ammonia 
(200 mL). An external cold bath (-78 °C) was used to aid the condensation, but throughout 132 
 
the reaction temperature of this cold bath was maintained between -30 °C and -40 °C. To 
the ammonia was added granular lithium (~50 mg) and the reaction was stirred until a 
homogeneous blue solution was obtained (15 min). To this solution was added iron nitrate 
nonahydrate  (~200  mg),  then  lithium  (394  mg,  57  mmol,  3.2  equiv)  was  added 
portionwise over 30 min. The grey solution was stirred for 1 h at -40 °C. To this solution 
was added propargyl alcohol (2.31) (1.57 mL, 27 mmol, 1.5 equiv) dropwise over 5 min 
and stirring was continued for a further 2 h. The bromide (2.30) (4.19 g, 17.7 mmol, 1.0 
equiv) was dissolved in dry Et2O (4 mL) and added to the reaction dropwise via cannula 
over 10 min. The mixture was stirred for 2 h and then dry DMSO (4 mL) was added 
slowly. The cold bath was removed and the ammonia was allowed to evaporate overnight 
(atm. pressure). Water (100 mL) was added, cautiously at first, followed by DCM (100 
mL) and the biphasic mixture was vigorously stirred for 30 min. The biphasic solution was 
filtered through celite, washing with water and DCM (50 mL). The phases were separated 
and the aqueous phase was extracted with DCM  (4 x 50 mL). The combined organic 
phases were dried over Na2SO4, filtered and evaporated. The crude product was purified 
by column chromatography (Petroleum ether/EtOAc 3:2 + 1% Et3N) to afford (2.34) as a 
white solid (302 mg, 8%, m.p. = 87-89 °C), and  (2.34) and (2.32) mixed as a yellow oil 
(1.96 g) which was purified by preparative HPLC to afford (2.32) as fine white crystals 
(1.69 g, 61%, m.p. = 55-57 °C) and an inseparable mixture of (2.32) and (2.33), (265 mg, 
((2.33)/(2.32) : 64/36; 5% yield of (2.33)). 
 
Data for (2.32) 
MW = 156.179 (C8H12O3). 
Rf = 0.42 (Hexane/Acetone 70:30). 
IR (neat): 2966 (m), 2923 (m), 2877 (w), 1696 (s), 1632 (m), 1443 (w), 1347 (w), 1248 
(m), 1001 (m), 947 (w), 940 (w), 790 (m) cm
-1. 
1H NMR (300 MHz; CDCl3):  5.82 (1H, dd, J = 17.3, 10.5 Hz, HB), 5.65 (1H, dd, J = 
17.3, 1.5 Hz, HA), 5.31 (1H, dd, J = 10.5, 1.5 Hz, HA’), 3.98 (6H, s, HD), 0.84 (3H, s, HF) 
ppm. 
13C NMR (75 MHz, CDCl3):  133.1 (CH, CB), 118.6 (CH2, CA), 105.9 (Q, CC), 72.8 (3 x 
CH2, CD), 30.5 (Q, CE), 14.5 (CH3, CF) ppm. 
CIMS m/z (%): 157 ((M+H)
+, 100),  126 (19), 72 (3), 55 (35). 
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Significant data for (2.33) 
MW = 212.242 (C11H16O4). 
Rf = 0.41 (Hexane/Acetone 70:30). 
1H NMR (300 MHz; CDCl3):  4.13 (2H, d, J = 2.4 Hz, HC), 3.88 (6H, s, HG), 3.70-3.63 
(2H, m, HD), 2.41 (1H, t, J = 2.4 Hz, HA), 2.11-1.93 (2H, m, HE), 0.79 (3H, s, HI) ppm. 
13C NMR (75 MHz, CDCl3):  108.0 (Q, CF), 79.9 (CH, CA), 74.1 (Q, CB), 72.5 (3 x CH2, 
CG), 65.3 (CH2, CC), 58.1 (CH2, CD), 36.5 (CH2, CE), 30.2 (Q, CH), 14.4 (CH3, CI) ppm. 
 
Data for (2.34) 
MW = 212.242 (C11H16O4). 
Rf = 0.25 (Hexane/Acetone 70:30). 
IR (neat): 3412 (br, m), 2935 (w), 2979 (m), 2360 (s), 2341 (s), 1472 (w), 1447 (w), 1399 
(m), 1379 (w), 1355 (m), 1302 (m), 1251 (m), 1188 (w), 1137 (w), 1042 (s), 989 (s), 973 
(s), 938 (m), 858 (s) cm
-1. 
1H NMR (300 MHz; CDCl3):  4.22-4.17 (2H, m, HA), 3.88 (6H, s, HG), 2.35 (2H, tt, J = 
8.4, 2.2 Hz, HD), 1.93-1.88 (2H, m, HE), 1.71 (1H, br, OH), 0.79 (3H, s, HI) ppm. 
13C NMR (75 MHz, CDCl3):  108.05 (Q, CF), 85.8 (Q, CB/C), 78.1 (Q, CB/C), 72.5 (3 x 
CH2, CG), 51.3 (CH2, CA), 35.8 (CH2, CE), 30.2 (Q, CH), 14.4 (CH3, CI), 13.2 (CH2, CD) 
ppm. 
CIMS m/z (%): 213 ((M+H)
+, 100),  212 (56), 195 (80), 183 (27), 181 (20), 164 (26), 149 
(10), 144 (21), 127 (42), 125 (30), 123 (14), 122 (12). 
 
5-(1,3-Dioxolan-2-yl)pent-2-yn-1-ol (2.36): 
 
 
This is a known compound
87 but was synthesised here via a new procedure devised by 
R.Clarkson.
21 
Into a 2 L, 3-neck flask equipped with a large cold finger was condensed ammonia (1 L). 
An  external  cold bath  (-78 °C)  was  used  to aid the condensation, but  throughout the 
reaction temperature of this cold bath was maintained between -30 °C and -40 °C. To the 
ammonia  was  added  granular  lithium  (~50  mg)  and  the  reaction  was  stirred  until  a 134 
 
homogeneous blue solution was obtained (15 min). To this solution was added iron nitrate 
nonahydrate (~200 mg), then lithium (2.38 g, 342 mmol, 3.2 equiv) was added portion 
wise over 30 min. The grey solution was stirred for 1 h at -40 °C. To this solution was 
added propargyl alcohol (2.31) (9.48 mL, 161 mmol, 1.5 equiv) dropwise over 15 min and 
stirring was continued for a further 2 h. The bromide (2.37) (12.81 mL, 107 mmol, 1.0 
equiv) was dissolved in dry Et2O (20 mL) and added to the reaction dropwise via cannula 
over 10 min. The mixture was stirred for 2 h and then dry DMSO (20 mL) was added 
slowly. The cold bath was removed and the ammonia was allowed to evaporate overnight 
(atm. pressure). Water (340 mL) was added, cautiously at first, followed by DCM (200 
mL) and the biphasic mixture was vigorously stirred for 30 min. The biphasic solution was 
filtered  through  celite,  washing  with  water  and  DCM  (200  mL).  The  phases  were 
separated and the aqueous phase was extracted with DCM (4 x 100 mL). The combined 
organic phases were dried over Na2SO4, filtered and evaporated. The crude product was 
purified by column chromatography (Hexane/Acetone 70:30) to afford (2.36) as a yellow 
oil (15.25 g, 91%). Alternatively,  the compound  could  also be distilled under reduced 
pressure (P = 1.5 mmHg, T = 106-108 °C). 
 
MW = 156.184 (C8H12O3). 
Rf = 0.27 (Hexane/Acetone 70:30). 
IR (neat): 3405 (br, m), 2961 (w), 2884 (m), 1433 (w), 1412 (m), 1362 (w), 1223 (w), 
1133 (s), 1070 (m), 1011 (s), 943 (m), 893 (m) cm
-1. 
1H NMR (300 MHz; CDCl3):  4.90 (1H, t, J = 4.7 Hz, HF), 4.15 (2H, t, J = 2.2 Hz, HA), 
3.95-3.75 (4H, m, HG), 2.73 (1H, br s, OH), 2.29 (2H, tt, J = 7.5, 2.1 Hz, HD), 1.81 (2H, 
td, J = 7.5, 4.7 Hz, HE) ppm. 
13C NMR (75 MHz, CDCl3):  103.1 (CH, CF), 85.1 (Q, CB/C), 78.7 (Q, CB/C), 64.9 (2 x 
CH2, CG), 51.1 (CH2, CA), 32.7 (CH2, CE), 13.5 (CH2, CD) ppm. 
CIMS: m/z (%): 174 ((M+NH4)
+, 10), 157 ((M+H)
+, 11), 139 (41), 112 (5), 95 (3), 86 (4), 
73 (100), 45 (5). 
The IR and NMR spectra correspond to the reported data.
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5-(1,3)-Dioxolan-2-yl-2-(Z)-penten-1-ol (2.35)  
 
 
Pre-Activation of Zinc dust: The Zn dust (20 g) was activated by stirring it in a 0.1 M HCl 
solution (300 mL) for ca. 15 min, until the gas evolution stopped. The grey solid was 
filtered  off,  washed  with  plenty  of  water  then  plenty  of  EtOH  and  dried under  high 
vacuum for at least 4 hours. 
Procedure: Into a 50 mL 2-neck flask equipped with a condenser was added activated zinc 
(8.37 g, 128 mmol, 4.0 equiv) followed by dry EtOH (30 mL) and 1,2-dibromoethane (970 
L, 11.2 mmol, 0.35 equiv). The slurry was stirred and placed into a preheated oil bath at 
100 °C until ethane evolution began. CAUTION, ethane evolves rapidly, ensure that heat 
source is removed as soon as reaction begins and there is adequate pressure release. Once 
the ethane evolution was complete (~5 min), the alkyne (2.36) (5.00 g, 32 mmol, 1.0 
equiv)  was added neat, washing through  with EtOH (5 mL). The reaction was stirred 
overnight (~14 h), cooled and filtered through celite, washing with DCM. The solvents 
were evaporated in vacuo and then DCM was added (100 mL). This solution was poured 
onto a room temperature, stirred solution of 7.5% (w/w) aqueous KOH and stirred for 5 
min. The mixture was filtered through celite, washing with 50 mL DCM. The phases were 
separated and the aqueous phase extracted with DCM (4 x 50 mL). The combined organic 
phases were dried over Na2SO4, filtered and evaporated. This  yielded (2.35) as a light 
yellow oil (4.92 g, 98%). (E/Z ratio = 4/96 based on 
1H NMR). 
 
Mw = 158.200 (C8H14O3). 
Rf = 0.30 (Hexane/EtOAc 50:50). 
IR (neat): 3394 (br, m), 2956 (m), 2884 (m), 1649 (w), 1403 (m), 1134 (s), 1029 (s), 945 
(m) cm
-1. 
1H NMR (300 MHz; CDCl3):  5.74-5.52 (2H, m, HB + HC), 4.89 (1H, t, J = 4.9 Hz, HF), 
4.20 (2H, d, J = 6.8 Hz, HA), 4.01-3.84 (4H, m, HG), 2.26 (2H, q, J = 7.6 Hz, HD), 1.75 
(2H, td, J = 7.6, 4.9 Hz, HE), 1.62 (1H, s, OH) ppm. 136 
 
13C NMR (75 MHz; CDCl3):  131.3 (CH, CB/C), 129.1 (CH, CB/C), 103.7 (CH, CF), 64.7 
(CH2, 2 x CG), 57.9 (CH2, CA), 33.2 (CH2, CE), 21.8 (CH2, CD) ppm. 
CIMS m/z (%): 159 ((M+H)
+, 6), 141 (100), 114 (70), 97 (89), 73 (88). 
The IR and NMR data correspond to the reported data.
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5-(1,3)-Dioxolan-2-yl)-2-(E)-penten-1-ol (2.42)  
 
 
This is a known compound
98 but no experimental procedure or analytical data has been 
reported apart from R.Clarkson.
21 
A solution of the alkyne (2.36) (5.02 g, 32 mmol, 1.0 equiv) in THF (20 mL) was added 
dropwise to a pre-cooled suspension of LAH (7.31 g, 192 mmol, 6.0 equiv) in THF (100 
mL). The dark grey suspension was refluxed for 100 min, and then cooled to 0 °C. The 
reaction was quenched by dropwise addition of 0.5 M H2SO4 (10 mL). Dry THF (100 mL) 
was added to prevent the mixture from solidifying. Water (50 mL) was added slowly until 
a white suspension was obtained. This was filtered, the solids were washed with EtOAc 
(100 mL), and the filtrate was evaporated in vacuo. The residue was partitionned between 
EtOAc/water  (100  mL/50  mL),  separated,  and  the  aqueous  phase  was  extracted  with 
EtOAc (2 x 100 mL). The combined organic phases were washed with brine (30 mL), 
dried over Na2SO4, filtered and evaporated. The crude product was purified by column 
chromatography (Hexane/EtOAc 40:60). This yielded (2.42) as a pale yellow oil (3.76 g, 
75%). 
 
Mw = 158.200 (C8H14O3). 
Rf = 0.30 (Hexane/EtOAc 50:50). 
IR (neat): 3413 (br, m), 2950 (m), 2870 (m), 1664 (w), 1403 (m), 1138 (s), 1081 (m), 964 
(s), 902 (m) cm
-1. 
1H NMR (300 MHz; CDCl3):  5.76-5.62 (2H, m, HB + HC), 4.88 (1H, t, J = 4.9 Hz, HF), 
4.09 (2H, d, J = 6.8 Hz, HA), 4.00-3.83 (4H, m, HG), 2.19 (2H, q, J = 7.6 Hz, HD), 1.75 
(2H, td, J = 7.6, 4.9 Hz, HE), 1.60 (1H, s, OH) ppm.  137 
 
13C NMR (75 MHz; CDCl3):  132.0 (CH, CB/C), 129.4 (CH, CB/C), 103.9 (CH, CF), 64.9 
(CH2, 2 x CG), 63.6 (CH2, CA), 33.2 (CH2, CE), 26.6 (CH2, CD) ppm. 
CIMS m/z (%): 176 ((M+NH4)
+, 43), 141 (100), 73 (6). 
HREIMS: For C8H14O3 (M-H)
+: calcd 157.0865, found 157.0865. 
 
2-(5-Chloropent-3-(Z)-enyl)-[1,3]-dioxolane (2.43) 
 
 
The allylic alcohol (2.35) (9.27 g, 58.6 mmol, 1.0 equiv) was dissolved in DCM (50 mL) 
and added via cannula to a solution of triphenyphosphine (16.91 g, 64.5 mmol, 1.1 equiv) 
in  DCM  (50  mL).  Upon  complete  dissolution,  the  mixture  was  cooled  to  0  °C  with 
stirring. To this mixture was added via cannula a solution of hexachloroacetone (HCA) 
(9.76 mL, 64.5 mmol, 1.1 equiv) in DCM (30 mL) over 2 min. The cold bath was then 
removed and the reaction was stirred for 10 min. The solvent was evaporated and the 
resulting crude (solid + oil) was taken in 150 mL of hot hexane and stirred for 5 min. After 
filtration, the resulting triphenylphosphine oxide was washed with 200 mL of hot hexane. 
The  filtrate  was  concentrated  and  the  resulting  crude  oil  was  distilled  under  reduced 
pressure (P = 0.96 mmHg, T= 72-76 °C) to afford (2.43) as a colourless oil (10.22 g, 
99%). 
 
Mw = 176.643 (C8H13O2Cl). 
Rf = 0.30 (Hexane/EtOAc 90:10). 
IR (neat): 2950 (m), 2879 (w), 1730 (w), 1649 (w), 1436 (w), 1393 (w), 1252 (m), 1138 
(s), 1053 (m), 1030 (m), 765 (m) cm
-1. 
1H NMR (300 MHz; CDCl3):  5.68-5.63 (2H, m, HB + HC), 4.88 (1H, t, J = 4.9 Hz, HF), 
4.12 (2H, d, J = 6.8 Hz, HA), 4.00-3.83 (4H, m, HG), 2.28 (2H, m, HD), 1.76 (2H, dt, J = 
7.6, 4.9 Hz, HE) ppm.  
13C NMR (75 MHz; CDCl3):  134.1 (CH, CB/C), 126.0 (CH, CB/C), 103.6 (CH, CF), 64.9 
(2 x CH2, CG), 39.3 (CH2, CA), 33.1 (CH2, CE), 21.6 (CH2, CD) ppm. 
CIMS m/z (%): 177/179 (3:1, (M+H)
+, 5), 143 (28), 99 (11), 73 (100). 
HREIMS For C8H13O2
35Cl (M-H)
+: calcd 175.0526, found 175.0520. 138 
 
Diethyl-[5-(1,3-dioxolan-2-yl)-2-(Z)-pentenyl]phosphonate (2.2) 
 
 
The allylic chloride (2.43) (10.22 g, 57.9 mmol, 1.0 equiv) and triethyl phosphite (19.84 
mL, 116 mmol, 2.0 equiv) were combined and heated between 110 and 130 °C for 48 h. 
The mixture was cooled and purified by vacuum distillation (0.55 mmHg). Excess triethyl 
phosphite was collected at 46 to 50 °C (colourless oil) and the phosphonate (2.2) was 
collected at 140 to 146 °C as a colourless oil (14.17 g, 88%).  
 
Mw = 278.290 (C12H23O5P). 
Rf = 0.17 (Hexane/Acetone 80:20). 
IR (neat): 2974 (m), 2884 (w), 1394 (w), 1393 (w), 1252 (m), 1139 (m), 1053 (s), 1025 
(s), 927 (s) cm
-1. 
1H NMR (300 MHz; CDCl3):  5.58 (1H, m, HE), 5.39 (1H, m, HD), 4.80 (1H, t, J = 4.6 
Hz, HH), 4.09-3.99 (4H, m, HB), 3.92-3.76 (4H, m, HI), 2.56 (2H, dd, J = 22.2, 7.7 Hz, 
HC), 2.20 (2H, m, HF), 1.71-1.66 (2H, m, HG), 1.26 (6H, t, J = 7.1 Hz, HA) ppm. 
13C NMR (75 MHz; CDCl3):  133.2 (d, J = 14.3 Hz, CH, CE), 118.4 (d, J = 11.0 Hz, CH, 
CD), 103.7 (CH, CH), 64.7 (2 x CH2, CI), 61.6 (d, J = 6.6 Hz, 2 x CH2, 2 x CB), 33.2 (d, J = 
2.6 Hz, CH2, CG), 25.6 (d, J = 140.0 Hz, CH2, CC), 21.7 (d, J = 2.1 Hz, CH2, CF), 16.3 (d, 
J = 6.0 Hz, 2 x CH3, CA) ppm. 
31P NMR (121 MHz; CDCl3):  28.60 ppm. 
CIMS m/z (%): 279 ((M+H)
+, 100), 235 (11), 206 (18), 156 (25), 140 (20), 99 (13), 73 
(78). 
HRES
+MS: For C12H23O5PNa (M+Na)
+: calcd 301.1175, found 301.1171. 
 
2-(5-Chloropent-3-(E)-enyl)-[1,3]-dioxolane (2.44) 
A
B
C
D
E F
G
O
O
O
O
HCA, PPh3
DCM
95%
Cl HO
(2.42) (2.44)  
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The allylic alcohol (2.42) (3.76 g, 23.8 mmol, 1.0 equiv) was dissolved in DCM (20 mL) 
and added via cannula to a solution of triphenyphosphine (6.87 g, 26.2 mmol, 1.1 equiv) in 
DCM (50 mL). Upon complete dissolution, the mixture was cooled to 0 °C with stirring. 
To this mixture was added via cannula a solution of hexachloroacetone (3.97 mL, 26.2 
mmol, 1.1 equiv) in DCM (30 mL) over 2 min. The cold bath was then removed and the 
reaction was stirred for 10 min. The solvent was evaporated and the resulting crude (solid 
+ oil)  was taken  in 150 mL of hot hexane and stirred for 5 min.  After  filtration, the 
resulting triphenylphosphine oxide was washed with 100 mL of hot hexane. The filtrate 
was concentrated and the resulting crude oil was distilled under reduced pressure (P= 0.53 
mmHg, T= 68-70 °C) to afford (2.44) as a colourless oil (3.99 g, 95%). 
 
Mw = 176.643 (C8H13O2Cl). 
Rf = 0.30 (Hexane/EtOAc 90:10). 
IR (neat): 2957 (s), 2889 (s), 1668 (w), 1441 (m), 1408 (m), 1252 (m), 1134 (s), 1039 (s), 
963 (s), 902 (m) cm
-1. 
1H NMR (300 MHz; CDCl3):  5.81 (1H, dt, J = 15.1, 6.7 Hz, HC), 5.65 (1H, dtt, J = 
15.1, 7.0, 1.4 Hz, HB), 4.88 (1H, t, J = 4.6 Hz, HF), 4.03 (2H, dd, J = 7.0, 0.8 Hz, HA), 
3.99-3.81 (4H, m, HG), 2.32-2.24 (2H, m, HD), 1.80-1.72 (2H, m, HE) ppm.  
13C NMR (75 MHz; CDCl3):  135.0 (CH, CC), 126.3 (CH, CB), 103.8 (CH, CF), 64.9 
(CH2, 2 x CG), 45.3 (CH2, CA), 32.9 (CH2, CE), 26.4 (CH2, CD) ppm. 
CIMS m/z (%): 177 ((M+H)
+, 28), 141 (55), 99 (14), 73 (100). 
HREIMS: For C8H13O2
35Cl (M-H)
+: calcd 175.0526, found 175.0524. 
 
Diethyl-[5-(1,3-dioxolan-2-yl)-2-(E)-pentenyl]phosphonate (2.45) 
 
 
The allylic chloride (2.44) (3.95 g, 22.4 mmol, 1.0 equiv) and triethyl phosphite (7.68 mL, 
44.8 mmol, 2.0 equiv) were combined and heated between 110 and 130 °C for 48 h. The 
mixture was cooled and purified by vacuum distillation (0.76 mmHg). Excess triethyl 
phosphite was collected at 46 to 50 °C (colourless oil) and the phosphonate (2.45) was 
collected at 136 to 142 °C as a colourless oil (5.64 g, 92%).  140 
 
 
Mw = 278.290 (C12H23O5P). 
Rf = 0.44 (Hexane/Acetone 60:40). 
IR (neat): 2983 (m), 2907 (w), 1484 (w), 1403 (w), 1238 (m), 1134 (m), 1044 (s), 1020 
(s), 959 (s) cm
-1. 
1H NMR (300 MHz; CDCl3):  5.64 (1H, m, HE), 5.45 (1H, m, HD), 4.85 (1H, t, J = 4.7 
Hz, HH), 4.15-4.03 (4H, m, HB), 4.00-3.79 (4H, m, HI), 2.53 (2H, dd, J = 22.1, 6.9 Hz, 
HC), 2.21-2.13 (2H, m, HF), 1.76-1.69 (2H, m, HG), 1.30 (6H, t, J = 7.1 Hz, HA) ppm.  
13C NMR (75 MHz; CDCl3):  134.9 (d, J = 14.6 Hz, CH, CE), 119.1 (d, J = 11.2 Hz, CH, 
CD), 103.9 (CH, CH), 64.8 (CH2, 2 x CI), 61.8 (d, J = 6.8 Hz, CH2, 2 x CB), 33.3 (d, J = 3.3 
Hz, CH2, CG), 30.4 (d, J = 139.7 Hz, CH2, CC), 27.0 (d, J = 2.2 Hz, CH2, CF), 16.4 (d, J = 
6.0 Hz, 2 x CH3, CA) ppm. 
31P NMR (121 MHz; CDCl3):  28.50 ppm. 
CIMS: m/z (%): 278 ((M+H)
+, 4), 235 (6), 206 (13), 156 (35), 127 (18), 99 (18), 73 (100). 
HRES
+MS: For C12H23O5P (M+Na)
+: calcd 301.1175, found 301.1176. 
 
1-bromo-2-(bromomethyl)-4-methoxybenzene (2.48) and 1-bromo-2-
(dibromomethyl)-4-methoxybenzene (2.50) 
 
 
A  solution  of  3-methylanisole  (2.49)  (12.4  mL,  98  mmol,  1.0  equiv)  and  N-
bromosuccinimide (37.2 g, 209 mmol, 2.0 equiv) in DCM (500 mL) was refluxed for 4 h 
while exposed to light from 2 x 100 W incandescent bulbs placed within 2 cm of the 
reaction vessel. The mixture was then cooled to room temperature, diluted with DCM (400 
mL) and washed with water (2 x 400 mL). The organic layer was dried over MgSO4, 
filtered and evaporated. The residue was recrystallized with Hexanes (250 mL) to give 
dibromide (2.48) as a light yellow solid (16.8 g, 61%). Tribromide (2.50) was isolated by 
column chromatography of the residue, eluting (Hexane/Acetone) = (99:1) as a colourless 
liquid (5.61 g, 16%).  
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Data for (2.48) 
Mw = 279.957 (C8H8OBr2). 
m.p. = 85-89 °C. 
Rf = 0.18 (neat Hexane). 
IR (film): 3080, 3012, 2941, 1571, 1476, 1283, 1250, 1145, 1051, 1013, 925, 876 cm
-1. 
1H NMR (400 MHz; CDCl3):  7.45 (1H, d, J = 9.0 Hz, HA), 6.99 (1H, d, J = 3.0 Hz, HD), 
6.74 (1H, dd, J = 9.0, 3.0 Hz, HB), 4.56 (2H, s, HG), 3.80 (3H, s, HH) ppm.  
13C NMR (100 MHz; CDCl3):  159.6 (Q, CC), 138.2 (Q, CF), 134.3 (CH, CA), 116.9 (CH, 
CD), 116.5 (CH, CB), 115.1 (Q, CE), 56.0 (CH3, CH), 33.9 (CH2, CG) ppm. 
 CIMS: m/z (%): 281/279 (M+H
+, 10), 202/200 (100), 186/184 (14), 159/157 (20), 122 
(72). 
The experimental data correspond well with the literature data.
104 
 
Data for (2.50) 
Mw = 358.853 (C8H7OBr3). 
Rf = 0.18 (neat Hexane). 
IR (film): 3023 (w), 2935 (w), 2835 (w), 1592 (m), 1468 (s), 1279 (s), 1241 (m), 1015 (s), 
806 (m), 714 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  7.54 (1H, d, J = 8.8 Hz, HA), 7.39 (1H, d, J = 2.9 Hz, HD), 
7.03 (1H, s, HG), 6.76 (1H, dd, J = 8.8, 2.9 Hz, HB), 3.86 (3H, s, HH) ppm.  
13C NMR (100 MHz; CDCl3):  159.7 (Q, CC), 141.3 (Q, CF), 133.4 (CH, CA), 118.0 (CH, 
CD), 116.1 (CH, CB), 110.1 (Q, CE), 55.8 (CH3, CH), 40.1 (CH2, CG) ppm. 
 CIMS: m/z (%): 364/362/360/358 (M+H
+, 6), 282/280/278 (54), 215/213 (26), 202/200 
(70), 122 (100). 
HRMS (CI) for C8H7O
79Br3: calcd 355.80470, found 355.80477. 
 
Preparation of allenyl magnesium bromide.
105,106 
 
 
A 500 mL three-necked flask was charged with magnesium turnings (5.30 g, 218.1 mmol) 
and HgCl2 (88 mg, 0.32 mmol), dried by heating under high vacuum and flushed with 142 
 
nitrogen. A solution of 0.99 mL (10.1 mmol) of propargylbromide (80% wt in toluene) in 
20 mL of Et2O was added. When Et2O began to reflux, the mixture was cooled to 5 °C 
under stirring and a solution of propargylbromide (15.6 mL, 173 mmol) in Et2O (90 mL) 
was added at such a rate to keep the temperature under 10 °C. The mixture was stirred at 
room temperature for 1 h until it became dark green. 
 
1-bromo-2-(but-3-ynyl)-4-methoxybenzene (2.51) 
 
 
To a stirred solution of dibromide (2.48) (17.0 g, 63 mmol, 1.0 equiv) in dry THF (50 mL) 
cooled to 0 °C, allenylmagnesium bromide (132 mmol in 80 mL of Et2O, 2.1 equiv) was 
slowly added at such a rate to keep the temperature under 10 °C. The mixture was allowed 
to warm to room temperature and stirred for 4 h. After cooling to 0 °C, the mixture was 
quenched with water (150 mL), 1 M HCl (150 mL) and extracted with Et2O (2 x 200 mL). 
After evaporation of the solvent, the crude product was purified by distillation (b.p. = 96-
98 °C/ 0.3 mmHg) to afford alkyne (2.51) (13.6 g, 94%) as a yellow liquid.  
 
Mw = 239.108 (C11H11OBr). 
Rf = 0.53 (Hexane/Acetone 90:10). 
IR (film): 3295 (m), 2936 (w), 2835 (w), 2117 (w), 1595 (m), 1573 (m), 1472 (s), 1241 (s) 
cm
-1. 
1H NMR (400 MHz; CDCl3):  7.43 (1H, d, J = 8.8 Hz, HA), 6.86 (1H, d, J = 3.1 Hz, HD), 
6.67 (1H, dd, J = 8.8, 3.1 Hz, HB), 3.80 (3H, s, HG), 2.93 (2H, t, J = 7.5 Hz, HH), 2.52 
(2H, td, J = 7.5, 2.6 Hz, HI), 2.01 (1H, t, J = 2.6 Hz, HK) ppm.  
13C NMR (100 MHz; CDCl3):  159.0 (Q, CC), 140.5 (Q, CF), 133.4 (CH, CA), 116.6 (CH, 
CD), 114.8 (Q, CE), 113.8 (CH, CB), 83.5 (Q, CJ), 69.3 (CH, CK), 55.6 (CH3, CG), 35.5 
(CH2, CH), 18.9 (CH2, CI) ppm. 
EIMS m/z (%): 240/238 (M
+, 11), 201/199 (27), 159 (100), 144 (21), 128 (11). 
Elemental analysis calcd for C11H11OBr: C, 55.26; H, 4.64. Found: C, 54.90; H, 4.69. 
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5-(2-bromo-5-methoxyphenyl)pent-2-yn-1-ol (2.47) 
 
 
To a solution of alkyne (2.51) (13.62 g, 56.9 mmol, 1.0 equiv) in THF (50 mL), cooled to 
0 °C, was slowly added a solution of LDA (34.15 mL, 68.3 mmol, 2 M solution in THF, 
1.2 equiv). The resulting black solution was stirred at 0 °C for 1 h. Gaseous formaldehyde, 
obtained  from  12  g  of  paraformaldehyde  by  heating  to  approximately  400  °C  with  a 
heatgun, was added by mean of a nitrogen stream, and the orange mixture obtained was 
stirred at room temperature for 30 min. After cooling to 0 °C, the reaction was quenched 
with NH4Cl/H2O 1:1 (100 mL) and extracted with DCM (3 x 100 mL). The organic layer 
was  dried  over  MgSO4,  filtered  and  concentrated  in  vacuo.  Purification  by  column 
chromatography (Hexane/Acetone 70:30) gave alcohol (2.47) (12.71 g, 83%) as a yellow 
oil which solidified upon storage in the fridge. 
 
Mw = 269.134 (C12H13O2Br). 
m.p. = 50-52 °C. 
Rf = 0.36 (Hexane/Acetone 70:30). 
IR (film): 3302 (m), 3219 (m), 2910 (w), 2832 (w), 1596 (m), 1571 (m), 1468 (s), 1248 (s) 
cm
-1. 
1H NMR (400 MHz; CDCl3):  7.41 (1H, d, J = 8.6 Hz, HA), 6.82 (1H, d, J = 3.1 Hz, HD), 
6.66 (1H, dd, J = 8.6, 3.1 Hz, HB), 4.25 (2H, dt, J = 5.5, 2.2 Hz, HL), 3.80 (3H, s, HG), 
2.91 (2H, t, J = 7.5 Hz, HH), 2.52 (2H, tt, J = 7.5, 2.2 Hz, HI), 1.58 (br s, OH) ppm.  
13C NMR (100 MHz; CDCl3):  159.0 (Q, CC), 140.7 (Q, CF), 133.4 (CH, CA), 116.6 (CH, 
CD), 114.8 (Q, CE), 113.8 (CH, CB), 85.4 (Q, CJ), 79.5 (Q, CK), 55.6 (CH3, CG), 51.5 (CH2, 
CL), 35.6 (CH2, CH), 19.3 (CH2, CI) ppm. 
CIMS m/z (%): 288/286 (M+NH4
+, 26), 270/268 (M+H
+, 20), 240/238 (8), 201/200 (40), 
189 (100). 
Elemental analysis calcd for C12H13O2Br: C, 53.55; H, 4.87. Found: C, 53.51; H, 4.90. 
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(Z)-5-(2-bromo-5-methoxyphenyl)pent-2-en-1-ol (2.52) 
 
 
Pre-Activation of Zinc dust: The Zn dust (20 g) was activated by stirring it in a 0.1 M HCl 
solution (300 mL) for ca. 15 min, until the gas evolution stopped. The grey solid was 
filtered  off,  washed  with  plenty  of  water  then  plenty  of  EtOH  and  dried under  high 
vacuum for at least 4 hours. 
Procedure: Into a 250 mL 3-neck flask equipped with a condenser was added activated 
zinc  (14.14  g,  216  mmol,  4.0  equiv)  followed  by  dry  EtOH  (50  mL)  and  1,2-
dibromoethane (1.63 mL, 18.9 mmol, 0.35 equiv). The slurry was stirred and placed into a 
preheated oil bath at 100 °C until ethane evolution began.  CAUTION,  ethane evolves 
rapidly, ensure heat source is removed as soon as reaction begins and there is adequate 
pressure  release. Once  the  ethane evolution  was  complete  (~5  min),  a solution of the 
alkyne (2.47) (14.54 g, 54 mmol, 1.0 equiv) in 60 mL dry EtOH was added. The reaction 
was refluxed for 3 h, cooled and filtered through celite, washing with DCM. The solvents 
were evaporated in vacuo and then DCM was added (100 mL) followed by water (100 
mL). The phases were separated and the aqueous phase extracted with DCM (4 x 50 mL). 
The  combined  organic  phases  were  dried  over  MgSO4,  filtered  and  evaporated.  This 
yielded (2.52) as a light yellow oil (14.35 g, 98%).  
 
Mw = 271.150 (C12H15O2Br). 
Rf = 0.34 (Hexane/Acetone 70:30). 
IR (film): 3314 (m, br), 2935 (m), 1594 (m), 1572 (m), 1469 (s), 1240 (s), 1016 (s) cm
-1. 
1H NMR (400 MHz; CDCl3):  7.40 (1H, d, J = 8.7 Hz, HA), 6.74 (1H, d, J = 3.0 Hz, HD), 
6.62 (1H, dd, J = 8.7, 3.0 Hz, HB), 5.74-5.48 (2H, m, HK + HJ), 4.09 (2H, d, J = 5.4 Hz, 
HL), 3.76 (3H, s, HG), 2.74 (2H, t, J = 7.6 Hz, HH), 2.39 (2H, dd, J = 14.9, 6.5 Hz, HI), 
1.88 (1H, br s, OH) ppm. 
13C NMR (100 MHz; CDCl3):  158.9 (Q, CC), 141.8 (Q, CF), 133.5 (CH, CA), 131.2 (CH, 
CK), 129.8 (CH, CJ), 116.6 (CH, CD), 115.0 (Q, CE), 113.3 (CH, CB), 58.6 (CH2, CL), 55.6 
(CH3, CG), 36.4 (CH2, CH), 27.7 (CH2, CI) ppm. 145 
 
CIMS m/z (%): 290/288 (M+ NH4
+, 2), 272/270 (M+H
+, 13), 201/200 (50), 191 (21), 147 
(100). 
Elemental analysis calcd for C12H15O2Br: C, 53.16; H, 5.58. Found: C, 53.24; H, 5.68. 
 
(Z)-1-bromo-2-(5-chloropent-3-enyl)-4-methoxybenzene  (2.46)  and  1-bromo-2-(4-
chlorohex-5-enyl)-4-methoxybenzene (2.54) 
 
 
The allylic alcohol (2.52) (14.35 g, 53 mmol, 1.0 equiv) was dissolved in DCM (100 mL) 
and added via cannula to a solution of triphenyphosphine (15.71 g, 60 mmol, 1.1 equiv) in 
DCM (50 mL). Upon complete dissolution, the mixture was cooled to 0 °C with stirring. 
To this mixture was added via cannula a solution of hexachloroacetone (9.00  mL, 60 
mmol, 1.1 equiv) in DCM (100 mL) over 15 min. The cold bath was then removed and the 
reaction was stirred for 10 min. The solvent was evaporated and the resulting crude (solid 
+ oil)  was taken  in 150 mL of hot hexane and stirred for 5 min.  After  filtration, the 
resulting triphenylphosphine oxide was washed with 200 mL of hot hexane. The filtrate 
was  concentrated and  the  resulting  crude oil was purified by  column  chromatography 
(Hexane/Acetone 90:10) to afford (2.46) as a colourless oil (15.09 g, 99%). 
When purification by distillation was attempted instead of column chromatography, an 
inseparable mixture of (2.46/2.54) (70/30) was obtained in 94% yield (b.p. = 126-130 °C/ 
0.2 mmHg). 
 
Data for (2.46) 
Mw = 289.596 (C12H14OBrCl). 
Rf = 0.47 (Hexane/Acetone 90:10). 
IR (film): 2935 (m), 2836 (w), 1594 (m), 1572 (m), 1470 (s), 1240 (s) cm
-1. 
1H NMR (400 MHz; CDCl3):  7.41 (1H, d, J = 8.6 Hz, HA), 6.77 (1H, d, J = 3.1 Hz, HD), 
6.64 (1H, dd, J = 8.6, 3.1 Hz, HB), 5.75-5.62 (2H, m, HK + HJ), 4.14 (2H, d, J = 6.8 Hz, 
HL), 3.80 (3H, s, HG), 2.78 (2H, t, J = 7.8 Hz, HH), 2.48-2.43 (2H, m, HI) ppm.  146 
 
13C NMR (100 MHz; CDCl3):  159.0 (Q, CC), 141.5 (Q, CF), 133.6 (CH, CA), 133.5 (CH, 
CK), 126.5 (CH, CJ), 116.5 (CH, CD), 114.1 (Q, CE), 113.4 (CH, CB), 55.6 (CH3, CG), 39.5 
(CH2, CL), 36.2 (CH2, CH), 27.5 (CH2, CI) ppm. 
CIMS m/z (%): 290/288 (M+H
+, 6), 254 (13), 201/200 (55), 175 (100). 
Elemental analysis calcd for C12H14OBrCl: C, 49.77; H, 4.87. Found: C, 49.72; H, 4.88. 
 
Significant data for (2.54) 
Mw = 289.596 (C12H14OBrCl). 
Rf = 0.47 (Hexane/Acetone 90:10). 
1H NMR (300 MHz; CDCl3):  7.41 (1H, d, J = 8.6 Hz, HA), 6.81 (1H, d, J = 3.0 Hz, HD), 
6.64 (1H, dd, J = 8.6, 3.1 Hz, HB), 5.96 (1H, ddd, J = 17.0, 10.1, 8.0 Hz, HK), 5.32 (1H, 
td, J = 17.0, 0.8 Hz, HL), 5.20 (1H, d, J = 10.1 Hz, HL’), 4.37 (1H, m, HJ), 3.80 (3H, s, 
HG), 2.95-2.83 (2H, m, HH), 2.12 (1H, m, HI) ppm. 
 
(Z)-diethyl 5-(2-bromo-5-methoxyphenyl)pent-2-enylphosphonate (2.3) 
 
 
The allylic chloride (2.46) (14.22 g, 49.1 mmol, 1.0 equiv) and triethylphosphite (16.85 
mL, 98.2 mmol, 2.0 equiv) were combined followed by the addition of NaI (7.36 g, 49.1 
mmol, 1.0 equiv). The mixture was heated at 60 °C for 2 h. The mixture was cooled, 
diluted  with  DCM  (100  mL),  filtered  through  celite  and  concentrated  in  vacuo.  The 
resulting crude was subjected to distillation to remove the excess of triethylphosphite (P = 
0.7  mmHg,  b.p.  =  46-50°C).  The  resulting  residue  was  purified  by  column 
chromatography (Hexane/Acetone 60:40) yielding phosphonate (2.3) as a light yellow oil 
(17.62 g, 92%).  
 
Mw = 391.237 (C16H24O4BrP). 
Rf = 0.38 (Hexane/Acetone 65:35). 
IR (film): 2980 (s), 2934 (s), 2906 (s), 1594 (s), 1571 (s), 1472 (m), 1240 (s) cm
-1. 147 
 
1H NMR (400 MHz; CDCl3):  7.41 (1H, d, J = 8.8 Hz, HA), 6.77 (1H, d, J = 2.9 Hz, HD), 
6.64 (1H, dd, J = 8.8, 2.9 Hz, HB), 5.68 (1H, m, HK), 5.49 (1H, m, HJ), 4.22-3.98 (4H, m, 
HM), 3.80 (3H, s, HG), 2.76 (2H, t, J = 8.1 Hz, HH), 2.58 (2H, dd, J = 21.3, 7.3 Hz, HL), 
2.43-2.35 (2H, m, HI), 1.31 (6H, t, J = 7.0 Hz, HN) ppm.  
13C NMR (100 MHz; CDCl3):  159.0 (Q, CC), 141.9 (Q, CF), 133.4 (CH, CA), 133.0 (CH, 
d, J = 13.1 Hz, CK), 119.1 (CH, d, J = 11.3 Hz, CJ), 116.4 (CH, CD), 114.9 (Q, CE), 113.3 
(CH, CB), 62.0 (2 x CH2, d, J = 6.8 Hz, CM), 55.6 (CH3, CG), 36.1 (CH2, CI), 27.6 (CH2, 
CH), 25.9 (CH2, d, J = 140.2 Hz, CL), 16.6 (2 x CH3, d, J = 5.6 Hz, CN) ppm. 
31P NMR (121 MHz; CDCl3): 28.46 ppm. 
CIMS m/z (%): 393/391 (M+H
+, 16), 313/311 (3), 202/200 (13), 175 (18), 161 (57). 
Elemental analysis calcd for C16H24O4BrP: C, 49.12; H, 6.18; P, 7.92. Found: C, 48.80; 
H, 6.35; P, 7.87. 
 
(E)-diethyl 5-(2-bromo-5-methoxyphenyl)pent-2-enylphosphonate (2.55) 
 
 
Following the same procedure described for the synthesis of Z-allylic phosphonate (2.3) 
above, a mixture of allylic chlorides (2.46/2.54 = 70/30) (11.17 g, 38.6 mmol) afforded an 
inseparable mixture of allylic phosphonates (2.3/2.55 = 70/30) (11.99 g , 81%). 
 
Significant data for (2.55) 
Mw = 391.237 (C16H24O4BrP). 
Rf = 0.38 (Hexane/Acetone 65:35). 
1H NMR (400 MHz; CDCl3):  7.40 (1H, d, J = 8.7 Hz, HA), 6.76 (1H, d, J = 4.4 Hz, HD), 
6.64 (1H, m, HB), 5.68 (1H, m, HK), 5.49 (1H, m, HJ), 4.22-3.98 (4H, m, HM), 3.80 (3H, s, 
HG), 2.76 (2H, t, J = 8.1 Hz, HH), 2.63-2.53 (2H, m, HL), 2.43-2.35 (2H, m, HI), 1.31 (6H, 
t, J = 7.0 Hz, HN) ppm. 
13C NMR (100 MHz; CDCl3):  159.0 (Q, CC), 141.8 (Q, CF), 134.6 (CH, d, J = 14.4 Hz, 
CK), 133.2 (CH, CA), 119.6 (CH, d, J = 11.0 Hz, CJ), 116.4 (CH, CD), 114.9 (Q, CE), 113.3 148 
 
(CH, CB), 62.0 (2 x CH2, d, J = 6.8 Hz, CM), 55.6 (CH3, CG), 36.2 (CH2, CI), 32.7 (CH2, 
CH), 30.5 (CH2, d, J = 140.0 Hz, CL), 16.6 (2 x CH3, d, J = 5.6 Hz, CN) ppm. 
31P NMR (121 MHz; CDCl3): 28.46 ppm. 
 
Diethyl-(2R,3S)-5-(2-bromo-5-methoxyphenyl)-2,3-dihydroxypentylphosphonate 
(2.56) and Diethyl-(2S,3S)-5-(2-bromo-5-methoxyphenyl)-2,3-
dihydroxypentylphosphonate (2.57) 
 
 
To a mixture of NMO.2H2O (0.329 g, 2.82 mmol, 1.1 equiv), 10 mL of water, 5 mL of 
acetone and osmium tetroxide (7.5 mg, 0.026 mmol, 0.01 equiv) in 2 mL tBuOH was 
added  the  mixture  of  phosphonates  (2.55,  2.3)  (1.02  g,  2.56  mmol,  1.0  equiv).  The 
reaction was complete after stirring overnight at room temperature under nitrogen. Water 
was added (10 mL), then DCM (20 mL). After separation of the two phases, the aqueous 
phase was extracted with DCM (3 x 10 mL). The combined organic phases were dried 
over  MgSO4,  filtered  and  concentrated  in  vacuo.  The  crude  product  was  purified  by 
column chromatography (DCM/MeOH 95:5) to afford inseparable diols (2.56) and (2.57) 
(0.847 g, 78%). Ratio (2.57)/(2.56) = 70/30, determined by 
31P NMR. 
 
Mw = 424.065 (C16H26BrO6P). 
Rf = 0.32 (DCM/MeOH 95:5). 
IR (neat): 3378 (br, w), 2983 (w), 2906 (w), 1462 (w), 1238 (m), 1086 (m), 1026 (s), 1011 
(s), 969 (s) cm
-1. 
1H NMR (400 MHz; CDCl3): Characteristic peaks  7.34 (1H, d, J = 8.7 Hz, HA), 6.79 
(1H, d, J = 3.0 Hz, HD), 6.57 (1H, dd, J = 8.7, 3.0 Hz, HB), 3.72 (3H, s, HG), 1.28 (3H, t, J 
= 7.1 Hz, HN), 1.28 (3H, t, J = 7.1 Hz, HN’) ppm.  
13C NMR (100 MHz; CDCl3): For (2.57)  158.8 (Q, CC), 142.1 (Q, CF), 133.0 (CH, CA), 
116.0 (CH, CD), 114.6 (Q, CE), 113.1 (CH, CB), 73.5 (d, J = 15.5 Hz, CH, CK), 69.5 (d, J 
= 5.6 Hz, CH, CJ), 61.9 (d, J = 6.4 Hz, CH2, CM), 61.8 (d, J = 6.7 Hz, CH2, CM’), 55.2 149 
 
(CH3, CG), 32.7 (CH2), 32.1 (CH2), 27.5 (d, J = 140.8 Hz, CH2, CL), 16.2 (d, J = 5.8 Hz, 
CH3, CN), 16.2 (d, J = 6.0 Hz, CH3, CN’) ppm.  
For (2.56)  158.8 (Q, CC), 142.2 (Q, CF), 133.0 (CH, CA), 116.0 (CH, CD), 114.6 (Q, CE), 
113.1 (CH, CB), 73.6 (d, J = 15.4 Hz, CH, CK), 68.9 (d, J = 5.0 Hz, CH, CJ), 61.9 (d, J = 
6.4 Hz, CH2, CM), 61.8 (d, J = 6.7 Hz, CH2, CM’), 55.2 (CH3, CG), 33.2 (CH2), 32.5 (CH2), 
30.1 (d, J = 139.7 Hz, CH2, CL), 16.2 (d, J = 5.8 Hz, CH3, CN), 16.2 (d, J = 6.0 Hz, CH3, 
CN’) ppm 
31P NMR (121 MHz; CDCl3): For (2.57)  32.56 ppm, For (2.56)  31.46 ppm. 
ES
+MS  m/z  (%):  875/873/871  (1:2:1,  (2M+Na)
+,  100),  449/447  (1:1,  (M+Na)
+,  58), 
427/425 (1:1, (M+H)
+, 38). 
HRES
+MS For C16H26O6P
79BrNa (M+Na)
+: calcd 447.0543, found 447.0552. 
 
Diethyl-((4R,5S)-5-(2-bromo-5-methoxyphenethyl)-2-thioxo-1,3-dioxolan-4-
yl)methylphosphonate (2.58)  and  Diethyl-((4S,5S)-5-(2-bromo-5-methoxyphenethyl)-
2-thioxo-1,3-dioxolan-4-yl)methylphosphonate (2.59). 
 
 
A THF (5 mL) solution of diols (2.56) and (2.57) (0.417 g, 0.98 mmol, 1.0 equiv) was 
added  at  room  temperature  to  a  THF  (5  mL)  solution  of  1,1-thiocarbonyldiimidazole 
(0.175 g, 0.98 mmol, 1.0 equiv). The reaction mixture was stirred for 4 days at room 
temperature until completion. DCM (10 mL) was added, followed by HCl 1M (10 mL). 
After separation of the two phases, the aqueous phase was extracted with DCM (3 x 10 
mL). The combined organic phases were dried over MgSO4, filtered and concentrated in 
vacuo.  The  crude  product  was  purified  by  column  chromatography  (Hexane/Acetone 
70:30)  to  afford trans-isothiocarbonate  (2.58) (0.110 g,  24%)  and  cis-isothiocarbonate 
(2.59) (0.285 g, 62%) as light yellow oils.     
 
Data for (2.58) 
Mw = 467.312 (C17H24O6PSBr). 
Rf = 0.43 (Hexane/Acetone 60:40). 150 
 
IR (neat): 2980 (w), 1572 (w), 1474 (m), 1277 (s), 1240 (s), 1160 (m), 1015 (s), 950 (br s) 
cm
-1. 
1H NMR (400 MHz; CDCl3):  7.41 (1H, d, J = 8.8 Hz, HA), 6.89 (1H, d, J = 3.0 Hz, HD), 
6.66 (1H, dd, J = 8.8, 3.0 Hz, HB), 4.90-4.72 (2H, m, HJ + HK), 4.23-4.00 (4H, m, HN), 
3.77 (3H, s, HG), 2.95 (1H, ddd, J = 14.5, 10.0, 5.0 Hz, HH), 2.81 (1H, ddd, J = 13.7, 9.7, 
6.8 Hz, HH’), 2.39 (1H, ddd, J = 19.9, 15.1, 4.5 Hz, HM), 2.28-1.97 (3H, m, HM’ + HI), 1.32 
(3H, t, J = 7.1 Hz, HO), 1.31 (3H, t, J = 7.1 Hz, HO’) ppm.  
13C NMR (100 MHz; CDCl3):  190.3 (CH, CL), 159.1 (Q, CC), 139.9 (Q, CF), 133.5 (CH, 
CA), 116.2 (CH, CD), 114.4 (Q, CE), 114.0 (CH, CB), 86.0 (CH, d, J = 4.8 Hz, CK), 81.2 
(CH, CJ), 62.6 (CH2, d, J = 6.5 Hz, CN), 62.4 (CH2, d, J = 6.5 Hz, CN’), 55.5 (CH3, CG), 
33.2 (CH2, CH), 31.4 (CH2, CI), 30.6 (CH2, d, J = 139.6 Hz, CM), 16.4 (CH3, d, J = 5.2 Hz, 
CO), 16.3 (CH3, d, J = 5.3 Hz, CO’) ppm. 
31P NMR (121 MHz; CDCl3):  22.82 ppm. 
ES
+MS m/z (%): 491/489 (1:1, (M+Na)
+, 53), 469/467 (1:1, (M+H)
+, 23). 
HRES
+MS For C17H24O6PS
79BrNa (M+Na)
+: calcd 489.0112, found 489.0108. 
 
Data for (2.59) 
Mw = 467.312 (C17H24O6PSBr). 
Rf = 0.37 (Hexane/Acetone 60:40). 
IR (neat): 2980 (w), 1803 (w), 1572 (w), 1473 (m), 1278 (s), 1239 (s), 1160 (m), 1017 (s), 
963 (br s) cm
-1. 
1H NMR (400 MHz; CDCl3):  7.39 (1H, d, J = 8.8 Hz, HA), 6.79 (1H, d, J = 3.0 Hz, HD), 
6.65 (1H, dd, J = 8.8, 3.0 Hz, HB), 5.18 (1H, p, J = 7.3 Hz, HJ), 4.89 (1H, ddd, J = 10.5, 
7.2, 3.0 Hz, HK), 4.20-4.01 (4H, m, HN), 3.76 (3H, s, HG), 3.00 (1H, ddd, J = 13.9, 9.3, 4.8 
Hz, HH), 2.80 (1H, ddd, J = 13.7, 8.7, 7.6 Hz, HH’), 2.30 (1H, ddd, J = 19.5, 15.3, 7.3 Hz, 
HM), 2.21-1.88 (3H, m, HM’ + HI), 1.30 (3H, t, J = 7.1 Hz, HO), 1.29 (3H, t, J = 7.1 Hz, 
HO’) ppm.  
13C NMR (100 MHz; CDCl3):  190.1 (CH, CL), 159.0 (Q, CC), 139.8 (Q, CF), 133.5 (CH, 
CA), 116.3 (CH, CD), 114.4 (Q, CE), 114.0 (CH, CB), 83.1 (CH, d, J = 8.5 Hz, CK), 79.0 
(CH, CJ), 62.6 (CH2, d, J = 6.5 Hz, CN), 62.3 (CH2, d, J = 6.4 Hz, CN’), 55.4 (CH3, CG), 
31.9 (CH2, CH), 28.6 (CH2, CI), 25.9 (CH2, d, J = 142.7 Hz, CM), 16.3 (CH3, d, J = 4.4 Hz, 
CO), 16.2 (CH3, d, J = 4.3 Hz, CO’) ppm. 
31P NMR (121 MHz; CDCl3):  23.18 ppm. 151 
 
ES
+MS m/z (%): 491/489 (1:1, (M+Na)
+, 56), 469/467 (1:1, (M+H)
+, 16). 
HRES
+MS For C17H24O6PS
79BrNa (M+Na)
+: calcd 489.0112, found 489.0114. 
 
Resolution of cis/trans-1,2-diaminocyclohexane (2.60)
114  
 
 
A 250 mL three-necked flask equipped with an overhead stirrer and a thermometer, was 
charged with L-(+)-tartaric acid (2.61) (30.0 g, 198 mmol, 1.0 equiv) and distilled water 
(80 mL). The mixture was stirred at room temperature until complete dissolution occurred. 
A mixture of commercially available cis/trans-1,2-diaminocyclohexane (2.60) (48.1 mL, 
388 mmol, 2.0 equiv) was added at such a rate that the temperature reached 70 °C. Glacial 
acetic acid (20.0 mL, 35 mmol, 0.18 equiv) was added at such a rate the temperature 
reached 90 °C. The slurry was stirred for 2 h, then cooled to 0 °C for 2 h. The precipitate 
was filtered, washed with cooled (5 °C) water (20 mL) and rinsed with cooled (5 °C) 
MeOH (5 x  20 mL).  The  solid  was  dried under  reduced pressure overnight  to  afford 
enantiopure (2.62) (34.3 g, 129 mmol) as a white solid. 
 
Mw = 264.276 (C10H20O6N2). 
IR (film): 2913 (w), 2857 (w), 1581 (m), 1562 (m), 1397 (s), 1379 (s), 1308 (s), 1136 (m), 
1054 (s) cm
-1. 
1H NMR (400 MHz; D2O):  4.38 (2H, s, HA+HB), 3.41 (2H, m, HE+HF), 2.24-2.15 (2H, 
m, HG/H), 1.90-1.82 (2H, m, HG/H), 1.65-1.45 (2H, m, HI/J), 1.45-1.32 (2H, m, HI/J) ppm.  
13C NMR (100 MHz; D2O):  178.5 (2 x Q, CD+C), 73.9 (2 x CH, CA+B), 52.2 (2 x CH, 
CE+F), 29.4 (2 x CH2, CH+G), 22.8 (2 x CH2, CI+J) ppm. 
The NMR data correspond well with literature data.
114 
 
Diethyl (1R,2R)-cyclohexane-1,2-diyldicarbamate (2.63) 
 
 152 
 
A 500 mL three-necked flask equipped with an overhead stirrer and a thermometer was 
charged with the diammonium salt (2.62) (32.0 g, 120 mmol, 1.0 equiv), toluene (320 mL) 
and cooled to 0 °C. Ethyl chloroformate (25.2 mL, 260 mmol, 2.2 equiv) and aqueous 
sodium hydroxide (20.2 g, 500 mmol in 26 mL of water, 4.2 equiv) were simultaneously 
added at such a rate to keep the temperature below 10 °C. The mixture was stirred for 3 h 
at room temperature and the precipitated salt was filtered-off, dissolved in DCM (250 mL) 
and washed with water (100 mL). The toluene phase was concentrated in vacuo, and the 
residue  added  to  the  DCM  solution.  The  crude  product  was  recrystallized  from 
DCM/Hexane (5/1) to afford carbamate (2.63) as a white solid (24.4 g, 79%).  
 
Mw = 258.314 (C12H22O4N2). 
m.p. = 165-169 °C. 
IR (film): 3320 (w), 2933 (w), 1680 (m), 1540 (m), 1240 (s), 1068 (s), 1046 (s) cm
-1. 
1H NMR (400 MHz; CDCl3):  4.99 (2H, 2 x NH), 4.09 (4H, q, J = 7.2 Hz, HI), 3.39-3.36 
(2H, m, HE+F), 2.05 (2H, d, J = 12.1 Hz, HA/D), 1.80-1.70 (2H, m, HA/D), 1.20 (6H, t, J = 
7.2 Hz, HJ), 1.33-1.10 (4H, m, HB+C) ppm.  
13C NMR (100 MHz; CDCl3):  157.2 (2 x Q, CG+H), 60.9 (2 x CH2, CI), 55.5 (2 x CH, 
CE+F), 33.0 (2 x CH2, CA+D), 24.9 (2 x CH2, CB+C), 14.7 (2 x CH3, CJ) ppm. 
ES
+MS m/z (%): 259 (M+H
+, 15). 
[]D = +44.8 ° (c 1.06, CHCl3). 
The experimental data correspond well to the reported data.
112 
 
(1R,2R)-N,N-dimethylcyclohexane-1,2-diamine (2.64) 
 
 
To a freshly prepared 1 M solution of LAH in THF (100 mL, 100 mmol, 4.0 equiv), cooled 
to 0 °C, was added dicarbamate (2.63) (6.21 g, 25.0 mmol, 1.0 equiv). The mixture was 
stirred 1 h at 0 °C, 1 h at room temperature and finally refluxed for 2 h.  After cooling to 0 
°C, water (2.5 mL), NaOH 4 M (2.5 mL) and water (10 mL) were sequentially added to the 
reaction mixture and stirring was continued for 1 h at room temperature. The thus formed 
white precipitate was filtered and rinsed with hot THF (2 x 50 mL). After evaporation of 153 
 
the THF, the residue was diluted with NaOH 4 M (50 mL) and extraction achieved with 
DCM (3 x 40 mL). The organic layer was dried over MgSO4, filtered and evaporated to 
afford pure diamine (2.64) (2.94 g, 89%). 
Mw = 142.242 (C8H18N2). 
IR (film): 3300 (w), 2850 (w), 1500 (m), 1440 (s), 1140 (s), 1100 (s), 830 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  2.36 (6H, s, HG+H), 2.12-2.03 (2H, m, HF+E), 2.02-1.96 
(2H, m, HA+D), 1.74-1.67 (2H, m, HA+D), 1.64 (2H, br s, NH), 1.25-1.115 (2H, m, HB/C), 
1.02-0.81 (2H, m, HB/C) ppm.  
13C NMR (100 MHz; CDCl3):  63.1 (2 x CH, CF+E), 33.6 (2 x CH3, CG+H), 30.7 (2 x CH2, 
CA+D), 25.1 (2 x CH2, CB+C) ppm. 
ES
+MS m/z (%): 143 (M+H
+, 34). 
[]D = -148.0° (c 0.77, CHCl3). 
The experimental data correspond well to the reported data.
112 
 
The phospholidine (2.65)
112,115 
 
 
A solution of diaminocyclohexane (2.64) (2.94 g, 20.7 mmol, 1.0 equiv) and HMPT (4.36 
mL, 24.0 mmol, 1.2  equiv) in toluene (20 mL) was  heated to 115  °C for 16 h under 
nitrogen. After cooling to room temperature, the solvent was evaporated and the residue 
distilled with Kugelröhr (135-139 °C, 0.35 mmHg) to afford phospholidine (2.65) as a 
colourless oil (3.43 g, 77%). The phospholidine (2.65) was dissolved in 80 mL of toluene 
and stored as a 0.2 M solution at room temperature under nitrogen. 
Data for (2.65) are unavailable due to the unstability of the compound. 
 
The Z-allylic phosphonamide (2.4) 
 
 154 
 
A 0.2 M solution of phospholidine (2.65) (48.4 mL, 9.69 mmol, 1.0 equiv) in toluene was 
refluxed for 45 min at 115 °C, with dry EtOH (0.66 mL, 11.14 mmol, 1.15 equiv) under 
nitrogen. After cooling to room temperature, the supposed 0.2 M solution of phospholane 
(2.66) (49.6  mL, 9.69  mmol,  1.0  equiv)  in  toluene  was  added to a  mixture of allylic 
chloride (2.46) (1.81 g, 6.25 mmol, 0.75 equiv) and NaI (0.94 g, 6.25 mmol, 0.75 equiv) at 
room temperature. The mixture was stirred for 2 h at 110 °C. Once cooled, the solvent was 
evaporated  and  the  residue  was  purified  by  column  chromatography  (EtOAc,  then 
EtOAc/MeOH 95:5) to afford phosphonamide (2.4) as a yellow sticky oil (2.32 g, 72% 
over 2 steps). 
Mw = 441.342 (C20H30O2BrPN2). 
Rf = 0.40 (EtOAc/MeOH 94:6). 
IR (film): 2938 (m), 2869 (w), 1584 (w), 1481 (m), 1250 (s), 1218 (s), 1170 (s), 1019 (s), 
814 (m), 755 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  7.40 (1H, d, J = 8.7 Hz, HA), 6.75 (1H, d, J = 3.0 Hz, HD), 
6.63 (1H, dd, J = 8.7, 3.1 Hz, HB), 5.60 (1H, m, HK), 5.45 (1H, m, HJ), 3.78 (3H, s, HG), 
2.77-2.35 (8H, m), 2.56 (3H, d, J = 0.9 Hz, HM/N), 2.52 (3H, d, J = 2.1 Hz, HM/N), 2.04-
1.93 (2H, m), 1.81 (2H, d, J = 8.9 Hz), 1.39-0.99 (4H,  m, HS+R) ppm.  
13C NMR (100 MHz; CDCl3):  158.9 (Q, CC), 141.8 (Q, CF), 133.2 (CH, CA), 131.5 
(CH, d, J = 13.0 Hz, CK), 120.7 (CH, d, J = 9.7 Hz, CJ), 116.3 (CH, CD), 114.8 (Q, CE), 
113.1 (CH, CB), 64.4 (CH, d, J = 4.5 Hz, CO/P), 64.4 (CH, d, J = 6.6 Hz, CO/P), 55.4 (CH3, 
CG), 36.1 (CH2, d, J = 2.3 Hz), 29.8 (CH3, CM/N), 28.6 (CH2, d, J = 9.9 Hz), 28.2 (CH3, d, 
J = 4.7 Hz, CM/N), 28.1 (CH2, d, J = 7.5 Hz), 27.6 (CH2, d, J = 1.8 Hz), 26.7 (CH2, d, J = 
110.1 Hz, CL), 24.3 (CH2, CS/R), 24.2 (CH2, CS/R) ppm. 
31P NMR (121 MHz; CDCl3): 42.13 ppm 
ES
+MS m/z (%): 481/479 (1:1, (M+K
+, 20)). 
HRES
+MS For C20H31N2O2P
79Br (M+H)
+: calcd 441.1301, found 441.1313. 
[]D = -17.7 ° (c 0.96, acetone). 155 
 
9.2  Experimental data for Chapter 3 
 
3-sec-Butoxy-2-ethylcyclopent-2-enone (3.31) 
 
 
This compound has been previously synthesized by Organon N.V, but no procedure or 
analytical data has been published:
 
2-Ethyl-1,3-cyclopentanedione (1.35) (20.06 g, 159 mmol, 1.0 equiv), sec-butyl alcohol 
(102 mL, 1113 mmol, 7.0 equiv), ClSO3H (0.63 mL, 9.5 mmol, 0.06 equiv) and toluene 
(272 mL) were refluxed for 7 days, separating water from the reaction mixture in a Dean-
Stark trap. The reaction was then cooled and the excess solvent was evaporated under 
reduced pressure. The crude product was purified by vacuum distillation (94-96 °C/0.4 
mmHg). This yielded (3.31) as a light yellow oil (27.42 g, 97%). 
 
MW = 182.265 (C11H18O2). 
Rf = 0.50 (Petroleum ether/Acetone 60:40). 
IR (neat): 2968 (s), 2933 (m), 2877 (w), 1684 (s), 1616 (s), 1462 (m), 1376 (s), 1343 (s), 
1312 (s), 1266 (s), 1233 (m), 1120 (s), 990 (m), 877(m) cm
-1. 
1H NMR (300 MHz; CDCl3):  4.37 (1H, sextet, J = 6.2 Hz, HH), 2.59-2.57 (2H, m, HE/F), 
2.40-2.36 (2H, m, HE/F), 2.10 (2H, q, J = 7.7 Hz, HB), 1.75-1.53 (2H, m, HJ), 1.27 (3H, d, 
J = 6.2 Hz, HI), 0.94 (3H, t, J = 7.7 Hz, HA), 0.93 (3H, t, J = 7.3 Hz, HK) ppm. 
13C NMR (75 MHz; CDCl3):  205.7 (Q, CD), 185.5 (Q, CG), 122.4 (Q, CC), 77.1 (CH, 
CH), 33.5 (CH2, CE/F), 29.8 (CH2, CJ), 24.9 (CH2, CE/F), 20.6 (CH3, CI), 14.5 (CH2, CB), 
12.5 (CH3, CA), 9.5 (CH3, CK) ppm. 
CIMS m/z (%): 183 ((M+H)
+, 100), 127 (16), 57(8). 
 
2-Ethylcyclopent-2-en-1-one (1.131) 156 
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This a known compound
56,137 but was synthesized here via an adaptation of an unpublished 
procedure devised by Organon N. V.; (Oss): 
To a stirred solution of the enol ether (3.31) (27.42 g, 150 mmol, 1.0 equiv) in dry hexane 
(207 mL) at 0 °C was added DIBAL-H (1 M in hexanes, 240 mL, 1.6 equiv) via cannula. 
The cold bath was removed and the solution was stirred at room temperature for 24 h. The 
reaction was then cooled to 0 °C, a water condenser was fitted, and 1 M HCl (322 mL) 
(precooled to 0 °C) was slowly poured in, followed by the addition of conc. HCl (30 mL). 
The  biphasic  mixture  was  vigorously  stirred  for  2  h  and  then  separated,  washing  the 
organic phase with water (2 x 50 mL). The combined aqueous phases were extracted with 
Et2O (3 x 50 mL), the combined organic layer was then washed with brine (50 mL), dried 
over  MgSO4,  filtered  and  evaporated.  The  crude  product  was  purified  by  column 
chromatography (Petroleum ether/Acetone 80:20) followed by vacuum distillation (47-49 
°C/5 mmHg), yielding (1.131) as a light yellow oil (4.95 g, 30%). 
 
MW = 110.157 (C7H10O). 
Rf = 0.41 (Petroleum ether/Acetone 80:20). 
IR (neat): 2966 (m), 2923 (m), 2877 (w), 1696 (s), 1632 (m), 1443 (w), 1347 (w), 1248 
(m), 1001 (m), 947 (w), 940 (w), 790 (m) cm
-1. 
1H NMR (300 MHz; CDCl3):  7.29-7.25 (1H, m, HD), 2.55-2.50 (2H, m, HB/C), 2.37-2.34 
(2H, m, HB/C), 2.19-2.11 (2H, m, HF), 1.06 (3H, t, J = 7.5 Hz, HG) ppm. 
13C NMR (75 MHz; CDCl3):  209.7 (Q, CA), 156.4 (CH, CD), 147.7 (Q, CE), 34.6 (CH2, 
CB/C), 26.2 (CH2, CB/C), 17.9 (CH2, CF), 11.9 (CH3, CG) ppm. 
The IR and NMR spectra correspond to the reported data.
56,137 
 
2-Bromo-3-iodo-1-propene (3.29): 
 
 157 
 
This is a known compound
138 but was prepared via the following procedure: 
In a 50 mL 2-neck flask equipped with a condenser was added dropwise 2,3-dibromo-1-
propene (3.32) (2.44 mL, 25 mmol, 1.0 equiv) to a solution of NaI (6.75 g, 45 mmol, 1.8 
equiv) in 20 mL of dry acetone. After refluxing for 4 h, the reaction mixture was cooled 
and  20  mL  of  water  was  added  followed  by  40  mL  of  Et2O.  The  two  phases  were 
separated and the dark purple organic layer was washed with 20 mL of diluted NaHCO3, 
20 mL of brine, dried over Na2SO4, filtered through celite and concentrated under vacuum. 
The resulting crude was purified by vacuum distillation (68-72 °C/ 5 mmHg), yielding 
(3.29) as a dark-purple oil (5.10 g, 82%). 
 
MW = 246.872 (C3H4BrI). 
Rf = 0.55 (Hexane/Acetone 1:1). 
IR (neat): 2359 (w), 1614 (m), 1421 (w), 1367 (w), 1190 (m), 1153 (s), 1088 (w), 1072 
(w), 892 (s), 828 (m), 694 (w), 670 (w), 581 (s), 558 (m), 541 (s) cm
-1. 
1H NMR (300 MHz; CDCl3):  6.02 (1H, m, HA), 5.54 (1H, d, J = 2.2 Hz, HA’), 4.22 (2H, 
d, J = 0.7 Hz, HC) ppm. 
13C NMR (75 MHz; CDCl3):  129.5 (Q, CB), 120.1 (CH2, CA), 20.0 (CH2, CC) ppm. 
CIMS m/z (%): 248/246 ((M+H)
+, 20), 167 (6), 138/136 (63), 95/93 (3), 79 (4), 78 (2), 58 
(7), 57 (100), 56 (24), 54 (9). 
The IR and NMR spectra correspond to the reported data.
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The -1,4-addition compound (3.1) and the -1,4-addition compound (3.33) and the 
non-alkylated compound (3.37). 
 
 
To a cooled (-78 °C) solution of the phosphonate (2.2) (8.41 g, 30.24 mmol, 1.2 equiv) in 
Et2O (80 mL) was added 
nBuLi (2.5 M in hexanes) (13.30 mL, 33.27 mmol, 1.32 equiv). 
The red solution was stirred for 30 min at -78 °C, and then a Et2O (20 mL) solution of the 158 
 
enone (1.100) (2.42 g, 25.20 mmol, 1.0 equiv) was added via cannula over 2 min. After 
the addition, the flask was placed in a 0 °C cold bath. After 1 h, 2-bromo-3-iodopropene 
(3.29) (11.19 g, 43.36 mmol, 1.8 equiv) was added neat over 30 seconds, followed by 
HMPA (20 mL) and the reaction mixture was warmed to room temperature over 1 h. 
Water (40 mL) was added and the reaction was extracted with EtOAc (4 x 50 mL). The 
combined organic phases were dried over Na2SO4, filtered and the solvent evaporated in 
vacuo.  The  crude  product  was  purified  by  column  chromatography  (Hexane/Acetone 
60:40) followed by preparative HPLC (Hexane/Acetone 65:35). This yielded (3.1) (6.71 g, 
54%), (3.33) (746 mg, 6%), (3.37) (283 mg, 3%) and (2.2) (1.19 g, 17%) as light yellow 
oils. 
 
Data for (3.1): 
Mw = 493.381 (C21H34O6PBr). 
Rf = 0.39 (Hexane/Acetone 60:40). 
IR (neat): 2960 (br m), 1739 (m), 1621 (w), 1451 (w), 1403 (w), 1361 (w), 1238 (m), 
1134 (m), 1049 (s), 1025 (s), 963 (m), 841 (w) cm
-1. 
1H NMR (400 MHz; CDCl3):  6.61 (1H, ddd, J = 21.8, 17.1, 10.0 Hz, HD), 6.02 (1H, t, J 
= 1.6 Hz, HR), 5.69 (1H, dd, J = 20.8, 17.1 Hz, HC), 5.56 (1H, br s, HR’), 4.83 (1H, t, J = 
4.5 Hz, HH), 4.17-4.07 (4H, m, HB), 3.99-3.81 (4H, m, HI), 3.06 (1H, d, J = 14.9 Hz, HP), 
2.52 (1H, d, J = 14.9 Hz, HP’), 2.44-2.20 (5H, m, HK + HK’ + HL + HJ + HE), 1.91-1.82 
(1H, m, HF), 1.73-1.63 (1H, m, HG), 1.55-1.35 (3H, m, HG’ + HL’ + HF’), 1.35 (6H, t, J = 
7.0 Hz, HA), 0.87 (3H, s, HO) ppm. 
13C NMR (100 MHz; CDCl3):  221.5 (Q, CM), 155.3 (d, J = 3.9 Hz, CH, CD), 129.9 (Q, 
CQ), 122.6 (CH2, CR), 119.0 (d, J = 187.1 Hz, CH, CC), 104.1 (CH, CH), 64.9 (CH2, CI), 
64.8 (CH2, CI’), 61.7 (d, J = 5.8 Hz, CH2, CB), 61.6 (d, J = 5.8 Hz, CH2, CB’), 51.6 (Q, 
CN), 47.2 (d, J = 20.9 Hz, CH, CE), 47.1 (CH2, CP), 43.7 (CH, CJ), 36.9 (CH2, CK), 30.9 
(CH2, CG), 25.8 (d, J = 1.9 Hz, CH2, CF), 24.0 (CH2, CL), 18.7 (CH3, CO), 16.5 (d, J = 6.3 
Hz, CH3, CA), 16.4 (d, J = 6.3 Hz, CH3, CA’) ppm. 
31P NMR (121 MHz; CDCl3):  17.88 ppm. 
ES
+MS  m/z  (%):  493/495  (1:1,  (M+H)
+,  100),  515/517  (1:1,  (M+Na)
+,  24),  987 
((2M+H)
+, 9). 
Elemental analysis calcd for C21H34O6PBr: C, 51.12; H, 6.95. Found: C, 50.83; H, 7.11. 
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Data for (3.33): 
Mw = 493.381 (C21H34O6PBr). 
Rf = 0.39 (Hexane/Acetone 60:40). 
IR (neat): 2978 (br m), 1737 (m), 1624 (w), 1444 (w), 1392 (w), 1361 (w), 1240 (m), 
1138 (m), 1049 (s), 1020 (s), 958 (m), 899 (w) cm
-1. 
1H NMR (400 MHz; CDCl3):  5.88-5.33 (4H, m, HR + HD + HE), 4.87 (1H, t, J = 4.7 Hz, 
HH), 4.21-4.00 (4H, m, HB), 4.00-3.76 (4H, m, HI), 3.04 (1H, d, J = 14.9 Hz, HP), 2.90 
(1H, m, HC), 2.78 (1H, m, HJ), 2.67-2.48 (2H, m, HK+HP’), 2.42-2.31 (2H, m, HL), 2.28-
2.08 (2H, m, HF), 1.85-1.54 (3H, m, HG+HK’), 1.34-1.27 (6H, m, HA), 0.82 (3H, s, HO) 
ppm. 
13C NMR (100 MHz; CDCl3):  221.2 (Q, CM), 132.6 (d, J = 12.9 Hz, CH, CD), 130.0 (Q, 
CQ), 124.6 (d, J = 11.8 Hz, CH, CE), 121.7 (CH2, CR), 103.8 (CH, CH), 64.9 (2 x CH2, CI), 
62.7 (d, J = 7.3 Hz, CH2, CB), 61.4 (d, J = 7.3 Hz, CH2, CB’), 52.4 (d, J = 17.1 Hz, Q, CN), 
47.4 (CH2, CP), 40.4 (d, J = 136.5 Hz, CH, CC), 40.2 (d, J = 2.4 Hz, CH, CJ), 37.7 (CH2, 
CL), 33.0 (d, J = 2.7 Hz, CH2, CG), 25.4 (CH2, CK), 22.5 (d, J = 2.5 Hz, CH2, CF), 18.4 
(CH3, CO), 16.5 (d, J = 5.8 Hz, CH3, CA), 16.4 (d, J = 6.2 Hz, CA’) ppm. 
31P NMR (121 MHz; CDCl3):  28.02 ppm. 
ES
+MS  m/z  (%):  493/495  (1:1,  (M+H)
+,  100),  515/517  (1:1,  (M+Na)
+,  36),  987 
((2M+H)
+, 15). 
HRES
+MS For C21H34O6P
79BrNa (M+Na)
+: calcd 515.1169, found 515.1171. 
 
Data for (3.37): 
This compound was isolated as a mixture of diastereoisomers (ratio 75:25) that could be 
separated by repeated preparative HPLC (Hexane/Acetone 2:1).
21  
For Major Diastereoisomer: 
Mw = 374.420 (C18H31O6P). 
Rf = 0.22 (Hexane/Acetone 60:40). 
IR (neat): 2974 (m), 2869 (m), 1734 (s), 1630 (w), 1247 (m), 1129 (m), 1053 (s), 1020 (s), 
959 (s) cm
-1. 
1H NMR (400 MHz; CDCl3):  6.63 (1H, ddd, J = 21.6, 17.1, 9.3 Hz, HD), 5.72 (1H, dd, J 
= 20.6, 17.1 Hz, HC), 4.84 (1H, t, J = 4.3 Hz, HH), 4.13-4.04 (4H, m, HB), 3.99-3.82 (4H, 
m, HI), 2.40-2.26 (2H, m), 2.19-2.08 (2H, m), 1.91-1.68 (4H, m), 1.60-1.44 (3H, m), 1.33 
(6H, t, J = 7.0 Hz, HA), 1.11 (3H, d, J = 6.8 Hz, HO) ppm. 160 
 
13C NMR (100 MHz; CDCl3):  220.1 (Q, CM), 154.7 (d, J = 3.9 Hz, CH, CD), 119.0 (d, J 
= 186.6 Hz, CH, CC), 104.1 (CH, CH), 64.9 (CH2, CI), 64.8 (CH2, CI’), 61.6 (d, J = 4.9 Hz, 
CH2, 2 x CB), 48.6 (CH), 48.4 (CH), 47.5 (CH), 37.0 (CH2), 31.5 (CH2), 25.0 (CH2), 24.4 
(CH2), 16.4 (d, J = 5.8 Hz, CH3, 2 x CA), 14.5 (CH3, CO) ppm. 
31P NMR (121 MHz; CDCl3):  17.92 ppm. 
CIMS m/z (%): 375 ((M+H)+, 100). 
HRES
+MS For C18H31O6P (M+H)
+: calcd 375.1931, found 375.1928. 
 
For Minor Diastereoisomer: 
Mw = 374.420 (C18H31O6P). 
Rf = 0.22 (Hexane/Acetone 60:40). 
IR (neat): 2974 (m), 2869 (m), 1734 (s), 1630 (w), 1247 (m), 1129 (m), 1053 (s), 1020 (s), 
959 (s) cm
-1. 
1H NMR (400 MHz; CDCl3):  6.54 (1H, ddd, J = 21.6, 17.1, 9.3 Hz, HD), 5.70 (1H, dd, J 
= 20.6, 17.1 Hz, HC), 4.84 (1H, t, J = 4.3 Hz, HH), 4.12-4.02 (4H, m, HB), 3.98-3.81 (4H, 
m, HI), 2.42-2.12 (6H, m), 1.83-1.50 (5H, m), 1.33 (6H, t, J = 7.0 Hz, HA), 0.97 (3H, d, J 
= 6.8 Hz, HO) ppm. 
13C NMR (100 MHz; CDCl3):  221.1 (Q, CM), 154.7 (d, J = 3.9 Hz, CH, CD), 118.7 (d, J 
= 186.6 Hz, CH, CC), 104.1 (CH, CH), 65.0 (CH2, CI), 64.9 (CH2, CI’), 61.7 (d, J = 4.9 Hz, 
CH2, 2 x CB), 45.2 (CH), 44.8 (CH), 43.9 (CH), 37.1 (CH2), 31.0 (CH2), 25.4 (CH2), 24.0 
(CH2), 16.4 (d, J = 6.3 Hz, CH3, 2 x CA), 8.4 (CH3, CO) ppm. 
31P NMR (121 MHz; CDCl3):  17.92 ppm. 
CIMS m/z (%): 375 ((M+H)+, 40), 278 (9), 233 (6), 207 (13), 191 (5), 156 (8), 97 (100), 
73 (51). 
HRES
+MS For C18H31O6P (M+H)
+: calcd 375.1931, found 375.1929. 
 
The -1,4-addition compound (3.2) and the -1,4-addition compound (3.34) and the 
dialkylated compound (3.36) and the non-alkylated compound (3.38). 
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To a cooled (-78 °C) solution of the phosphonate (2.2) (4.94 g, 17.76 mmol, 1.2 equiv) in 
THF (50 mL) was added 
nBuLi (1.6 M in Hexanes) (8.62 mL, 19.54 mmol, 1.32 equiv). 
The red solution was stirred for 15 min at -78 °C, and then a THF (15 mL) solution of 2-
ethyl-cyclopentenone (1.131) (1.63 g, 14.80 mmol, 1.0 equiv) was added via cannula over 
2 min. After the addition, the flask was placed in a 0 °C cold bath. After 1 h, 2-bromo-3-
iodopropene (3.29) (6.57 g, 26.64 mmol, 1.8 equiv) was added neat over 30 seconds and 
the reaction mixture was warmed to room temperature over 1 h. Water (50 mL) was added 
and the reaction mixture was extracted with Et2O (4 x 50 mL). The combined organic 
phases were dried over Na2SO4, filtered and the solvent evaporated in vacuo. The crude 
product was purified by column chromatography (Hexane/Acetone 65:35)  followed by 
preparative HPLC (Hexane/Acetone 65:35). This yielded (3.2) (3.22 g, 43%), (3.34) (601 
mg, 8%), (3.36) (464 mg, 5%) and (3.38) (402 mg, 7%) as light yellow oils. 
 
Data for (3.2): 
Mw = 507.408 (C22H36O6PBr). 
Rf = 0.41 (Hexane/Acetone 60:40). 
IR (neat): 2968 (m), 2884 (m), 1730 (s), 1630 (m), 1446 (w), 1403 (w), 1389 (w), 1252 
(s), 1147 (m), 1053 (s), 1025 (s), 963 (s), 840 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  6.61 (1H, ddd, J = 21.8, 17.2, 10.0 Hz, HD), 6.04 (1H, t, J 
= 1.5 Hz, HS), 5.70 (1H, dd, J = 20.9, 17.2 Hz, HC), 5.56 (1H, br s, HS’), 4.84 (1H, t, J = 
1.5 Hz, HH), 4.15-4.04 (4H, m, HB), 3.99-3.81 (4H, m, HI), 3.13 (1H, d, J = 14.8 Hz, HQ), 
2.41 (1H, d, J = 14.9 Hz, HQ’), 2.45-2.21 (5H, m), 1.88 (1H, m), 1.68 (1H, m), 1.61-1.40 
(3H, m), 1.46 (2H, q, J = 7.5 Hz, HO), 1.33 (6H, t, J = 7.1 Hz, HA), 0.80 (3H, t, J = 7.5 Hz, 
HP) ppm. 
13C NMR (100 MHz; CDCl3):  220.4 (Q, CM), 155.6 (d, J = 4.1 Hz, CH, CD), 130.5 (Q, 
CR), 122.7 (CH2, CS), 118.9 (d, J = 186.7 Hz, CH, CC), 104.1 (CH, CH), 64.9 (CH2, CI), 
64.8 (CH2, CI’), 61.7 (d, J = 5.8 Hz, CH2, CB), 61.6 (d, J = 5.8 Hz, CH2, CB’), 54.0 (Q, 
CN), 46.7 (d, J = 21.0 Hz, CH, CE), 45.4 (CH2, CQ), 44.1 (CH, CJ), 37.0 (CH2, CK/L), 30.9 
(CH2, CG), 25.9 (d, J = 2.0 Hz, CH2, CF), 25.4 (CH2, CO), 24.2 (CH2, CK/L), 16.5 (d, J = 
6.3 Hz, CH3, CA), 16.4 (d, J = 6.3 Hz, CH3, CA’), 8.4 (CH3, CP) ppm. 
31P NMR (121 MHz; CDCl3):  18.06 ppm. 
ES
+MS m/z (%): 507/509 (1:1, (M+H)
+, 100). 
HRES
+MS For C22H36O6P
79BrNa (M+Na)
+: calcd 529.1325, found 529.1329. 162 
 
Data for (3.34): 
Mw = 507.408 (C22H36O6PBr). 
Rf = 0.41 (Hexane/Acetone 60:40). 
IR (neat): 2975 (m), 2878 (m), 1730 (s), 1630 (m), 1455 (w), 1403 (w), 1397 (w), 1249 
(s), 1053 (s), 1025 (s), 963 (m), 840 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  5.69-5.37 (4H, m, HS + HD + HE), 4.82 (1H, t, J = 4.7 Hz, 
HH), 4.13-3.95 (4H, m, HB), 3.93-3.78 (4H, m, HI), 3.08 (1H, d, J = 14.9 Hz, HQ), 2.99 
(1H, ddd, J = 21.6, 10.7, 10.7 Hz, HC), 2.80 (1H, m, HJ), 2.51 (1H, ddt, J = 10.3, 6.9, 3.8 
Hz, HK), 2.40 (1H, d, J = 14.9 Hz, HQ’), 2.35-2.27 (2H, m, HL), 2.22-2.09 (2H, m, HF), 
1.82-1.57 (3H, m, HG + HK’), 1.44-1.28 (2H, m, HO), 1.26 (3H, t, J = 7.0 Hz, HA), 1.25 
(3H, t, J = 7.0 Hz, HA’), 0.76 (3H, t, J = 7.5 Hz, HP) ppm. 
13C NMR (100 MHz; CDCl3):  220.0 (Q, CM), 132.6 (d, J = 13.0 Hz, CH, CD), 130.6 (Q, 
CR), 124.8 (d, J = 12.0 Hz, CH, CE), 121.6 (CH2, CS), 103.8 (CH, CH), 64.9 (2 x CH2, CI), 
62.7 (d, J = 7.3 Hz, CH2, CB), 61.4 (d, J = 7.3 Hz, CH2, CB’), 54.8 (d, J = 16.8 Hz, Q, CN), 
45.9 (Q, CQ), 40.5 (d, J = 1.6 Hz, CH, CJ), 39.8 (d, J = 131.6 Hz, CH, CC), 37.6 (CH2, CL), 
33.1 (d, J = 2.6 Hz, CG), 25.5 (CH2, CK/O), 25.2 (CH2, CK/O), 22.5 (d, J = 2.4 Hz, CF), 16.5 
(d, J = 5.8 Hz, CH3, CA), 16.4 (d, J = 6.2 Hz, CH3, CA’), 8.5 (CH3, CP) ppm. 
31P NMR (121 MHz; CDCl3):  27.06 ppm. 
ES
+MS m/z (%): 1039/1037/1035 (1:2:1, (2M+Na)
+, 100), 531/529 (1:1, (M+Na)
+, 50), 
509/507 (1:1, (M+H)
+, 48). 
HRES
+MS For C22H37O6P
79Br (M+H)
+: calcd 507.1506, found 507.1514. 
 
Data for (3.36): 
This  compound  was  isolated  as  an  inseparable  mixture  of  diastereoisomers  in 
approximately a 2:1 ratio.  
Mw = 626.355 (C25H39O6PBr2). 
Rf = 0.44 (Hexane/Acetone 60:40). 
IR (neat): 2978 (m), 2874 (w), 1734 (s), 1621 (m), 1389 (w), 1243 (s), 1134 (m), 1053 (s), 
1020 (s), 949 (s), 840 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  6.71-6.54 (1H, m, HD), 6.05-6.01 (1H, m, HS), 5.69 (1H, 
dd, J = 20.8, 17.3 Hz, HC), 5.66-5.62 (1H, m, HV), 5.59-5.55 (1H, m, HS’), 5.50-5.46 (1H, 
m, HV’), 4.56-5.42 (1H, m, HV’(minor only)), 4.85-4.80 (1H, m, HH), 4.14-4.03 (4H, m, HB), 
3.98-3.80 (4H, m, HI), 3.21 (1H, d, J = 14.8 Hz, HQ), 3.14-3.04 (1H, m), 2.91-2.65 (2H, 163 
 
m), 2.49-2.27 (4H, m), 2.22 (1H, dd, J = 14.7, 10.2 Hz), 2.04-1.96 (1H, m), 1.93-1.60 (3H, 
m), 1.56-1.20 (8H, m, includes HA), 0.80-0.72 (3H, m, HP) ppm. 
13C NMR (100 MHz; CDCl3): Major diastereoisomer:  218.4 (Q, CM), 155.2 (d, J = 4.2 
Hz, CD), 132.6 (Q, CU), 129.9 (Q, CR), 123.1 (CH2, CS), 119.3 (d, J = 186.7 Hz, CH, CC), 
118.6 (CH2, CV), 104.1 (CH, CH), 64.9 (CH2, CI), 64.8 (CH2, CI’), 61.7 (d, J = 5.7 Hz, 
CH2, CB), 61.6 (d, J = 5.7 Hz, CH2, CB’), 55.8 (Q, CN), 47.2 (d, J = 21.0 Hz, CH, CE), 43.6 
(CH, CJ), 43.6 (CH2, CQ), 42.0 (CH2, CT), 41.8 (CH, CL), 30.9 (CH2, CG), 28.7 (CH2, CK), 
25.9 (d, J = 21.0 Hz, CH2, CF), 24.8 (CH2, CO), 16.4 (d, J = 6.3 Hz, CH3, CA), 16.3 (d, J = 
6.3 Hz, CH3, CA’), 7.9 (CH3, CP) ppm. Minor diastereoisomer:  219.4 (Q, CM), 155.5 (d, 
J = 4.2 Hz, CD), 132.0 (Q, CU), 130.2 (Q, CR), 122.8 (CH2, CS), 119.2 (d, J = 186.7 Hz, 
CH, CC), 118.2 (CH2, CV), 104.1 (CH, CH), 64.9 (CH2, CI), 64.8 (CH2, CI’), 61.7 (d, J = 
5.7 Hz, CH2, CB), 61.6 (d, J = 5.7 Hz, CH2, CB’), 54.5 (Q, CN), 47.0 (CH, CJ), 46.3 (d, J = 
21.0 Hz, CH, CE), 46.0 (CH2, CQ), 44.1 (CH2, CT), 42.4 (CH, CL), 31.0 (CH2, CG), 30.7 
(CH2, CK), 26.0 (d, J = 2.0 Hz, CH2, CF), 25.7 (CH2, CO), 16.4 (d, J = 6.3 Hz, CH3, CA), 
16.3 (d, J = 6.3 Hz, CH3, CA’), 8.7 (CH3, CP) ppm 
31P NMR (121 MHz; CDCl3):  17.92 ppm. 
ES
+MS m/z (%): 651/649/647 (1:2:1, (M+Na)
+, 34), 625/627/629 (1:2:1, (M+H)
+, 100). 
HRES
+MS For C25H39O6P
79Br2 (M+H)
+: calcd 625.0924, found 625.0933. 
 
Data for (3.38): 
Mw = 388.447 (C19H33O6PBr). 
Rf = 0.22 (Hexane/Acetone 60:40). 
IR (neat): 2964 (m), 1729 (s), 1626 (m), 1455 (w), 1399 (w), 1223 (m), 1157 (m), 1049 
(s), 1025 (s), 959 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  6.60 (1H, ddd, J = 21.1, 17.1, 9.4 Hz, HD), 5.70 (1H, ddd, 
J = 21.6, 17.1, 9.4 Hz, HC), 4.84 (1H, t, J = 4.3 Hz, HH), 4.12-4.02 (4H, m, HB), 3.98-3.80 
(4H, m, HI), 2.37-2.21 (2H, m), 2.14-1.98 (3H, m), 1.91-1.84 (1H, m), 1.80-1.65 (3H, m), 
1.62-1.41 (4H, m), 1.32 (6H, t, J = 7.1 Hz, HA), 0.86 (3H, t, J = 7.4 Hz, HP) ppm. 
13C NMR (100 MHz; CDCl3):  220.1 (Q, CM), 154.6 (d, J = 4.1 Hz, CH, CD), 119.0 (d, J 
= 186.4 Hz, CH, CC), 104.0 (CH, CH), 64.9 (CH2, CI), 64.8 (CH2, CI’), 61.7 (d, J = 5.6 Hz, 
CH, CB), 61.6 (d, J = 5.6 Hz, CH2, CB’), 53.0 (CH, CJ/N), 48.5 (d, J = 20.6 Hz, CH, CE), 
43.9 (d, J = 1.4 Hz, CH, CJ/N), 37.9 (CH2), 31.6 (CH2), 24.3 (2 x CH2), 21.7 (CH2), 16.3 
(d, J = 6.3 Hz, CH3, 2 x CA), 10.6 (CH3, CP) ppm. 164 
 
31P NMR (121 MHz; CDCl3):  18.11 ppm. 
ES
+MS m/z (%): 799 ((2M+Na)
+, 100), 411 ((M+Na)
+, 35), 389 ((M+H)
+, 32). 
HRES
+MS For C19H33O6P (M+Na)
+: calcd 411.1907, found 411.1910. 
 
(Z)-diethyl-2-bromo-8-(1,3-dioxolan-2-yl)octa-1,5-dien-4-ylphosphonate  (3.40)  and 
(E)-diethyl-3-(2-(1,3-dioxolan-2-yl)ethyl)-5-bromohexa-1,5-dienylphosphonate (3.41). 
 
 
To a cooled solution (-78 °C) of the phosphonate (2.2) (200 mg, 0.72 mmol, 1.0 equiv) in 
Et2O  (5mL)  was  added 
nBuLi  (2.5  M  in  Hexanes)  (154  L,  0.79  mmol,  1.1  equiv) 
dropwise over 2 min. The red solution was stirred at -78 °C for 15 min and then for 5 min 
at 0 °C before the iodide (3.29) (267 mg, 1.08 mmol, 1.5 equiv) was added neat over 30 
seconds. The reaction mixture was warmed to room temperature over 1 h. Water (5 mL) 
was added and the reaction was extracted with Et2O (3 x 20 mL). The combined organic 
phases were dried over Na2SO4, filtered and the solvent evaporated in vacuo. The crude 
product was purified by column chromatography (Hexane/Acetone 70:30)  followed by 
preparative HPLC (Hexane/Acetone 70:30). This yielded (3.40) (230 mg, 81%) and (3.41) 
(27 mg, 9%) as colourless oils.  
 
Data for (3.40): 
Mw = 397.251 (C15H26O5PBr). 
Rf = 0.33 (Hexane/Acetone 70:30). 
IR (neat): 1626 (w), 1432 (w), 1394 (w), 1242 (s), 1141 (m), 1055 (s), 1027 (s), 966 (s), 
727 (s) cm
-1. 
1H NMR (400 MHz; CDCl3): 5.65 (1H, m, HE), 5.53 (1H, br s, HL), 5.38 (1H, br s, HL’), 
5.11 (1H, tdt, J = 10.7, 5.0, 1.6 Hz, HD), 4.85 (1H, t, J = 4.8 Hz, HH), 4.07 (4H, m, HB), 
3.86 (m, 4H, HI), 3.25 (1H, dtd, J = 21.6, 11.0, 3.1 Hz, HC), 2.86 (1H, m, HJ), 2.58 (1H, 
ddd, J = 18.8, 11.1, 7.6 Hz, HJ’), 2.31-2.13 (2H, m, HF), 1.70 (2H, td, J = 7.9, 4.6 Hz, HG), 
1.28 (6H, d, J = 7.2 Hz, HA) ppm.  165 
 
13C NMR (100 MHz; CDCl3): 134.5 (d, J = 13.6 Hz, CH, CE), 131.1 (d, J = 21.4 Hz, Q, 
CK), 122.9 (d, J = 9.7 Hz, CH, CD), 118.8 (CH2, CL), 103.9 (CH, CH), 64.8 (CH2, 2 x CI), 
62.3 (d, J = 6.8 Hz, CH2, CB), 61.9 (d, J = 6.8 Hz, CH2, CB’), 41.0 (d, J = 2.9 Hz, CH2, 
CJ), 35.3 (d, J = 141.9 Hz, CH2, CC), 33.6 (d, J = 2.9 Hz, CH2, CG), 22.4 (d, J = 1.9 Hz, 
CH2, CF), 16.4 (d, J = 5.8 Hz, CH3, CA), 16.3 (d, J = 5.8 Hz, CH3, CA’) ppm. 
31P NMR (121 MHz; CDCl3):  28.46 ppm. 
ES
+MS m/z (%): 815/817/819 (1:2:1, (2M+Na)
+, 100), 460/462 (1:1, (M+Na+MeCN)
+, 
49), 419/421 (1/1, (M+Na)
+, 57), 397/399 (1:1, (M+H)
+, 28). 
HRES
+MS For C15H26O5P
79Br (M+H)
+: calcd 397.0774, found 397.0771. 
 
Data for (3.41): 
Mw = 397.251 (C15H26O5PBr). 
Rf = 0.26 (Hexane/Acetone 70:30). 
IR (neat): 1630 (w), 1239 (m), 1143 (w), 1054 (m), 1027 (s), 946 (m), 911 (m), 731 (s) 
cm
-1. 
1H NMR (400 MHz; CDCl3):  6.51 (1H, ddd, J = 21.8, 17.1, 8.8 Hz, HD), 5.53 (1H, dd, J 
= 20.2, 17.1 Hz, HC), 5.47 (1H, br d, J = 1.2 Hz, HL), 5.43 (1H, br d, J = 1.2 Hz, HL’), 
4.85 (1H, t, J = 4.1 Hz, HH), 4.05 (4H, m, HB), 3.90 (4H, m, HI), 2.65 (1H, m, HE), 2.53 
(1H, dd, J = 14.3, 5.7 Hz, HJ), 2.44 (1H, dd, J = 14.3, 8.5 Hz, HJ’), 1.71-1.59 (3H, m, HG + 
HF’), 1.48 (1H, m, HF), 1.32 (6H, d, J = 7.0 Hz, HA) ppm.  
13C NMR (100 MHz; CDCl3):  154.5 (d, J = 4.4 Hz, CH, CD), 131.6 (Q, CK), 118.8 
(CH2, CL), 118.6 (d, J = 184.7 Hz, CH, CC), 104.0 (CH, CH), 64.9 (CH2, 2 x CI), 61.7 (d, J 
= 5.3 Hz, CH2, CB), 61.6 (d, J = 5.3 Hz, CH2, CB’), 45.9 (d, J = 1.5 Hz, CH2, CJ), 42.3 (d, 
J = 21.4 Hz, CH, CE), 31.3 (CH2, CG), 27.2 (d, J = 1.0 Hz, CH2, CF), 16.4 (d, J = 6.3 Hz, 
CH3, 2 x CA) ppm. 
31P NMR (121 MHz; CDCl3):  18.63 ppm. 
ES
+MS m/z  (%):  815/817/819 (1:2:1, (2M+Na)
+,  73), 460/462 (1:1, (M+Na+MeCN)
+, 
100), 419/421 (1:1, (M+Na)
+, 58), 397/399 (1:1, (M+H)
+, 55). 
HRES
+MS For C15H26O5P
79Br (M+H)
+: calcd 397.0774, found 397.0771. 
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The -1,4-addition compound (3.3) and the non-allylated compound (3.50) and the bis-
allylated compound (3.51). 
 
To a solution of the Z-allylic phosphonate (2.3) (0.990 g, 2.53 mmol, 1.0 equiv) in THF 
(20 mL), cooled to -78 °C, 
nBuLi (2.5 M in Hexane, 1.11 mL, 2.78 mmol, 1.1 equiv) was 
added slowly and the mixture was stirred for 15 min at -78 °C. After warming to 0 °C, a 
solution of 2-methyl-2-cyclopentenone (1.100) (0.322 mL, 3.29 mmol, 1.3 equiv) in THF 
(10 mL) was immediately added over 2 min. via cannula. The solution was stirred for 1 h 
at 0 °C and then quenched with freshly distilled allyl bromide (3.28) (2.19 mL, 25.3 mmol, 
10 equiv). The solution was warmed to room temperature and stirred for 1 h. Water (50 
mL) was added and the reaction was extracted with DCM (3 x 50 mL), dried over MgSO4, 
filtered  and  concentrated  in  vacuo.  The  crude  product  was  purified  by  column 
chromatography (Hexane/Acetone 65:35) to afford (3.3) as a light yellow oil (921 mg, 
69%), (3.50) as a light yellow oil (141 mg, 11%), and (3.51) as a colourless oil (72 mg, 
5%). Recrystallization of (3.3) in DCM/Hexane gave colourless crystals. 
 
Data for 3.3: 
Mw = 527.428 (C25H36O5BrP). 
Rf = 0.42 (Hexane/Acetone 65:35). 
IR (film): 2975 (m), 1740 (s), 1629 (w), 1472 (m), 1575 (m), 1239 (s), 1022 (s) cm
-1. 
1H NMR (400 MHz; CDCl3):  7.39 (1H, d, J = 8.7 Hz, HA), 6.71 (1H, d, J = 2.9 Hz, HD), 
6.64 (1H, ddd, J = 17.1, 11.0, 7.3 Hz, HK), 6.63 (1H, dd, J = 8.8, 3.0 Hz, HB), 5.77 (1H, 
dd, J = 20.6, 17.2 Hz, HL), 5.45 (1H, dtd, J = 17.1, 9.6, 5.3 Hz, HV), 5.18 (1H, d, J = 17.0 
Hz, HW), 5.08 (1H, d, J = 10.2 Hz, HW’), 4.16-4.09 (4H, m, HM), 3.77 (3H, s, HG), 2.68 
(1H, ddd, J = 13.3, 11.8, 5.0 Hz, HH), 2.53-2.45 (2H, m, HH’ + HQ), 2.41-2.31 (2H, m, HU 
+ HJ), 2.22-2.09 (3H, m, HO + HI + HQ’), 2.04-1.89 (2H, m, HU’ + HP), 1.58-1.46 (2H, m, 
HI’ + HP’), 1.35 (6H, td, J = 7.0, 2.0 Hz, HN), 0.91 (3H, s, HT) ppm. 
13C NMR (100 MHz; CDCl3): 222.1 (Q, CR), 159.0 (Q, CC), 155.3 (CH, d, J = 3.6 Hz, 
CK), 142.0 (Q, CE), 134.1 (CH, CV), 133.3 (CH, CA), 118.9 (CH2, CW), 118.7 (CH, d, J = 167 
 
186.0 Hz, CL), 116.0 (CH, CD), 114.6 (Q, CF), 113.2 (CH, CB), 61.7 (CH2, d, J = 5.5 Hz, 
CM), 61.6 (CH2, d, J = 5.6 Hz, CM’), 55.4 (CH3, CG), 52.1 (Q, CS), 46.8 (CH, d, J = 20.9 
Hz, CJ), 44.4 (CH, CO), 40.8 (CH2, CU), 37.1 (CH2, CI), 34.0 (CH2, CQ), 31.8 (CH2, CH), 
23.6 (CH2, CP), 18.2 (CH3, CT), 16.5 (CH3, CN), 16.4 (CH3, CN’) ppm. 
31P NMR (121 MHz; CDCl3): 17.92 ppm. 
ES
+MS  m/z  (%):  552/551/550/549  (1:5:1:5,  (M+Na
+,  90)),  530/529/528/527  (1:6:1:6, 
(M+H
+, 100)). 
HRES
+MS For C25H37O5P
79Br (M+H)
+: calcd 527.1557, found 527.1551. 
X-Ray: X-Ray data available in Appendix II. 
 
Data for (3.50)  
This  compound  was  isolated  as  an  inseparable  mixture  of  diastereoisomers  in 
approximately in a 75:25 ratio. 
Mw = 487.117 (C22H32O5BrP). 
Rf = 0.35 (Hexane/Acetone 65:35). 
IR (film): 2977 (w), 1737 (s), 1472 (m), 1240 (s), 1022 (s), 959 (s) cm
-1. 
1H NMR (400 MHz; CDCl3): Major diastereoisomer  7.40 (1H, d, J = 8.7 Hz, HA), 
6.75 (1H, m, HK), 6.72 (1H, d, J = 3.0 Hz, HD), 6.63 (1H, dd, J = 8.8, 3.1 Hz, HB), 5.79 
(1H, dd, J = 20.4, 17.1 Hz, HL), 4.16-4.06 (4H, m, HM), 3.78 (3H, s, HG), 2.77-2.48 (2H, 
m), 2.39-2.26 (2H, m), 2.18-2.04 (2H, m), 1.96-1.45 (5H, m), 1.34 (6H, t, J = 7.2 Hz, HN), 
1.08 (3H, d, J = 6.4 Hz, HT) ppm. Minor diastereoisomer observed 7.39 (1H, d, J = 
8.7 Hz, HA), 3.77 (3H, s, HG), 1.06 (3H, d, J = 7.5 Hz, HT) ppm. 
13C NMR (100 MHz; CDCl3): Major diastereoisomer 219.9 (Q, CR), 159.0 (Q, CC), 
154.7 (CH, d, J = 4.0 Hz, CK), 141.8 (Q, CF), 133.4 (CH, CA), 119.2 (CH, d, J = 186.3 Hz, 
CL), 116.0 (CH, CD), 114.6 (Q, CF), 113.3 (CH, CB), 61.7 (2 x CH2, d, J = 5.5 Hz, CM), 
55.4 (CH3, CG), 48.5 (CH, d, J = 20.9 Hz, CJ), 48.3 (CH, CS/O), 47.5 (CH, CS/O), 36.9 
(CH2, CI), 34.5 (CH2, CQ), 30.5 (CH2, CH), 24.6 (CH2, CP), 16.4 (2 x CH3, d, J = 6.0 Hz, 
CN), 14.4 (CH3, CT) ppm. Minor diastereoisomer observed 218.7 (Q, CR), 142.1 (Q, 
CF), 133.2 (CH, CA), 115.8 (CH, CD), 113.2 (CH, CB), 48.8 (CH, d, J = 11.8 Hz, CJ), 44.7 
(CH), 40.4 (CH), 38.3 (CH, d, J = 4.5 Hz), 35.2 (CH2), 32.9 (CH2), 32.0 (CH2), 31.5 
(CH2), 30.9 (CH2), 14.1 (CH3, CT) ppm. 
31P  NMR  (121  MHz;  CDCl3):  Major  diastereoisomer17.53  ppm.  Minor 
diastereoisomer28.81 ppm. 168 
 
ES
+MS m/z (%): 511/509 (1:1, (M+Na
+, 100)), 489/487 (1:1 (M+H
+, 60)). 
HRES
+MS For C22H32O5P
79BrNa (M+Na)
+: calcd 509.1068, found 509.1063. 
 
Data for (3.51): 
This  compound  was  isolated  as  an  inseparable  mixture  of  diastereoisomers  in 
approximately a 80:20 ratio. 
Mw = 567.492 (C28H40O5BrP). 
Rf = 0.44 (Hexane/Acetone 65:35). 
IR (film): 2977 (w), 2934 (w), 1733 (m), 1472 (m), 1240 (s), 1051 (s), 1022 (s), 859 (m) 
cm
-1. 
1H NMR (400 MHz; CDCl3): Major diastereoisomer  7.41 (1H, d, J = 8.7 Hz, HA), 
6.72 (1H, d, J = 3.0 Hz, HD), 6.68 (1H, m, HK), 6.64 (1H, dd, J = 8.7, 3.0 Hz, HB), 5.78 
(1H, dd, J = 20.7, 17.2 Hz, HL), 5.72 (1H, m, HY), 5.46 (1H, dtd, J = 16.9, 9.7, 5.3 Hz, 
HV), 5.24-4.99 (4H, m, HW+HZ), 4.19-4.09 (4H, m, HM), 3.78 (3H, s, HG), 2.69 (1H, m), 
2.56-2.45 (2H, m), 2.43-2.25 (3H, m), 2.24-2.07 (2H, m), 2.02-1.86 (3H, m), 1.70 (1H, 
m), 1.55 (1H, m), 1.37 (3H, t, J = 7.1 Hz, HN), 1.36 (3H, t, J = 7.1 Hz, HN’), 0.94 (3H, s, 
HT) ppm. Minor diastereoisomer observed 0.88 (3H, s, HT) ppm. 
13C NMR (100 MHz; CDCl3): Major diastereoisomer 223.2 (Q, CR), 159.0 (Q, CC), 
155.3 (CH, d, J = 3.7 Hz, CK), 142.1 (Q, CE), 135.6 (CH, CY), 134.2 (CH, CV), 133.4 (CH, 
CA), 119.0 (CH2, CW), 118.9 (CH, d, J = 187.1 Hz, CL), 117.0 (CH2, CZ), 116.1 (CH, CD), 
114.6 (Q, CF), 113.3 (CH, CB), 61.8 (CH2, d, J = 10.6 Hz, CM), 61.7 (CH2, d, J = 10.6 Hz, 
CM’), 55.4 (CH3, CG), 53.0 (Q, CS), 47.0 (CH, d, J = 20.9 Hz, CJ), 44.6 (CH, CO/Q), 41.9 
(CH, CO/Q), 40.4 (CH2, CU), 34.8 (CH2), 34.0 (CH2), 31.9 (CH2), 28.5 (CH2), 18.6 (CH3, 
CT), 16.5 (2 x CH3, d, J = 6.3 Hz, CN) ppm. 
31P NMR (121 MHz; CDCl3): 17.92 ppm. 
ES
+MS  m/z (%): 589/591 (1:1, (M+Na
+, 100)), 567/569 (1:1, (M+H
+, 47)). 
HRES
+MS For C28H40O5P
79BrNa (M+Na)
+: calcd 589.1694, found 589.1650. 
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The -1,4-addition compound (3.4) and the bis-allylated compound (3.56) and the non-
allylated compound (3.57). 
 
 
To a solution of the Z-allylic phosphonamide (2.4) (0.393 g, 0.89 mmol, 1.0 equiv) in THF 
(4 mL), cooled to -78 °C, 
nBuLi (2.5 M in hexane, 0.392 mL, 0.98 mmol, 1.1 equiv) was 
added slowly and the mixture was stirred for 45 min at -78 °C. After warming to 0 °C, 2-
methyl-2-cyclopentenone (0.096 mL, 1.16 mmol, 1.3 equiv) was immediately added. The 
solution was stirred for 1 h at 0 °C and then quenched with freshly distilled allyl bromide 
(0.336  mL,  4.45  mmol,  5.0  equiv).  HMPA  (2  mL)  was  added  and  the  solution  was 
warmed to room temperature and stirred for 1 h. Water (5 mL) was added and the reaction 
was extracted with DCM (3 x 25 mL), dried over MgSO4, filtered and concentrated in 
vacuo.  The  crude  product  was  purified  by  column  chromatography  (EtOAc,  then 
EtOAc/MeOH 99/1) to  afford  (3.4)  as  a light  yellow  oil (267 mg,  52%),  (3.57)  as a 
colourless oil (43 mg, 9%), and (3.56) as a colourless oil (38 mg, 7%). 
 
Data for (3.4):  
Mw = 577.553 (C29H42BrN2O3P). 
Rf = 0.40 (EtOAc/MeOH 99/1). 
IR (film): 2936 (m), 2864 (w), 1735 (m), 1470 (m), 1243 (s), 1210 (s), 1169 (s), 1008 (s), 
830 (w) cm
-1. 
1H NMR (400 MHz; CDCl3):  7.40 (1H, d, J = 8.7 Hz, HA), 6.72 (1H, d, J = 3.1 Hz, 
HD), 6.64 (1H, dd, J = 8.7, 3.1 Hz, HB), 6.64 (1H, m, HK), 5.61 (1H, dd, J = 21.3, 16.7 Hz, 
HL), 5.51 (1H, m, HT), 5.23 (1H, d, J = 17.0 Hz, HU), 5.11 (1H, d, J = 10.2 Hz, HU’), 3.79 
(3H, s, HG), 2.86-2.63 (2H, m), 2.60-2.32 (4H, m), 2.59 (3H, d, J = 3.2 Hz, HV/W), 2.55 
(3H, d, J = 2.6 Hz, HV/W), 2.26-2.13 (3H, m), 2.08-1.80 (6H, m), 1.60-1.43 (2H, m), 1.40-
1.06 (5H, m), 0.95 (3H, s, HR) ppm. 
13C NMR (100 MHz; CDCl3): 222.4 (Q, CP), 159.0 (Q, CC), 155.3 (CH, d, J = 1.8 Hz, 
CK), 142.2 (Q, CE), 133.8 (CH, CT), 133.3 (CH, CA), 121.8 (CH, d, J = 150.4 Hz, CL), 170 
 
119.3 (CH2, CU), 115.8 (CH, CD), 114.7 (Q, CF), 113.3 (CH, CB), 64.7 (CH, d, J = 7.2 Hz, 
CX/Y), 63.9 (CH, d, J = 5.2 Hz, CX/Y), 55.5 (CH3, CG), 52.2 (Q, CQ), 47.2 (CH, d, J = 18.2 
Hz, CJ), 44.5 (CH, CM), 41.1 (CH2), 37.3 (CH2), 34.3 (CH2), 31.8 (CH2), 29.0 (CH3, d, J = 
1.1 Hz, CV/W), 28.9 (CH3, d, J = 5.2 Hz, CV/W), 28.8 (CH2, d, J = 10.3 Hz, CZ), 28.2 (CH2, 
d, J = 7.6 Hz, CZ’), 24.3 (CH2), 24.2 (CH2), 23.8 (CH2), 18.3 (CH3, CR) ppm. 
31P NMR (121 MHz; CDCl3): 32.14 ppm. 
ES
+MS m/z (%): 617/615 (1:1, (M+K
+, 100)). 
HRES
+MS For C29H43N2O3P
79Br (M+H)
+: calcd 577.2189, found 577.2198. 
[]D = +114.6° (c 0.65, DCM). 
 
Data for (3.56): 
This  compound  was  isolated  as  an  inseparable  mixture  of  diastereoisomers  in 
approximately a 75:25 ratio. 
Mw = 617.597 (C32H46BrN2O3P). 
Rf = 0.47 (EtOAc/MeOH 99:1). 
IR (film): 2936 (w), 1733 (m), 1471 (m), 1210 (m), 1169 (m), 908 (s), 725 (s) cm
-1. 
1H NMR (400 MHz; CDCl3): Major diastereoisomer  7.40 (1H, d, J = 8.7 Hz, HA), 
6.76-6.58 (3H, m, HB+HD+HK), 5.62 (1H, dd, J = 21.3, 16.7 Hz, HL), 5.79-5.42 (2H, m, 
HT+HAB), 5.32-4.96 (4H, m, HU+HAC), 3.79 (3H, s, HG), 2.84-1.07 (29H, m), 0.97 (3H, s, 
HR) ppm, Minor diastereoisomer observed 0.91 (3H, s, HR) ppm. 
13C NMR (100 MHz; CDCl3): Major diastereoisomer 223.4 (Q, CP), 159.1 (Q, CC), 
155.2 (CH, d, J = 2.0 Hz, CK), 142.3 (Q, CE), 135.6 (CH, CT/AB), 133.9 (CH, CT/AB), 133.3 
(CH, CA), 121.7 (CH, d, J = 150.3 Hz, CL), 119.3 (CH2, CU/AC), 117.0 (CH2, CU/AC), 115.9 
(CH, CD), 114.7 (Q, CF), 113.3 (CH, CB), 64.7 (CH, d, J = 7.2 Hz, CX/Y), 63.9 (CH, d, J = 
5.2 Hz, CX/Y), 55.5 (CH3, CG), 53.1 (Q, CQ), 47.3 (CH, d, J = 18.3 Hz, CJ), 44.7 (CH, CM), 
41.9 (CH, CO), 40.7 (CH2), 34.8 (CH2), 34.3 (CH2), 31.9 (CH2), 29.1 (CH3, CV/W), 28.9 
(CH3, CV/W), 28.8 (CH2), 28.7 (CH2), 28.2 (CH2, d, J = 7.6 Hz, CZ), 24.3 (CH2), 24.2 
(CH2), 18.6 (CH3, CR)ppm. 
31P  NMR  (121  MHz;  CDCl3):  Major  diastereoisomer  32.23  ppm,  Minor 
diastereoisomer 32.16 ppm. 
ES
+MS  m/z (%): 639/641 (1:1, (M+Na
+, 100)), 617/619 (1:1, (M+H
+, 78)). 
HRES
+MS For C32H46O3P
79BrN2Na calcd 639.2327, found 639.2322. 171 
 
Data for (3.57): 
This  compound  was  isolated  as  an  inseparable  mixture  of  diastereoisomers  in 
approximately a 1:1 ratio. 
Mw = 537.469 (C26H38BrN2O3P). 
Rf = 0.27 (EtOAc/MeOH 99:1). 
IR (film): 2934 (m), 1737 (s), 1445 (m), 1242 (m), 1170 (s), 1008 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  7.41 (1H, d, J = 8.7 Hz, HA), 6.74 (1H, d, J = 3.0 Hz, HD), 
6.73 (1H, ddd, J = 20.1, 16.8, 9.5 Hz, HK), 6.64 (1H, dd, J = 8.7, 3.0 Hz, HB), 5.59 (1H, 
dd, J = 20.5, 16.6 Hz, HL), 3.79 (3H, s, HG), 2.83-2.71 (2H, m), 2.58-2.46 (2H, m), 2.56 
(3H, s, HT/S), 2.53 (3H, d, J = 0.5 Hz, HT/S), 2.40-2.32 (2H, m), 2.19-1.80 (9H, m), 1.70-
1.51 (3H, m), 1.39-1.27 (3H, m), 1.12 (3H, d, J = 6.6 Hz, HR) ppm. 
13C NMR (100 MHz; CDCl3): 220.3 (Q, CP), 159.0 (Q, CC), 155.0 (CH, CK), 142.1 (Q, 
CE), 133.4 (CH, CA), 121.8 (CH, d, J = 150.0 Hz, CL), 116.0 (CH, CD), 114.7 (Q, CF), 
113.2 (CH, CB), 64.8 (CH, d, J = 7.4 Hz, CU/V), 63.8 (CH, d, J = 5.3 Hz, CU/V), 55.5 (CH3, 
CG), 49.2 (CH, d, J = 18.0 Hz, CJ), 48.4 (CH, CM/Q), 47.8 (CH, CM/Q), 37.0 (CH2), 34.7 
(CH2), 33.0 (CH2), 30.8 (CH2), 29.0 (CH3, d, J = 1.4 Hz, CS/T), 28.7 (CH3, d, J = 5.1 Hz, 
CS/T), 28.2 (CH2, d, J = 7.3 Hz, CW), 24.9 (CH2), 24.3 (CH2), 24.2 (CH2), 14.8 (CH3, CR) 
ppm. 
31P NMR (121 MHz; CDCl3): 32.22 ppm. 
ES
+MS m/z (%): 539/537 (1:1, (M+H)
+, 100). 
HRES
+MS For C26H39O3PN2
79Br (M+H
+): calcd 537.1876, found 537.1880. 172 
 
9.3  Experimental data for Chapter 4 
 
The silyl enol ether (4.18) 
 
 
To a cooled solution (-50 °C) of the ketone (3.1) (292 mg, 0.59 mmol, 1.0 equiv) in DCM 
(5 mL) was added Et3N (247 L, 1.8 mmol, 3.0 equiv) then TBDMS-OTf (407 L, 1.8 
mmol, 3.0 equiv) dropwise. The reaction was stirred for 3 h at -50 °C and then sat. aq. 
NaHCO3 (5 mL) was added and the reaction was warmed to room temperature. The phases 
were  separated  and  the  aqueous  phase  was  extracted  with  DCM  (3  x  10  mL).  The 
combined organic phases were dried over Na2SO4, filtered and concentrated in vacuo. The 
crude product was purified by column chromatography (Hexane/Acetone 80:20) whereby 
the silica was pre-neutralized by making the slurry in the said solvent system, containing 
~1% of Et3N. This yielded (4.18) as a colourless oil (309 mg, 86%). 
 
Mw = 607.630 (C27H48O6PBrSi). 
Rf = 0.42 (Hexane/Acetone 75:25). 
IR (neat): 2959 (m), 2931 (m), 2855 (m), 1646 (m), 1616 (w), 1469 (w), 1389 (w), 1356 
(w), 1252 (s), 1223 (s), 1138 (m) 1058 (s), 1025 (s), 963 (s), 868 (m), 840 (s) cm
-1. 
1H NMR (400 MHz; CDCl3):  6.63 (1H, ddd, J = 21.8, 17.2, 9.5 Hz, HD), 5.81 (s, 1H, 
HR), 5.64 (1H, dd, J = 21.8, 17.2 Hz, HC), 5.53 (1H, br s, HR’), 4.78 (1H, t, J = 4.5 Hz, 
HH), 4.40 (1H, br s, HL), 4.09-4.01 (4H, m , HB), 3.92-3.76 (4H, m, HI), 2.76 (1H, d, J = 
15.2 Hz, HP), 2.38-2.23 (5H, m), 1.91-1.84 (1H, m), 1.74-1.58 (2H, m), 1.49-1.41 (1H, m), 
1.30 (6H, t, J = 7.1 Hz, HA), 0.90 (9H, s, HU), 0.87 (3H, HO), 0.14 (3H, s, HS), 0.10 (3H, s, 
HS’) ppm.  
13C NMR (100 MHz; CDCl3): 157.9 (Q, CM), 156.5 (d, J = 3.6 Hz, CH, CD), 130.5 (Q, 
CQ), 120.7 (CH2, CR), 118.4 (d, J = 186.6 Hz, CH, CC), 104.3 (CH, CH), 96.9 (CH, CL), 
64.8 (CH2, CI), 64.7 (CH2, CI’), 61.6 (d, J = 5.6 Hz, CH2, CB), 61.5 (d, J = 5.6 Hz, CH2, 
CB’), 49.7 (Q, CN), 46.9 (d, J = 20.7 Hz, CH, CE), 45.8 (CH2, CP), 43.2 (CH, CJ), 31.2 173 
 
(CH2, CG/K), 31.0 (CH2, CK/G), 26.1 (d, J = 2.1 Hz, CH2, CF), 25.6 (CH3, 3 x CU), 20.0 
(CH3, CO), 18.0 (Q, CT), 16.4 (d, J = 6.3 Hz, 2 x CH3, CA), -4.8 (CH3, CS), -5.5 (CH3, CS’) 
ppm.  
31P NMR (121 MHz; CDCl3):  18.30 ppm. 
ES
+MS m/z (%): 1249/1251/1253 (1:2:1, (2M+Na)
+, 29), 670/672 (1:1, (M+Na+MeCN)
+, 
100), 629/631 (1:1, (M+Na)
+, 81). 
HRES
+MS: We have not obtained HRMS or elemental analysis of this compound, but 
copies of the 
1H and 
13C NMR spectra are included in Appendix I. 
 
The C-ring cyclised silyl enol ether (4.19) 
 
 
A solution of the vinyl bromide (4.18) (301 mg, 0.50 mmol, 1.0 equiv) in THF (10 mL) 
was cooled to -116 °C in an EtOH/liquid N2 cold bath and treated with 
tBuLi (1.5 M in 
pentanes) (727 L, 1.1 mmol, 2.2 equiv). After the dropwise addition, the reaction was 
stirred for 15 min, then the cold bath was removed and the reaction was allowed to warm 
to room temperature over 1 h. Saturated aq. NaHCO3 (10 mL) was added and the reaction 
was extracted with EtOAc (3 x 10 mL). The combined organic phases were dried over 
MgSO4, filtered and concentrated in vacuo. The crude product was purified by column 
chromatography (Hexane/EtOAc 1:1). This  yielded (4.19) as a colourless oil (242 mg, 
95%), as a single diastereoisomer. 
 
Mw = 528.734 (C27H49O6PSi). 
Rf = 0.22 (Hexane/EtOAc 1:1). 
IR (film): 2956 (m), 2922 (m), 2855 (m), 1621 (m), 1460 (m), 1393 (w), 1346 (m), 1252 
(s), 1228 (s), 1138 (m) 1058 (s), 1025 (s), 954 (s), 902 (m), 850 (s), 779 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  5.00 (1H, s, HR), 4.93 (1H, s, HR’), 4.85 (1H, t, J = 4.1 Hz, 
HH), 4.52 (1H, dd, J = 3.1, 1.4 Hz, HL), 4.14-4.03 (4H, m, HB), 4.00-3.80 (4H, m, HI), 2.54 
(1H, d, J = 13.1 Hz, HP), 2.23-1.90 (6H, m), 1.87-1.69 (2H, m), 1.65-1.49 (4H, m), 1.28 174 
 
(6H, t, J = 7.0 Hz, HA), 0.90 (9H, s, HU), 0.72 (3H, HO), 0.16 (3H, s, HS), 0.14 (3H, s, HS’) 
ppm.  
13C NMR (100 MHz; CDCl3): 163.4 (Q, CM), 147.3 (d, J = 1.3 Hz, Q, CQ), 111.7 (CH2, 
CR), 104.8 (CH, CH), 99.2 (CH, CL), 64.9 (CH2, CI), 64.8 (CH2, CI’), 61.5 (d, J = 6.6 Hz, 
CH2, CB), 61.4 (d, J = 5.6 Hz, CH2, CB’), 54.1 (d, J = 1.7 Hz, CH, CD), 47.8 (Q, CN), 46.9 
(d, J = 20.7 Hz, CH, CE), 42.1 (CH2, CP), 42.1 (d, J = 4.9 Hz, CH, CJ), 39.9 (d, J = 12.9 
Hz, CH, CE), 29.0 (CH2, CG/K), 28.9 (CH2, CG/K), 25.6 (d, J = 141.2 Hz, CH2, CC), 25.5 
(CH3, 3 x CU), 24.2(CH2, CF), 22.4 (CH3, CO), 17.9 (Q, CT), 16.4 (d, J = 6.2 Hz, CH3, 2 x 
CA), -4.6 (CH3, CS), -5.1 (CH3, CS’) ppm.  
31P NMR (121 MHz; CDCl3):  32.50 ppm. 
ES
+MS m/z (%): 551 ((M+Na)
+, 100), 529 ((M+H)
+, 46). 
HRES
+MS For C27H50O6PSi (M+H)
+: calcd 529.3109, found 529.3118. 
 
The C-ring cyclised ketone (4.24) 
 
 
A solution of the silyl enol ether (4.19) (259 mg, 0.49 mmol, 1.0 equiv) in THF (5 mL) 
was treated with TBAF (1 M in THF, 489 L, 1.3 equiv) and the mixture was stirred at 
room temperature for 30 min. Saturated aq. NaHCO3 (5 mL) was added and the reaction 
was extracted with DCM (3 x 10 mL). The combined organic phases were dried over 
MgSO4, filtered and concentrated in vacuo. The crude product was purified by column 
chromatography (Hexane/Acetone 60:40). This yielded (4.24) as a colourless oil (198 mg, 
98%), as a single diastereoisomer. 
 
Mw = 414.473 (C21H35O6P). 
Rf = 0.42 (Hexane/Acetone 60:40). 
IR (film): 2959 (w), 2887 (w), 1737 (s), 1643 (w), 1453 (w), 1406 (w), 1239 (m),  1138 
(m), 1058 (s), 1023 (s), 947 (s), 902 (m), 729 (s) cm
-1. 175 
 
1H NMR (400 MHz; CDCl3):  5.01 (1H, s, HR), 4.91 (s, 1H, HR’), 4.81 (1H, t, J = 4.3 Hz, 
HH),, 4.05-3.98 (4H, m, HB), 3.93-3.78 (4H, m, HI), 2.44-2.37 (1H, m, HL), 2.35 (1H, d, J 
= 13.0 Hz, HP), 2.18-1.96 (6H, m), 1.74-1.44 (7H, m), 1.25 (3H, t, J = 7.1 Hz, HA), 1.24 
(3H, t, J = 7.1 Hz, HA’), 0.74 (3H, HO) ppm.  
13C NMR (100 MHz; CDCl3): 219.8 (Q, CM), 145.2 (d, J = 1.3 Hz, Q, CQ), 112.6 (CH2, 
CR), 104.3 (CH, CH), 64.9 (CH2, CI), 64.8 (CH2, CI’), 61.4 (d, J = 6.6 Hz, CH2, CB), 61.3 
(d, J = 5.6 Hz, CH2, CB’), 48.6 (d, J = 1.7 Hz, CH, CD), 48.5 (Q, CN), 42.9 (CH2, CP), 40.7 
(d, J = 4.6 Hz, CH, CJ), 40.6 (d, J = 13.6 Hz, CH, CE), 35.8 (CH2, CL), 28.2 (CH2, CG/K), 
24.8 (d, J = 142.0 Hz, CH2, CC), 22.9 (CH2, CF), 22.3 (CH2, CG/K), 16.3 (d, J = 6.2 Hz, 
CH3, 2 x CA), 14.0 (CH3, CO) ppm.  
31P NMR (121 MHz; CDCl3):  31.72 ppm. 
ES
+MS m/z (%): 851 ((2M+Na)
+, 26), 437 ((M+Na)
+, 100), 415 ((M+H)
+, 28). 
HRES
+MS For C21H36O6P (M+H)
+: calcd 415.224, found 415.2243. 
 
The C-ring cyclised aldehyde (4.25) 
 
 
To a solution of the acetal (4.24) (180 mg, 0.43 mmol, 1.0 equiv) in MeCN (5 mL) and a 
borate-HCl buffer (pH 8) (5 mL) was added CAN (16 mg, 0.03 mmol, 0.06 equiv) in one 
portion and the mixture was heated at 60 °C for 18 h. The reaction was cooled to room 
temperature, water (5 mL) and DCM (10 mL) were added and the phases were separated. 
The  aqueous  phase  was  extracted with  DCM (3 x  10 mL)  and  the  combined organic 
phases were dried over Na2SO4, filtered and evaporated in vacuo. The orange crude oil 
was purified by column chromatography eluting (Hexane/Acetone 7:3) to afford (4.25) as 
a light yellow oil (145 mg, 91%). 
Mw = 370.420 (C19H31O5P). 
Rf = 0.45 (Hexane/Acetone 60:40). 
IR (film): 2978 (w), 2936 (w), 2907 (w), 1736 (s), 1723 (s), 1642 (w), 1453 (w), 1391 
(w), 1237 (m), 1162 (m), 1054 (s), 1023 (s), 956 (s), 897 (m), 795 (m) cm
-1. 176 
 
1H NMR (400 MHz; CDCl3):  9.79 (1H, HH), 5.03 (1H, s, HQ), 4.96 (s, 1H, HQ’),  4.08-
3.99 (4H, m, HB), 2.67-2.58 (1H, m), 2.48-2.37 (3H, m), 2.19-1.92 (6H, m), 1.89-1.84 
(2H, m), 1.27 (3H, t, J = 7.1 Hz, HA), 1.26 (3H, t, J = 7.1 Hz, HA’), 0.76 (3H, HO) ppm.  
13C NMR (100 MHz; CDCl3): 219.3 (Q, CL), 201.5 (CH, CH), 144.8 (d, J = 1.4 Hz, Q, 
CP), 112.9 (CH2, CQ), 61.6 (d, J = 6.6 Hz, CH2, CB), 61.5 (d, J = 5.6 Hz, CH2, CB’), 48.6 
(d, J = 1.7 Hz, CH, CD), 48.5 (Q, CM), 42.8 (CH2, CO), 40.4 (d, J = 9.7 Hz, CH, CE), 40.3 
(CH, CI), 38.7 (CH2, CK), 35.8 (CH2, CG), 24.9 (d, J = 142.3 Hz, CH2, CC), 22.5 (CH2, 
CF/J), 21.1 (CH2, CF/J), 16.4 (d, J = 6.1 Hz, CH3, CA), 16.3 (d, J = 6.1 Hz, CH3, CA’), 14.0 
(CH3, CN) ppm.  
31P NMR (121 MHz; CDCl3):  31.69 ppm. 
ES
+MS m/z (%): 763 ((2M+Na)
+, 21), 393 ((M+Na)
+, 100), 371 ((M+H)
+, 70). 
HRES
+MS For C19H31O5PNa (M+Na)
+: calcd 393.1801, found 393.1800. 
 
The C-ring cyclised carboxylic acid (4.26) 
 
 
To a stirred and cooled (0 °C) solution of the aldehyde (4.25) (93 mg, 0.25 mmol, 1.0 
equiv) in 2-methyl-2-propanol (
tBuOH) (2 mL) and acetonitrile (1.50 mL) was added 2-
methyl-2-butene (309 L, 3.0 mmol, 12.0 equiv). Sodium chlorite (165 mg, 1.5 mmol, 6.0 
equiv) and sodium dihydrogen phosphate (175 mg, 1.5 mmol, 6.0 equiv) were combined 
and dissolved in H2O (3 mL) and then added dropwise to the cooled aldehyde solution. 
The  reaction  was  stirred  for  30  min  before  the  addition  of  5%  (w/w)  aq.  sodium 
metabisulfate solution (2.5 mL). The pH was adjusted (pH 6) before extraction of the 
crude mixture with DCM (3 x 15 mL). The combined organic phases were dried over 
MgSO4,  filtered  and evaporated in  vacuo.  The  crude product  was  purified by  column 
chromatography (DCM/MeOH 95:5) to afford (4.26) (92 mg, 95%) as a colourless oil. 
Recrystallization in Et2O afforded (4.26) as fine white crystals (m.p. = 143-145 °C). 
 
Mw = 386.419 (C19H31O6P). 
Rf = 0.38 (DCM/MeOH 95:5). 177 
 
IR (film): 3446 (br w), 2978 (w), 2936 (w), 2907 (w), 1736 (s), 1642 (w), 1453 (w), 1391 
(w), 1237 (m), 1162 (m), 1054 (s), 1023 (s), 956 (s), 897 (m), 795 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  6.40 (1H, br hump, OH), 5.00 (1H, s, HQ), 4.98 (s, 1H, 
HQ’), 4.15-4.03 (4H, m, HB), 2.66 (1H, d, J = 13.5 Hz, HO), 2.53-2.38 (2H, m), 2.32-1.83 
(9H, m), 1.73-1.57 (3H, m), 1.31 (3H, t, J = 7.1 Hz, HA), 1.29 (3H, t, J = 7.1 Hz, HA’),  
0.74 (3H, HN) ppm.  
13C NMR (100 MHz; CDCl3):  218.2 (Q, CL), 176.2 (Q, CH), 145.0 (d, J = 2.9 Hz, Q, 
CP), 112.2 (CH2, CQ), 62.2 (d, J = 6.9 Hz, CH2, CB), 62.1 (d, J = 6.9 Hz, CH2, CB’), 48.7 
(d, J = 1.8 Hz, CH, CE), 48.4 (Q, CM), 42.9 (CH2, CO), 41.6 (d, J = 9.8 Hz, CH, CD), 40.3 
(CH, CI), 38.7 (CH2, CK), 36.4 (CH2, CG), 24.9 (d, J = 142.6 Hz, CH2, CC), 22.8 (CH2, 
CF/J), 21.6 (CH2, CF/J), 16.3 (d, J = 6.1 Hz, CH3, CA), 16.2 (d, J = 6.1 Hz, CH3, CA’), 14.0 
(CH3, CN) ppm.  
31P NMR (121 MHz; CDCl3):  32.29 ppm.  
ES
+MS m/z (%): 795 ((2M+Na)
+, 36), 409 ((M+Na)
+, 70), 387 ((M+H)
+, 100). 
HRES
+MS For C19H32O6P (M+H)
+: calcd 387.1931, found 387.1934.   
X-ray: X-ray data available in Appendix II. 
 
The aldehyde (4.27) 
 
 
To a solution of the acetal (3.1) (1.03 g, 2.03 mmol, 1.0 equiv) in MeCN (10 mL) and a 
borate-HCl buffer (pH 8) (10 mL) was added CAN (44 mg, 0.08 mmol, 0.04 equiv) in one 
portion and the mixture was heated at 60 °C for 18 h. The reaction was cooled to room 
temperature, water (20 mL) and DCM (20 mL) were added and the phases were separated. 
The  aqueous  phase  was  extracted with  DCM (3 x  20 mL)  and  the  combined organic 
phases were dried over Na2SO4, filtered and evaporated in vacuo. The orange crude oil 
was purified by column chromatography eluting (Hexane/EtOAc 1:9) to afford (4.27) as a 
light yellow oil (875 mg, 93%). 
 
Mw = 449.327 (C19H30O5PBr). 178 
 
Rf = 0.24 (Hexane/EtOAc 1:4). 
IR (neat): 2988 (m), 2935 (m), 2902 (m), 1730 (s), 1621 (m), 1446 (w), 1389 (m), 1243 
(s), 1162 (m), 1049 (s), 1020 (s), 964 (s), 845 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  9.75 (1H, s, HH), 6.56 (1H, ddd, J = 21.7, 17.2, 10.0 Hz, 
HD), 5.97 (1H, t, J = 1.7 Hz, HQ), 5.66 (1H, dd, J = 20.5, 17.3 Hz, HC), 5.55 (1H, br s, 
HQ’), 4.16-4.04 (4H, m, HB), 3.06 (1H, d, J = 14.8 Hz, HO), 2.48 (1H, d, J = 14.8 Hz, HO’), 
2.53-2.20 (7H, m, HG+HI+HJ+HK), 2.19-2.07 (1H, m, HE), 1.56-1.43 (2H, m, HF), 1.33 
(6H, t, J = 7.1 Hz, HA), 0.86 (3H, s, HN) ppm.  
13C NMR (100 MHz; CDCl3):  221.1 (Q, CL), 201.1 (CH, CH), 154.3 (d, J = 3.9 Hz, CH, 
CD), 129.8 (Q, CP), 122.5 (CH2, CQ), 119.9 (d, J = 187.5 Hz, CH, CC), 61.8 (d, J = 8.6 Hz, 
CH2, CB), 61.7 (d, J = 8.6 Hz, CH2, CB’), 51.7 (Q, CM),  47.0 (CH2, CO), 46.7 (d, J = 21.0 
Hz, CH, CE), 43.8 (CH, CI), 40.9 (CH2, CK), 36.8 (CH2, CG), 23.9 (CH2, CJ), 23.8 (d, J = 
2.1 Hz, CH2, CF), 18.7 (CH3, CN), 16.4 (d, J = 6.0 Hz, CH3, 2 x CA) ppm. 
31P NMR (121 MHz; CDCl3):  17.41 ppm. 
ES
+MS m/z (%): 901/899/897 (1:2:1, (2M+H)
+, 18), 449/451 (1:1, (M+H)
+, 100). 
HRES
+MS For C19H30O5PBr (M+H)
+: calcd 449,1087, found 449.1094. 
 
The aldehyde (4.28) 
 
 
To a solution of the acetal (3.2) (760 mg, 1.50 mmol, 1.0 equiv) in MeCN (15 mL) and a 
borate-HCl buffer (pH 8) (10 mL) was added CAN (50 mg, 0.09 mmol, 0.06 equiv) in one 
portion and the mixture was heated at 60 °C for 18 h. The reaction was cooled to room 
temperature, water (20 mL) and DCM (20 mL) were added and the phases were separated. 
The  aqueous  phase  was  extracted with  DCM (3 x  20 mL)  and  the  combined organic 
phases were dried over Na2SO4, filtered and evaporated in vacuo. The orange crude oil 
was purified by column chromatography eluting (Hexane/Acetone 60:40) to afford (4.28) 
as a light yellow oil (669 mg, 95%). 
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Mw = 463.354 (C20H32O5PBr). 
Rf = 0.38 (Hexane/Acetone 60:40). 
IR (neat): 3465 (br, w), 2988 (m), 2935 (m), 2902 (m), 1730 (s), 1621 (m), 1446 (w), 
1389 (m), 1243 (s), 1162 (m), 1096 (s), 1020 (s), 964 (s), 845 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  9.78 (1H, s, HH), 6.57 (1H, ddd, J = 21.7, 17.2, 10.0 Hz, 
HD), 6.01 (1H, t, J = 1.7 Hz, HR), 5.69 (1H, dd, J = 20.6, 17.2 Hz, HC), 5.57 (1H, br s, 
HR’), 4.16-4.04 (4H, m, HB), 3.15 (1H, d, J = 14.8 Hz, HP), 2.48 (1H, d, J = 14.8 Hz, HP’), 
2.54-2.25 (7H, m), 2.16 (1H, m), 1.75-1.57 (2H, m), 1.55-1.45 (1H, m), 1.45 (2H, q, J = 
7.3 Hz, HN), 1.34 (6H, t, J = 7.1 Hz, HA), 0.81 (3H, s, HO) ppm.  
13C NMR (100 MHz; CDCl3):  220.0 (Q, CL), 201.3 (CH, CH), 154.6 (d, J = 3.9 Hz, CH, 
CD), 130.4 (Q, CQ), 122.7 (CH2, CR), 119.8 (d, J = 187.4 Hz, CH, CC), 61.9 (d, J = 5.9 Hz, 
CH2, CB), 61.8 (d, J = 5.9 Hz, CH2, CB’), 54.1 (Q, CM), 46.1 (d, J = 21.0 Hz, CH, CE), 45.3 
(CH2, CP), 44.2 (CH, CI), 40.9 (CH2), 36.9 (CH2), 25.4 (CH2, CN), 24.1 (CH2), 23.9 (d, J = 
2.0 Hz, CH2, CF), 16.5 (d, J = 6.1 Hz, CH3, CA), 16.4 (d, J = 6.1 Hz, CH3, CA’), 8.4 (CH3, 
CO) ppm. 
31P NMR (121 MHz; CDCl3):  17.46 ppm. 
ES
+MS m/z (%): 947/949/951 (1:2:1, (2M+H)
+, 14), 485/487 (1:1 (M+Na)
+, 25), 463/465 
(1:1, (M+H)
+, 100). 
HRES
+MS For C20H32O5PBr (M+Na)
+: calcd 485.1063, found 485.1073. 
 
The carboxylic acid (4.29) 
 
To a stirred and cooled (0 °C) solution of the aldehyde (4.27) (341 mg, 0.76 mmol, 1.0 
equiv) in 2-methyl-2-propanol (
tBuOH) (5.83 mL) and acetonitrile (3.50 mL) was added 
2-methyl-2-butene  (965  L,  9.11  mmol,  12.0  equiv).  Sodium  chlorite  (515  mg,  4.55 
mmol, 6.0 equiv) and sodium dihydrogen phosphate (546 mg, 4.55 mmol, 6.0 equiv) were 
combined and dissolved in H2O (9.3 mL) and then added dropwise to the cooled aldehyde 
solution. The reaction was stirred for 30 min before the addition of 5% (w/w) aq. sodium 
metabisulfate solution (7.43 mL). The pH was adjusted (pH 6) before extraction of the 
crude mixture with DCM (3 x 15 mL). The combined organic phases were dried over 180 
 
MgSO4,  filtered  and evaporated in  vacuo.  The  crude product  was  purified by  column 
chromatography (DCM/MeOH 95:5) to afford (4.29) (348 mg, 95%) as a colourless oil. 
Recrystallization in Et2O afforded (4.29) as fine white crystals (m.p. = 165-167 °C). 
 
Mw = 465.327 (C19H30O6PBr). 
Rf = 0.24 (DCM/MeOH 97:3). 
IR (film): 3423 (br, w), 2983 (w), 2931 (w), 2903 (w), 1734 (s), 1621 (w), 1399 (w), 1370 
(w), 1214 (m), 1191 (m), 1162 (m), 1049 (s), 1030 (s), 968 (s), 850 (w) cm
-1. 
1H NMR (400 MHz; CDCl3):  7.87 (1H, br hump, OH), 6.59 (1H, ddd, J = 27.2, 17.2, 
10.0 Hz, HD), 5.90 (1H, br s, HQ), 5.71 (1H, dd, J = 21.1, 17.2 Hz, HC), 5.53 (1H, br s, 
HQ’), 4.16-4.04 (4H, m, HB), 3.05 (1H, d, J = 14.9 Hz, HO), 2.47 (1H, d, J = 14.8 Hz, HO’), 
2.43-2.04 (8H, m), 1.60-1.42 (2H, m), 1.33 (6H, t, J = 7.1 Hz, HA), 0.85 (3H, s, HN) ppm.  
13C NMR (100 MHz; CDCl3):  221.3 (Q, CL), 176.4 (Q, CH), 154.8 (d, J = 4.0 Hz, CH, 
CD), 129.8 (Q, CP), 122.4 (CH2, CQ), 119.2 (d, J = 188.0 Hz, CH, CC), 62.1 (d, J = 5.9 Hz, 
CH2, CB), 62.0 (d, J = 8.6 Hz, CH2, CB’), 51.7 (Q, CM), 47.0 (CH2, CO), 46.9 (d, J = 21.4 
Hz, CH, CE), 43.6 (CH, CI), 36.8 (CH2), 31.0 (CH2), 26.5 (d, J = 2.0 Hz, CH2, CF), 23.9 
(CH2), 19.0 (CH3, CN), 16.3 (d, J = 6.2 Hz, CH3, 2 x CA) ppm. 
31P NMR (121 MHz; CDCl3):  17.88 ppm. 
ES
+MS m/z (%): 933/931/929 (1:2:1, (2M+H)
+, 23), 467/465 (1:1, (M+H)
+, 100). 
HRES
+MS: For C19H30O6P
79Br (M+Na)
+: calcd 487.0861, found 487.0875. 
X-ray: X-ray data available in Appendix II. 
 
The carboxylic acid (4.30) 
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To a stirred and cooled (0 °C) solution of the aldehyde (4.28) (344 mg, 0.76 mmol, 1.0 
equiv) in 2-methyl-2-propanol (
tBuOH) (5.83 mL) and acetonitrile (3.50 mL) was added 
2-methyl-2-butene  (965  L,  9.11  mmol,  12.0  equiv).  Sodium  chlorite  (515  mg,  4.55 
mmol, 6.0 equiv) and sodium dihydrogen phosphate (546 mg, 4.55 mmol, 6.0 equiv) were 
combined and dissolved in H2O (9.3 mL) and then added dropwise to the cooled aldehyde 181 
 
solution. The reaction was stirred for 30 min before the addition of 5% (w/w) aq. sodium 
metabisulfate solution (7.43 mL). The pH was adjusted (pH 6) before extraction of the 
crude mixture with DCM (3 x 15 mL). The combined organic phases were dried over 
MgSO4,  filtered  and evaporated in  vacuo.  The  crude product  was  purified by  column 
chromatography (DCM/MeOH 95:5) to afford (4.30) (362 mg, 95%) as a colourless oil.  
 
Mw = 479.354 (C20H32O6PBr). 
Rf = 0.28 (DCM/MeOH 95:5). 
IR (film): 3385 (br, w), 2983 (m), 2940 (w), 2883 (w), 1730 (s), 1626 (w), 1550 (w), 1446 
(w), 1370 (w), 1233 (m), 1157 (m), 1049 (s), 1025 (s), 968 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  8.50 (1H, br hump, OH), 6.59 (1H, ddd, J = 21.9, 17.2, 
10.0 Hz, HD), 5.92 (1H, t, J = 1.6 Hz, HR), 5.71 (1H, dd, J = 21.0, 17.2 Hz, HC), 5.54 (1H, 
br s, HR’), 4.17-4.05 (4H, m, HB), 3.13 (1H, d, J = 14.7 Hz, HP), 2.42-2.05 (9H, m), 1.63-
1.49 (2H, m), 1.44 (2H, q, J = 7.3 Hz, HN), 1.33 (6H, t, J= 7.1 Hz, HA), 0.80 (3H, t, J = 
7.3 Hz, HO) ppm.  
13C NMR (100 MHz; CDCl3):  220.2 (Q, CL), 176.3 (Q, CH), 155.1 (d, J = 4.0 Hz, CH, 
CD), 130.4 (Q, CQ), 122.5 (CH2, CR), 119.2 (d, J = 188.0 Hz, CH, CC), 62.1 (d, J = 5.9 Hz, 
CH2, CB), 62.0 (d, J = 5.9 Hz, CH2, CB’), 54.1 (Q, CM), 46.3 (d, J = 21.1 Hz, CH, CE), 45.3 
(CH2, CP), 44.0 (CH, CI), 36.9 (CH2), 31.0 (CH2), 26.6 (d, J = 1.9 Hz, CH2, CF), 25.4 
(CH2, CN), 24.0 (CH2), 16.4 (d, J = 6.2 Hz, CH3, CA), 16.3 (d, J = 6.2 Hz, CH3, CA’), 8.3 
(CH3, CO) ppm. 
31P NMR (121 MHz; CDCl3):  18.02 ppm. 
ES
+MS m/z (%): 481/479 (1:1, (M+H)
+, 100). 
HRES
+MS For C20H32O6P
79Br (M+H)
+: calcd 479.1193, found 479.1197. 
 
The methyl ester (4.31) 
 
 
To a solution of the aldehyde (4.27) (200 mg, 0.45 mmol, 1.0 equiv) in dry MeOH (2 mL) 
was added Oxone
R (274 mg, 0.47 mmol, 1.05 equiv) in one portion. The mixture was 182 
 
stirred at room temperature for 18 h, then DCM  (5  ml)  was added. The reaction was 
filtered through celite and the solvent was evaporated in vacuo. The resulting crude oil 
was purified by column chromatography eluting (Hexane/EtOAc 30:70) to afford (4.31) as 
a light yellow oil (88 mg, 41%) along with 21% of recovered (4.27). 
 
Mw = 479.342 (C20H32O6PBr). 
Rf = 0.61 (Hexane/EtOAc 20:80). 
IR (neat): 3465 (br, w), 2988 (m), 2935 (m), 2902 (m), 1730 (s), 1621 (m), 1446 (w), 
1389 (m), 1243 (s), 1162 (m), 1096 (s), 1020 (s), 964 (s), 845 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  6.56 (1H, ddd, J = 21.7, 17.2, 10.0 Hz, HD), 5.98 (1H, t, J 
= 1.5 Hz, HR), 5.66 (1H, dd, J = 20.6, 17.2 Hz, HC), 5.54 (1H, br s, HR’), 4.13-4.04 (4H, 
m, HB), 3.66 (3H, s, HI), 3.06 (1H, d, J = 14.8 Hz, HP), 2.48 (1H, d, J = 14.8 Hz, HP’), 
2.42-2.06 (8H, m), 1.56-1.44 (2H, m), 1.32 (6H, t, J = 7.1 Hz, HA), 0.85 (3H, s, HO) ppm.  
13C NMR (100 MHz; CDCl3):  221.1 (Q, CM), 173.3 (Q, CH), 154.4 (d, J = 3.9 Hz, CH, 
CD), 129.8 (Q, CQ), 122.5 (CH2, CR), 118.8 (d, J = 187.5 Hz, CH, CC), 61.8 (d, J = 8.6 Hz, 
CH2, CB), 61.7 (d, J = 8.6 Hz, CH2, CB’), 51.7 (Q, CN), 51.6 (CH3, CI), 47.1 (CH2, CP), 
46.8 (d, J = 21.0 Hz, CH, CE), 43.7 (CH, CJ), 36.8 (CH2), 31.0 (CH2), 26.6 (d, J = 1.2 Hz, 
CH2, CF), 23.9 (CH2), 18.7 (CH3, CO), 16.4 (d, J = 6.0 Hz, 2 x CH3, CA) ppm. 
31P NMR (121 MHz; CDCl3):  18.32 ppm. 
ES
+MS m/z (%) : 961/959/957 (1:2:1, (2M+H)
+, 18), 479/481 (1:1, (M+H)
+, 100). 
HRES
+MS For C20H32O6P
79BrNa (M+Na)
+: calcd 501.1012, found 501.1011. 
 
The methyl ester (4.32) 
 
 
To a solution of the acid (4.29) (471 mg, 0.98 mmol, 1.0 equiv) in DMF (5 mL) was added 
K2CO3  (677  mg,  4.95  mmol,  5.0  equiv).  The  mixture  was  stirred  15  min  at  room 
temperature before the dropwise addition of MeI (175 L, 2.94 mmol, 3.0 equiv). The 
reaction mixture was stirred for a further 2 h at room temperature, filtered through celite, 
washed with DCM (50 mL) and concentrated in vacuo.  The crude oil was partitioned 183 
 
between water/DCM (30 mL) and the aqueous phase was extracted with DCM (3 x 20 
mL). The combined organic phases were dried over Na2SO4, filtered and concentrated in 
vacuo.  The  crude  product  was  purified  by  column  chromatography  (Hexane/Acetone 
70:30) to afford (4.32) (393 mg, 81%) as a light yellow oil.  
 
Mw = 493.369 (C21H34O6PBr). 
Rf = 0.28 (Hexane/Acetone 60:40). 
IR (neat): 2979 (br w), 2906 (w), 1733 (s), 1624 (m), 1437 (w), 1388 (m), 1242 (s), 1163 
(m), 1051 (s), 1023 (s), 960 (s), 845 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  6.52 (1H, ddd, J = 21.7, 17.2, 10.0 Hz, HD), 5.95 (1H, t, J 
= 1.5 Hz, HS), 5.63 (1H, dd, J = 20.6, 17.3 Hz, HC), 5.54 (1H, br s, HS’), 4.07-3.99 (4H, m, 
HB), 3.61 (3H, s, HI), 3.08 (1H, d, J = 14.8 Hz, HQ), 2.37-2.04 (9H, m), 1.55-1.42 (2H, m), 
1.39 (2H, q, J = 7.5 Hz, HO), 1.27 (6H, t, J = 7.1 Hz, HA), 0.74 (3H, s, HP) ppm.  
13C NMR (100 MHz; CDCl3):  219.9 (Q, CM), 173.3 (Q, CH), 154.6 (d, J = 4.0 Hz, CH, 
CD), 130.4 (Q, CR), 122.6 (CH2, CS), 120.6 (d, J = 186.7 Hz, CH, CC), 61.8 (d, J = 8.6 Hz, 
CH2, CB), 61.7 (d, J = 8.6 Hz, CH2, CB’), 54.1 (Q, CN), 51.6 (CH3, CI), 46.2 (d, J = 21.0 
Hz, CH, CE), 45.3 (CH2, CQ), 44.1 (CH, CJ), 36.9 (CH2), 31.0 (CH2), 26.7 (d, J = 1.2 Hz, 
CH2, CF), 25.4 (CH2, CO), 24.1 (CH2), 16.4 (d, J = 6.0 Hz, CH3, 2 x CA), 8.30 (CH3, CP) 
ppm. 
31P NMR (121 MHz; CDCl3):  17.50 ppm. 
ES
+MS m/z (%): 1009/1011 (2:1, (2M+Na)
+, 20), 515/517 (1:1, (M+Na)
+, 24), 493/495 
(1:1, (M+H)
+, 100). 
HRES
+MS For C21H34O6P
79BrNa (M+Na)
+: calcd 515.1169, found 515.1163. 
 
The silyl enol ether (4.33) 
 
 
To a cooled solution (-50 °C) of the ketone (4.31) (1.18 mg, 2.5 mmol, 1.0 equiv)  in 
DCM (10 mL) was added Et3N (1.02 mL, 7.5 mmol, 3.0 equiv) and TBDMS-OTf (1.69 184 
 
mL, 7.5 mmol, 3.0 equiv). The reaction was stirred for 2 h at -50 °C and then sat.aq. 
NaHCO3 (10 mL)  was added  and the reaction  was warmed to room temperature. The 
phases were separated and the aqueous phase was extracted with DCM (3 x 20 mL). The 
combined organic phases were dried over Na2SO4, filtered and concentrated in vacuo. The 
crude product was purified by column chromatography (Hexane/Acetone 80:20) whereby 
the silica was pre-neutralized by making the slurry in the said solvent system, containing 
~1% of Et3N. This yielded (4.33) as a colourless oil (1.18 mg, 91%).  
 
Mw = 593.603 (C26H46O6PSiBr). 
Rf = 0.41 (Hexane/Acetone 70:30). 
IR (film): 2961 (m), 2926 (m), 2855 (m), 1734 (s), 1621 (m), 1460 (m), 1393 (w), 1346 
(m), 1255 (s), 1229 (s), 1138 (m) 1056 (s), 1025 (s), 954 (s), 902 (m), 851 (s) cm
-1. 
1H NMR (400 MHz; CDCl3):  6.62 (1H, ddd, J = 21.7, 17.2, 10.0 Hz, HD), 5.81 (1H, br 
s, HR), 5.65 (1H, dd, J = 20.6, 17.2 Hz, HC), 5.55 (1H, br s, HQ’), 4.42 (1H, br s, HL), 4.11-
4.04 (4H, m, HB), 3.64 (3H, s, HI), 2.79 (1H, d, J = 14.8 Hz, HP), 2.27 (1H, d, J = 14.8 Hz, 
HP’), 2.40-2.21 (4H, m), 2.19-2.11 (1H, m), 2.02-1.87 (2H, m), 1.49-1.38 (1H, m), 1.32 
(6H, t, J = 7.1 Hz, HA), 0.91 (9H, s, HU), 0.87 (3H, s, HN), 0.15 (3H, s, HS), 0.12 (3H, s, 
HS’) ppm.  
13C NMR (100 MHz; CDCl3):  173.6 (Q, CH), 157.8 (Q, CM), 155.5 (d, J = 3.3 Hz, CH, 
CD), 130.5 (Q, CQ), 122.7 (CH2, CR), 119.1 (d, J = 186.8 Hz, CH, CC), 97.0 (CH, CL), 61.7 
(d, J = 5.7 Hz, CH2, CB), 61.6 (d, J = 5.7 Hz, CH2, CB’), 51.6 (CH3, CI), 49.8 (Q, CN), 46.6 
(d, J = 20.7 Hz, CH, CE), 45.9 (CH2, CP), 43.2 (CH, CJ), 31.2 (2 x CH2, CG + CK), 27.0 
(CH2, CF), 25.6 (CH3, 3 x CU), 20.0 (CH3, CO), 18.0 (Q, CT), 16.4 (d, J = 2.5 Hz, CH3, 2 x 
CA), -4.7 (CH3, CS), -5.5 (CH3, CS’) ppm. 
31P NMR (121 MHz; CDCl3):  18.32 ppm. 
ES
+MS m/z (%): 593/595 (1:1, (M+H)
+, 100), 616/618 (1:1, (M+Na)
+, 24), 1188/1190 
(1:1, (2M+H)
+, 8). 
HRES
+MS For C26H46O6PSi
79BrNa (M+Na)
+: calcd 615.1877, found 615.1885. 
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The silyl enol ether (4.1) 
 
 
To a cooled solution (-50 °C) of the ketone (4.32) (1.58 g, 3.21 mmol, 1.0 equiv) in DCM 
(5 mL) was added Et3N (1.34 mL, 9.63 mmol, 3.0 equiv) then, dropwisely over 2 min, 
TBDMS-OTf (2.21 mL, 9.63 mmol, 3.0 equiv) was added. The reaction was stirred for 2 h 
at -50/-40 °C and then sat. aq. NaHCO3 (10 mL) was added and the reaction was warmed 
to room temperature. The phases were separated and the aqueous phase was extracted with 
DCM (5 x 20 mL). The combined organic phases were dried over Na2SO4, filtered and 
concentrated  in  vacuo.  The  crude  product  was  purified  by  column  chromatography 
(Hexane/Acetone 80:20) whereby the silica was pre-neutralized by making the slurry in 
the said solvent system, containing ~1% of Et3N. This yielded (4.1) as a colourless oil 
(1.59 g, 82%). 
 
Mw = 607.630 (C27H48O6PSiBr). 
Rf = 0.42 (Hexane/Acetone 70:30). 
IR (film): 2956 (m), 2922 (m), 2855 (m), 1733 (s), 1621 (m), 1460 (m), 1393 (w), 1346 
(m), 1252 (s), 1228 (s), 1138 (m) 1058 (s), 1025 (s), 954 (s), 850 (s), 779 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  6.62 (1H, ddd, J = 21.7, 17.2, 9.4 Hz, HD), 5.83 (1H, br s, 
HS), 5.65 (1H, dd, J = 21.2, 17.2 Hz, HC), 5.56 (1H, br s, HS’), 4.56 (1H, br s, HL), 4.11-
4.04 (4H, m, HB), 3.64 (3H, s, HI), 2.82 (1H, d, J = 15.2 Hz, HQ), 2.20 (1H, d, J = 15.2 
Hz, HQ’), 2.40-2.12 (6H, m), 2.01-1.85 (2H, m), 1.53-1.16 (2H, m, HO), 1.32 (6H, t, J = 
7.0 Hz, HA), 0.91 (9H, s, HV), 0.81 (3H, t, J = 7.5 Hz, HP), 0.18 (3H, s, HT), 0.17 (3H, s, 
HT’) ppm.  
13C NMR (100 MHz; CDCl3):  173.6 (Q, CH), 156.0 (d, J = 3.5 Hz, CH, CD), 155.2 (Q, 
CM), 131.0 (Q, CR), 120.9 (CH2, CS), 119.1 (d, J = 186.7 Hz, CH, CC), 98.4 (CH, CL), 61.7 
(d, J = 5.7 Hz, CH2, CB), 61.6 (d, J = 5.7 Hz, CH2, CB’), 53.0 (Q, CN), 51.5 (CH3, CI), 46.2 
(d, J = 20.7 Hz, CH, CE), 45.7 (CH2, CQ), 43.1 (CH, CJ), 32.5 (CH2), 31.2 (CH2), 28.0 186 
 
(CH2, CO), 27.2 (CH2, CF), 25.6 (CH3, 3 x CV), 17.9 (Q, CU), 16.4 (d, J = 2.7 Hz, CH3, 2 x 
CA), 9.4 (CH3, CP), -4.7 (CH3, CT), -5.5 (CH3, CT’) ppm. 
31P NMR (121 MHz; CDCl3):  17.90 ppm. 
ES
+MS m/z (%): 607/609 (1:1, (M+H)
+, 100), 629/631 (1:1, (M+Na)
+, 34). 
HRES
+MS For C27H49O6PSi
79Br (M+H)
+: calcd 607.2214, found 607.2226. 
 
The acetal (4.34) 
 
 
In a dry 5 mL pear shape flask were combined the ketone (4.31) (127 mg, 0.23 mmol, 1.0 
equiv), ethylene glycol (64 L, 1.14 mmol, 5.0 equiv), trimethyl orthoformate (125 L, 
1.14 mmol, 5.0 equiv) and pTSA (1.3 mg, 0.007 mmol, 0.03 equiv). The reagents were 
stirred for 28 h, then EtOAc (10 mL) was added and the solution was washed with sat. aq. 
NaHCO3 (5 mL), dried over MgSO4, filtered and evaporated in vacuo. The crude product 
was purified by column chromatography (Hexane/Acetone 60:40) to afford (4.34) (54 mg, 
44%) as a light yellow oil and (4.31) (23 mg, 18%).  
 
Mw = 523.395 (C22H36O7PBr). 
Rf = 0.36 (Hexane/Acetone 70:30). 
IR (film): 3248 (br, m), 2969 (w), 1734 (s), 1621 (w), 1432 (w), 1366 (w), 1233 (m), 1162 
(m), 1053 (s), 1020 (s) cm
-1. 
1H NMR (400 MHz; CDCl3): 6.46 (1H, ddd, J = 27.2, 17.1, 10.0 Hz, HD), 5.62 (1H, dd, 
J = 20.6, 17.1 Hz, HC), 5.51 (1H, br s, HR), 5.42 (1H, br s, HR’), 4.12-4.00 (4H, m, HB), 
3.98-3.75 (4H, m, HS), 3.64 (3H, s, HI), 2.75 (1H, d, J = 14.4 Hz, HP), 2.52 (1H, d, J = 
14.4 Hz, HP’), 2.31-2.09 (3H, m), 2.01-1.83 (3H, m), 1.72-1.65 (2H, m), 1.52-1.32 (2H, 
m), 1.31 (6H, t, J = 7.1 Hz, HA), 1.16 (3H, s, HS) ppm.  
13C NMR (100 MHz; CDCl3):  173.5 (Q, CH), 155.7 (d, J = 3.8 Hz, CH, CD), 130.6 (Q, 
CQ), 119.9 (CH, CR), 119.0 (Q, CM), 118.6 (d, J = 186.0 Hz, CH, CC), 63.7 (CH2, CS), 63.2 
(CH2, CS’), 61.7 (d, J = 5.6 Hz, CH2, CB), 61.6 (d, J = 5.6 Hz, CH2, CB’), 51.5 (CH3, CI), 
49.1 (CH, CJ), 49.0 (Q, CN), 46.8 (CH2, CP), 46.8 (d, J = 20.8 Hz, CH, CE), 31.1 (CH2), 187 
 
31.0 (CH2), 26.6 (d, J = 2.1 Hz, CH2, CF), 24.0 (CH2), 16.4 (CH3, CO), 16.4 (d, J = 6.0 Hz, 
2 x CH3, CA) ppm. 
31P NMR (121 MHz; CDCl3):  17.88 ppm. 
ES
+MS m/z (%): 545/547 (1:1, (M+Na)
+, 31), 523/525 (1:1, (M+H)
+, 100). 
HRES
+MS For C22H36O7P
79BrNa (M+Na)
+: calcd 545.1274, found 545.1280. 
 
The -keto phosphonate (4.35) and the -keto phosphonate (4.35) and the 
monocyclised ketone (4.36) and the monocyclised ester (4.38) 
 
 
 
A solution of the vinyl bromide (4.33) (1.14 g, 1.92 mmol, 1.0 equiv) in THF (10 mL) was 
cooled  to  -116  °C  in  an  EtOH/liquid  N2  cold  bath  and  treated  with 
tBuLi  (1.5  M  in 
pentanes) (3.07 mL, 5.89 mmol, 2.4 equiv). After the quick addition (over 20 seconds), the 
reaction was stirred for 15 min, then the cold bath was removed and the reaction was 
allowed to warm to room temperature over 1 h. Saturated aq. NaHCO3 (10 mL) was added 
and H2O (20 mL) and the reaction was extracted with DCM (3 x 30 mL). The combined 
organic phases were dried over Na2SO4, filtered and concentrated in vacuo. The crude 
product  was  purified  by  column  chromatography  (Hexane/EtOAc  70:30)  using  pre-
neutralised silica gel. This yielded (4.35) (424 mg, 46%), (4.35) (45 mg, 5%), (4.36) 
(140 mg, 13%) and (4.38) (109 mg, 11%) as light yellow oils. 
 
Data for (4.35) 
Mw = 482.665 (C25H43O5PSi). 
Rf = 0.36 (Hexane/EtOAc 60:40). 188 
 
IR (film): 2958 (m), 2854 (m), 1721 (m), 1625 (m), 1472 (w), 1334 (w), 1251 (s), 1236 
(s), 1161 (w), 1054 (s), 1025 (s), 963 (m), 840 (s), 784 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  4.93 (1H, s, HQ), 4.85 (1H, s, HQ’), 4.46 (1H, dd, J = 3.0, 
1.4 Hz, HK), 4.13-4.02 (4H, m, HB), 3.43 (1H, ddd, J = 26.1, 8.6, 1.9 Hz, HC), 2.86 (1H, 
ddd, J = 17.3, 9.7, 2.6 Hz, HG), 2.75-2.65 (1H, m, HD), 2.41-2.25 (2H, m, HG’+HO), 2.17-
1.69 (6H, m, HO’+2HF+HJ+ HJ’+HI), 1.39-1.30 (1H, m, HE), 1.31 (3H, t, J = 6.6 Hz, HA), 
1.29 (3H, t, J = 6.6 Hz, HA’), 0.93 (9H, s, HT), 0.73 (3H, s, HN), 0.17 (3H, s, HR),  0.15 
(3H, s, HR’) ppm.  
13C NMR (100 MHz; CDCl3): 207.2 (d, J = 4.7 Hz, Q, CH), 163.5 (Q, CL), 145.4 (Q, 
CP), 110.8 (CH2, CQ), 98.4 (CH, CK), 62.8 (d, J = 7.3 Hz, CH2, CB), 62.7 (d, J = 7.3 Hz, 
CH2, CB’), 54.0 (CH, CI), 51.8 (d, J = 123.1 Hz, CH, CC), 47.2 (d, J = 4.0 Hz, CH, CE), 
45.5 (Q, CM), 45.2 (CH2, CO), 37.9 (d, J = 9.2 Hz, CH, CD), 37.5 (CH2, CG), 28.1 (2 x 
CH2, CJ), 25.8 (CH2, CF), 25.7 (3 x CH3, CT), 18.1 (Q, CS), 16.3 (d, J = 6.1 Hz, CH2, CA), 
16.3 (d, J = 6.2 Hz, CH2, CA’), 15.6 (CH3, CN), -4.7 (CH3, CT), -5.00 (CH3, CT’) ppm. 
31P NMR (121 MHz; CDCl3):  23.14 ppm. 
ES
+MS m/z (%): 988 ((2M+Na)
+, 22), 483 ((M+H)
+, 100). 
HRES
+MS For C25H44O5PSi (M+H)
+: calcd 483.2690, found 483.2684. 
 
Data for (4.35) 
Mw = 482.665 (C25H43O5PSi). 
Rf = 0.48 (Hexane/EtOAc 60:40). 
IR (film): 2956 (m), 2931 (m), 2857 (m), 1717 (m), 1621 (m), 1472 (w), 1334 (w), 1252 
(s), 1232 (s), 1161 (w), 1051 (s), 1025 (s), 963 (m), 840 (s), 784 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  5.03 (1H, t, J = 1.6 Hz, HQ), 4.93 (1H, J = 1.6 Hz, HQ’), 
4.44 (1H, dd, J = 3.0, 1.4 Hz, HK), 4.18-4.01 (4H, m, HB), 3.56 (1H, ddd, J = 20.0, 4.0, 
1.8 Hz, HC), 2.85 (1H, dt, J = 14.0, 6.9 Hz, HG), 2.61 (1H, dq, J = 11.4, 3.5 Hz, HI), 2.33 
(1H, m, HG’), 2.26 (1H, m, HO), 2.24-1.91 (4H, m), 1.85 (1H, m, HF), 1.39 (1H, m, HE), 
1.28 (6H, t, J = 6.6 Hz, HA), 1.27 (1H, m, HJ), 0.95 (9H, s, HT), 0.93 (3H, s, HN), 0.17 
(3H, s, HR), 0.15 (3H, s, HR’) ppm.  
13C NMR (100 MHz; CDCl3): 205.6 (Q, CH), 163.3 (Q, CL), 144.9 (d, J = 2.2 Hz, Q, 
CP), 111.7 (CH2, CQ), 98.3 (CH, CK), 62.6 (d, J = 7.0 Hz, CH2, CB), 61.9 (d, J = 7.0 Hz, 
CH2, CB’), 54.3 (d, J = 127.2 Hz, CH, CC), 53.8 (CH, CI), 50.8 (d, J = 4.5 Hz, CH, CD), 
45.2 (Q, CM), 44.7 (CH2, CO), 40.2 (CH2, CG), 34.2 (d, J = 1.2 Hz, CH, CE), 31.2 (CH2, 189 
 
CJ), 28.3 (CH2, CF), 25.6 (3 x CH3, CT), 18.0 (Q, CS), 16.3 (d, J = 5.7 Hz, CH3, CA), 16.2 
(d, J = 5.7 Hz, CH3, CA’), 15.9 (CH3, CN), -4.7 (CH3, CR), -5.00 (CH3, CR’) ppm.  
31P NMR (121 MHz; CDCl3):  23.05 ppm. 
ES
+MS m/z (%): 988 ((2M+Na)
+, 33), 483 ((M+H)
+, 100). 
HRES
+MS For C25H44O5PSi (M+H)
+: calcd 483.2690, found 483.2699. 
 
Data for (4.36) 
Mw = 540.787 (C29H53O5PSi). 
Rf = 0.40 (Hexane/EtOAc 60:40). 
IR (film): 2956 (w), 2931 (w), 1704 (m), 1621 (m), 1249 (s), 1229 (s), 1054 (s), 1026 (s), 
951 (s), 836 (s) cm
-1. 
1H NMR (400 MHz; CDCl3): 5.04 (1H, s, HS), 4.93 (1H, s, HS’), 4.45 (1H, m, HM), 
4.17-4.00 (4H, m, HB), 2.67-2.43 (2H, m), 2.28 (1H, d, J = 12.8 Hz, HQ), 2.25-2.01 (5H, 
m), 1.96-1.60 (4H, m), 1.43 (1H, m), 1.31 (3H, t, J = 7.1 Hz, HA), 1.30 (3H, t, J = 7.1 Hz, 
HA’), 1.16 (9H, s, HJ), 0.94 (9H, s, HV), 0.74 (3H, s, HP), 0.17 (3H, s, HT), 0.15 (3H, s, HT’) 
ppm.  
13C NMR (100 MHz; CDCl3):  215.9 (Q, CH), 163.6 (Q, CN), 147.1 (Q, CR), 112.1 (CH2, 
CS), 98.2 (CH, CM), 61.4 (d, J = 6.4 Hz, 2 x CH2, CB), 52.7 (CH, CK), 45.33 (Q, CO), 45.30 
(CH, CK), 44.2 (Q, CI), 41.4 (d, J = 4.5 Hz, CH, CE), 40.0 (d, J = 13.2 Hz, CH, CD), 31.5 
(CH2), 29.3 (CH2), 26.4 (3 x CH3, CJ), 25.6 (3 x CH3, CV), 24.5 (CH2), 25.1 (d, J = 141.0 
Hz, CH2, CC), 18.0 (Q, CT), 16.4 (d, J = 6.0 Hz, 2 x CH3, CA), 15.3 (CH3, CP), -4.7 (CH3, 
CT), -5.1 (CH3, CT’) ppm. 
 31P NMR (121 MHz; CDCl3):  32.79 ppm. 
ES
+MS m/z (%): 563 ((M+Na)
+, 100), 540 ((M+H)
+, 64). 
HRES
+MS For C29H53O5PSiNa (M+Na)
+: calcd 563.3298, found 563.3300. 
 
Data for (4.38) 
Mw = 514.707 (C26H47O6PSi). 
Rf = 0.18 (Hexane/EtOAc 1:1). 
IR (film): 2978 (w), 2936 (w), 2907 (w), 1736 (s), 1642 (w), 1453 (w), 1391 (w), 1237 
(m), 1162 (m), 1054 (s), 1023 (s), 956 (s), 897 (m), 795 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  5.03 (1H, s, HR), 4.94 (1H, s, HR’),  4.45 (1H, dd, J = 2.9, 
1.3 Hz, HL), 4.12-4.05 (4H, m, HB), 3.68 (3H, s, HI), 2.51-2.43 (1H, m), 2.34-2.07 (7H, 190 
 
m), 1.94-1.67 (4H, m), 1.43-1.42 (1H, m), 1.30 (6H, t, J = 7.0 Hz, HA), 0.94 (9H, HU), 
0.74 (3H, HO), 0.17 (3H, HS), 0.15 (3H, HS’) ppm.  
13C NMR (100 MHz; CDCl3): 174.6 (Q, CH), 164.0 (Q, CM), 147.5 (d, J = 1.3 Hz, Q, 
CQ), 112.7 (CH2, CR), 99.2 (CH, CL), 62.0 (d, J = 6.6 Hz, CH2, CB), 61.9 (d, J = 6.6 Hz, 
CH2, CB’), 52.9 (d, J = 1.7 Hz, CH, CD), 51.9 (CH3, CI), 45.8 (CH2), 45.7 (Q, CN), 41.6 (d, 
J = 4.7 Hz, CH, CJ), 40.5 (CH, d, J = 12.6 Hz, CE), 30.1 (CH2, CG/K), 29.6 (CH2, CG/K), 
25.9 (d, J = 141.8 Hz, CH2, CC), 26.1 (CH3, 3 x CU), 25.9 (CH2, CF), 18.5 (CH3, CO), 16.8 
(d, J = 6.2 Hz, CH3, 2 x CA), 17.9 (Q, CT), -4.6 (CH3, CS), -5.1 (CH3, CS’) ppm.  
31P NMR (121 MHz; CDCl3):  31.64 ppm. 
ES
+MS m/z (%): 515 ((M+H)
+, 100). 
HRES
+MS For C26H48O6PSi (M+H)
+: calcd 515.2952, found 515.2945. 
 
The -keto phosphonate (4.2) and the -keto phosphonate (4.2) and the 
monocyclised ketone (4.37) and the monocyclised ester (4.39) 
 
 
A solution of the vinyl bromide (4.1) (994 mg, 1.64 mmol, 1.0 equiv) in THF (8 mL) was 
cooled  to  -116  °C  in  an  EtOH/liquid  N2  cold  bath  and  treated  with 
tBuLi  (1.5  M  in 
pentanes) (2.31 mL, 3.94 mmol, 2.4 equiv). After the quick addition (over 10 seconds), the 
reaction was stirred for 15 min, then the cold bath was removed and the reaction was 
allowed to warm to room temperature over 1 h. Saturated aq. NaHCO3 (10 mL) was added 
and H2O (20 mL) and the reaction was extracted with DCM (3 x 50 mL). The combined 
organic phases were dried over Na2SO4, filtered and concentrated in vacuo. The crude 
product  was  purified  by  column  chromatography  (Hexane/EtOAc  70:30)  using  pre-
neutralized silica gel. This afforded (4.2) as a colourless oil (306 mg, 39%), (4.2) as a 191 
 
colourless oil (54 mg, 11%), (4.37) as a colourless oil (177 mg, 15%) and (4.39) as a 
colourless oil (90 mg, 10%). 
 
Data for (4.2) 
Mw = 496.692 (C26H45O5PSi). 
Rf = 0.36 (Hexane/EtOAc 1:1). 
IR (neat): 2956 (m), 2931 (m), 2854 (m), 1706 (m), 1617 (m), 1462 (w), 1352 (w), 1243 
(s), 1229 (s), 1053 (s), 1024 (s), 960 (s), 841 (s), 783 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  4.94 (1H, s, HR), 4.82 (1H, s, HR’), 4.52 (1H, d, J = 1.8 
Hz, HK), 4.25-3.98 (4H, m, HB), 3.41 (1H, ddd, J = 25.9, 8.7, 1.7 Hz, HC), 2.85 (1H, ddd, J 
= 17.2, 9.8, 2.5 Hz, HG), 2.69 (1H, m, HD), 2.59 (1H, d, J = 13.0 Hz, HP), 2.12-1.66 (6H, 
m), 1.47-1.35 (1H, m, HE), 1.30 (3H, t, J = 7.0 Hz, HA), 1.29 (3H, t, J = 7.0 Hz, HA’), 
1.26-1.14 (2H, m, HN), 0.92 (9H, s, HU), 0.83 (3H, t, J = 7.4 Hz, HO), 0.16 (3H, s, HS), 
0.15 (3H, s, HS’) ppm.  
13C NMR (100 MHz; CDCl3): 207.3 (d, J = 5.1 Hz, Q, CH), 163.3 (Q, CL), 145.2 (Q, 
CQ), 110.5 (CH2, CR), 99.0 (CH, CK), 62.8 (d, J = 6.1 Hz, CH2, CB), 62.7 (d, J = 6.1 Hz, 
CH2, CB’), 55.5 (CH, CI), 51.8 (d, J = 123.0 Hz, CH, CC), 48.1 (Q, CM), 47.0 (d, J = 4.1 
Hz, CH, CD), 41.8 (CH2, CP), 37.6 (d, J = 9.4 Hz, CH, CE), 37.4 (CH2, CG), 27.9 (CH2, CJ), 
25.8 (CH2, CF), 25.6 (3 x CH3, CU), 22.6 (CH2, CN), 17.9 (Q, CT), 16.3 (d, J = 6.1 Hz, 
CH3, CA), 16.2 (d, J = 6.1 Hz, CH3, CA’), 8.3 (CH3, CO), -4.6 (CH3, CS), -5.1 (CH3, CS’) 
ppm. 
31P NMR (121 MHz; CDCl3):  22.66 ppm. 
ES
+MS m/z (%): 1016 ((2M+Na)
+, 100), 497 ((M+H)
+, 44). 
HRES
+MS For C26H46O5PSi (M+H)
+: calcd 497.2847, found 497.2833. 
 
Data for (4.2) 
Mw = 496.692 (C26H45O5PSi). 
Rf = 0.48 (Hexane/EtOAc 1:1). 
IR (neat): 2956 (m), 2931 (m), 2857 (m), 1717 (m), 1619 (m), 1472 (w), 1334 (w), 1252 
(s), 1232 (s), 1161 (w), 1051 (s), 1025 (s), 963 (m), 840 (s), 784 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  5.03 (1H, s, HR), 4.93 (1H, s, HR’), 4.52 (1H, t, J = 2.1 Hz, 
HK), 4.16-4.01 (4H, m, HB), 3.56 (1H, ddd, J = 20.0, 4.0, 1.8 Hz, HC), 2.87 (1H, td, J = 
14.0, 6.9 Hz), 2.66 (1H, qd, J = 11.4, 3.5 Hz), 2.61 (1H, d, J = 13.8 Hz, HP), 2.46 (1H, m), 192 
 
2.26-1.98 (3H, m), 1.93 (1H, d, J = 13.6 Hz, HP’), 1.67-1.52 (2H, m), 1.44-1.05 (3H, m), 
1.31 (3H, t, J = 7.1 Hz, HA), 1.31 (3H, t, J = 7.1 Hz, HA’), 0.93 (9H, s, HU), 0.90 (3H, t, J 
= 7.5 Hz, HO), 0.18 (3H, s, HS), 0.15 (3H, s, HS’) ppm. 
13C NMR (100 MHz; CDCl3): 205.8 (Q, CH), 163.0 (Q, CL), 144.7 (d, J = 2.1 Hz, Q, 
CQ), 111.6 (CH2, CR), 98.9 (CH, CK), 62.6 (d, J = 7.1 Hz, CH2, CB), 62.0 (d, J = 7.1 Hz, 
CH2, CB’), 55.4 (CH, CI), 54.3 (d, J = 127.1 Hz, CH, CC), 50.8 (d, J = 4.1 Hz, CH, CD), 
47.8 (Q, CM), 41.7 (CH2, CP), 40.2 (CH, CE), 34.1 (CH2, CG), 31.4 (CH2, CJ), 28.2 (CH2, 
CF), 25.6 (3 x CH3, CU), 22.9 (CH2, CN), 17.9 (Q, CT), 16.2 (d, J = 6.2 Hz, CH3, CA), 16.2 
(d, J = 6.1 Hz, CH3, CA’), 8.5 (CH3, CO), -4.6 (CH3, CS), -5.1 (CH3, CS’) ppm. 
31P NMR (121 MHz; CDCl3):  22.56 ppm. 
ES
+MS: m/z (%): 1016 ((2M+Na)
+, 32), 519 ((M+Na)
+, 100), 497 ((M+H)
+, 12). 
HRES
+MS For C26H46O5PSi (M+H)
+: calcd 497.2847, found 497.2844. 
 
Data for (4.37) 
Mw = 554.814 (C30H55O6PSi). 
Rf = 0.40 (Hexane/EtOAc 1:1). 
IR (neat): 2957 (m), 2931 (m), 2858 (w), 1704 (m), 1620 (m), 1462 (w), 1391 (w), 1352 
(m), 1230 (s), 1161 (w), 1055 (s), 1026 (s), 960 (s), 841 (s), 763 (s) cm
-1. 
1H NMR (400 MHz; CDCl3):  5.00 (1H, s, HT), 4.91 (1H, s, HT’), 4.50 (1H, t, J = 2.2 Hz, 
HM), 4.12-4.00 (4H, m, HB), 2.67-2.39 (3H, m), 2.23-2.08 (3H, m), 2.01-1.89 (3H, m), 
1.86-1.73 (2H, m), 1.60 (1H, ddd, J = 14.9, 10.7, 5.4 Hz), 1.45 (1H, m), 1.28 (3H, t, J = 
7.1 Hz, HA), 1.27 (3H, t, J = 7.1 Hz, HA’), 1.34-1.15 (2H, m, HP), 1.12 (9H, s, HJ), 0.91 
(9H, s, HW), 0.82 (3H, t, J = 7.4 Hz, HQ), 0.15 (3H, s, HU), 0.14 (3H, s, HU’) ppm.  
13C NMR (100 MHz; CDCl3):  215.9 (Q, CH), 163.4 (Q, CN), 147.0 (Q, CS), 111.9 (CH2, 
CT), 98.9 (CH, CM), 61.42 (d, J = 6.5 Hz, CH2, CB), 61.41 (d, J = 6.4 Hz, CH2, CB), 54.4 
(CH, CK), 47.9 (Q, CI), 44.2 (CH2, CR), 42.1 (Q, CO), 41.3 (d, J = 4.5 Hz, CH, CE), 39.9 
(d, J = 13.2 Hz, CH, CD), 31.9 (CH2, CG), 29.2 (CH2, CL), 26.4 (CH2, CF), 25.6 (3 x CH3, 
CJ), 24.8 (3 x CH3, CW), 25.3 (d, J = 140.9 Hz, CH2, CC), 22.4 (CH2, CP), 17.9 (Q, CV), 
16.4 (d, J = 6.1 Hz, 2 x CH2, CA), 8.3 (CH3, CQ), -4.6 (CH3,CU), -5.1 (CH3, CU’) ppm. 
31P NMR (121 MHz; CDCl3):  32.92 ppm. 
ES
+MS m/z (%): 1132 ((2M+Na)
+, 15), 577 ((M+Na)
+, 100), 555 ((M+H)
+, 82). 
HRES
+MS For C30H55O6PSi (M+H)
+: calcd 555.3629, found 555.3628. 
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Data for (4.39) 
Mw = 528.734 (C27H49O6PSi). 
Rf = 0.18 (Hexane/EtOAc 1:1). 
IR (neat): 2978 (w), 2931 (w), 2907 (w), 1737 (s), 1619 (w), 1462 (w), 1437 (w), 1390 
(w), 1229 (s), 1164 (m), 1054 (s), 1026 (s), 959 (s), 839 (s), 782 (s) cm
-1. 
1H NMR (400 MHz; CDCl3):  5.00 (1H, s, HS), 4.93 (1H, s, HS’), 4.50 (1H, s, HL), 4.18-
3.99 (4H, m, HB), 3.65 (3H, s, HI), 2.53 (1H, d, J = 13.1 Hz, HQ), 2.44 (1H, ddd, J = 15.8, 
10.6, 5.2 Hz), 2.26 (1H, ddd, J = 15.9, 11.2, 6.0 Hz), 2.21-1.67 (9H, m, HQ’ + 8H), 1.48 
(1H, td, J = 16.1, 8.3 Hz), 1.29 (6H, t, J = 7.0 Hz, HA), 1.36-1.14 (2H, m, HO), 0.91 (9H, s, 
HV), 0.83 (3H, t, J = 7.4 Hz, HP), 0.15 (3H, s, HT), 0.13 (3H, s, HT') ppm. 
13C NMR (100 MHz; CDCl3):  174.2 (Q, CH), 163.3 (Q, CM), 146.9 (Q, CR), 112.0 (CH2, 
CS), 99.0 (CH, CL), 61.5 (d, J = 6.6 Hz, CH2, CB), 61.5 (d, J = 6.5 Hz, CH2, CB’), 54.2 
(CH, CD), 51.5 (CH3, CI), 47.8 (Q, CN), 42.0 (CH2, CQ), 40.9 (d, J = 4.7 Hz, CH, CJ), 39.9 
(d, J = 12.7 Hz, CH, CE), 29.8 (CH2, CG/K), 29.0 (CH2, CG/K), 25.6 (CH2, CF), 25.6 (3 x 
CH3, CV), 25.5 (d, J = 141.4 Hz, CH2, CC), 22.5 (CH2, CO), 17.9 (Q, CU), 16.4 (d, J = 6.1 
Hz, 2 x CH2, CA), 8.3 (CH3, CP), -4.6 (CH3, CT), -5.1 (CH3, CT’) ppm. 
31P NMR (121 MHz; CDCl3):  32.46 ppm. 
ES
+MS m/z (%): 1080 ((2M+Na)
+, 12), 551 ((M+Na)
+, 100), 529 ((M+H)
+, 50). 
HRES
+MS For C27H50O6PSi (M+H)
+: calcd 529.3114, found 529.3111. 
 
The  -keto  phosphonate  (4.40)  and  the  monocyclised  ketone  (4.42)  and  the 
monocyclised ester (4.41) 
 
 
A solution of the vinyl bromide (4.33) (350 mg, 0.59 mmol, 1.0 equiv)  in THF (10 mL) 
was cooled to -116 °C in an EtOH/liquid N2 cold bath and treated with 
tButyllithium (1.5 
M in pentanes) (965 L, 1.1 mmol, 2.2 equiv). After the dropwise addition, the reaction 194 
 
was stirred for 15 min, then the cold bath was removed and the reaction was allowed to 
warm to room temperature over 1 h. Saturated aq. NaHCO3 (10 mL) was added and the 
reaction was extracted with DCM (3 x 10 mL). The combined organic phases were dried 
over Na2SO4, filtered and concentrated in vacuo. The crude mixture was dissolved in THF 
(5 mL) and treated with HCl 2M (5 mL) and the mixture was stirred for 30 min at room 
temperature. Water was added (10 mL) and the mixture was extracted with DCM (3 x 20 
mL),  filtered  and  concentrated  in  vacuo.  The  crude  product  was  purified  by  column 
chromatography (Hexane/Acetone 60:40). This yielded (4.40) as a colourless oil (89 mg, 
41%) as a single diastereoisomer , (4.42) as a colourless oil (40 mg, 18%) and (4.41) as a 
colourless oil (14 mg, 6%). Recrystallization of (4.40) in (DCM/Hexane 1:3) afforded 
fine colourless needles.  
 
Data for (4.40) 
Mw = 368.404 (C19H29O5P). 
Rf = 0.38 (Hexane/Acetone 60:40). 
IR (film): 2978 (w), 2936 (w), 2907 (w), 1736 (s), 1707 (s), 1644 (w), 1453 (w), 1391 
(w), 1242 (m),  1163 (w), 1049 (s), 1018 (s), 959 (s), 852 (m),  784 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  4.96 (1H, t, J = 1.7 Hz, HQ), 4.87 (1H, s, HQ’),  4.13-4.02 
(4H, m, HB), 3.38 (1H, ddd, J = 26.4, 8.4, 1.9 Hz, HC), 2.85 (1H, ddd, J = 17.4, 9.5, 2.8 
Hz,  HG),  2.75-2.60  (1H,  m,  HD),  2.51-2.29  (3H,  m,  HG’+HK+HO),  2.20-1.74  (5H,  m, 
HK’+HO’+2HF+HJ), 1.68-1.47 (2H, m, HJ’+HI), 1.39-1.29 (1H, m, HE), 1.28 (3H, t, J = 6.6 
Hz, HA), 1.24 (3H, t, J = 6.6 Hz, HA’), 0.78 (3H, HN) ppm.  
13C NMR (100 MHz; CDCl3): 218.9 (Q, CL), 206.4 (d, J = 5.2 Hz, Q, CH), 143.5 (d, J = 
1.8 Hz, Q, CP), 111.3 (CH2, CQ), 62.9 (d, J = 7.0 Hz, CH2, CB), 62.7 (d, J = 7.0 Hz, CH2, 
CB’), 50.3 (d, J = 123.9 Hz, CH, CC), 50.5 (CH, CI), 48.8 (Q, CM), 46.4 (d, J = 4.0 Hz, CH, 
CD), 42.8 (CH2, CO), 38.8 (d, J = 9.2 Hz, CH, CE), 37.4 (CH2, CG), 35.8 (CH2, CK), 25.3 
(CH2, CF), 21.6 (CH2, CJ), 16.2 (d, J = 6.1 Hz, 2 x CH3, CA), 14.2 (CH3, CN) ppm.  
31P NMR (121 MHz; CDCl3):  22.67 ppm. 
ES
+MS m/z (%): 759 ((2M+Na)
+, 42), 369 ((M+H)
+, 100). 
HRES
+MS: not necessary, X-ray obtained instead. 
X-ray: X-ray data available in Appendix II. 
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Data for (4.41) 
Mw = 400.446 (C20H33O6P). 
Rf = 0.22 (Hexane/Acetone 60:40). 
IR (film): 2978 (w), 2936 (w), 2907 (w), 1736 (s), 1723 (s), 1642 (w), 1453 (w), 1391 
(w), 1237 (m),  1162 (m), 1054 (s), 1023 (s), 956 (s), 897 (m),  795 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  5.05 (1H, s, HR), 4.97 (1H, s, HR’),  4.10-4.03 (4H, m, 
HB), 3.67 (3H, s, HI), 2.50-2.39 (3H, m), 2.32-2.24 (1H, m), 2.18-1.99 (6H, m), 1.92-1.87 
(2H, m), 1.68-1.46 (3H, m), 1.29 (6H, t, J = 7.0 Hz, HA), 0.78 (3H, HO), ppm.  
13C NMR (100 MHz; CDCl3): 219.5 (Q, CM), 173.8 (Q, CH), 144.9 (d, J = 1.4 Hz, Q, 
CQ), 112.9 (CH2, CR), 61.6 (d, J = 6.5 Hz, CH2, CB), 61.5 (d, J = 6.5 Hz, CH2, CB’), 51.6 
(CH3, CI), 48.9 (d, J = 1.7 Hz, CH, CJ), 48.6 (Q, CN), 42.9 (CH2, CP), 40.7 (d, J = 8.7 Hz, 
CH, CD), 40.6 (CH, CE), 35.9 (CH2, CK/L), 29.2 (CH2, CF/G), 24.9 (d, J = 142.3 Hz, CH2, 
CC), 24.6 (CH2, CF/G), 22.6 (CH2, CK/L), 16.4 (d, J = 6.1 Hz, 2 x CH3, CA), 14.1 (CH3, CO) 
ppm.  
31P NMR (121 MHz; CDCl3):  31.64 ppm. 
ES
+MS m/z (%): 823 ((2M+Na)
+, 33), 423 ((M+Na)
+, 75), 401 ((M+H)
+, 70). 
HRES
+MS For C20H34O6P (M+H)
+: calcd 401.2093, found 401.2100. 
 
Data for (4.42) 
Mw = 426.527 (C23H39O5P). 
Rf = 0.41 (Hexane/Acetone 60:40). 
IR (film): 2965 (m), 2905 (w), 1737 (s), 1703 (m), 1239 (m), 1052 (s), 1024 (s), 956 (s), 
730 (m) cm
-1. 
1H NMR (400 MHz; CDCl3): 5.04 (1H, s, HS), 4.95 (1H, s, HS’), 4.09-3.99 (4H, m, HB), 
2.68-2.58  (1H,  m,  HG),  2.50-2.34  (3H,  m,  HM+HQ+HG’),  2.26-2.01  (5H,  m, 
HC+HC’+HM’+HD+HQ’), 1.96 (1H, m), 1.89-1.70 (2H, m), 1.69-1.53 (2H, m, contains HK), 
1.52-1.41 (1H, m, HE), 1.27 (3H, t, J = 7.1 Hz, HA), 1.26 (3H, t, J = 7.1 Hz, HA’), 1.13 
(9H, s, HJ), 0.76 (3H, s, HP) ppm. 
13C NMR (100 MHz; CDCl3): 219.9 (Q, CN), 215.8 (Q, CH), 145.3 (Q, CR), 112.9 (CH2, 
CS), 61.8 (d, J = 6.5 Hz, CH2, CB’), 61.8 (d, J = 6.4 Hz, CH2, CB), 49.1 (Q, CO), 48.8 (CH, 
CK), 44.5 (Q, CI), 43.2 (CH2, CQ), 41.1 (d, J = 4.2 Hz, CH, CE), 40.9 (d, J = 13.8 Hz, CH, 
CD), 36.1 (CH2, CM), 31.2 (CH2, CG), 26.6 (3 x CH3, CJ), 24.9 (d, J = 142.0 Hz, CH2, CC), 
23.9 (CH2, CF/L), 22.9 (CH2, CF/L), 16.6 (d, J = 6.0 Hz, 2 x CH2, CA), 14.3 (CH3, CP) ppm. 196 
 
31P NMR (121 MHz; CDCl3):  32.05 ppm. 
ES
+MS m/z (%): 875 ((2M+Na)
+, 32), 427 ((M+H)
+, 100). 
HRES
+MS For C23H39O5PNa (M+Na)
+: calcd 449.2427, found 449.2418. 
 
The -keto phosphonate (4.40) 
 
 
The silyl enol (4.35) (119 mg, 0.25 mmol, 1.0 equiv) was dissolved in THF (5 mL) and 
treated with TBAF (1 M in THF, 0.50 mL, 0.50 mmol, 2.0 equiv) and the mixture was 
stirred  for  1  h  at  room  temperature.  Water  was  added  (5  mL)  and  the  reaction  was 
extracted with DCM (3 x 10 mL), dried over MgSO4, filtered and concentrated in vacuo. 
The crude product was purified by column chromatography (Hexane/Acetone 60:40). This 
yielded (4.40) as a colourless oil (57 mg, 62%) and (4.40) as a colourless oil (30 mg, 
33%). 
 
Data for (4.40) 
Mw = 368.404 (C19H29O5P). 
Rf = 0.56 (Hexane/Acetone 60:40). 
IR (film): 2970 (w), 2936 (w), 1733 (s), 1706 (s), 1644 (w), 1445 (w), 1391 (w), 1242 
(m), 1049 (s), 1019 (s), 955 (s) cm
-1. 
1H NMR (400 MHz; CDCl3):  5.11 (1H, t, J = 2.2 Hz, HQ), 5.02 (1H, t, J = 2.2 Hz, HQ’), 
4.24-4.02 (4H, m, HB), 3.58 (1H, ddd, J = 19.9, 4.1, 2.0 Hz, HC), 2.88 (1H, dt, J = 14.0, 
6.9 Hz, HG), 2.73 (1H, dq, J = 11.2, 3.6 Hz, HE), 2.56-2.47 (3H, m, HG’+HO+HK), 2.33-
2.02 (5H, m, HO’+HK’+HD+HF+HJ), 1.69 (1H, tt, J = 12.4, 9.1 Hz, HJ’), 1.41 (1H, m, HI), 
1.33 (3H, t, J = 7.0 Hz, HA), 1.32 (3H, t, J = 7.0 Hz, HA’), 1.31 (1H, m, HF’) 0.99 (3H, s, 
HN) ppm.  
13C NMR (100 MHz; CDCl3): 219.9 (Q, CL), 204.8 (Q, CH), 143.2 (d, J = 2.3 Hz, Q, 
CP), 112.8 (CH2, CQ), 62.8 (d, J = 7.1 Hz, CH2, CB), 62.2 (d, J = 7.3 Hz, CH2, CB’), 54.1 
(d, J = 127.1 Hz, CH, CC), 50.5 (CH, CI), 49.9 (d, J = 4.7 Hz, CH, CD), 48.3 (Q, CM), 42.3 197 
 
(CH2, CO), 40.0 (CH2, CG), 36.0 (CH2, CK), 35.3 (CH, CE), 30.8 (CH2, CF), 22.0 (CH2, CJ), 
16.2 (d, J = 6.6 Hz, CH3, CA), 16.2 (d, J = 7.4 Hz, CH3, CA), 14.5 (CH3, CN) ppm.
31P NMR (121 MHz; CDCl3):  22.66 ppm. 
ES
+MS m/z (%): 759 ((2M+Na)
+, 100), 391 ((M+Na)
+, 17), 369 ((M+H)
+, 14). 
HRES
+MS For C19H30O5P (M+H)
+: calcd 369.1825, found 369.1828. 
 
The -keto phosphonate (4.43) and the -keto phosphonate (4.43) 
 
 
The silyl enol (4.2) (123 mg, 0.25 mmol, 1.0 equiv) was dissolved in THF (5 mL) and 
treated with TBAF (1 M in THF, 0.50 mL, 0.50 mmol, 2.0 equiv) and the mixture was 
stirred  for  1  h  at  room  temperature.  Water  was  added  (5  mL)  and  the  reaction  was 
extracted with DCM (3 x 10 mL), dried over MgSO4, filtered and concentrated in vacuo. 
The crude product was purified by column chromatography (Hexane/Acetone 60:40). This 
yielded (4.43) as a colourless oil (58 mg, 66%) and (4.43) as a colourless oil (25 mg, 
30%) which was recrystallized in (DCM/Hexane 1:3) to afford fine colourless needles. 
Data for (4.43) 
Mw = 382.431 (C20H31O5P). 
Rf = 0.46 (Hexane/Acetone 60:40). 
IR (neat): 2970 (w), 2936 (w), 1733 (s), 1706 (s), 1644 (w), 1445 (w), 1391 (w), 1242 
(m), 1049 (s), 1019 (s), 955 (s) cm
-1. 
1H NMR (400 MHz; CDCl3):  4.99 (1H, s, HR), 4.87 (1H, s, HR’), 4.15-4.02 (4H, m, HB), 
3.39 (1H, ddd, J = 26.2, 8.5, 1.8 Hz, HC), 2.87 (1H, ddd, J = 17.3, 9.8, 2.8 Hz, HG), 2.70 
(1H, d, J = 13.5 Hz, HP), 2.76-2.60 (1H, m, HD), 2.49-2.31 (2H, m), 2.14 (1H, ddd, J = 
10.1, 8.7, 5.6 Hz), 1.98 (2H, ddd, J = 9.5, 6.4, 3.5 Hz), 1.92 (1H, d, J = 13.9 Hz, HP’), 
1.87-1.73 (1H, m), 1.73-1.57 (2H, m), 1.28 (6H, dd, J = 14.8, 7.2 Hz, HA), 1.48-1.21 (3H, 
m, HE + HN), 0.73 (3H, t, J = 7.4 Hz, HO) ppm. 
13C NMR (100 MHz; CDCl3):  217.6 (Q, CL), 206.6 (d, J = 5.2 Hz, Q,  CH), 143.5 (d, J = 
1.4 Hz, Q,  CQ), 111.0 (CH2, CR), 62.9 (d, J = 7.0 Hz, CH2, CB), 62.8 (d, J = 6.9 Hz, CH2, 
CB), 52.0 (Q, CM), 51.3 (CH, CI), 51.4 (d, J = 124.0 Hz, CH, CC), 46.2 (d, J = 3.9 Hz, CH, 198 
 
CD), 38.8 (CH2, CP), 38.6 (d, J = 9.4 Hz, CH, CE), 37.4 (CH2, CG), 35.8 (CH2, CK), 25.4 
(CH2, CF), 20.9 (CH2, CJ), 18.3 (CH2, CN), 16.3 (d, J = 6.0 Hz, CH3, CA), 16.2 (d, J = 6.2 
Hz, CH3, CA’), 6.9 (CH3, CO) ppm. 
31P NMR (121 MHz; CDCl3):  22.67 ppm. 
ES
+MS m/z (%): 787 ((2M+Na)
+, 40), 405 ((M+Na)
+, 100), 383 ((M+H)
+, 13). 
HRES
+MS For C20H31O5PNa (M+Na)
+: calcd 405.1801, found 405.1808. 
 
Data for (4.43) 
Mw = 382.431 (C20H31O5P). 
Rf = 0.58 (Hexane/Acetone 60:40). 
IR (neat): 2964 (w), 2937 (w), 1732 (s), 1716 (s), 1644 (w), 1444 (w), 1391 (w), 1244 
(m), 1044 (s), 1019 (s), 952 (s) cm
-1. 
1H NMR (400 MHz; CDCl3):  5.08 (1H, s, HR), 5.00 (1H, s, HR’), 4.20-4.00 (4H, m, HB), 
3.56 (1H, ddd, J = 19.9, 3.9, 1.9 Hz, HC), 2.87 (1H, dt, J = 14.1, 7.0 Hz), 2.78 (1H, dd, J = 
11.2, 3.4 Hz), 2.72 (1H, d, J = 14.3 Hz, HP), 2.51 (1H, m), 2.47 (1H, dd, J = 19.2, 9.1 Hz), 
2.33-2.08 (3H, m), 2.07-1.96 (1H, m), 1.87 (1H, d, J = 14.2 Hz, HP’), 1.83-1.70 (2H, m), 
1.50-1.42 (1H, m), 1.31 (3H, t, J = 7.1 Hz, HA), 1.31 (3H, t, J = 7.1 Hz, HA’), 1.40-1.24 
(2H, m), 0.78 (3H, t, J = 7.4 Hz, HO) ppm. 
13C NMR (100 MHz; CDCl3):  218.4 (Q, CL), 204.9 (Q, CH), 143.0 (d, J = 2.2 Hz, Q,  
CQ), 112.4 (CH2, CR), 62.8 (d, J = 7.0 Hz, CH2, CB), 62.2 (d, J = 7.1 Hz, CH2, CB), 54.1 
(d, J = 127.0 Hz, CH, CC), 51.5 (Q, CM), 51.3 (CH, CI), 49.8 (d, J = 4.8 Hz, CH, CE), 40.0 
(CH2, CP), 38.6 (CH2, CG), 35.9 (CH2, CK), 35.1 (d, J = 1.3 Hz, CH, CD), 31.0 (CH2, CF), 
21.3 (CH2, CJ), 18.5 (CH2, CN), 16.2 (d, J = 5.8 Hz, CH3, CA), 16.2 (d, J = 5.8 Hz, CH3, 
CA’), 7.0 (CH3, CO) ppm. 
31P NMR (121 MHz; CDCl3):  22.68 ppm. 
ES
+MS: m/z (%): 787 ((2M+Na)
+, 24), 405 ((M+Na)
+, 81), 383 ((M+H)
+, 100). 
HRMS: not necessary, X-ray obtained instead.  
X-ray: X-ray data available in Appendix II. 
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The C-ring cyclised ester (4.44) 
 
 
The ester (4.39) (90 mg, 0.17 mmol, 1.0 equiv) was dissolved in THF (5 mL) and treated 
with TBAF (1 M in THF, 0.34 mL, 0.34 mmol, 2.0 equiv) and the mixture was stirred for 
30 min at room temperature. H2O was added (5 mL) and the reaction was extracted with 
DCM (3  x 10 mL), dried over  MgSO4, filtered and concentrated in  vacuo. The crude 
product was purified by column chromatography (Hexane/Acetone 60:40). This yielded 
(4.44) as a colourless oil (65 mg, 94%). 
 
Mw = 414.473 (C21H35O6P). 
Rf = 0.39 (Hexane/Acetone 60:40). 
IR (film): 2971 (w), 2955 (w), 2905 (w), 1731 (s), 1641 (w), 1438 (m), 1390 (w), 1233 
(m), 1172 (m), 1050 (s), 1023 (s), 958 (s), 891 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  5.03 (1H, s, HS), 4.97 (1H, s, HS’), 4.17-3.95 (4H, m, HB), 
3.66 (3H, s, HI), 2.63 (1H, d, J = 13.5 Hz, HQ), 2.48-2.37 (2H, m), 2.26 (1H, td, J = 9.8, 
8.0 Hz), 2.21-2.03 (4H, m), 2.00-1.92 (1H, m), 1.86 (1H, d, J = 13.6 Hz, HQ’), 1.87 (2H, 
m), 1.76-1.52 (3H, m), 1.46-1.34 (1H, m, HO), 1.28 (6H, t, J = 7.1 Hz, HA), 1.27-1.17 (1H, 
m, HO’), 0.72 (3H, t, J = 7.4 Hz, HP) ppm. 
13C NMR (100 MHz; CDCl3):  218.1 (Q, CM), 173.8 (Q, CH), 144.9 (Q, CR), 112.5 (CH2, 
CS), 61.6 (d, J = 2.7 Hz, CH2, CB), 61.5 (d, J = 2.6 Hz, CH2, CB’), 51.7 (Q, CN), 51.6 (CH3, 
CI), 49.6 (CH, CJ), 40.4 (CH, CE), 40.4 (d, J = 17.6 Hz, CH, CD), 38.8 (CH2, CQ), 35.8 
(CH2, CL), 29.1 (CH2, CG), 24.7 (CH2, CF), 25.0 (d, J = 142.2 Hz, CH2, CC), 21.9 (CH2, 
CK), 18.1 (CH2, CO), 16.3 (d, J = 6.2 Hz, 2 x CH3, CA), 6.8 (CH3, CP) ppm. 
31P NMR (121 MHz; CDCl3):  31.69 ppm. 
ES
+MS m/z (%): 852 ((2M+Na)
+, 7), 437 ((M+Na)
+, 100), 415 ((M+H)
+, 8). 
HRES
+MS For C21H35O6PNa (M+Na)
+: calcd 437.2063, found 437.2063.  
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The C-ring cyclised carboxylic acid (4.45) 
 
 
To a solution of the ester (4.44) (60 mg, 0.14 mmol, 1.0 equiv) in MeOH (5 mL) was 
added NaOH 4 M (3 mL). The mixture was stirred at room temperature for 90 min until 
completion. The pH was adjusted (pH 6) before extraction of the crude mixture with DCM 
(3  x  15  mL).  The  combined  organic  phases  were  dried  over  MgSO4,  filtered  and 
evaporated  in  vacuo.  The  crude  product  was  purified  by  column  chromatography 
(DCM/MeOH 95:5) to afford (4.45) (55 mg, 99 %) as a colourless oil. Recrystallization in 
(DCM/Hexane) afforded (4.45) as fine white crystals (m.p. = 108-112 °C). 
 
Mw = 400.446 (C20H33O6P). 
Rf = 0.38 (DCM/MeOH 95:5). 
IR (film): 3446 (br w), 2978 (w), 2936 (w), 2907 (w), 1736 (s), 1642 (w), 1453 (w), 1391 
(w), 1237 (m),  1162 (m), 1054 (s), 1023 (s), 956 (s), 897 (m),  795 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  6.40 (1H, br hump, OH), 5.00 (1H, s, HR), 4.98 (s, 1H, 
HR’), 4.15-4.03 (4H, m, HB), 2.66 (1H, d, J = 13.5 Hz, HP), 2.53-2.38 (2H, m), 2.32-1.83 
(9H, m), 1.73-1.57 (3H, m), 1.41-1.22 (2H, m, HN), 1.31 (3H, t, J = 7.1 Hz, HA), 1.29 (3H, 
t, J = 7.1 Hz, HA’), 0.74 (3H, t, J = 7.4 Hz, HO) ppm.  
13C NMR (100 MHz; CDCl3): 218.2 (Q, CL), 176.2 (Q, CH), 145.0 (d, J = 2.9 Hz, Q, 
CQ), 112.2 (CH2, CR), 62.2 (d, J = 6.9 Hz, CH2, CB), 62.1 (d, J = 6.9 Hz, CH2, CB’), 51.6 
(Q, CM), 49.1 (d, J = 1.2 Hz, CH, CI), 40.8 (d, J = 12.1 Hz, CH, CD), 39.5 (d, J = 4.4 Hz, 
CH, CE), 38.8 (CH2, CP), 35.8 (CH2), 29.2 (CH2), 25.0 (d, J = 142.4 Hz, CC), 24.6 (CH2), 
21.7 (CH2), 18.1 (CH2, CN), 16.3 (d, J = 6.1 Hz, 2 x CH3, CA), 6.8 (CH3, CO) ppm.  
31P NMR (121 MHz; CDCl3):  32.38 ppm. 
ES
+MS m/z (%): 824 ((2M+Na)
+, 36), 423 ((M+Na)
+, 70), 401 ((M+H)
+, 100). 
HRES
+MS For C20H33O6P (M+H)
+: calcd 401.2088, found 401.2088. 
X-ray: X-ray data available in Appendix II.  
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The C-ring cyclised ketone (4.46) 
 
 
The ketone (4.37) (0.150 g, 0.27 mmol, 1.0 equiv) was dissolved in THF (5 mL) and 
treated with TBAF (1 M in THF, 0.54 mL, 0.54 mmol, 2.0 equiv) and the mixture was 
stirred for 30 min at room temperature. Water was added (5 mL) and the reaction was 
extracted with DCM (3 x 10 mL), dried over MgSO4, filtered and concentrated in vacuo. 
The crude product was purified by column chromatography (Hexane/Acetone 70:30). This 
yielded (4.46) as a colourless oil (0.107 g, 94%). 
 
Mw = 440.269 (C24H41O5P). 
Rf = 0.35 (Hexane/Acetone 70:30). 
IR (film): 2968 (w), 2906 (w), 1734 (s), 1702 (s), 1461 (w), 1233 (m), 1051 (s), 1024 (s), 
957 (s) cm
-1. 
1H NMR (400 MHz; CDCl3): 5.04 (1H, s, HT), 4.97 (1H, s, HT’), 4.11-3.96 (4H, m, HB), 
2.68-2.56  (2H,  m,  HG+HR),  2.48-2.36  (2H,  m,  HG’+HM),  2.27-2.03  (4H,  m, 
HD+HM’+HC+HC’), 2.00-1.51 (7H, m, HK+HE+HF+HF’+HL+HL’+HR’), 1.41 (1H, m, HP), 
1.28 (3H, t, J = 7.0 Hz, HA), 1.28 (3H, t, J = 7.1 Hz, HA’), 1.22 (1H, m, HP’), 1.14 (9H, s, 
HJ), 0.72 (3H, t, J = 7.4 Hz, HQ) ppm.  
13C NMR (100 MHz; CDCl3): 218.2 (Q, CN), 215.5 (Q, CH), 145.0 (Q, CS), 112.3 (CH2, 
CT), 61.5 (d, J = 6.5 Hz, CH2, CB), 61.5 (d, J = 6.5 Hz, CH2, CB’), 51.8 (Q, CO), 49.7 (CH, 
CK), 44.3 (Q, CI), 40.6 (d, J = 4.3 Hz, CH, CE), 40.4 (d, J = 13.7 Hz, CH, CD), 38.9 (CH2, 
CR), 35.8 (CH2, CM), 30.9 (CH2, CG), 26.3 (3 x CH3, CJ), 24.7 (d, J = 141.9 Hz, CH2, CC), 
23.8 (CH2, CF), 22.0 (CH2, CL), 18.1 (CH2, CP), 16.4 (d, J = 6.1 Hz, 2 x CH2, CA), 6.9 
(CH3, CQ) ppm. 
31P NMR (121 MHz; CDCl3):  32.14 ppm. 
ES
+MS m/z (%): 464/463 (1:3, (M+Na)
+, 100), 442/441 (1:3, (M+H)
+, 12). 
HRES
+MS For C24H41O5PNa (M+Na)
+: calcd 463.2584, found 463.2587. 
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The Weinreb amide (4.50) and the urea (4.52) 
 
 
To  a  DCM  (7  mL)  solution  of  acid  (4.29)  (246  mg,  0.53  mmol,  1.0  equiv)  were 
successively added at room temperature N,O-dimethylhydroxylamine hydrochloride (52 
mg, 0.53 mmol, 1.0 equiv), Et3N (0.074 mL, 0.53 mmol, 1.0 equiv) and finally DCC (110 
mg, 0.53 mmol, 1.0 equiv). After an overnight stirring at room temperature under N2, 0.5 
equiv of all the reagents were added in the same order and stirring continued for 4 h. Et2O 
(10 mL) was added and the precipitated solid filtered and rinsed with Et2O. The combined 
etherate  phases  were  concentrated  and  the  resulting  crude  purified  by  column 
chromatography (Hexane/Acetone 60:40) to afford Weinreb amide (4.50) (150 mg, 56%) 
as a colourless oil, and urea (4.52) (75 mg, 21%) as a white solid. 
 
 
Data for (4.50) 
Mw = 508.383 (C21H35BrNO6P). 
Rf = 0.42 (Hexane/Acetone 60:40). 
IR (neat): 2972 (w), 2937 (w), 1737 (s), 1656 (s), 1388 (w), 1240 (s), 1020 (s) cm
-1. 
1H NMR (400 MHz; CDCl3):  6.60 (1H, ddd, J = 21.7, 17.2, 9.7 Hz, HD), 5.97 (1H, s, 
HS), 5.68 (1H, dd, J = 20.9, 17.2 Hz, HC), 5.54 (1H, s, HS’), 4.18-3.97 (4H, m, HB), 3.64 
(3H, s, HJ), 3.15 (3H, s, HI), 3.05 (1H, d, J = 14.9 Hz, HQ), 2.49 (1H, d, J = 14.9 Hz, HQ’), 
2.44-2.23 (7H, m, contains HE+HK+HM), 2.13 (1H, m), 1.64-1.40 (2H, m), 1.32 (3H, t, J = 
7.0 Hz, HA), 1.31 (3H, t, J = 7.0 Hz, HA’), 0.86 (3H, s, HP) ppm. 
13C NMR (100 MHz; CDCl3):  221.4 (Q, CN), 173.6 (Q, CH), 155.0 (d, J = 3.8 Hz, CH, 
CD), 129.9 (Q, CR), 122.4 (CH2, CS), 119.3 (d, J = 187.1 Hz, CH, CC), 61.7 (d, J = 5.8 Hz, 
CH2, CB), 61.6 (d, J = 5.7 Hz, CH2, CB’), 61.2 (CH3, CJ), 51.7 (Q, CO), 47.0 (CH2, CQ), 
46.8 (d, J = 20.9 Hz, CH, CE), 43.8 (CH, CK), 36.9 (CH2, CM), 32.2 (CH3, CI), 28.6 (CH2), 
26.1 (CH2), 23.8 (CH2), 18.7 (CH3, CP), 16.4 (d, J = 5.8 Hz, CH3, CA), 16.4 (d, J = 6.0 Hz, 
CH3, CA’) ppm. 203 
 
31P NMR (121 MHz; CDCl3):  17.73 ppm. 
ES
+MS m/z (%): 510/508 (1:1, (M+H)
+, 100). 
HRES
+MS For C21H35
79BrNO6PNa (M+Na)
+: calcd 530.1278, found 530.1275. 
 
Data for (4.52) 
Mw = 671.643 (C32H52BrN2O6P). 
Rf = 0.66 (Hexane/Acetone 60:40). 
IR (film): 3249 (br w), 2933 (m), 2855 (w), 1742 (m), 1687 (s), 1651 (s), 1537 (m), 1226 
(s), 1022 (s), 969 (s) cm
-1 
1H NMR (400 MHz; CDCl3):  7.34 (1H, br s, NH), 6.50 (1H, ddd, J = 21.3, 17.1, 9.9 Hz, 
HD), 5.84 (1H, s, HN), 5.62 (1H, dd, J = 21.8, 17.1 Hz, HC), 5.53 (1H, s, HN’), 4.18-4.03 
(4H, m, HB), 4.02-3.90 (1H, m, HH), 3.73-3.54 (1H, m, HG), 3.06 (1H, d, J = 14.9 Hz, HL), 
2.46-2.24 (7H, m, contains HL’), 2.08 (1H, m), 2.02-1.44 (14H, m), 1.39-1.07 (15H, m), 
0.85 (3H, s, HK) ppm. 
13C NMR (100 MHz; CDCl3):  221.3 (Q, CI), 171.0 (Q, CE), 153.8 (d, J = 18.6 Hz, CH, 
CD), 153.7 (Q, CF), 130.0 (Q, CM), 122.0 (CH2, CN), 118.9 (d, J = 188.1 Hz, CH, CC), 62.0 
(d, J = 6.1 Hz, CH2, CB), 61.9 (d, J = 6.1 Hz, CH2, CB’), 54.8 (CH, CH), 52.3 (Q, CJ) 50.1 
(CH, CG), 47.0 (CH2, CL), 47.0 (d, J = 20.9 Hz, CH, CO), 44.1 (CH), 37.4 (CH2), 33.03 
(CH2), 33.00 (CH2), 32.0 (CH2), 31.6 (CH2), 31.2 (CH2), 26.6 (CH2), 26.5 (CH2), 26.4 
(CH2), 25.9 (CH2), 25.8 (CH2), 25.4 (CH2), 25.3 (CH2), 24.3 (CH2), 19.3 (CH3, CK), 16.91 
(d, J = 6.1 Hz, CH3, CA), 16.90 (d, J = 6.1 Hz, CH3, CA’) ppm. 
31P NMR (121 MHz; CDCl3):  17.43 ppm. 
ES
-MS m/z (%): 671/669 (1:1, (M-H)
+, 62). 
HRES
+MS For C32H52
79BrN2O6PNa (M+Na)
+: calcd 693.2639, found 693.2632. 
 
The Weinreb amide (4.51) 
 
 204 
 
To  a  DCM  (10  mL)  solution  of  acid  (4.30)  (540  mg,  1.17  mmol,  1.0  equiv)  were 
successively added at room temperature N,O-dimethylhydroxylamine hydrochloride (227 
mg, 2.34 mmol, 2.0 equiv), Et3N (0.326 mL, 2.34 mmol, 2.0 equiv) and finally DIC (0.362 
mL, 2.34 mmol, 2.0 equiv). After an overnight stirring at room temperature (16 h) under 
N2, Et2O (20 mL) was added and the precipitated solid filtered and rinsed with Et2O. The 
combined etherate phases were concentrated and the resulting crude purified by column 
chromatography (Hexane/Acetone 60:40) to afford Weinreb amide (4.51) (525 mg, 86%) 
as a light yellow oil. 
 
Mw = 522.410 (C22H37BrNO6P). 
Rf = 0.22 (Hexane/Acetone 70:30). 
IR (neat): 2974 (w), 2939 (w), 1735 (s), 1658 (s), 1390 (w), 1238 (s), 1020 (s) cm
-1. 
1H NMR (400 MHz; CDCl3):  6.60 (1H, ddd, J = 21.8, 17.2, 9.9 Hz, HD), 5.98 (1H, s, 
HS), 5.69 (1H, dd, J = 20.9, 17.2 Hz, HC), 5.54 (1H, s, HS’), 4.12-3.99 (4H, m, HB), 3.64 
(3H, s, HJ), 3.15 (3H, s, HI), 3.13 (1H, d, J = 15.4 Hz, HQ), 2.50-2.23 (7H, m), 2.37 (1H, d, 
J = 14.9 Hz, HQ’), 2.15 (1H, m), 1.62 (1H, m), 1.46 (1H, m), 1.44 (2H, q, J = 7.4 Hz, HP), 
1.32 (3H, t, J = 7.0 Hz, HA), 1.30 (3H, t, J = 7.0 Hz, HA’), 0.78 (3H, t, J = 7.5 Hz, HT) 
ppm. 
13C NMR (100 MHz; CDCl3):  220.2 (Q, CN), 173.7 (Q, CH) 155.4 (d, J = 3.9 Hz, CH, 
CD), 130.5 (Q, CR), 122.5 (CH2, CS), 119.3 (d, J = 187.1 Hz, CH, CC), 61.7 (d, J = 5.7 Hz, 
CH2, CB), 61.6 (d, J = 5.8 Hz, CH2, CB’), 61.2 (CH3, CJ), 54.1 (Q, CO ), 46.3 (d, J = 20.8 
Hz, CH, CE), 45.3 (CH2, CQ), 44.3 (CH, CK), 37.0 (CH2, CM), 30.7 (CH3, CI) 28.7 (CH2), 
26.3 (CH2), 25.4 (CH2, CP), 24.0 (CH2), 16.4 (d, J = 5.9 Hz, CH3, CA), 16.4 (d, J = 6.1 Hz, 
CH3, CA’), 8.3 (CH3, CT) ppm. 
31P NMR (121 MHz; CDCl3):  17.82 ppm. 
ES
+MS: m/z (%): 546/544 (1:1, (M+Na)
+, 100), 524/522 (1:1, (M+H)
+, 63). 
HRES
+MS For C22H37
79BrNO6PNa (M+Na)
+: calcd 544.1434, found 544.1434. 
 
The Weinreb amide (4.48) 
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To a stirred solution of Me(OMe)NH2Cl (192 mg, 1.97 mmol, 6.0 equiv) in THF (3 mL) 
was added n-BuLi (2.5 M hexane solution) (1.18 mL, 2.96 mmol, 9.0 equiv) at -78 °C 
under N2, and the resulting solution was allowed to warm to room temperature and stirred 
for further 15 min at the same temperature. The solution was cooled to -78 °C again, and a 
solution of methyl ester (4.1) (199 mg, 0.33 mmol, 1.0 equiv) in THF (3 mL) was added to 
the  solution,  and  the  resulting  solution  was  stirred  for  further  45  min  at  the  same 
temperature. The solution was treated with saturated aqueous ammonium chloride solution 
and extracted with Et2O. The extract was washed with brine,  dried over  Na2SO4,  and 
concentrated to leave a residue, which was subjected to column chromatography using 
pre-neutralized silica gel (Hexane/Acetone 70:30) to afford (4.48) (189 mg, 95%) as a 
colourless oil. 
 
Mw = 636.670 (C28H51BrNO6PSi). 
Rf = 0.34 (Hexane/Acetone 70:30). 
IR (neat): 2930 (w), 2856 (w), 1650 (m), 1231 (s), 1024 (s), 961 (s), 839 (s) cm
-1. 
1H NMR (400 MHz; CDCl3):  6.64 (1H, ddd, J = 21.8, 17.2, 9.4 Hz, HD), 5.80 (1H, s, 
HS), 5.67 (1H, dd, J = 21.5, 17.2 Hz, HC), 5.55 (1H, s, HS’), 4.54 (1H, s, HM), 4.18-3.93 
(4H, m, HB), 3.62 (3H, s, HJ), 3.12 (3H, s, HI), 2.81 (1H, d, J = 15.2 Hz, HQ), 2.44-2.23 
(5H, m), 2.20 (1H, d, J = 15.2 Hz, HQ’), 2.03-1.90 (2H, m), 1.54-1.35 (2H, m, HP + 1H), 
1.30 (3H, t, J = 7.1 Hz, HA), 1.29 (3H, t, J = 7.0 Hz, HA’), 1.25-1.13 (1H, m, HP’), 0.89 
(9H, s, HW), 0.81 (3H, t, J = 7.4 Hz, HT), 0.16 (3H, s, HU), 0.15 (3H, s, HU’) ppm. 
13C NMR (100 MHz; CDCl3):  157.3 (d, J = 3.4 Hz, CH, CD), 155.2 (Q, CN), 131.1 (Q, 
CR), 120.9 (CH2, CS), 118.7 (d, J = 186.8 Hz, CH, CC), 98.6 (CH, CM), 61.7 (d, J = 5.5 Hz, 
CH2, CB), 61.5 (d, J = 5.7 Hz, CH2, CB’), 61.3 (CH3, CJ), 53.1 (Q, CO), 46.3 (d, J = 20.9 
Hz, CH, CE), 45.7 (CH2, CQ), 43.3 (CH, CK), 30.6 (CH3, CI), 32.5 (CH2), 29.0 (CH2), 28.1 
(CH2), 26.8 (d, J = 1.4 Hz, CH2, CF), 25.7 (3 x CH3, CW), 18.0 (Q, CV), 16.5 (d, J = 6.1 
Hz, CH3, CA), 16.4 (d, J = 6.1 Hz, CH3, CA’), 9.5 (CH3, CT), -4.9 (CH3, CU), -5.2 (CH3, 
CU’) ppm. (CH not observed). 
31P NMR (121 MHz; CDCl3):  18.15 ppm. 
ES
+MS m/z (%): 660/658 (1:1, (M+Na)
+, 100), 638/636 (1:1, (M+H)
+, 65). 
HRES
+MS For C28H51
79BrNO6PSiNa (M+Na)
+: calcd 658.2299, found 658.2292.  
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The B-ring cyclised phosphonate (4.56) 
 
 
To a cooled (-78 °C) solution of Weinreb amide (4.51) (0.115 g, 0.22 mmol, 1.0 equiv) in 
THF (10 mL) was slowly added LDA (2 M in THF, 0.275 mL, 0.55 mmol, 2.5 equiv). The 
reaction mixture was stirred at -78 °C for 2 h, then TBDMSOTf (0.126 mL, 0.55 mmol, 
2.5 equiv) was added and stirring continued for 15 min at -78°C. The mixture was warmed 
to room temperature and then sat.aq. NaHCO3 (5 mL) was added followed by DCM (10 
mL). The phases were separated and the aqueous phase was extracted with DCM (5 x 10 
mL). The combined organic phases were dried over Na2SO4, filtered and concentrated in 
vacuo.  The  crude  product  was  purified  by  column  chromatography  (Hexane/Acetone 
70:30) whereby the silica was pre-neutralized by making the slurry in the said solvent 
system, containing ~1% of Et3N. This yielded (4.56) as a colourless oil (0.104 g, 74%), as 
an inseparable mixture of diastereoisomers in approximately a 4:1 ratio. 
 
Mw = 636.671 (C28H51BrNO6PSi). 
Rf = 0.55 (Hexane/Acetone 70:30). 
IR (neat): 2930 (w), 2854 (w), 1736 (m), 1245 (s), 1096 (s), 1024 (s), 834 (s) cm
-1. 
1H NMR (400 MHz; CDCl3): Major diastereoisomer  6.99 (1H, dd, J = 22.2, 2.5 Hz, 
HD), 5.97 (1H, s, HW), 5.50 (1H, s, HW’), 4.20-3.95 (4H, m, HB), 3.50 (3H, s, HI), 3.29 
(1H, d, J = 15.0 Hz, HU), 2.72-2.52 (5H, m, HE+HJ+HU’), 2.50-2.28 (4H, m), 2.25-1.99 
(2H, m), 1.60-1.42 (5H, m), 1.31 (6H, dt, J = 7.1, 4.0 Hz, HA), 0.94 (9H, s, HM), 0.86 (3H, 
t,  J =  7.5  Hz,  HT),  0.17  (3H,  s,  HK), 0.14  (3H,  s,  HK’)  ppm;  Minor diastereoisomer 
observed  6.92-6.82 (1H, m, HD), 5.45 (1H, s, HW’), 3.25 (1H, d, J = 17.2 Hz, HU), 0.17 
(3H, s, HK), 0.11 (3H, s, HK’) ppm. 
13C NMR (100 MHz; CDCl3): Major Diastereoisomer  220.3 (Q, CQ), 150.6 (d, J = 7.1 
Hz, CH, CD), 135.5 (d, J = 184.5 Hz, Q, CC), 130.2 (Q, CV), 122.1 (CH2, CW), 91.6 (d, J = 
4.9 Hz, Q, CH), 61.5 (d, J = 6.7 Hz, CH2, CB), 61.3 (d, J = 5.6 Hz, CH2, CB’), 59.0 (CH3, 
CI), 54.1 (Q, CR), 46.4 (CH2, CU), 45.3 (CH, CN), 37.4 (CH3, CJ), 37.4 (CH2, CP), 35.3 (d, 207 
 
J = 15.4 Hz, CH, CE), 31.9 (d, J = 3.9 Hz, CH2, CG), 26.2 (3 x CH3, CM), 25.9 (CH2), 24.1 
(CH2), 23.5 (CH2), 18.9 (Q, CL), 16.4 (d, J = 6.3 Hz, CH3, CA), 16.3 (d, J = 7.3 Hz, CH3, 
CA’), 8.5 (CH3, CT), -1.8 (CH3, CK), -1.9 (CH3, CK’) ppm. 
31P  NMR  (121  MHz;  CDCl3):  Major  diastereoisomer    18.33  ppm,  Minor 
diastereoisomer  19.48 ppm.  
ES
+MS m/z (%): 659/657 (1:1, (M+Na)
+, 100). 
HRES
+MS For C28H51
79BrNO6PSiNa (M+Na)
+: calcd 658.2299, found 658.2305. 
 
The B-ring cyclised -keto phosphonate (4.57) 
 
 
To a cooled (-78 °C) solution of Weinreb amide (4.51) (0.054 g, 0.10 mmol, 1.0 equiv) in 
THF (2 mL) was slowly added LDA (2 M in THF, 0.129 mL, 0.26 mmol, 2.5 equiv). The 
reaction mixture was stirred at -78 °C for 15 min, then warmed to room temperature and 
stirring continued for 30 min. and TBDMSOTf (0.059 mL, 0.26 mmol, 2.5 equiv) was 
added. The mixture was stirred at room temperature for 15 min and then sat.aq. NaHCO3 
(2 mL) was added followed by DCM (5 mL). The phases were separated and the aqueous 
phase was extracted with DCM (5 x 5 mL). The combined organic phases were dried over 
Na2SO4, filtered and concentrated in vacuo. The crude product was purified by column 
chromatography (Hexane/Acetone 60:40) to afford (4.57) as a light yellow oil (0.032 g, 
68%). 
 
Mw = 461.327 (C20H30BrO5). 
Rf = 0.33 (Hexane/Acetone 60:40). 
IR (neat): 2978 (w), 1732 (m), 1190 (s), 1086 (m), 1016 (s) 971 (s) cm
-1. 
1H NMR (400 MHz; CDCl3):  7.92 (1H, d, J = 21.4 Hz, HD), 5.96 (1H, s, HR), 5.46 (1H, 
s,  HR’),  4.36-4.04  (4H,  m,  HB),  3.37  (1H,  d,  J  =  15.0  Hz,  HP),  2.80-2.57  (3H,  m, 
HE+HG+HP’), 2.53-2.38 (4H, HK+HK’+HI+HG’), 2.33-2.15 (2H, m, HJ+HF), 1.88 (1H, ddt, 
J = 13.3, 9.3, 4.2 Hz, HF’), 1.75-1.64 (1H, m, HJ’), 1.58 (2H, q, J = 7.6 Hz, HN), 1.33 (6H, 
t, J = 7.1 Hz, HA), 0.91 (3H, t, J = 7.4 Hz, HO) ppm. 208 
 
13C NMR (100 MHz; CDCl3):  219.1 (Q, CL), 195.5 (d, J = 5.2 Hz, Q, CH), 164.7 (d, J = 
5.8 Hz, CH, CD), 131.2 (d, J = 180.8 Hz, Q, CC), 129.6 (Q, CQ), 122.4 (CH2, CR), 62.6 (d, 
J = 6.3 Hz, CH2, CB), 62.5 (d, J = 6.3 Hz, CH2, CB’), 53.7 (Q, CM), 46.6 (CH2, CP), 44.1 
(CH, CI), 38.6 (d, J = 14.2 Hz, CH, CE), 37.5 (d, J = 7.8 Hz, CH2, CG), 37.1 (CH2, CK), 
27.1 (CH2), 26.1 (CH2), 24.5 (CH2), 16.4 (d, J = 6.3 Hz, 2 x CH3, CA), 8.5 (CH3, CO) ppm. 
31P NMR (121 MHz; CDCl3):  13.96 ppm. 
ES
+MS m/z (%): 485/483 (1:1, (M+Na)
+, 100), 463/461 (1:1, (M+H)
+, 45). 
HRES
-MS For C20H29
79BrO5P (M-H)
+: calcd 459.0930, found 459.0931. 
 
The C-ring cyclised Weinreb amide (4.60) 
 
 
A solution of the vinyl bromide (4.48) (0.190 g, 0.298 mmol, 1.0 equiv) in THF (2 mL) 
was cooled to -116 °C in an EtOH/liquid N2 cold bath and treated with 
tBuLi (1.6 M in 
pentanes) (0.447 mL, 0.715 mmol, 2.4 equiv). After the quick addition (over 20 seconds), 
the reaction was stirred for 15 min, then the reaction was allowed to warm to -78 °C and 
stirring continued for 30 min. TBDMSOTf (0.204 mL, 0.894 mmol, 3.0 equiv) was added 
at -78 °C and the reaction mixture was warmed to room temperature over 1 h. Saturated 
aq. NaHCO3 (3 mL) was added and H2O (10 mL) and the reaction was extracted with 
DCM (3 x 10 mL). The combined organic phases were dried over Na2SO4, filtered and 
concentrated  in  vacuo.  The  crude  product  was  purified  by  column  chromatography 
(Hexane/Acetone 70:30) to afford  (4.60) as a colourless oil (0.082 g, 62%). 
 
Mw = 443.243 (C22H38NO6P). 
Rf = 0.22 (Hexane/Acetone 70:30). 
IR (neat): 2966 (w), 1732 (s), 1655 (m), 1387 (m), 1231 (m), 1023 (s), 957 (s) cm
-1. 
1H NMR (400 MHz; CDCl3):  5.06 (1H, s, HT), 4.99 (1H, s, HT’), 4.19-3.97 (4H, m, HB), 
3.71 (3H, s, HJ), 3.18 (3H, s, HI), 2.65 (1H, d, J = 13.5 Hz, HR), 2.54 (1H, m), 2.48-2.33 
(2H, m), 2.28-2.08 (4H, m), 2.01 (1H, m), 1.93-1.84 (3H, m), 1.82-1.58 (4H, m), 1.44 (1H, 209 
 
m), 1.30 (3H, t, J = 6.9 Hz, HA), 1.29 (3H, t, J = 7.1 Hz, HA’), 0.74 (3H, t, J = 7.4 Hz, HQ) 
ppm. 
13C NMR (100 MHz; CDCl3):  218.3 (Q, CN), 174.1 (Q, CH), 145.1 (Q, CS), 112.4 (CH2, 
CT), 61.6 (d, J = 6.9 Hz, CH2, CB), 61.5 (d, J = 6.8 Hz, CH2, CB’), 61.3 (CH3, CJ), 51.8 (Q, 
CO), 49.6 (CH, CK), 40.6 (d, J = 2.0 Hz, CH, CE), 40.5 (d, J = 20.4 Hz, CH, CD), 38.9 
(CH2, CR), 35.9 (CH2), 32.2 (CH3, CI), 26.9 (CH2), 24.3 (CH2), 24.9 (d, J = 141.9 Hz, 
CH2, CC), 21.9 (CH2), 18.1 (CH2), 16.4 (d, J = 6.1 Hz, 2 x CH3, CA), 6.9 (CH3, CQ) ppm. 
31P NMR (121 MHz; CDCl3):  32.04 ppm. 
ES
+MS m/z (%): 466 ((M+Na)
+, 100), 444 ((M+H)
+, 63). 
HRES
+MS For C22H38NO6PNa (M+Na)
+: calcd 466.2329, found 466.2331. 
 
The MEM-ester (4.61) 
 
 
To a stirred, precooled (0 °C) solution of (4.30) (0.232 g, 0.501 mmol, 1.0 equiv) in DCM 
(5 mL) under N2 were added DIPEA (0.137 mL, 0.551 mmol, 1.1 equiv) and MEMCl 
(0.098 mL, 0.601 mmol, 1.2 equiv), and the resulting solution was stirred at 0 °C for 2 h 
under N2. The reaction was quenched by adding 0.1  N HCl (3 mL). The product was 
extracted into  DCM (3  x 10 mL) and the combined extracts were  dried over  MgSO4, 
filtered  and  concentrated  in  vacuo.  The  crude  product  was  purified  by  column 
chromatography  (Hexane/Acetone  60:40),  affording  (4.61)  (0.235  g,  83%)  as  a  light 
yellow oil.  
 
Mw = 567.447 (C24H40BrO8P). 
Rf = 0.37 (Hexane/Acetone 60:40). 
IR (neat): 3465 (br, w), 2988 (m), 2935 (m), 2902 (m), 1730 (s), 1621 (m), 1446 (w), 
1389 (m), 1243 (s), 1162 (m), 1096 (s), 1020 (s), 964 (s), 845 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  6.58 (1H, ddd, J = 21.7, 17.2, 9.9 Hz, HD), 6.01 (1H, s, 
HV), 5.70 (1H, dd, J = 20.5, 17.3 Hz, HC), 5.55 (1H, s, HV’), 5.34-5.29 (2H, m, HI), 4.17-
4.02 (4H, m, HB), 3.79-3.75 (2H, m, HJ/K), 3.58-3.51 (2H, m, HJ/K), 3.37 (3H, s, HL), 3.14 210 
 
(1H, d, J = 14.8 Hz, HT), 2.47-2.10 (9H, m), 1.64-1.48 (2H, m), 1.44 (2H, q, J = 7.4 Hz, 
HR), 1.33 (6H, t, J = 7.1 Hz, HA), 0.79 (3H, t, J = 7.5 Hz, HS) ppm. 
13C NMR (100 MHz; CDCl3):  219.9 (Q, CP), 172.4 (Q, CH), 154.5 (d, J = 4.0 Hz, CH, 
CD), 130.4 (Q, CU), 122.6 (CH2, CV), 119.8 (d, J = 186.8 Hz, CH, CC), 89.4 (CH2, CI), 
71.5 (CH2, CJ/K), 69.6 (CH2, CJ/K), 61.7 (d, J = 5.2 Hz, CH2, CB), 61.7 (d, J = 5.1 Hz, CH2, 
CB’), 59.0 (CH3, CL), 54.1 (Q, CQ), 46.1 (d, J = 21.1 Hz, CH, CE), 45.3 (CH2, CT), 44.1 
(CH, CM), 36.9 (CH2, CO), 31.2 (CH2, CG), 26.6 (d, J = 1.5 Hz, CH2, CF), 25.3 (CH2, CR), 
24.1 (CH2, CN), 16.4 (d, J = 6.2 Hz, CH3, CA), 16.4 (d, J = 6.1 Hz, CH3, CA’), 8.3 (CH3, 
CS) ppm. 
31P NMR (121 MHz; CDCl3):  17.56 ppm. 
ES
+MS m/z (%): 591/589 (1:1, (M+Na)
+, 60), 569/567 (1:1, (M+H)
+, 40). 
HRES
+MS: We have not obtained HRMS or elemental analysis of this compound, but 
copies of the 
1H and 
13C NMR spectra are included in Appendix I. 
 
The phenyl ester (4.63) 
 
 
To a solution of carboxylic acid (4.30) (0.558 g, 1.21 mmol, 1.0 equiv) in DCM (10 mL) 
were successively added PhOH (0.170 g, 1.81 mmol, 1.5 equiv), DIC (0.284 mL, 1.21 
mmol,  1.5  equiv)  and  finally  DMAP  (0.032  g,  0.24  mmol,  0.2  equiv).  The  reaction 
mixture was stirred at room temperature for 5 days, then water (10 mL) was added. The 
phases were  separated  and the aqueous phase extracted with DCM (3 x 10  mL). The 
combined organic phases were dried over MgSO4, filtered and concentrated. The resulting 
crude was purified by column chromatography (Hexane/Acetone 70:30) to afford (4.63) as 
a light yellow oil (0.530 g, 79%). 
 
Mw = 555.438 (C26H36BrO6P). 
Rf = 0.34 (Hexane/Acetone 60:40). 
IR (neat): 2978 (w), 1755 (m), 1734 (m), 1241 (m), 1129 (m), 1021 (s), 957 (s) cm
-1. 211 
 
1H NMR (400 MHz; CDCl3):  7.44-7.36 (2H, m, HJ), 7.25 (1H, m, HL), 7.10-7.06 (2H, 
m, HK), 6.66 (1H, ddd, J = 21.7, 17.2, 10.1 Hz, HD), 6.08-5.99 (1H, s, HV), 5.78 (1H, dd, J 
= 20.5, 17.3 Hz, HC), 5.59 (1H, s, HV’), 4.22-4.05 (4H, m, HB), 3.17 (1H, d, J = 14.8 Hz, 
HT), 2.62 (1H, ddd, J = 16.5, 8.0, 5.0 Hz, HG), 2.53-2.24 (7H, m, contains HT’+HG’), 1.72-
1.58 (3H, m), 1.51-1.45 (2H, m, HR), 1.35 (3H, t, J = 7.0 Hz, HA), 0.82 (3H, t, J = 7.5 Hz, 
HS) ppm. 
13C NMR (100 MHz; CDCl3):  219.9 (Q, CP), 171.5 (Q, CH), 154.8 (d, J = 3.9 Hz, CH, 
CD), 150.5 (Q, CI), 130.4 (Q, CU), 129.5 (2 x CH, CJ), 125.9 (CH, CL), 122.7 (CH2, CV), 
121.4 (2 x CH, CK), 119.6 (d, J = 186.5 Hz, CH, CC), 61.8 (d, J = 4.0 Hz, CH2, CB), 61.8 
(d, J = 3.9 Hz, CH2, CB’), 54.1 (Q, CQ), 46.1 (d, J = 21.0 Hz, CH, CE), 45.4 (CH2, CT), 
44.2 (CH, CM), 36.9 (CH2, CO), 31.3 (CH2, CG), 26.7 (CH2), 25.4 (CH2), 24.1 (CH2), 16.5 
(d, J = 3.2 Hz, CH3, CA’), 16.4 (d, J = 3.1 Hz, CH3, CA), 8.4 (CH3, CS) ppm. 
31P NMR (121 MHz; CDCl3):  17.52 ppm. 
ES
+MS m/z (%): 579/577 (1:1, (M+Na)
+, 100), 557/555 (1:1, (M+H)
+, 28). 
HRES
+MS For C26H36
79BrO6PNa (M+Na)
+: calcd 577.1325, found 577.1322. 
 
The silyl enol ether (4.64) 
 
 
To a cooled solution (-50 °C) of the ketone (4.63) (0.497 g, 0.895 mmol, 1.0 equiv) in 
DCM (1.5 mL) was added Et3N (0.374 mL, 2.69 mmol, 3.0 equiv) then, dropwisely over 2 
min, TBDMS-OTf (0.616 mL, 2.69 mmol, 3.0 equiv) was added. The reaction mixture 
was stirred for 2 h at -50/-40 °C and then sat.aq. NaHCO3 (5 mL) was added and the 
reaction was warmed to room temperature. The phases were separated and the aqueous 
phase was extracted with DCM (5 x 10 mL). The combined organic phases were dried 
over  Na2SO4,  filtered  and  concentrated  in  vacuo.  The  crude  product  was  purified  by 
column chromatography (Hexane/Acetone 70:30) whereby the silica was pre-neutralized 
by making the slurry in the said solvent system, containing ~1% of Et3N. This yielded 
(4.64) as a colourless oil (0.358 g, 72%). 
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Mw = 669.699 (C32H50BrO6PSi). 
Rf = 0.42 (Hexane/Acetone 65:35). 
IR (neat): 2929 (w), 2855 (w), 1756 (m), 1232 (m), 1134 (m), 1022 (s), 836 (s) cm
-1. 
1H NMR (400 MHz; CDCl3):  7.39-7.35 (2H, m, HJ), 7.22 (1H, m, HL), 7.08-7.06 (2H, 
m, HK), 6.71 (1H, ddd, J = 21.7, 17.2, 9.6 Hz, HD), 5.87 (1H, br s, HV), 5.77 (1H, dd, J = 
21.1, 17.2 Hz, HC), 5.60 (1H, br s, HV’), 4.59 (1H, s, HO), 4.16-4.08 (4H, m, HB), 2.87 (1H, 
d,  J  =  15.2  Hz,  HT),  2.58  (1H,  ddd,  J  =  16.2,  8.5, 5.0  Hz,  HG),  2.53-2.33  (4H,  m, 
HG’+HM+HE+HG’), 2.25 (1H, d, J = 15.2 Hz, HT’), 2.14 (1H, m, HF), 2.98 (1H, m, HN’), 
1.71-1.44 (2H, m, HF’+HR), 1.35 (6H, t, J = 7.1 Hz, HA), 1.25 (1H, m, HR’) 0.93 (9H, s, 
HY), 0.85 (3H, t, J = 7.4 Hz, HS), 0.20 (3H, s, HW), 0.19 (3H, s, HW’)ppm. 
13C NMR (100 MHz; CDCl3):  171.6 (Q, CH), 155.9 (d, J = 3.5 Hz, CH, CD), 155.2 (Q, 
CP), 150.6 (Q, CI), 131.0 (Q, CU), 129.4 (2 x CH, CJ), 125.8 (CH, CL), 121.4 (2 x CH, CK), 
121.0 (CH2, CV), 119.4 (d, J = 186.7 Hz, CH, CC), 98.4 (CH, CO), 61.7 (d, J = 5.8 Hz, 
CH2, CB), 61.6 (d, J = 5.9 Hz, CH2, CB’), 53.0 (Q, CQ), 45.9 (d, J = 20.8 Hz, CH, CE), 45.7 
(CH2, CT), 43.2 (CH, CM), 32.5 (CH2, CN), 31.4 (CH2, CG), 28.0 (CH2, CR), 27.1 (CH2, 
CF), 25.6 (3 x CH3, CY), 17.9 (Q, CX), 16.5 (d, J = 2.7 Hz, CH3, CA), 16.4 (d, J = 2.7 Hz, 
CH3, CA’), 9.5 (CH3, CS), -5.0 (CH3, CW), -5.3 (CH3, CW’) ppm. 
31P NMR (121 MHz; CDCl3):  17.86 ppm. 
ES
+MS m/z (%): 693/691 ((M+Na)
+, 100), 671/669 ((M+H)
+, 10). 
HRES
+MS For C32H51
79BrO6PSi (M+H
+): calcd 669.2370, found 669.2365. 
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9.4  Experimental data for Chapter 5 
 
The aldol compound (5.4) 
 
 
To a stirred suspension of LiCl (5 mg, 0.115 mmol, 1.5 equiv) in dry MeCN (5 mL) under 
nitrogen at room temperature, was added a MeCN (2 mL) solution of -ketophosphonate 
(4.35) (37 mg, 0.077 mmol, 1.0 equiv), DBU (14 mL, 0.092 mmol, 1.2 equiv) and finally 
aldehyde (4.3) (20 mg, 0.154 mmol, 2.0 equiv). Almost all of the salt soon dissolved and 
the  reaction  mixture  was  stirred  overnight  at  room  temperature  (16  h).  Saturated  aq. 
NaHCO3 was added (5 mL) and the aqueous phase was extracted with DCM (3 x 10 mL). 
The combined organic phases were dried over Na2SO4, filtered and concentrated in vacuo. 
The crude product was purified by column chromatography (Hexane/EtOAc 45:55) using 
pre-neutralized silica gel to afford (5.4) as a colourless oil (17 mg, 36%).   
 
Mw = 594.792 (C31H51O7PSi). 
Rf = 0.34 (Hexane/EtOAc 45:55). 
1H NMR (300 MHz; CDCl3):  6.69 (1H, m, HI), 4.96 (1H, br s, HV), 4.87 (1H, br s, HV’), 
4.45 (1H, m, HP), 4.17-4.02 (4H, m, HB), 4.03-3.91 (4H, m, HM), 3.57 (1H, dd, J = 27.3, 
8.6 Hz, HC), 2.75-1.73 (11H, m), 1.36 (3H, s, HL), 1.28 (6H, q, J = 6.7 Hz, HA), 0.95 (9H, 
s, HY), 0.75 (3H, s, HS), 0.18 (3H, s, HW), 0.16 (3H, s, HW’) ppm.  
13C NMR (75 MHz; CDCl3): 190.6 (Q, CH), 163.6 (Q, CQ), 145.3 (d, J = 1.5 Hz, Q, CU), 
137.8 (Q, CG), 134.0 (CH, CI), 110.7 (CH2, CV), 109.5 (Q, CK), 98.3 (CH, CP), 64.9 (2 x 
CH2, CM), 62.9 (d, J = 7.1 Hz, CH2, CB), 62.6 (d, J = 6.9 Hz, CH2, CB’), 53.6 (CH, CN), 
49.8 (d, J = 123.3 Hz, CH, CC), 46.9 (Q, CR), 45.6 (CH, CE), 45.2 (CH2, CT), 38.0 (CH2), 
37.3 (d, J = 8.5 Hz, CH, CD), 30.0 (CH2), 28.1 (CH2), 25.6 (3 x CH3, CY), 24.5 (CH3, CL), 
18.1 (Q, CX), 16.3 (d, J = 6.4 Hz, 2 x CH3, CA), 15.6 (CH3, CS), -4.7 (CH3, CW), -5.0 (CH3, 
CW’) ppm.  214 
 
31P NMR (121 MHz; CDCl3):23.84 ppm. 
ES
+MS m/z (%): 618/617 (1:3, (M+Na)
+, 100), 596/595 (1:3, (M+H)
+, 80). 
HRES
+MS For C31H51O7PSiNa (M+Na)
+: calcd 617.3039, found 617.3044. 
 
The HWE product (5.5) and the diol (5.6) and the dimer (5.7) 
 
 
To  a  solution  of  the  phosphonate  (4.35)  (125  mg,  0.26  mmol,  1.0  equiv)  and 
formaldehyde (37% w/w in H2O, 400 L, ca. 15.0 equiv) in THF (1.5 mL) was added a 
solution of K2CO3 (8 M, 500 L, 15.0 equiv) dropwise. The mixture was stirred for 5 h at 
room temperature then H2O (5 mL) was added and the reaction was extracted with DCM 
(4 x 10 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude product 
was purified by column chromatography (Hexane/Acetone 90:10 to 70:30) to afford (5.5) 
(38 mg, 41%) as a colourless oil that dimerized to (5.7), (5.6) as a white solid (7 mg, 6%), 
(4.35) (36 mg, 29%) as a colourless oil and (4.35) (14 mg, 11%) as a colourless oil. 
 
Data for (5.5) 
Mw = 358.590 (C22H34O2Si). 
Rf = 0.79 (Hexane/Acetone 95:5). 
No other data available, compound too unstable. 
Data for (5.6) 
Mw = 418.642 (C24H38O4Si). 
Rf = 0.36 (Hexane/Acetone 70:30). 
IR (film): 3422 (br w), 2958 (m), 2930 (m), 2857 (m), 1681 (w), 1644 (w), 1619 (m), 
1472 (w), 1369 (m), 1253 (m), 1228 (m), 1044 (w), 839 (s), 782 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  6.08 (1H, t, J = 2.5 Hz, HA), 5.81 (1H, t, J = 2.5 Hz, HA’), 
4.82 (1H, s, HQ), 4.72 (1H, s, HQ’), 4.35 (1H, s, HK), 3.90 (1H, d, J = 9.5 Hz, HH), 3.51 215 
 
(3H, m, HH’), 2.76 (1H, d, J = 8.4 Hz, HC), 2.68 (1H, br s, OH), 2.50 (1H, br s, OH), 2.22-
1.16 (8H, m), 0.83 (9H, s, HT), 0.61 (3H, s, HN), 0.18 (3H, s, HR), 0.16 (3H, s, HR’) ppm.  
13C NMR (100 MHz; CDCl3): 209.6 (Q, CG), 163.6 (Q, CL), 145.1 (Q, CB), 144.1 (Q, 
CP), 126.5 (CH2, CA), 111.4 (CH2, CQ), 98.4 (CH, CK), 67.4 (CH2, CH), 65.8 (CH2, CH’), 
54.2 (CH), 52.3 (Q, CF), 52.1 (CH), 46.2 (Q, CM), 45.2 (CH2), 35.7 (CH), 31.7 (CH2), 27.8 
(CH2), 25.6 (3 x CH3, CT), 18.1 (Q, CS), 15.8 (CH3, CN), -4.6 (CH3, CR), -4.8 (CH3, CR’) 
ppm.  
ES
+MS m/z (%): 419 ((M+H)
+, 100). 
HRES
+MS For C24H39O4Si (M+H)
+: calcd 419.2612, found 419.2620. 
 
Data for (5.7) 
Mw = 717.179 (C44H68O4Si2). 
Rf = 0.82 (Hexane/Acetone 95:5). 
IR (film): 2955 (m), 2930 (m), 2855 (m), 1727 (m), 1678 (w), 1618 (s), 1471 (w), 1463 
(w), 1450 (w), 1332 (w), 1250 (m), 1227 (m), 1156 (m), 1104 (m), 835 (s), 781 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  5.11 (1H, s), 4.95 (1H, s), 4.68 (1H, s), 4.39 (3H, br s), 
2.65-2.48 (2H, m), 2.16-2.05 (3H, m), 2.14-1.62 (12H, m), 1.54-1.06 (9H, m), 0.80 (9H, 
s), 0.78 (9H, s), 0.68 (3H, s), 0.67 (3H, s), 0.17 (6H, s), 0.15 (6H, s) ppm.  
13C NMR (100 MHz; CDCl3): 208.9 (Q), 165.3 (Q), 164.5 (Q), 149.6 (Q), 149.5 (Q), 
142.7 (Q), 116.0 (CH2), 110.6 (CH2), 103.3 (Q), 99.9 (CH), 99.4 (CH), 85.7 (Q), 56.7 
(CH), 55.7(CH), 54.5 (CH), 54.0 (CH), 47.8 (CH2), 47.6 (Q), 46.4 (Q), 45.9 (CH2), 41.7 
(CH), 37.2 (CH2), 36.7 (CH), 31.8 (CH2), 29.5 (CH2), 29.3 (CH2), 28.7 (CH2), 26.8 (CH2), 
26.6 (6 x CH3), 23.2 (CH2), 19.1 (2 x Q), 19.0 (CH2), 16.8 (CH), 16.6 (CH), -3.7 (2 x 
CH3), -4.1 (2 x CH3) ppm.  
MS: We have not been able to obtain MS data, but copies of 
1H and 
13C are included in 
Appendix I. 
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The A-ring annelated steroid (5.13) 
 
 
This is known compound but no NMR data have been reported.
48 
To  a  solution  of  the  phosphonate  (4.35)  (0.633  g,  1.28  mmol,  1.0  equiv)  and 
formaldehyde (37% w/w in H2O, 1.43 mL, 19.13 mmol, 15.0 equiv) in THF (10 mL) was 
added an aqueous solution of K2CO3 (8M, 2.39 mL, 19.13 mmol, 15.0 equiv) dropwise. 
The mixture was stirred for 5 h at room temperature then H2O (10 mL) was added and the 
reaction  was  extracted  with  DCM  (5  x  10  mL),  dried  over  Na2SO4,  filtered  and 
concentrated  in  vacuo.  Ethylacetoacetate  (322  L,  2.55  mmol, 2.0  equiv)  was  slowly 
added to a 0.3 M solution of NaOMe in MeOH (8.49 mL, 2.55 mmol, 2.0 equiv). The 
mixture  was  stirred  for  15  min  before  being  added  by  cannula  to  a  solution  of  the 
previously obtained crude enone in dry MeOH (5 mL). The resulting mixture was stirred 
for 1 h at room temperature then NaOH 5 N (4 mL) was added and stirring continued for 
30 min. The biphasic mixture was acidified with HCl 2 N until two clean phases were 
obtained  and  efficient  stirring  was  continued  for  30  min.  The  reaction  mixture  was 
extracted with DCM (5 x 10 mL), dried over MgSO4 and concentrated in vacuo for 1 h so 
as to achieve complete decarboxylation (P = 5 torr, water bath = 70 °C). The final crude 
product was purified by column chromatography (Hexane/Acetone 70:30)  followed by 
preparative  HPLC  (Hexane/Acetone  80:20).  This  yielded  (5.13)  (98  mg,  27%)  as 
colourless crystals. 
 
Mw = 284.393 (C19H24O2). 
m.p. = 188-192 °C. 
Rf = 0.47 (Hexane/Acetone 60:40). 
IR (film): 2930 (w), 2875 (w), 1737 (s), 1670 (s), 1616 (w), 1454 (w), 1353 (w), 1258 
(w), 1039 (w), 902 (w) cm
-1. 
1H NMR (400 MHz; CDCl3):  5.90 (1H, br s, HD), 4.95 (1H, s, HS), 4.86 (1H, s, HS’), 
2.59-1.14 (18H, m), 0.89 (3H, s, HR) ppm.  217 
 
13C NMR (100 MHz; CDCl3): 219.4 (Q, CQ), 199.8 (Q, CC), 165.6 (Q, CE), 144 9 (Q, 
CK), 125.9 (CH, CD), 110.9 (CH2, CS), 54.2 (CH), 51.2 (CH), 49.4 (Q, CM), 43.8 (CH2, 
CL), 41.1 (CH), 37.5 (CH), 36.9 (CH2), 36.0 (CH2), 35.1 (CH2), 29.4 (CH2), 28.2 (CH2), 
21.5 (CH2), 14.3 (CH3, CR) ppm.  
CIMS m/z (%): 285 ((M+H)
+, 100). 
HRMS: not necessary, X-ray obtained instead. 
X-ray: X-ray data available in Appendix II. 
  
The A-ring annelated steroid (1.71) 
 
 
This  is  a  known  compound  but  only  partial  analytical  data  are  described  in  the 
literature.
27,43 
To a solution of the phosphonate (4.2) (0.482 g, 0.97 mmol, 1.0 equiv) and formaldehyde 
(37% w/w in H2O, 1.09 mL, 14.55 mmol, 15.0 equiv) in THF (10 mL) was added an 
aqueous  solution  of  K2CO3  (8  M,  1.82  mL,  14.55  mmol,  15.0  equiv)  dropwise.  The 
mixture was stirred for 5 h at room temperature then H2O (10 mL) was added and the 
reaction  was  extracted  with  DCM  (5  x  10  mL),  dried  over  Na2SO4,  filtered  and 
concentrated  in  vacuo.  Ethylacetoacetate  (245  L,  1.94  mmol, 2.0  equiv)  was  slowly 
added to a 0.3 M solution of NaOMe in MeOH (6.46 mL, 1.94 mmol, 2.0 equiv). The 
mixture  was  stirred  for  15  min  before  being  added  by  cannula  to  a  solution  of  the 
previously obtained crude enone in dry MeOH (5 mL). The resulting mixture was stirred 
for 1 h at room temperature then NaOH 5 N (4 mL) was added and stirring continued for 
30 min. The biphasic mixture was acidified with HCl 2 N until two clean phases were 
obtained  and  efficient  stirring  was  continued  for  30  min.  The  reaction  mixture  was 
extracted with DCM (5 x 10 mL), dried over MgSO4 and concentrated in vacuo for 1 h so 
as to achieve complete decarboxylation (P = 5 torr, water bath = 70 °C). The final crude 
product was purified by column chromatography (Hexane/Acetone 70:30)  followed by 
preparative  HPLC  (Hexane/Acetone  80:20).  This  yielded  (1.71)  (93  mg,  32%)  as 
colourless crystals. 218 
 
 
MW = 298.419 (C20H26O2). 
m.p. = 148-152 °C. 
Rf = 0.47 (Hexane/Acetone 60:40). 
IR (film): 2961 (w), 2876 (w), 1727 (m), 1662 (m), 1460 (w), 1352 (w), 1258 (s), 1220 
(w), 1074 (s), 1018 (s), 901 (m), 796 (s) cm
-1. 
1H NMR (400 MHz; CDCl3):  5.91 (1H, br s, HD), 5.02 (1H, s, HT), 4.91 (1H, s, HT’), 
2.68-2.60 (2H, m), 2.56-2.11 (7H, m), 1.99-1.92 (2H, m), 1.87 (1H, d, J = 12.9 Hz), 1.76-
1.49 (6H, m, contains HR’), 1.32 (1H, m, HR), 1.17 (1H, m), 0.79 (3H, t, J = 7.4 Hz, HS) 
ppm. 
13C NMR (100 MHz; CDCl3): 217.9 (Q, CQ), 199.7 (Q, CC), 165.6 (Q, CE), 144.9 (Q, 
CK), 125.9 (CH, CD), 110.4 (CH2, CT), 54.1 (CH), 52.7 (Q, CM), 52.0 (CH), 40.9 (CH), 
39.5 (CH2), 37.6 (CH), 36.9 (CH2), 36.0 (CH2), 35.1 (CH2), 29.5 (CH2), 28.3 (CH2), 20.8 
(CH2), 18.2 (CH2), 7.1 (CH3, CS) ppm. 
CIMS m/z (%): 299 ((M+H)
+, 100). 
HRMS: not necessary, X-ray obtained instead. 
X-ray: X-ray data available in Appendix II. 
 
The thioketal steroid (5.14) 
 
 
To (5.13)  (0.097  g,  0.311  mmol,  1.0 equiv)  was slowly  added, over  15  min  at room 
temperature, MeOH (6 mL) so as to achieve complete dissolution. Ethane-1,2-dithiol (54 
L, 0.616 mmol, 1.8 equiv) was added followed by dropwise addition of BF3.Et2O (34 L, 
0.259 mmol, 0.9 equiv) and the mixture was stirred for 16 hours. After usual work-up, the 
crude product was purified by column chromatography (Hexane/Acetone 80:20) to afford 
(5.15) as a white solid (98 mg, 84%). 
 
MW = 360.576 (C21H28OS2). 
Rf = 0.46 (Hexane/Acetone 80:20). 219 
 
IR (film): 2958 (m), 2917 (s), 2848 (w), 1729 (s), 1448 (m), 1258 (m), 1037 (m), 1004 
(w), 889 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  5.69 (1H, s, HD), 4.93 (1H, s, HS), 4.84 (1H, s, HS’), 3.41-
3.22 (4H, m, HT), 2.48 (1H, m), 2.34-1.91 (10H, m), 1.83 (1H, m), 1.60-1.27 (5H, m), 1.07 
(1H, m), 0.85 (3H, s, HR) ppm. 
13C NMR (100 MHz; CDCl3): 219.8 (Q, CQ), 145.6 (Q, CK), 141.0 (Q, CE), 126.6 (CH, 
CD), 110.6 (CH2, CS), 65.7 (Q, CC), 54.7 (CH), 51.5 (CH), 49.6 (Q, CM), 44.0 (CH2, CL), 
41.6 (CH), 40.4 (CH2), 40.0 (CH2), 39.7 (CH2), 36.1 (CH2), 35.9 (CH), 34.7 (CH2), 30.4 
(CH2), 28.6 (CH2), 21.5 (CH2), 14.3 (CH3, CR) ppm. 
X-ray: X-ray data available in Appendix II. 
 
The thioketal steroid (5.15) 
 
 
To steroid (1.71) (0.093 g, 0.311 mmol, 1.0 equiv) was slowly added, over 15 min at room 
temperature, MeOH (6 mL) so as to achieve complete dissolution. Ethane-1,2-dithiol (52 
L, 0.591 mmol, 1.8 equiv) was added followed by dropwise addition of BF3.Et2O (33 L, 
0.249 mmol, 0.9 equiv) and the mixture was stirred for 16 hours. After usual work-up, the 
crude product was purified by column chromatography (Hexane/Acetone 80:20) to afford 
(5.15) as a white solid (103 mg, 89%). 
 
MW = 374.603 (C22H30OS2). 
Rf = 0.49 (Hexane/Acetone 80:20). 
IR (film): 2960 (m), 2918 (m), 2850 (w), 1733 (m), 1456 (w), 1258 (m), 1011 (s), 789 (s) 
cm
-1. 
1H NMR (400 MHz; CDCl3):  5.68 (1H, br s, HD), 4.95 (1H, s, HT), 4.84 (1H, s, HT’), 
3.41-3.34 (3H, m, HU), 3.25 (1H, m, HU), 2.59 (1H, d, J = 12.7 Hz, HL), 2.42 (1H, dd, J = 
19.3, 8.8 Hz), 2.36-1.78 (10H, m), 1.71-1.37 (5H, m, contains HR), 1.33-1.24 (2H, m, 
contains HR’), 1.04 (1H, m), 0.77 (3H, t, J = 7.4 Hz, HS) ppm. 220 
 
13C NMR (100 MHz; CDCl3): 218.5 (Q, CO), 145.7 (Q, CK), 141.0 (Q, CE), 125.6 (CH, 
CD), 110.2 (CH2, CT), 65.7 (Q, CC), 54.6 (CH), 52.9 (Q, CM), 52.2 (CH), 41.3 (CH), 40.4 
(CH2),  40.0 (CH2),  39.6 (CH2), 39.6 (CH2), 36.1 (CH2), 35.9 (CH), 34.7 (CH2), 30.5 
(CH2), 28.6 (CH2), 20.8 (CH2, CR), 18.1 (CH2), 7.2 (CH3, CS) ppm. 
X-ray: X-ray data available in Appendix II. 
 
The C17-ethinyl steroid (5.20) and the 3,4-steroid (5.21) 
 
Thioketal (5.14) (0.019 g, 0.053 mmol) was dissolved in ethanol (3 mL), and Raney nickel 
was added. The mixture was refluxed (80 °C) with sequential addition of Raney nickel 
every  2  h  until  completion  (4  h  overall).  The  reaction  mixture  was  cooled  to  room 
temperature, water (5 mL) and DCM (5 mL) were added and the phases were separated. 
The  aqueous  phase  was  extracted with  DCM (3 x  10 mL)  and  the  combined organic 
phases were dried over MgSO4, filtered and evaporated. The crude product was purified 
by  column chromatography (Hexane/Acetone  90:10)  to  afford  (5.16)  and (5.17)  as  an 
unseparable mixture (0.010 g, 73%) (ratio (5.16)/(5.17) = 80:20). 
To a cooled (-40 °C) solution of steroids (5.16)/(5.17) (0.010 g, 0.037 mmol, 1.0 equiv) in 
dry THF (2 mL) was added sodium acetylide (18% wt in Xylene, 0.224 mL, 0.740 mmol, 
20 equiv). The reaction mixture was stirred at -40 °C for 30 min, then 30 min at 0 °C. The 
mixture was allowed to warm up to room temperature and stirring continued for 14 h. The 
mixture  was diluted with  DCM  (5  mL)  and slowly  poured onto water (5 mL). After 
extraction with DCM (3 x 5 mL), the combined organic phases were dried over Na2SO4, 
filtered  and  evaporated  in  vacuo.  The  crude  product  was  purified  by  column 
chromatography  (Hexane/Acetone  85:15)  to  afford  steroid  (5.20)  and  its  3,4-isomer 
(5.21) as an unseparable mixture (0.008 g, 76%) (ratio (5.20)/(5.21) = 80:20). 
 
 221 
 
Significant data for (5.20) 
MW = 296.446 (C21H28O). 
Rf = 0.34 (Hexane/Acetone 85:15). 
1H NMR (400 MHz; CDCl3): Characteristic peaks 5.48 (1H, br s), 4.86 (1H, m), 4.79 
(1H, br s), 2.59 (1H, s), 2.44 (1H, d, J = 11.9 Hz), 0.83 (3H, s) ppm. 
13C NMR (100 MHz; CDCl3): 147.6 (Q), 139.9 (Q), 121.3 (CH), 109.1 (CH2), 87.3 (Q), 
79.0 (Q), 74.0 (CH), 54.8 (CH), 50.8 (CH), 48.9 (Q), 45.5 (CH2), 42.8 (CH), 39.3 (CH2), 
36.6 (CH), 35.5 (CH2), 31.7 (CH2), 29.1 (CH2), 25.7 (CH2), 22.6 (CH2), 21.9 (CH2), 13.0 
(CH3) ppm. 
 
Desogestrel (1.14) and the 3,4-steroid (5.22) 
 
 
Thioketal (5.15) (0.065 g, 0.174 mmol) was dissolved in ethanol (10 mL), and Raney 
nickel was added. The mixture was refluxed (80 °C) with sequential addition of Raney 
nickel every 2 h until completion (6 h overall). The reaction mixture was cooled to room 
temperature, water (15 mL) and DCM (15 mL) were added and the phases were separated. 
The  aqueous  phase  was  extracted with  DCM (3 x  10 mL)  and  the  combined organic 
phases were dried over MgSO4, filtered and evaporated. The crude product was purified 
by  column chromatography (Hexane/Acetone  90:10)  to  afford  (5.18)  and (5.19)  as  an 
unseparable mixture (0.039 g, 78%) (ratio (5.18)/(5.19) = 80:20). 
Acetylene was passed through a suspension of KO
tBu (0.056 g, 0.499 mmol, 5.0 equiv) in 
dry THF (0.6 mL) at -25 °C for 1 hour. A solution of steroids (5.18)/(5.19) (0.028 g, 0.098 
mmol, 1.0 equiv) in dry THF (300 L) was added and acetylene was passed through the 
mixture  for  1  h  at  -25  °C.  The  resulting  mixture  was  allowed  to  warm  up  to  room 
temperature,  diluted  with  DCM  (5  mL)  and  slowly  poured onto  water  (5  mL).  After 
extraction with DCM (3 x 5 mL), the combined organic phases were dried over Na2SO4, 
filtered  and  evaporated  in  vacuo.  The  crude  product  was  purified  by  column 222 
 
chromatography (Hexane/Acetone 85:15) to afford desogestrel (1.14) and its 3,4-isomer 
(5.22) as an unseparable mixture (0.029 g, 95%) (ratio (1.14)/(5.22) = 80:20). 
 
Significant data for desogestrel (1.14) 
MW = 310.473 (C22H30O). 
Rf = 0.36 (Hexane/Acetone 85:15). 
1H NMR (400 MHz; CDCl3): Characteristic peaks 5.48 (1H, s), 4.99 (1H, s), 4.79 (1H, 
s), 2.62 (1H, d, J = 9.0 Hz), 2.61 (1H, s), 1.05 (3H, t, J = 7.4 Hz) ppm. 
13C NMR (100 MHz; CDCl3): 147.5 (Q), 139.9 (Q), 121.3 (CH), 108.5 (CH2), 87.9 (Q), 
81.1 (Q), 74.0 (CH), 54.7 (CH), 52.4 (CH), 50.4 (Q), 42.6 (CH), 40.6 (CH2), 39.8 (CH2), 
36.6 (CH), 35.5 (CH2), 31.7 (CH2), 29.1 (CH2), 25.7 (CH2), 22.0 (CH2), 21.9 (CH2), 19.8 
(CH2), 9.1 (CH3) ppm. 
These data correspond to literature data.
26 
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9.5   Experimental data for Chapter 6 
 
The  C-ring  cyclised  bromide  (rac-6.1,  6.1)  and  the  C-ring  cyclised  debrominated 
adduct (rac-6.2, 6.2) and the phosphonic acid (6.3). 
Route 1: 
 
 
A 0.01 M solution of phosphonate (3.3) (246 mg, 0.47 mmol, 1.0 equiv) in toluene (47 
mL) was degassed by bubbling nitrogen through it for 10 minutes. The 2
nd generation 
Hoveyda-Grubbs catalyst (102 mg, 0.165 mmol, 0.35 equiv) was added and the solution 
was  heated  to  80  °C  for  2 days.  After  cooling  to  room  temperature,  the  solvent  was 
removed and the crude product was purified by column chromatography (Hexane/Acetone 
80:20) followed by HPLC (Hexane/Acetone 95:5) to afford (rac-6.1) as a brown oil (103 
mg, 61%) and (rac-6.2) as a colourless oil (1-2 mg, traces). 
 
Route 2: 
 
 
To a solution of phosphonamide (3.4) (0.189 g, 0.327 mmol, 1.0 equiv) in THF (3 mL) 
was added 2 N HCl (0.335 mL, 0.670 mmol). The mixture was stirred at 65 °C for 16 
hours, then diluted with EtOAc and washed with 1 N HCl. The organic layer was dried 
over MgSO4 and evaporated to give phosphonic acid (6.3) (0.144 g, 97 %), which was 
used in the next step without further purification. A 0.01 M solution of phosphonic acid 
(6.3) in DCM (32 mL) was degassed by bubbling nitrogen through it for a few minutes. 224 
 
The 2
nd generation Grubbs catalyst (0.095 g, 0.115 mmol, 0.35 equiv) was added and the 
mixture was refluxed for 24 hours. After cooling to room temperature, the solvent was 
evaporated  and  the  crude  mixture  was  purified  by  column  chromatography 
(Hexane/Acetone 80:20) followed by HPLC (Hexane/Acetone 95:5) to afford (6.1) as a 
brown oil (0.053 g, 44%) and (6.2) (3 mg, 4%) as a colourless oil. 
 
Data for (rac-6.1, 6.1): 
Mw = 363.289 (C19H23BrO2). 
Rf = 0.44 (Hexane/Acetone 80:20). 
IR (neat): 2962 (m), 2911 (m), 2835 (m), 1727 (s), 1570 (m), 1463 (m), 1239 (s) cm
-1. 
1H NMR (400 MHz; CDCl3):  7.42 (1H, d, J = 8.7 Hz, HA), 6.79 (1H, d, J = 3.0 Hz, HD), 
6.64 (1H, dd, J = 8.7, 3.0 Hz, HB), 5.82-5.61 (2H, m, HR + HS), 3.79 (3H, s, HG), 2.85 (1H, 
ddd, J = 12.9, 12.0, 5.1 Hz, HH), 2.68 (1H, ddd, J = 13.3, 11.7, 5.3 Hz, HH’), 2.45 (1H, m, 
HM), 2.25-2.03 (5H, m, HJ + HL + HM’ + 2HQ), 1.85 (1H, m, HI), 1.67-1.58 (3H, m, HI’ + 
HL’ + HK), 0.92 (3H, s, HP) ppm. 
13C NMR (100 MHz; CDCl3): 221.6 (Q, CN), 159.0 (Q, CC), 142.8 (Q, CE), 133.3 (CH, 
CA), 130.3 (CH, CS), 125.8 (CH, CR), 116.0 (CH, CD), 114.8 (Q, CF), 113.0 (CH, CB), 55.4 
(CH3, CG), 46.8 (Q, CO), 46.0 (CH, CK), 38.1 (CH, CJ), 35.8 (CH2, CI), 33.5 (CH2, CM), 
33.4 (CH2, CH), 32.7 (CH2, CQ), 22.8 (CH2, CL), 14.3 (CH3, CP) ppm. 
CIMS m/z  (%):  382/380  (M+NH4
+,  8),  365/363  (M+H
+,  2),  347/345  (12),  302  (47), 
285/283 (30), 267 (84), 122 (100). 
HRES
+MS For C19H24O2
79Br (M+H)
+: calcd 363.0954, found 363.0951. 
[]D = +31.3 ° (c 0.82, CHCl3). 
 
Data for (rac-6.2, 6.2): 
Mw = 284.178 (C19H24O2). 
Rf = 0.44 (Hexane/Acetone 80:20). 
IR (neat): 2918 (w), 2857 (w), 1736 (s), 1584 (m), 1453 (m), 1259 (s), 1152 (m), 1046 
(m), 780 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  7.22 (1H, dd, J = 8.8, 7.3 Hz, HA), 6.83-6.72 (3H, m, HB + 
HF + HD), 5.74-5.66 (2H, m, HR + HS), 3.80 (3H, s, HG), 2.78 (1H, ddd, J = 13.5, 11.0, 5.5 
Hz, HH), 2.61 (1H, ddd, J = 13.5, 10.6, 5.8 Hz, HH’), 2.47 (1H, m, HM), 2.22-2.04 (5H, m, 225 
 
HJ + HL + HM’ + 2HQ), 1.90 (1H, dddd, J = 17.2, 11.1, 6.4, 4.2 Hz, HI), 1.71-1.51 (3H, m, 
HI’ + HL’ + HK), 0.88 (3H, s, HP) ppm. 
13C NMR (100 MHz; CDCl3): 221.6 (Q, CN), 159.7 (Q, CC), 144.1 (Q, CE), 130.3 (CH, 
CS), 129.3 (CH, CA), 125.6 (CH, CR), 120.7 (CH, CF), 114.2 (CH, CD), 111.0 (CH, CB), 
55.1 (CH3, CG), 46.8 (Q, CO), 46.3 (CH, CK), 37.9 (CH, CJ), 35.8 (CH2, CM), 34.3 (CH2, 
CI), 33.5 (CH2, CH), 32.8 (CH2, CQ), 22.8 (CH2, CL), 14.3 (CH3, CP) ppm. 
CIMS m/z (%): 302 ((M+NH4)
+, 6), 285 ((M+H)
+, 8), 267 (30), 122 (100). 
HRMS (CI) For C19H24O2: calcd 284.17763, found 284.17803. 
 
Data for (6.3): 
Mw = 471.322 (C21H28BrO5P). 
IR (neat): 2936, 2870, 1734, 1471, 1240, 1161, 992, 929, 808 cm
-1. 
1H NMR (400 MHz; CDCl3):  7.46 (1H, d, J = 8.5 Hz, HA), 6.89 (1H, d, J = 3.0 Hz, HD), 
6.76 (1H, dd, J = 8.5, 3.0 Hz, HB), 6.33 (1H, ddd, J = 21.1, 17.1, 10.0 Hz, HK), 5.85 (1H, 
dd, J = 19.6, 17.1 Hz, HL), 5.45 (1H, m, HT), 5.18 (1H, d, J = 17.1 Hz, HU), 5.06 (1H, d, J 
= 10.0 Hz, HU’), 3.76 (3H, s, HG), 2.65 (1H, td, J = 13.0, 4.5 Hz, HH), 2.48 (1H, td, J = 
13.0, 5.0 Hz, HH’), 2.37-2.25 (2H, m), 2.18 (1H, dd, J = 14.0, 9.0 Hz, HS), 2.20-1.93 (4H, 
m), 1.85 (1H, m), 1.55-1.40 (2H, m), 0.94 (3H, s, HR) ppm. 
13C NMR (100 MHz; CDCl3): 222.0 (Q, CP), 158.7 (Q, CC), 149.2 (CH, CK), 142.3 (Q, 
CE), 134.7 (CH, CT), 133.1 (CH, CA), 123.7 (CH, d, J = 179.3 Hz, CL), 118.4 (CH2, CU), 
116.0 (CH, CD), 113.7 (CH + Q, CB+CF), 55.3 (CH3, CG), 51.6 (Q), 45.7 (CH, d, J = 20.4 
Hz, CJ), 43.9 (CH, CM), 40.2 (CH2, CS), 36.6 (CH2, CI), 33.2 (CH2, CO), 31.7 (CH2, CH), 
23.0 (CH2, CN), 17.7 (CH3, CR) ppm. 
 31P NMR (121 MHz; CDCl3):  12.41 ppm. 
ES
+MS m/z (%): 472/470 (1:1, (M+H)
+, 100). 
HRES
+MS For C21H29
79BrO5P (M+H)
+: calcd 471.0930, found 471.0929. 
[]D = +34.0 ° (c 0.60, CHCl3). 
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The 11,12-steroid (6.4). 
 
 
To a carefully degassed solution of bromide (6.1) (35 mg, 0.096 mmol, 1.0 equiv) and 
nBu4OAc (100 mg, 0.333 mmol, 3.5 equiv) in DMF/MeCN/H2O (1:1:0.2, 1.2 mL) was 
added the Herrmann catalyst (2.5 mg, 1.92 mol, 0.02 equiv) at 50 °C. The mixture was 
stirred at 115 °C for 3 h. After cooling to room temperature, the mixture was diluted with 
Et2O, washed with H2O and brine, dried over MgSO4 and concentrated in vacuo yielding 
(6.4) as a colourless oil (27 mg, quantitative). 
 
Mw = 282.377 (C19H22O2). 
Rf = 0.46 (Hexane/Acetone 80:20).  
IR (film): 2921 (m), 2852 (w), 1738 (s), 1609 (w), 1499 (m), 1465 (m), 1247 (s), 1037 (s) 
cm
-1. 
1H NMR (400 MHz; CDCl3):  7.20 (1H, d, J = 8.6 Hz, HA), 6.75 (1H, dd, J = 8.6, 2.7 
Hz, HB), 6.65 (1H, d, J = 2.7 Hz, HD), 6.18 (1H, dd, J = 9.9, 1.6 Hz, HQ), 6.06 (1H, dd, J 
= 9.9, 4.1 Hz, HR), 3.78 (3H, s, HG), 3.54 (1H, m, HS), 2.79 (1H, ddd, J = 15.4, 10.8, 4.3 
Hz, HH), 2.61 (1H, td, J = 15.9, 4.9 Hz, HH’), 2.55-2.47 (2H, m, HM + HJ), 2.19 (1H, m, 
HM’), 2.03-1.92 (2H, m, HL + HI), 1.85 (1H, dt, J = 12.4, 5.4 Hz, HK), 1.76 (1H, ddd, J = 
17.1, 8.9, 4.0 Hz, HI’), 1.66 (1H, ddd, J = 17.8, 10.8, 6.1 Hz, HL’), 1.03 (3H, s, HP) ppm. 
13C NMR (100 MHz; CDCl3): 216.5 (Q, CN), 157.3 (Q, CC), 138.6 (Q, CE), 130.5 (CH, 
CR), 130.4 (CH, CQ), 130.4 (Q, CF), 128.8 (CH, CA), 113.4 (CH, CB), 112.2 (CH, CD), 55.2 
(CH3, CG), 49.6 (Q, CO), 43.3 (CH, CK), 38.7 (CH, CS), 36.6 (CH2, CM), 31.4 (CH, CJ), 
26.4 (CH2, CH), 25.0 (CH2, CI), 20.9 (CH2, CL), 17.6 (CH3, CP) ppm. 
CIMS m/z (%): 300 (M+NH4
+, 18), 283 (M+H
+, 100).  
HRMS we were not able to obtain HRMS data, product too unstable.  
[]D = -119.2 ° (c 0.25, CHCl3). 
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3-O-Methyl-Estrone (1.113) and the cis-C8,9-steroid (6.5) 
 
 
A solution of alkene (6.4) (43 mg, 0.15 mmol, 1.0 equiv), cyclohexadiene (1.54 mL, 15 
mmol, 100 equiv) and Pd/C (10% wt, 97 mg, 0.6 equiv) in dry EtOH (4 mL) was stirred 
for 20 h at 110 °C. Once cooled, the reaction mixture was diluted with DCM, filtered on 
celite  and  evaporated.  The  crude  product  was  purified  by  column  chromatography 
(Hexane/Acetone 80:20) to give a mixture of (1.113)/(6.5) in a 70/30 ratio (42 mg, 98%). 
Recrystallization in DCM/Hexane afforded pure (1.113) as fine white crystals.  
 
Mw = 284.393 (C19H24O2). 
m.p. = 144-147 °C. 
Rf = 0.45 (Hexane/Acetone 80:20). 
IR (film): 2914 (m), 2848 (w), 1736 (s), 1608 (m), 1504 (m), 1245 (m) cm
-1
. 
1H NMR (400 MHz; CDCl3):  7.22 (1H, d, J = 8.6 Hz, HA), 6.73 (1H, dd, J = 8.6, 2.6 
Hz, HB), 6.66 (1H, d, J = 2.6 Hz, HD), 3.79 (3H, s, HG), 2.94-2.90 (2H, m, HH), 2.51 (1H, 
dd, J = 18.8, 8.3 Hz, HK), 2.41 (1H, m, HI), 2.27 (1H, m), 2.20-1.95 (4H, m), 1.69-1.40 
(6H, m), 0.92 (3H, s, HP) ppm. 
13C NMR (100 MHz; CDCl3): 220.9 (Q, CN), 157.6 (Q, CC), 137.7 (Q, CE), 132.0 (Q, 
CF), 126.3 (CH, CA), 113.9 (CH, CD), 111.6 (CH, CB), 55.2 (CH3, CG), 50.4 (CH, CJ), 48.0 
(Q, CO), 44.0 (CH, CS), 38.4 (CH, CK), 35.9 (CH2, CM), 31.7 (CH2, CQ), 29.7 (CH2, CH), 
26.6 (CH2, CI), 25.9 (CH2, CR), 21.6 (CH2, CL), 13.9 (CH3, CP) ppm. 
CIMS m/z (%): 285 (M+H
+, 100). 
[]D = +157.2 ° (c 1.0, CHCl3).  
The experimental data correspond well to the reported data.
55,205,219 
 
Significant data for (6.5): 
Mw =284.393 (C19H24O2). 228 
 
Rf = 0.45 (Hexane/Acetone 80:20). 
1H NMR (400 MHz; CDCl3): Characteristic peaks  7.25 (1H, d, J = 8.5 Hz, HA), 6.73 
(1H, dd, J = 8.6, 2.6 Hz, HB), 6.63 (1H, d, J = 3.0 Hz, HD), 3.78 (3H, s, HG), 3.03 (1H, m), 
2.82 (1H, m), 2.70 (1H, dt, J = 17.1, 4.5 Hz), 0.98 (3H, s, HP) ppm. 
13C NMR (100 MHz; CDCl3):  220.8 (Q, CN), 157.5 (Q, CC), 138.5 (Q, CE), 130.0 (Q, 
CF), 127.5 (CH, CA), 114.0 (CH, CD), 112.2 (CH, CB), 55.3 (CH3, CG), 48.0 (Q, CO), 42.5 
(CH), 37.5 (CH), 35.5 (CH2), 34.0 (CH), 27.5 (CH2), 26.1 (CH2), 24.9 (CH2), 24.3 (CH2), 
21.9 (CH2), 13.5 (CH3, CP) ppm. 
The experimental data correspond well to the reported data.
242,243
 
 
The 9,11-steroid (6.6): 
 
 
A solution of steroid (6.4) (49 mg, 0.177 mmol, 1.0 equiv) in dry DMSO (5 mL) was 
treated  with  KOtBu  (52  mg,  0.460  mmol,  2.5  equiv)  with  stirring  for  1  h  at  room 
temperature. Water (5 mL) and brine (2.5 mL) were added and the mixture was extracted 
with  Et2O  (3  x  10  mL).  The  combined  organic  layers  were  dried  over  Na2SO4. 
Evaporation  of  the  solvent  and  purification  of  the  resulting  residue  by  column 
chromatography  (Hexane/Acetone  70:30)  afforded  steroid  (6.6)  (20  mg,  41%)  as  an 
orange oil. 
 
MW = 282.377 (C19H22O2). 
Rf =  0.29 (Hexane/Acetone 80:20). 
IR (film): 2905 (m), 1723 (s), 1600 (m), 1492 (s), 1208 (m), 1036 (s) cm
-1. 
1H NMR (400 MHz; CDCl3):  7.55 (1H, d, J = 8.8 Hz, HA), 6.77 (1H, dd, J = 8.8, 2.5 
Hz, HB), 6.64 (1H, d, J = 2.3 Hz, HD), 6.22 (1H, m, HK), 3.81 (3H, s, HS), 3.01-2.88 (2H, 
m), 2.81 (1H, dd, J = 18.6, 6.9 Hz, HN), 2.56 (1H, m), 2.46-2.38 (2H, m), 2.31 (1H, dd, J 
= 18.6, 13.6 Hz), 2.12-1.97 (3H, m), 1.61-1.50 (2H, m), 1.12 (3H, s, HR) ppm. 
13C NMR (100 MHz; CDCl3): 203.6 (Q, CQ), 158.9 (Q, CC), 137.2 (Q, CE), 135.2 (Q, 
CF), 126.5 (Q, CJ), 125.3 (CH, CA), 115.9 (CH, CK), 113.4 (CH, CB/D), 113.0 (CH, CB/D), 229 
 
55.3 (CH3, CS), 46.4 (Q, CM), 40.4 (CH, CN), 37.7 (CH, CI), 37.0 (CH2, CP), 33.0 (CH2, 
CL), 29.7 (CH2), 27.94 (CH2), 27.86 (CH2), 14.7 (CH3, CR) ppm. 
The NMR data correspond to literature data.
205,221-223 
 
Estrone (1.6) 
 
 
To a cooled (0 °C) solution of MeCN (2 mL) and DCM (1 mL) was added AlCl3 (0.070 g, 
0.53 mmol, 10.0 equiv) followed by NaI (0.078 g, 0.125 mmol, 2.4 equiv) and finally 
methyl-estrone (1.113) (0.015 g, 0.053 mmol, 1.0 equiv). The mixture was stirred for 5 h 
at room temperature, diluted with DCM (5 mL), poured onto 2 N HCl solution (5 mL), 
extracted with DCM (3 x 5 mL), dried over MgSO4 and finally concentrated in vacuo. The 
crude product was purified by column chromatography (Hexane/Acetone 70:30) to afford 
estrone (1.6) (0.014 g, 92 %) as a white solid.  
 
Mw = 270.366 (C18H22O2). 
m.p. = 248-252 °C. 
Rf = 0.36 (Hexane/Acetone 80:20). 
IR (film): 3271 (br, m), 2924 (m), 2860 (m), 1716 (s), 1704 (s) 1621 (m), 1579 (m), 1496 
(m), 1287 (s), 1246 (s), 1055 (s), 816 (s) cm
-1
. 
1H NMR (400 MHz; CDCl3): 7.16 (1H, d, J = 8.4 Hz, HA), 6.65 (1H, dd, J = 8.4, 2.3 
Hz, HB), 6.60 (1H, d, J = 2.4 Hz, HD), 4.70 (1H, br s, OH), 2.88 (2H, m, HG), 2.52 (1H, 
dd, J = 18.8, 8.5 Hz, HJ), 2.39 (1H, m), 2.25 (1H, m), 2.20-1.93 (4H, m), 1.69-1.39 (6H, 
m), 0.92 (3H, s, HO) ppm. 
13C NMR (100 MHz; CDCl3): 221.0 (Q, CM), 153.4 (Q, CC), 138.1 (Q, CE), 132.1 (Q, 
CF), 126.5 (CH, CA), 115.3 (CH, CD), 112.8 (CH, CB), 50.4 (CH, CR), 48.0 (Q, CN), 44.0 
(CH, CJ), 38.4 (CH, CI), 35.9 (CH2, CL), 31.6 (CH2, CP), 29.5 (CH2, CH), 26.5 (CH2, CH/Q), 
25.9 (CH2, CH/Q), 21.6 (CH2, CK), 13.9 (CH3, CO) ppm. 
CIMS m/z (%): 271 (M+H
+, 100). 
The experimental data correspond well will literature data.
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9.6  Experimental data for Chapter 7 
 
The carbonate (7.16) 
 
 
To a solution of the Z-allylic phosphonate (2.3) (1.03 g, 2.63 mmol, 1.0 equiv) in THF (20 
mL), cooled to -78 °C, 
nBuLi (2.5 M in Hexane, 1.15 mL, 2.89 mmol, 1.1 equiv) was 
added slowly and the mixture was stirred for 15 min at -78 °C. After warming to 0 °C, a 
solution of 2-methyl-2-cyclopentenone (1.100) (0.333 mL, 2.89 mmol, 1.3 equiv) in THF 
(10 mL) was immediately added over 2 min. via cannula. The solution was stirred for 1 h 
at 0 °C and then quenched with methyl cyanoformate (7.14) (2.02 mL, 26.3 mmol, 10 
equiv). The solution was warmed to room temperature and stirred for 1 h. Water (50 mL) 
was added and the reaction was extracted with DCM (3 x 50 mL), dried over MgSO4, 
filtered  and  concentrated  in  vacuo.  The  crude  product  was  purified  by  column 
chromatography (Hexane/Acetone 70:30) to afford (7.16) as a light yellow oil (1.08 g, 
79%). 
 
MW = 544.123 (C24H34BrO7P). 
Rf = 0.54 (Hexane/Acetone 65:35). 
IR (neat): 2956 (w), 1758 (s), 1572 (w), 1472 (m), 1236 (s), 1050 (s), 1020 (s), 957 (s), 
784 (m) cm
-1. 
1H NMR (400 MHz; CDCl3):  7.39 (1H, d, J = 8.7 Hz, HA), 6.78 (1H, ddd, J = 22.1, 
17.2, 7.6 Hz, HK), 6.74 (1H, d, J = 3.0 Hz, HB), 6.63 (1H, dd, J = 8.7, 3.0 Hz, HD), 5.80 
(1H, dd, J = 20.4, 17.2 Hz, HL), 4.16-4.04 (4H, m, HM), 3.81 (3H, s, HG/V), 3.78 (3H, s, 
HG/V), 2.79-2.66 (2H, m, HO+HH), 2.54 (1H, m, HH’), 2.48-2.42 (3H, m, HJ+HQ+HQ’), 1.97 
(1H, ddd, J = 16.5, 13.3, 7.7 Hz, HP), 1.82-1.66 (2H, m, HI+HP’), 1.60 (1H, dtd, J = 15.3, 
10.5, 5.0 Hz, HI’), 1.50 (3H, s, HT), 1.35 (6H, t, J = 7.1 Hz, HN) ppm. 231 
 
13C NMR (100 MHz; CDCl3): 159.0 (Q, CC), 155.3 (d, J = 4.2 Hz, CH, CK), 153.0 (Q, 
CU), 145.9 (Q, CR), 142.0 (Q, CE), 133.3 (CH, CA), 123.3 (Q, CS), 118.2 (d, J = 186.1 Hz, 
CH, CL), 115.9 (CH, CD), 114.7 (Q, CF), 113.4 (CH, CB), 61.7 (d, J = 5.2 Hz, CH2, CM), 
61.7 (d, J = 5.3 Hz, CH2, CM’), 55.4 (CH3, CG/V), 55.1 (CH3, CG/V), 48.9 (CH, CO), 45.9 (d, 
J = 20.3 Hz, CH, CJ), 34.6 (CH2, CH), 29.7 (CH2, CQ), 28.0 (CH2, CI), 22.1 (CH2, CP), 16.4 
(d, J = 5.0 Hz, 2 x CH3, CN), 10.6 (CH3, CT) ppm. 
31P NMR (121 MHz; CDCl3):  18.85 ppm. 
ES
+MS m/z (%): 569/567 (1:1, (M+Na)
+, 37), 547/545 (1:1, (M+H)
+, 13). 
HRES
+MS for C24H34O7
79BrP (M+H)
+: calcd 545.1298, found 545.1300. 
 
The silyl enol ether (7.17) 
 
 
To a solution of the Z-allylic phosphonate (2.3) (1.03 g, 2.63 mmol, 1.0 equiv) in THF (20 
mL), cooled to -78 °C, 
nBuLi (1.6 M in Hexane, 1.81 mL, 2.89 mmol, 1.1 equiv) was 
added slowly and the mixture was stirred for 15 min at -78 °C. After warming to 0 °C, a 
solution of 2-methyl-2-cyclopentenone (1.100) (0.334 mL, 3.42 mmol, 1.3 equiv) in THF 
(10 mL) was immediately added over 2 min. via cannula. The solution was stirred for 1 h 
at 0  °C  and then  quenched  with  TBDMSOTf (1.21  mL, 5.26  mmol,  2.0 equiv).  The 
solution was warmed to room temperature and stirred for 1 h. Water (10 mL) was added 
and the reaction was extracted with DCM (3 x 10 mL), dried over Na2SO4, filtered and 
concentrated  in  vacuo.  The  crude  product  was  purified  by  column  chromatography 
(Hexane/Acetone 70:30) using pre-neutralized silica gel to afford (7.17) as a light yellow 
oil (1.27 g, 84%). 
 
Mw = 601,625 (C28H46BrO5PSi). 
Rf = 0.48 (Hexane/Acetone 65:35). 
IR (film): 2936 (m), 2855 (m), 1727 (m), 1471 (w), 1242 (m), 1101 (m), 1052 (s), 1022 
(s), 959 (m) cm
-1. 232 
 
1H NMR (400 MHz; CDCl3):  7.39 (1H, d, J = 8.7 Hz, HA), 6.79 (1H, ddd, J = 22.1, 
17.2, 8.5 Hz, HK), 6.72 (1H, d, J = 3.0 Hz, HD), 6.63 (1H, dd, J = 8.7, 3.0 Hz, HB), 5.77 
(1H, dd, J = 20.9, 17.2 Hz, HL), 4.16-4.05 (4H, m, HM), 3.78 (3H, s, HG), 2.78-2.59 (2H, 
m, HO+HH), 2.51 (1H, ddd, J = 13.5, 10.4, 6.3 Hz, HH’), 2.43 (1H, m, HJ), 2.27-2.12 (2H, 
m, HQ), 1.90-1.80 (1H, m, HP), 1.75-1.66 (1H, m, HI), 1.62-1.51 (2H, m, HI’+HP’), 1.47 
(3H, s, HT), 1.35 (6H, t, J = 7.1 Hz, HN), 0.93 (9H, s, HW), 0.10 (3H, s, HU) ppm. 
13C NMR (100 MHz; CDCl3): 158.9 (Q, CC), 156.5 (d, J = 4.1 Hz, CH, CH), 148.9 (Q, 
CR), 142.4 (Q, CE), 133.3 (CH, CA), 117.5 (d, J = 186.0 Hz, CH, CL), 116.0 (CH, CD), 
114.7 (Q, CF), 113.2 (CH, CB), 113.1 (Q, CS), 61.6 (d, J = 3.9 Hz, 2 x CH2, CM), 55.4 
(CH3, CG), 49.3 (CH, CO), 46.6 (d, J = 20.1 Hz, CH, CJ), 34.9 (CH2, CH), 32.8 (CH2, CQ), 
28.1 (CH2, CI), 25.7 (3 x CH3, CW), 22.0 (CH2, CP), 18.1 (Q, CV), 16.4 (d, J = 5.1 Hz, 2 x 
CH3, CN), 10.7 (CH3, CT), -4.0 (CH3, CU) ppm. 
31P NMR (121 MHz; CDCl3):  19.22 ppm. 
ES
+MS m/z (%): 626/623 (1:1, (M+Na)
+, 100), 603/601 (1:1, (M+H)
+, 30). 
HRES
+MS For C28H46
79BrO5PSiNa (M+Na)
+: calcd 623.1928, found 623.1942. 
 
The alcohol (7.12) 
 
 
To a  stirred solution of  silyl  enol  ether  (7.17) (0.133 g,  0.221 mmol, 1.0 equiv) and 
paraformaldehyde (0.066 g, 2.21 mmol, 10 equiv) in DCM (3 mL) was slowly  added 
AlMe3 (2 M in Hexane, 0.221 mL, 2.0 equiv). The mixture was stirred at room temperature 
for 5 h, then water was added (2 mL). The reaction was extracted with DCM (3 x 5 mL), 
dried over Na2SO4 and concentrated  in vacuo. The resulting crude product was dissolved 
in THF (3 mL), treated with HCl 2 M (2 mL) and stirred at room temperature for 1 h. After 
usual  work-up,  the  crude  product  was  purified  by  column  chromatography 
(Hexane/Acetone 60:40) to afford alcohol (7.12) as a light yellow oil (0.064 g, 56%).  
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Mw = 517,390 (C23H34BrO6P). 
Rf = 0.27 (Hexane/Acetone 65:35). 
1H NMR (400 MHz; CDCl3):  7.40 (1H, d, J = 8.7 Hz, HA), 6.73 (1H, d, J = 3.0 Hz, HD), 
6.71 (1H, m, HK), 6.64 (1H, dd, J = 8.8, 3.0 Hz, HB), 5.78 (1H, dd, J = 20.6, 17.3 Hz, HL), 
4.21-4.05 (4H, m, HM), 3.78 (3H, s, HG), 3.77 (1H, d, J = 9.7 Hz, HU), 3.44 (1H, d, J = 9.7 
Hz, HU’), 2.71 (1H, ddd, J = 13.2, 11.8, 5.0 Hz, HQ), 2.58-2.45 (2H, m, HQ’+HO), 2.44-
2.32 (2H, m, HJ+HI), 2.28-2.06 (2H, m, HP+HI’), 1.99 (1H, m, HH), 1.69-1.41 (2H, m, 
HP’+HH’), 1.35 (6H, t, J = 7.1 Hz, HN), 0.83 (3H, s, HT) ppm. 
13C NMR (100 MHz; CDCl3): 222.8 (Q, CR), 159.1 (Q, CC), 155.4 (d, J = 3.8 Hz, CH, 
CK), 142.0 (Q, CE), 133.4 (CH, CA), 119.0 (d, J = 186.7 Hz, CH, CL), 116.0 (CH, CD), 
114.6 (Q, CF), 113.2 (CH, CB), 65.4 (CH2, CU), 61.8 (d, J = 5.5 Hz, 2 x CH2, CM), 55.4 
(CH3, CG), 53.7 (Q, CS), 46.6 (d, J = 20.9 Hz, CH, CJ), 42.5 (CH, CO), 37.0 (CH2, CI), 34.0 
(CH2, CQ), 32.0 (CH2, CH), 23.5 (CH2, CP), 16.4 (d, J = 6.2 Hz, 2 x CH3, CN), 13.7 (CH3, 
CT) ppm. 
31P NMR (121 MHz; CDCl3):  17.97 ppm. 
ES
+MS m/z (%): 541/539 (1:1, (M+Na)
+, 100), 519/517 (1:1, (M+H)
+, 10). 
HRES
+MS For C23H34
79BrO6PNa (M+Na)
+: calcd 539.1174, found 539.1176. 
 
The mesylate (7.19) 
 
 
Triethylamine (45 L, 0.33 mmol, 2.5 equiv) in DCM (1 mL) was added dropwise to 
alcohol (7.12) (67 mg, 0.13 mmol, 1.0 equiv) and methanesulfonyl chloride (20 L, 0.26 
mmol, 2.0 equiv) in DCM (2 mL) at -20 °C. After 20 min, the mixture was allowed to 
warm to room temperature. After an additional 40 min, the mixture was poured into water 
(5 mL), and the organic phase was dried over Na2SO4, filtered and concentrated in vacuo. 
The crude product was purified by column chromatography (Hexane/Acetone 60:40) to 
afford (7.19) as a colourless oil (62 mg, 81%).  
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Mw = 595.481 (C24H36O8PS). 
Rf = 0.29 (Hexane/Acetone 65:35). 
1H NMR (400 MHz; CDCl3):  7.41 (1H, d, J = 8.7 Hz, HA), 6.73 (1H, d, J = 3.0 Hz, 
HD), 6.63 (1H, ddd, J = 21.8, 17.3, 9.7 Hz, HK), 6.65 (1H, dd, J = 8.8, 2.8 Hz, HB), 5.84 
(1H, dd, J = 20.4, 17.3 Hz, HL), 4.31 (1H, d, J = 9.8 Hz, HU), 4.21-4.06 (4H, m, HM), 4.02 
(1H, d, J = 9.8 Hz, HU’), 3.79 (3H, s, HG), 3.01 (3H, s, HV), 2.70 (1H, m, HQ), 2.57-2.08 
(6H, m, HI+HI’+HJ+HO+HP+HQ’), 2.01 (1H, m, HH), 1.67-1.48 (2H, m, HH’+HP’), 1.36 
(6H, t, J = 7.0 Hz, HN), 0.89 (3H, s, HT) ppm. 
13C NMR (100 MHz; CDCl3): 218.4 (Q, CR), 159.0 (Q, CC), 153.4 (d, J = 3.1 Hz, CH, 
CK), 141.7 (Q, CE), 133.4 (CH, CA), 120.4 (d, J = 187.3 Hz, CH, CL), 116.0 (CH, CD), 
114.6 (Q, CF), 113.3 (CH, CB), 71.5 (CH2, CU), 62.0 (d, J = 5.6 Hz, CH2, CM), 62.0 (d, J = 
5.5 Hz, CH2, CM’), 55.4 (CH3, CG), 51.9 (Q, CS), 46.6 (d, J = 20.8 Hz, CH, CJ), 42.2 (CH, 
CO), 36.7 (CH3, CV), 36.3 (CH2, CI), 34.0 (CH2, CQ), 31.9 (CH2, CH), 23.2 (CH2, CP), 16.4 
(d, J = 6.1 Hz, 2 x CH3, CN), 13.5 (CH3, CT) ppm. 
31P NMR (121 MHz; CDCl3):  16.89 ppm. 
ES
+MS m/z (%): 619/617 (1:1, (M+Na)
+, 100), 597/595 (1:1, (M+H)
+, 65). 
HRES+MS For C24H36O8PS
79BrNa (M+Na)
+: calcd 617.0944, found 617.0954. 235 
 
Appendix I : Copies of 
1H and 
13C NMR spectra 236 
 
1H NMR spectrum (CDCl3, 400 MHz) of (4.18). 
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13C NMR spectrum (CDCl3, 100 MHz) of (4.18). 
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1H NMR spectrum (CDCl3, 400 MHz) of (4.61). 
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13C NMR spectrum (CDCl3, 100 MHz) of (4.61). 
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1H NMR spectrum (CDCl3, 400 MHz) of (5.7). 
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13C NMR spectrum (CDCl3, 100 MHz) of (5.7). 
ppm (f1)
0 50 100 150 200
2
0
7
.
9
2
1
1
8
0
.
9
1
7
1
6
4
.
3
4
2
1
6
3
.
5
0
6
1
4
8
.
6
4
5
1
4
8
.
5
8
8
1
4
1
.
7
2
1
1
1
4
.
9
9
6
1
0
9
.
6
0
9
1
0
2
.
3
5
9
9
8
.
9
0
9
9
8
.
4
0
4
8
4
.
7
9
3
7
7
.
0
0
0
5
5
.
7
5
8
5
4
.
7
7
3
5
3
.
6
0
3
5
3
.
0
3
5
4
6
.
9
0
5
4
6
.
6
8
4
4
5
.
4
0
9
4
4
.
9
9
0
4
0
.
7
8
6
3
6
.
2
5
7
3
5
.
7
9
8
3
0
.
8
5
7
2
8
.
5
3
8
2
8
.
3
7
2
2
7
.
7
4
4
2
5
.
9
1
5
2
5
.
6
6
0
2
2
.
2
5
7
1
8
.
2
0
8
1
8
.
1
1
4
1
8
.
0
8
8
1
5
.
8
3
1
1
5
.
6
2
5
-
4
.
5
9
8
-
4
.
6
2
6
-
4
.
9
8
3
 
O
O
TBSO
OTBS
H
H H
H
H H
(5.7)
O
O
TBSO
OTBS
H
H H
H
H H
(5.7)239 
 
Appendix II: X-ray data 240 
 
X-ray data for (3.3) 
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Thermal ellipsoids drawn at the 35% probability level 243 
 
X-ray data for (4.26) 
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One of the 2 independent molecules in the asymmetric unit. Thermal ellipsoids drawn at 
the 35% probability level, disorder omitted for clarity. 248 
 
X-ray data for (4.29) 
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Thermal ellipsoids drawn at the 50% 
Hydrogen bonded chains extend along the b axis 251 
 
X-ray data for (4.40) 
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Thermal ellipsoids drawn at the 35% 254 
 
X-ray data for (4.43) 
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N.B. As well as the enantiomer illusrated, the crystal structure also contains the 
opposite enantiomer and thus is a racemic mixture 258 
 
X-ray data for (4.45)  
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N.B. As well as the enantiomer illusrated, the crystal structure also 
contains the opposite enantiomer and thus is a racemic mixture 
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X-ray data for (1.71)  
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Residue 1; thermal ellipsoids drawn at the 35% probability level. 265 
 
X-ray data for (5.13) 
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Thermal ellipsoids drawn at the 50% probability level 268 
 
X-ray data for (5.14) 
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Thermal ellipsoids drawn at the 35% probability level 271 
 
X-ray data for (5.15) 
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Thermal ellipsoids drawn at the 50% probability level 274 
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